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Summary	Multidrug-resistant	(MDR)	tuberculosis	(TB),	defined	as	TB	disease	or	infection	caused	by	Mycobacterium	tuberculosis	with	resistance	to	at	least	both	isoniazid	and	rifampicin,	threatens	global	TB	control,	with	an	estimated	490,000	incident	cases	of	MDR-TB	globally	in	2016.		The	burden	of	paediatric	MDR-TB	has	been	poorly	characterized	to	date.		However,	recent	modeling	studies	estimate	that	there	are	approximately	26,000-32,000	incident	MDR-TB	cases	in	children	(<	15	years	of	age)	worldwide	each	year.	Traditionally,	treatment	regimens	for	adults	and	children	were	constructed	using	a	minimum	of	four	second-line	antituberculosis	drugs	likely	to	be	effective,	including	a	second-line	injectable	medication,	for	up	to	6	months,	and	a	total	duration	of	treatment	of	up	to	18-24	months.		In	2016,	the	World	Health	Organization	(WHO)	recommended	a	shortened	(9-12	month)	treatment	regimen,	which	still	includes	an	injectable	drug	for	four	months.		In	addition,	the	development	and	increasing	use	of	the	novel	TB	drugs	bedaquiline	and	delamanid,	are	radically	altering	the	MDR-TB	treatment	landscape,	although	children	have	lagged	behind	in	accessing	these	important	developments.	Treatment	outcomes	for	adults	with	MDR-TB	have	been	persistently	poor,	with	54%	successfully	treated	in	2014	both	overall	globally,	and	in	South	Africa.	In	contrast,	treatment	outcomes	among	children	with	MDR-TB	are	generally	good,	with	78-90%	successfully	treated	under	routine	clinical	conditions.		However,	current	paediatric	MDR-TB	treatment	regimens	have	important	limitations.		These	current	regimens	remain	long	(9-18	months	or	more),	which	is	costly	and	burdensome.		There	are	also	frequent	adverse	effects,	including	from	the	second-line	injectable	medications	(amikacin,	kanamycin,	capreomycin)	that	cause	permanent	sensorineural	hearing	loss	in	up	to	24%	of	children	treated	long-term.		Additionally,	the	injectables	are	mainly	given	by	painful	daily	intramuscular	injections,	resulting	in	trauma	and	distress	for	patients,	their	caregivers	and	healthcare	providers.		Therefore,	it	is	an	urgent	priority	to	develop	more	optimal	treatment	regimens	for	children	with	MDR-TB	that	retain	their	efficacy	but	are	shorter,	more	child-friendly,	are	better	tolerated,	safer	and	which	do	not	require	the	use	of	an	injectable	medication.		The	purpose	of	this	doctoral	research	was	to	address	critical	knowledge	gaps	in	paediatric	MDR-TB	treatment,	with	the	aim	of	informing	more	effective,	safer,	and	more	child-friendly	MDR-TB	treatment	strategies	in	children.		I	identified	critical	knowledge	
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gaps	related	to	the	pharmacokinetics,	including	the	effects	of	formulation,	optimal	dosing,	safety,	and	tolerability	of	key	second-line	and	novel	antituberculosis	drugs	in	children,	and	completed	complementary	studies	on	ofloxacin,	levofloxacin,	linezolid,	amikacin	and	bedaquiline	designed	to	address	these	knowledge	gaps.		In	an	observational	study	of	the	pharmacokinetics	and	safety	of	ofloxacin	in	children	routinely	treated	for	MDR-TB	disease	or	exposure,	exposures	after	a	daily	20mg/kg	ofloxacin	dose	were	well	below	target	exposures	from	adults	receiving	the	routine	800	mg	dose.		Ofloxacin	was	safe	and	well	tolerated,	with	few	musculoskeletal	complaints	or	serious	adverse	events.		This	data	adds	to	the	evidence	of	the	safety	of	fluoroquinolones	in	children	even	with	long-term	use,	and	identifies	the	need	to	revise	ofloxacin	paediatric	doses.	Subsequently,	in	this	large	observational	study,	the	population	pharmacokinetics	of	levofloxacin	among	children	with	MDR-TB	disease	or	exposure	was	characterized	using	non-linear	mixed	effects	modeling.		One	hundred	and	nine	children	treated	with	the	routinely	available	adult	250	mg	tablet	formulation	of	levofloxacin	at	daily	doses	of	15	mg/kg	or	20	mg/kg	were	included.		Levofloxacin’s	apparent	oral	clearance	(CL/F)	was	higher	than	expected	based	on	previously	published	data,	possibly	due	to	the	formulation	studied.		Simulations	using	the	final	model	targeting	exposures	in	adults	with	TB	receiving	750	mg	of	levofloxacin	identified	weight-banded	doses	that	were	much	higher	than	previously	in	use	(18	mg/kg	to	nearly	40	mg/kg	daily).		It	was	concluded	that	levofloxacin	dosing	in	children	should	be	reassessed,	formulation	effects	explored	further,	and	that	safety	should	be	carefully	evaluated	if	higher	levofloxacin	doses	are	used.		Building	on	this	data,	I	completed	an	evaluation	of	the	safety	of	long-term	levofloxacin	in	children	treated	for	MDR-TB.		Among	70	children,	median	age	2.1	years,	treated	for	a	median	of	11.6	months,	levofloxacin	was	generally	safe	and	was	well	tolerated.		There	were	no	Grade	4	or	serious	adverse	events,	and	few	musculoskeletal	events.		There	was	no	QT-interval	prolongation	and	no	association	of	QT	interval	with	levofloxacin	concentration.		This	study	supported	the	safety	of	long-term	fluoroquinolone	treatment	in	children,	and	provided	novel	data	on	the	QT	prolonging	effect	of	levofloxacin,	which	is	needed,	as	increasingly	levofloxacin	is	being	combined	with	other	QT	prolonging	medications.	
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The	effects	of	drug	formulation	in	pharmacokinetic	studies	are	critically	important.		In	a	lead-in	pharmacokinetics	study	to	the	TB-CHAMP	trial	(phase	3	cluster	randomized	trial	comparing	levofloxacin	vs.	placebo	for	prevention	of	TB	in	child	contacts	of	MDR-TB	cases),	24	children	had	pharmacokinetic	sampling	with	a	novel	dispersible	tablet	formulation	of	levofloxacin.		The	levofloxacin	exposures	were	much	higher	with	this	novel	formulation	compared	to	those	seen	in	the	previously	reported	study	using	the	adult	250	mg	levofloxacin	tablet.		Combining	these	two	data	sets	using	non-linear	mixed	effects	modeling	identified	that	reduced	bioavailability	of	the	adult	250	mg	tablet	formulation	compared	to	the	dispersible	levofloxacin	tablet	was	the	explanation	for	the	substantial	differences	in	exposures.		This	study	highlighted	the	importance	of	formulation	considerations	to	paediatric	pharmacokinetic	studies	and	provided	practical	weight-banded	dosing	guidelines	for	use	of	this	formulation	now	becoming	available	in	the	field.	Linezolid	is	a	key	drug	with	an	increasingly	important	role	in	the	treatment	of	MDR-TB	strains	with	additional	resistance	and	in	central	nervous	system	TB	disease.		I	performed	a	structured	review	of	the	literature	on	linezolid	to	inform	its	use	in	children	for	MDR-TB	treatment	and	identify	knowledge	gaps	for	future	research.		Few	children	treated	with	linezolid	for	MDR-TB	were	described	in	the	literature.		As	in	adults,	linezolid	appeared	to	be	effective	but	was	associated	with	frequent	adverse	events.		There	was	no	data	on	linezolid	pharmacokinetics	in	children	with	TB.		Practical	interim	guidance	was	provided	for	linezolid	use	in	children.		Priority	research	needs	identified	included	studying	linezolid	pharmacokinetics	in	children	with	TB,	characterization	of	its	safety	with	long-term	use,	and	its	optimal	dose	for	TB	in	MDR-TB	regimens	going	forward.	Following	on	this	review,	an	analysis	of	linezolid	pharmacokinetics	and	safety	from	children	with	MDR-TB	was	performed	with	data	from	48	children	combined	from	two	observational	studies	using	non-linear	mixed	effects	modeling.		Seventeen	children	received	long-term	linezolid	and	were	monitored	longitudinally	for	safety;	31	children	only	contributed	cross-sectional	pharmacokinetic	data	after	a	single-dose	of	linezolid.	After	accounting	for	the	effects	of	weight	with	allometric	scaling,	no	other	covariates	significantly	contributed	to	the	model.		Exposures	were	higher	than	expected,	based	on	previously	reported	data.		Ten	of	17	participants	had	a	linezolid	related	adverse	event,	
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including	five	Grade	3	or	4	events;	anaemia	was	the	most	common	event.		This	first	data	on	linezolid	pharmacokinetics	in	children	demonstrated	higher	than	expected	exposures	and	frequent,	serious	linezolid-related	adverse	events,	and	will	inform	the	use	and	future	dosing	recommendations	of	this	increasingly	important	antituberculosis	medication	in	children.	While	drug	substitutions	for	injectable	drugs	are	not	yet	available	for	many	children,	improving	the	tolerability	of	the	continued	use	of	second-line	injectable	medications	is	an	important	question	to	address	in	children.		A	randomized	two-period	crossover	study	was	designed	to	characterize	the	effect	of	co-administration	of	lidocaine	on	the	pain	and	pharmacokinetics	of	intramuscular	amikacin.		Children	each	received	a	dose	of	amikacin	with	and	without	additional	lidocaine	on	separate	days,	and	were	randomized	to	the	sequence	of	treatments;	pain	assessments	and	pharmacokinetic	sampling	were	performed	on	each	day.			Twelve	children	were	enrolled	and	completed	the	study.		The	addition	of	lidocaine	reduced	pain	immediately	after	the	injection,	was	safe,	and	did	not	affect	the	pharmacokinetics	of	amikacin	in	children,	and	should	be	considered	as	a	routine	policy	in	patients	with	MDR-TB	receiving	an	injectable	agent.		The	novel	drug	bedaquiline	is	increasingly	used	globally	and	in	South	Africa	for	adults	with	MDR-TB,	and	ongoing	paediatric	trials	will	characterize	the	pharmacokinetics,	safety	and	optimal	dose	in	children.		The	paediatric	formulation,	which	is	being	evaluated	in	at	least	one	of	the	ongoing	paediatric	trials,	may	not	be	available	for	routine	care	for	some	time.		In	order	to	inform	the	rational	use	of	the	adult	bedaquiline	formulation	in	young	children,	a	randomized	two-period	crossover	study	in	healthy	adult	volunteers	was	designed.	Adult	bedaquiline	tablets	administered	suspended	in	water	were	bioequivalent	to	adult	tablets	swallowed	whole.		The	suspended	tablets	were	also	found	to	be	acceptable	and	palatable	to	the	majority	of	participants,	an	important	finding	considering	that	crushing	or	suspending	some	tablets,	such	as	the	fluoroquinolones,	reduces	their	palatability	and	acceptability	substantially.		This	data	will	accelerate	access	to	bedaquiline	for	young	children	in	research	and	routine	care.	In	conclusion,	this	doctoral	research	has	addressed	a	number	of	important	key	knowledge	gaps	related	to	more	optimal	paediatric	MDR-TB	treatment.		This	research	has	raised	a	number	of	follow-up	questions	that	have	informed	subsequent	studies	that	
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will	continue	to	advance	the	field	towards	a	goal	of	effective,	safe,	shorter	MDR-TB	treatment	for	all	children.					 	
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Opsomming	Multimiddel-weerstandige	(MMW)	tuberkulose	(TB),	wat	gedefinieër	word	as	as	TB	siekte	of	infeksie	wat	veroorsaak	word	deur	Mycobacterium	tuberculosis	met	weerstandigheid	teen	ten	minste	isoniasied	en	rifampisien,	bedreig	wêreldwye	TB	beheer,	met	‘n	geskatte	490,000	nuwe	gevalle	van	MMW-TB	wêreldwyd	in	2016.	Die	lading	van	pediatriese	MMW-TB	is	tot	op	hede	swak	omskryf.	Onlangse	modeleringstudies	beraam	egter	dat	daar	elke	jaar	ongeveer	26,000-32,000	nuwe	MMW-TB	gevalle	in	kinders	(<15	jaar	oud)	wêreldwyd	voorkom.	Tradisioneel	was	die	behandelingsregimens	vir	volwassenes	en	kinders	saamgestel	deur	‘n	minimum	van	vier	waarskynlik	effektiewe	tweede-linie	antituberkulosemiddels	te	gebruik,	insluitend	‘n	tweede-linie	inspuitbare	middel	vir	tot	6	maande	en	totale	behandelingsduur	van	tot	18-24	maande.	In	2016	het	die	Wêreldgesondheids-organisasie	(WGO)	‘n	verkorte	(9-12	maande)	behandelingsregimen,	wat	steeds	‘n	inspuitbare	middel	vir	4	maande	ingesluit	het,	aanbeveel.	Hierby	het	die	ontwikkeling	en	toenemende	gebruik	van	die	nuwe	TB	middels,	bedakwilien	en	delamanid,	gelei	tot	radikale	veranderinge	in	die	MMW-TB	omgewing,	alhoewel	kinders	in	die	toegang	tot	hierdie	belangrike	ontwikkelinge	agtergebly	het.	Die	uitkomste	van	behandeling	van	MMW-TB	in	volwassenes	was	aanhoudend	swak	met	54%	suksesvolle	behandeling	in	2014	beide	algeheel	globaal,	sowel	as	in	Suid-Afrika.	In	teenstelling	hiermee	is	die	uitkomste	van	behandeling	in	kinders	met	MMW-TB	oor	die	algemeen	goed,	met	78-90%	suksesvolle	behandeling	onder	roetine	kliniese	sorg.	Huidige	pediatriese	MMW-TB	behandeling	het	egter	belangrike	beperkings.	Die	huidige	behandeling	bly	egter	van	lange	duur	(9-18	maande	of	langer)	wat	dit	duur	en	moeilik	maak.		Daar	is	ook	dikwels	nadelige	gevolge,	soos	byvoorbeeld	permanente	sensorineurale	gehoorsverlies	in	tot	24%	van	kinders	wat	langtermyn	behandeling	ontvang	en	wat	deur	die	tweede-linie	inspuitbare	middels	(amikasien,	kanamisien,	kapreomisien)	veroorsaak	word.	Daarby	word	die	inspuitbare	middels	hoofsaaklik	per	pynlike	binnespierse	inspuiting	toegedien	wat	trauma	en	angstigheid	in	die	pasiënt,	die	versorger	en	die	gesondheidsverskaffers	veroorsaak.	Daarom	is	dit	‘n	belangrike	prioriteit	om	meer	optimale	behandelingsregimens	vir	kinders	met	MMW-TB	te	ontwikkel	wat	hulle	effektiwiteit	behou,	van	korter	duur	en	meer	kindervriendelik	is,	wat	beter	verduur	word,	veiliger	is	en	wat	nie	enige	inspuitbare	middels	bevat	nie.		
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Die	oogmerk	van	hierdie	doktorale	navorsing	was	om	kritieke	kennisleemtes	in	die	behandeling	van	pediatriese	MMW-TB	aan	te	spreek,	met	die	doel	om	meer	effektiewe,	veiliger	en	meer	kindervriendelike	MMW-TB	behandelingstrategieë	in	kinders	toe	te	lig.	Ek	het	kritieke	kennisleemtes	verwant	aan	die	farmakokinetika,	insluitend	die	effek	van	formulerings,	optimale	dosering,	veiligheid	en	verdraagsaamheid	van	sleutel	tweede-linie	en	nuwe	antituberkulose	middels	in	kinders	geïdentifiseer	en	het	komplimentêre	studies	oor	ofloksasien,	levofloksasien,	linezolied,	amikasien	en	bedakwilien	ontwerp	om	hierdie	kennisleemtes	aan	te	spreek.	In	‘n	waarnemingstudie	oor	die	farmakokinetika	en	veiligheid	van	ofloksasien	in	kinders	wat	normaalweg	vir	MMW-TB	siekte	of	blootstelling	behandel	is,	was	die	blootstellingsvlakke	na	‘n	daaglikse	dosis	van	20	mg/kg	ofloksasien	duidelik	laer	as	die	teikenblootstellingsvlakke	wat	bereik	word	deur	volwassenes	wat	‘n	roetine	dosis	van	800	mg		ontvang.	Ofloksasien	was	veilig	en	is	goed	verduur	met	min	muskuloskeletale	klagtes	of	ernstige	nadelige	gevolge.	Hierdie	inligting	dra	by	tot	die	bewyse	dat	die	fluorokwinolone	veilig	is	in	kinders	selfs	met	langtermyn	gebruik	en	toon	die	behoefte	aan	om	die	pediatriese	dosisse	van	ofloksasien	te	hersien.	Hierna,	in	hierdie	groot	waarnemingstudie,	is	die	populasiefarmakokinetika	van	levofloksasien	in	kinders	met	MMW-TB	siekte	of	blootstelling	bepaal	deur	die	nie-lineêre	gemengde-effekte	modeleringstegniek	te	gebruik.	Eenhonderd-en-nege	kinders	wat	met	die	normaalweg	beskikbare	volwasse-formulering	250mg	levofloksasien	tablette	behandel	is	met	‘n	daaglikse	dosis	van	15	mg/kg	of	20	mg/kg,	is	ingesluit.	Levofloksasien	se	oënskynlike	mondelingse	opruiming	(CL/F)	van	levofloksasien	was	hoër	as	wat	verwag	was	volgens	vorige	gepubliseerde	inligting,	moontlik	as	gevolg	van	die	formulering	wat	bestudeer	is.	Simulasies	wat	die	finale	model	gebruik	het	wat	blootstellingsvlakke	in	volwassenes	wat	750	mg	levofloksasien	ontvang,	geteiken	het,	het	gewigsgebaseerde	dosisse	geïdentifiseer	wat	baie	hoër	is	as	wat	voorheen	gebruik	is	(18	mg/kg	tot	byna	40	mg/kg	daagliks).		Daar	is	tot	die	slotsom	gekom	dat	levofloksasiendoserings	in	kinders	hersien	moet	word,	formuleringseffekte	verder	ondersoek	moet	word	en	dat,	as	hoër	doserings	van	levofloksasien	gebruik	sou	word,	veiligheid	versigtig	nagegaan	moet	word.	Op	grond	van	hierdie	inligting	het	ek	die	veiligheid	van	die	langtermyngebruik	van	levofloksasien	in	kinders	met	MMW-TB	bestudeer	en	voltooi.	In	70	kinders,	mediane	
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ouderdom	2.1	jaar,	wat	behandel	is	vir	‘n	mediane	duur	van	11.6	maande,	was	levofloksasien	oor	die	algemeen	veilig	en	is	dit	goed	verduur.	Geen	Graad	4	of	ernstige	nadelige	effekte	het	voorgekom	nie	en	net	enkele	muskuloskeletale	effekte	het	voorgekom.	Geen	verlenging	van	QT-interval	het	voorgekom	nie	en	daar	was	geen	verband	waargeneem	tussen	levofloksasienkonsentrasies	en	QT-intervalle	nie.	Hierdie	studie	het	die	veiligheid	van	die	langtermyn-gebruik	van	fluorokwinoloon-behandeling	in	kinders	ondersteun	en	het	nuwe	inligting	oor	die	QT-verlengingseffek	van	levofloksasien	verskaf	wat	baie	nodig	is,	want	levofloksasien	word	toenemend	tesame	met	ander	QT-verlengende	middels	aangewend.	Die	effekte	van	middelformulerings	in	farmakokinetikastudies	is	van	kritiese	belang.	Tydens	‘n	inleidende	farmakokinetikastudie	vir	die	TB-CHAMP	studie	(fase-3	cluster	ewekansige	studie	wat	levofloksasien	met	plasebo	vergelyk	vir	die	voorkoming	van	TB	in	kinderkontakte	van	MMW-TB	gevalle)	het	24	kinders	farmakokinetiese	monsterneming	gehad	tydens	die	gebruik	van	‘n	nuwe	oplosbare	tablet	van	levofloksasien.	Die	levofloksasien	blootstellingsvlakke	was	baie	hoër	met	hierdie	nuwe	formulering	in	vergelyking	met	dié	wat	in	die	vorige	studie	met	die	gebruik	van	die	250	mg	volwasse	tablette	gevind	is.	Deur	hierdie	twee	inligtingstelle	te	kombineer	deur	gebruik	te	maak	van	die	nie-lineêre	gemengde-effekte	modeleringstegniek,	het	dit	geblyk	dat	die	verminderde	biobeskikbaarheid	tussen	die	volwasse	250	mg	tablette	en	die	oplosbare	levofloksasien	tablette	die	rede	is	vir	die	aansienlike	verskil	in	blootstellingsvlakke.	Hierdie	studie	het	die	belangrikheid	van	middelformulerings	oorwegings	in	pediatriese	farmakokinetika	beklemtoon	en	het	praktiese	gewigs-gebaseerde	doseringsriglyne	daargestel	vir	die	gebruik	van	hierdie	formulering	wat	nou	in	die	veld	beskikbaar	raak.	Linezolied	is	‘n	sleutelmiddel	met	‘n	toenemend	belangrike	rol	in	die	behandeling	van	MMW-TB	stamme	met	bykomende	weerstandigheid	sowel	as	in	sentraal	senuweestelsel	TB	siekte.	Ek	het	‘n	gestruktureerde	oorsig	van	die	literatuur	oor	linezolied	onderneem	om	duidelikheid	te	kry	oor	die	gebruik	daarvan	in	kinders	met	MMW-TB	en	om	kennisleemtes	vir	toekomstige	navorsing	te	identifiseer.	Slegs	enkele	kinders	wat	behandel	is	vir	MMW-TB	is	in	die	literatuur	opgeteken.	Soos	in	die	geval	van	volwassenes,	het	linezolied	effektief	blyk	te	wees,	maar	was	met	gereelde	nadelige	effekte	geassosieer.	Daar	was	geen	inligting	oor	oor	die	farmakokinetika	van	linezolied	
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in	kinders	met	TB	beskikbaar	nie.	Praktiese	tussentydse	riglyne	vir	die	gebruik	van	linezolied	in	kinders	is	voorsien.		Navorsingsprioriteite	wat	geïdentifiseer	is,	het	linezolied	farmakokinetika	in	kinders	met	TB,	kenmerke	van	linezolied	se	veiligheid	met	langtermyn	gebruik	en	sy	optimale	dosering	vir	TB	in	MMW-regimens	vorentoe,	ingesluit.	Na	hierdie	oorsig	is	‘n	analise	van	linezolied-farmakokinetika	en	veiligheid	in	kinders	met	MMW-TB	gedoen	met	inligting	verkry	van	48	kinders	saamgevat	uit	twee	waarnemingstudies	deur	gebruik	te	maak	van	nie-lineêre	gemengde-effekte	modelering.	Sewentien	kinders	het	langtermyn	linezolied	ontvang	en	is	longitudinaal	vir	veiligheid	opgevolg;	31	kinders	het	slegs	deursnit	farmakokinetiese	inligting	na	‘n	enkeldosis	linezolied	verskaf.	Na	die	effek	van	gewig	met	behulp	van	‘n	allometriese	skaal	in	bereking	gebring	is,	het	geen	ander	medevariante	betekenisvol	tot	die	model	bygedra	nie.	Blootstellingsvlakke	was	hoër	as	wat	verwag	was	in	vergelyking	met	vorige	gerapporteerde	inligting.	Tien	van	17	deelnemers	het	‘n	linezolied-verwante	nadelige	effek	getoon,	wat	vyf	Graad	3	of	4	effekte	ingesluit	het;	anemie	was	die	mees	algemene	effek.	Hierdie	eerste	inligting	oor	linezolied-farmakokinetika	in	kinders	het	hoër	as	verwagte	blootstellingsvlakke	en	gereelde,	ernstige	linezolied-verwante	nadelige	effekte	aangetoon;	dit	sal	die	gebruik	en	toekomstige	doseringsaanbevelings	van	hierdie	toenemend-belangrike	antituberkulose	middel	toelig.	Terwyl	middelvervangings	vir	die	inspuitbare	middels	vir	baie	kinders	nog	nie	beskikbaar	is	nie,	is	dit	belangrik	om	die	verbeterde	verduring	van	die	voortgesette	gebruik	van	die	tweede-linie	inspuitbare	middels	in	kinders	aan	te	spreek.	‘n	Ewekansige	twee-periode	oorkruis-studie	is	ontwerp	om	die	effek	van	mede-toediening	van	lidokaïen	op	die	pyn	en	farmakokinetika	van	binnespierse	amikasien	te	bepaal.	Kinders	het	elk	‘n	dosis	van	amikasien	met	en	sonder	addisionele	lidokaïen	op	aparte	dae	ontvang	en	was	ewekansig	vir	die	volgorde	van	toediening	ingedeel;	pynevaluering	en	monsterneming	vir	farmakokinetika	is	op	beide	dae	uitgevoer.	Twaalf	kinders	is	ingesluit	en	almal	het	die	studie	voltooi.	Die	toevoeging	van	lidokaïen	het	die	pyn	onmiddelik	na	die	toediening	van	die	inspuiting	verlig,	was	veilig,	het	nie	die	farmakokinetika	van	amikasien	beïnvloed	nie	en	behoort	as	roetine	beleid	in	pasiënte	met	MMW-TB	wat	inspuitbare	middels	ontvang,	oorweeg	te	word.	
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Die	nuwe	middel	bedakwilien	word	toenemend	wêreldwyd	en	in	Suid-Afrika	vir	die	behandeling	van	volwassenes	mt	MMW-TB	gebruik	en	voortgesette	pediatriese	studies	sal	die	farmakokinetika,	veiligheid	en	optimale	dosering	in	kinders	toelig.	Die	pediatriese	formulering	wat	in	ten	minste	een	van	die	voortgesette	studies	evalueer	word,	sal	moontlik	nie	binnekort	vir	roetinegebruik	beskikbaar	wees	nie.	Om	die	rasionele	gebruik	van	die	volwasse	bedakwilienformulering	in	jong	kinders	toe	te	lig,	is	‘n	ewekansige	twee-periode	oorkruis-studie	in	gesonde	volwasse	vrywilligers	ontwerp.	Volwasse	bedakwilien-tablette	toegedien	opgelos	in	water	was	bioekwivalent	aan	volwasse	tablette	wat	heel	ingesluk	is.	Die	opgeloste	tablette	was	ook	aanvaarbaar	en	smaakaanvaarbaar	vir	die	meerderheid	van	die	deelnemers	wat	‘n	belangrike	bevinding	is	as	inaggeneem	word	dat	die	fyndruk	en	oplos	van	sommige	tablette,	soos	byvoorbeeld	die	fluorokwinolone,	die	smaak	en	aanvaarbaarheid	aansienlik	verminder.	Hierdie	inligting	sal	toegang	tot	bedakwilien	vir	jong	kinders	in	navorsing	en	in	algemene	sorg	bespoedig.	Ten	slotte	het	hierdie	doktorale	navorsing	‘n	aantal	belangrike	kennisleemtes	aangespreek	in	verband	met	die	meer	optimale	behandeling	van	MMW-TB	in	kinders.	Hierdie	navorsing	het	gelei	tot	‘n	aantal	opvolgvrae	wat	daaropvolgende	studies	toegelig	het	wat	op	hulle	beurt	die	weg	na	‘n	doelwit	van	effektiewe,	veilige,	korter	MMW-TB	behandeling	vir	alle	kinders	baan.		 	
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Chapter	1:	Introduction,	rationale	and	literature	review	
1.1	Epidemiology	of	multidrug-resistant	tuberculosis,	impact	on	children	and	
public	health	relevance	Multidrug-resistant	(MDR)	tuberculosis	(TB),	defined	as	TB	disease	or	infection	caused	by	Mycobacterium	tuberculosis	with	resistance	to	at	least	both	isoniazid	and	rifampicin,	is	a	growing	health	problem,	threatening	global	TB	control.	Rifampicin	monoresistant	(RMR)	TB	(i.e.;	M.	tuberculosis	with	rifampicin	resistance	but	isoniazid	susceptibility),	was	previously	unusual	but	is	now	being	identified	more	often	and	is	treated	with	the	same	drug	regimens	as	MDR-TB.		The	World	Health	Organization	(WHO)	estimates	that	in	2016	there	were	490,000	incident	cases	of	MDR-TB	globally,	with	an	additional	110,000	TB	cases	with	rifampicin	resistance	(without	documentation	of	isoniazid	susceptibility)	(1).		Of	these	600,000	estimated	incident	cases,	there	were	roughly	240,000	deaths	and	only	350,000	cases	were	notified	(i.e.	were	registered	and	treated)	(1).			MDR-TB	with	additional	resistance	to	either	a	second-line	injectable	drugs	or	a	fluoroquinolone	is	often	referred	to	as	pre-extensively	drug-resistant	(pre-XDR)-TB,	with	extensively	drug-resistant	(XDR)	TB	defined	as	MDR-TB	with	additional	resistance	to	both	a	fluoroquinolone	and	a	second-line	injectable	TB	drug.		XDR-TB	is	also	increasingly	diagnosed	worldwide,	with	6.7%	of	MDR-TB	cases	having	XDR-TB	and	20%	of	MDR-TB	isolates	tested	having	fluoroquinolone	resistance	in	2016	(1).		There	is	an	evolving	understanding	of	how	M.	tuberculosis	acquires	drug	resistance.		Drug	resistance	may	be	acquired,	primarily	through	true	or	functional	monotherapy	due	to	suboptimal	regimen	prescription	or	adherence	to	treatment,	differential	lesion	penetration	by	different	drugs,	or	pharmacokinetic	variability	that	selects	for	resistant	organisms	(2,	3).		Until	recently	it	was	believed	that	the	majority	of	patients	with	MDR-TB	had	acquired	their	resistance	during	therapy	for	one	of	these	reasons.		However,	patients	with	MDR-TB	may	also	transmit	their	resistant	strain	on	to	others,	including	children.		More	recent	analysis	has	demonstrated	that	globally,	transmission	of	drug-resistant	strains	of	M.	tuberculosis	likely	accounts	for	95.9%	of	MDR-TB	in	new	TB	cases	and	even	61.3%	of	MDR-TB	in	retreatment	cases	(4).		This	has	important	implications	for	children,	for	whom	the	risk	of	acquiring	drug	resistance	during	treatment	is	low	
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because	they	usually	have	a	low	burden	of	organisms	(paucibacillary	disease)(5),	but	who	are	susceptible	to	transmission	of	resistant	strains	(6).	The	burden	of	paediatric	MDR-TB	has	been	underestimated	and	poorly	characterized	to	date.		Until	recently	it	was	largely	believed	that	children	were	at	low	risk	for	MDR-TB,	in	part	due	to	the	inaccurate	previous	belief	that	MDR-TB	was	most	commonly	due	to	acquisition	of	resistance	during	inadequate	treatment,	rather	than	due	to	primary	transmission	of	MDR-TB	as	described	above.		The	underestimated	risk	of	MDR-TB	in	children	also	persisted	because	of	challenges	in	confirming	the	diagnosis	in	children,	due	to	the	paucibacillary	nature	of	TB	in	the	majority	of	paediatric	cases,	and	challenges	in	obtaining	respiratory	samples,	especially	in	young	children	(7,	8).	However,	recent	data	have	shown	that	children	have	a	similar	setting-specific	risk	of	MDR-TB	as	antituberculosis	treatment-naïve	adults	(9).		Modeling	studies	estimate	that	there	are	roughly	26,000-32,000	incident	MDR-TB	cases	in	children	(defined	by	the	WHO	as	<	15	years	of	age)	worldwide	each	year	(10,	11),	and	that	there	may	be	as	many	as	two	million	children	currently	infected	globally	with	MDR	strains	of	M.	tuberculosis	(11).		South	Africa	has	one	of	the	highest	burdens	of	MDR-TB	globally	(12),	including	a	substantial	paediatric	disease	burden,	with	13.2%	of	the	overall	national	burden	of	TB	in	South	Africa	occurring	in	children	<15	years	of	age	in	2016	(13).		In	enhanced	hospital-based	surveillance	at	Tygerberg	Hospital,	Western	Cape	Province,	South	Africa	from	2003-2013,	the	prevalence	of	MDR-TB	among	children	with	bacteriologically	confirmed	TB	ranged	from	5.4%	to	8.9%	(14).		Due	to	improved	implementation	of	prevention	of	mother	to	children	transmission	(PMTCT)	of	HIV,	the	HIV	prevalence	in	children	with	bacteriologically	confirmed	TB	has	declined	from	a	high	of	29%	during	2007-2009,	to	15.3%	between	2011-2013,	and	is	expected	to	continue	to	decrease	further	with	additional	improvements	to	PMTCT	programs	(14).			MDR-TB	will	remain	an	important	health	problem	in	children	in	South	Africa	and	globally	for	the	foreseeable	future.		
1.2		Treatment	of	MDR-TB	in	children:	evolving	approaches,	successes	and	
limitations	
1.2.1	A	landscape	of	rapidly	evolving	approaches	to	MDR-TB	treatment	
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Data	contributing	to	this	doctoral	research	was	collected	between	2012	and	2018,	a	time	when	new	evidence	and	policy	guidelines	for	MDR-TB	treatment	have	been	rapidly	evolving,	especially	for	adults.			Treatment	regimens	for	MDR-TB	in	adults	and	children	have	traditionally	been	constructed	using	the	“second-line	antituberculosis	drugs”.		Prior	to	2016,	the	WHO	categorized	antituberculosis	drugs	in	five	groups	(see	Table	1.1)	(15).		MDR-TB	treatment	regimens	during	this	period	were	recommended	to	include	pyrazinamide,	a	second-line	injectable	agent	from	Group	2,	a	fluoroquinolone	from	Group	3,	and	then	additional	drugs	from	Groups	4	and	5	to	create	a	treatment	regimen	with	at	least	4-5	effective	drugs	(15,	16).		WHO	guidelines	recommended	an	intensive	phase	duration	(i.e.	injectable-agent	duration)	of	at	least	8	months,	and	a	total	treatment	duration	of	at	least	20	months	(16).		Prior	to	2016,	there	was	limited	formal	guidance	on	treatment	regimens	for	children	with	MDR-TB.		However,	the	same	general	approach	to	constructing	a	regimen	was	taken.		One	exception	was	that	children,	who	frequently	had	paucibacillary	TB,	could	often	be	successfully	treated	with	shorter	durations	of	injectables	and	overall	treatment,	as	part	of	individualized	treatment	regimens	(see	2.1.2)	(17).			Many	of	the	studies	contributing	to	this	doctoral	work	were	conceived	and	implemented	during	the	time	these	approaches	guided	MDR-TB	treatment.	WHO	MDR-TB	treatment	guidelines	were	revised	in	2016	and	a	number	of	important	changes	were	made	to	global	MDR-TB	recommendations	(18):		antituberculosis	drug	groupings	were	altered	to	reflect	emerging	data	(Table	1.2),	with	the	fluoroquinolones	recognized	as	the	key	drugs	for	MDR-TB	treatment,		stronger	roles	were	identified	for	the	repurposed	drugs	linezolid	and	clofazimine,	and	recommendations	were	made	regarding	the	inclusion	of	the	novel	TB	drugs	bedaquiline	and	delamanid	under	specific	conditions	(18)	
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Table	1.1	World	Health	Organization	antituberculosis	drug	groupings	prior	to	2016	
Group	 Group	Name	 Drugs	1	 First-line	oral	agents	 Isoniazid	Rifampicin	Ethambutol	Pyrazinamide	Rifabutin	Rifapentine	2	 Injectable	agents	 Kanamycin	Amikacin	Capreomycin	Streptomycin	3	 Fluoroquinolones	 Moxifloxacin	Levofloxacin	Ofloxacin	4	 Oral	bacteriostatic	second-line	agents	 Ethionamide	Prothionamide	Cycloserine	Terizidone	Para-aminosalicylic	acid	5	 Agents	with	unclear	efficacy	or	concerns	regarding	usage	 Clofazimine	Linezolid	Amoxicillin-clavulanic	acid	Thiacetazone	Meropenem-clavulanic	acid	Imipenem/cilastatin	High-dose	isoniazid	Clarithromycin	
Table	1.2.	Revised	WHO	groupings	of	medicines	for	the	treatment	of	rifampicin-resistant	
and	multidrug-resistant	tuberculosis	(2016)	
Group	A.		Fluoroquinolones	 Levofloxacin	Moxifloxacin	Gatifloxacin	
Group	B.		Second-line	injectable	agents	 Amikacin	Capreomycin	Kanamycin	(Streptomycin)	
Group	C.		Other	core	second-line	agents	 Ethionamide/prothionamide	Cycloserine/terizidone	Linezolid	Clofazimine	
Group	D.		Add-on	agents	 D1	 Pyrazinamide	Ethambutol	High-dose	isoniazid	
D2	 Bedaquiline	Delamanid	
D3	 Para-aminosalicylic	acid	(PAS)	Imipenem-cilastin	Meropenem	Amoxicillin-clavulanate	(Thioacetazone)	
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	Most	significantly,	these	guidelines	have	recommended	a	shortened	(9-12	month)	treatment	regimen	for	patients,	including	for	children,	with	pulmonary	RMR-TB	and	MDR-TB	who	did	not	have	evidence	of	fluoroquinolone	or	second-line	injectable	resistance	and	previous	exposure	to	second-line	drugs.		The	new	shorter	regimen	included	4-6	months	of	kanamycin,	moxifloxacin,	prothionamide,	clofazimine,	pyrazinamide,	high-dose	isoniazid,	and	ethambutol,	followed	by	5	months	of	moxifloxacin,	clofazimine,	pyrazinamide,	and	ethambutol	(18).		This	recommendation	was	based	on	multiple	high	quality	observational	studies	in	adults	with	MDR-TB	that	consistently	demonstrated	cure	in	80%	(19-21),	and	is	now	further	supported	by	preliminary	results	from	a	randomized	controlled	trial	(STREAM	1,	NCT02409290)	of	this	regimen	in	adults	(22).	Children	and	adults	not	eligible	to	receive	this	9-12	month	shortened	regimen	were	recommended	to	be	treated	with	a	more	conventional	approach	for	20-24	months	duration	with	at	least	five	effective	drugs,	including	pyrazinamide,	a	drug	from	Group	A,	a	drug	from	Group	B,	and	2	drugs	from	Group	C.		If	a	regimen	with	five	effective	drugs	cannot	be	constructed,	then	drugs	from	D2	and	D3	should	be	added	based	on	these	guidelines.	The	revised	2016	WHO	MDR-TB	treatment	guidelines	have	for	the	first	time	included	some	specific	paediatric	recommendations.		In	addition	to	recommending	the	new	9-12	month	shortened	regimen	and	the	more	conventional	approach	described	above,	the	new	guidelines	allow	that	children	with	clinically	diagnosed	MDR-TB	(i.e.	MDR-TB	that	is	not	microbiologically	confirmed,	and	diagnosed	based	on	signs,	symptoms,	radiography	and	exposure	to	MDR-TB,	which	usually	reflects	less	severe	clinical	spectrum	of	disease),	could	be	treated	without	an	injectable	drug	in	the	standard	(i.e.	not	shortened)	regimen,	usually	for	15-18	months	(see	supportive	data	for	this	recommendation	in	1.2.2)	(18).		These	important	changes	reflect	data	from	ongoing	and	emerging	paediatric	data,	including	individual	studies	and	a	global	evidence	synthesis	(23),	some	generated	during	this	doctoral	research.		In	addition	to	the	new	WHO	MDR-TB	treatment	recommendations	made	in	2016,	the	development	and	increasing	use	of	the	novel	TB	drugs	bedaquiline	and	delamanid	is	radically	altering	the	MDR-TB	treatment	landscape.	Bedaquiline	is	a	diarylquinoline	that	inhibits	mycobacterial	ATP-synthase,	resulting	in	potent	activity	against	M.	
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tuberculosis	in	vitro	(24)	and	in	mice,	with	the	potential	to	shorten	treatment	substantially	(25-27). The	U.S.	Food	and	Drug	Administration	(FDA)	granted	accelerated	approval	for	bedaquiline	in	2012	for	MDR-TB	treatment	in	adults,	and	the	WHO	issued	recommendations	for	its	use	(28),	based	on	phase	2	studies	in	adults	with	MDR-TB	showing	significantly	improved	culture	conversion	(29)	and	treatment	outcome	at	120	weeks	(30).		Delamanid	is	a	nitro-dihydro-imidazooxazole	antibiotic	that	blocks	M.	tuberculosis	mycolic	acid	synthesis	(31),	resulting	in	potent	antimycobacterial	activity	in	vitro	and	treatment	shortening	potential	in	mice	(31).	Delamanid	was	granted	conditional	registration	from	the	European	Medicine	Authority	(EMA)	in	2013	for	MDR-TB	treatment	(32),	and	WHO	issued	guidance	for	its	use	in	adults	with	limited	treatment	options	(33),	based	on	a	Phase	2	trial	showing	delamanid	in	combination	with	an	optimized	background	regimen	(OBR)	in	adults	with	MDR-TB,	resulted	in	improved	2-month	culture	conversion	(34)	and	24-month	treatment	outcomes	(35).		Although	both	drugs	are	likely	to	be	critical	for	future	MDR-TB	treatment	regimens	in	adults	and	children	(see	Section	1.5.1),	paediatric	trials	of	both	drugs	have	been	delayed	and	few	children	have	accessed	these	medications	to	date	in	routine	care.	
1.2.2	Successes	of	current	MDR-TB	treatment	regimens	in	children:	markedly	better	
treatment	outcomes	compared	to	adults		Treatment	outcomes	for	adults	with	MDR-TB	have	been	persistently	poor	(12),	with		54%	reported	successfully	treated	in	2014	both	overall	globally	and	in	South	Africa	from	routine	programmatic	data	(1).	This	is	also	consistent	with	data	from	the	metropolitan	Cape	Town	area.		Among	adults	with	MDR-TB	treated	in	the	Khayelitsha	sub-district	from	2008-2012,	only	359	of	757	(47.4%)	were	successfully	treated	(i.e.	cured	or	treatment	completed)	(36).		A	systematic	review	and	individual	patient	data	meta-analysis	of	observational	or	experimental	studies	of	adults	treated	for	MDR-TB	reported	61%	of	12,030	patients	had	successful	outcomes	(37).		In	contrast,	treatment	outcomes	among	children	with	MDR-TB	are	generally	good.		In	a	2012	systematic	review	including	eight	studies,	82%	of	315	children	treated	for	MDR-TB	had	a	successful	outcome	(defined	as	a	composite	outcome	of	bacteriological	cure	or	treatment	completed)	(38).		In	a	recently	completed	large	systematic	review	and	individual	patient	data	meta-analysis	including	975	children	from	18	countries	treated	
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for	probable	or	confirmed	MDR-TB,	78%	were	successfully	treated	(23)	according	to	WHO	outcome	definitions	(39).		Better	outcomes,	with	>90%	successfully	treated	(cured	or	treatment	completed)	have	been	reported	in	some	observational	studies	in	the	context	of	routine	care	(17).		All	these	data	include	children	treated	with	traditional	regimens	prior	to	those	recommended	in	2016,	including	the	use	of	older	fluoroquinolones	including	ofloxacin	in	the	majority	of	cases.		There	is	limited	data	on	treatment	outcomes	among	children	treated	with	the	WHO-	shortened	9-12	month	regimen	recommended	in	2016	several	years	after	data	collection	for	this	doctoral	thesis	work	was	started.		This	policy	recommendation	was	based	on	adult	data	(see	Section	1.2.1),	and	only	a	small	observational	cohort	from	West	Africa	including	47	children	<18	years	of	age	with	MDR-TB	treated	with	the	shortened	regimen,	which	reported	successful	outcomes	in	83%	(40).		The	good	outcomes	among	children	treated	with	more	traditional	and	shortened	regimens	highlights	the	potential	for	children	to	benefit	from	effective	but	shorter	and	safer	MDR-TB	regimens,	especially	given	the	paucibacillary	nature	of	the	majority	of	TB	and	MDR-TB	cases	in	children.	
1.2.3		Limitations	of	current	MDR-TB	treatment	regimens	in	children:	regimens	are	long,	
toxic	and	poorly	tolerated	Despite	the	good	treatment	outcomes	described	above,	current	paediatric	MDR-TB	treatment	regimens	have	important	limitations.			Even	considering	the	newly	recommended	shortened	regimen	of	9-12	months,	current	regimens	remain	long,	and	some	children	will	still	require	the	more	typical	duration	of	15-18	months	or	more.		This	is	costly	and	burdensome	for	children,	their	caregivers	and	the	health	system,	and	is	a	challenge	for	adherence.			Secondly,	the	second-line	antituberculosis	medications	are	often	poorly	tolerated	and	associated	with	frequent	and	severe	adverse	effects.		Although	mostly	mild,	adverse	events	such	as	rash	and	vomiting	are	frequent,	occurring	in	24%	and	18%	of	children	treated	for	MDR-TB,	respectively;	other	events	such	as	pain,	lethargy,	headache,	sleep	disturbance,	and	reduced	appetite	are	also	common	(17).		Abnormal	thyroid	function	tests	have	been	documented	in	up	to	54%	of	children	treated	with	ethionamide	or	para-aminosalicylic	acid,	with	23%	requiring	levothyroxine	supplementation	(17,	41);	
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untreated,	this	hypothyroidism	may	have	effects	on	neurodevelopment,	particularly	in	young	children.		Additionally,	the	use	of	multiple	hepatotoxic	drugs	raises	the	risk	of	liver	injury	during	treatment,	although	this	risk	has	not	been	well	characterized.		Additionally,	the	lack	of	child-friendly	formulations	of	almost	all	second-line	antituberculosis	drugs	means	that	adult	tablets	must	often	be	crushed	or	split	for	administration	in	young	children	who	cannot	swallow	these	tablets	whole.		Although	not	well	characterized,	this	formulation	manipulation	often	reduces	the	palatability	and	acceptability	of	these	medications	further	(42).	Acceptability	is	the	overall	suitability	of	a	dosage	formulation,	including	factors	such	as	palatability,	dose	volume	or	size,	dosing	frequency,	dosing	device	for	liquid	medications,	and	directions	for	use	(43).		Palatability	is	defined	as	the	overall	acceptance	of	the	taste,	smell,	volume	or	size,	and	texture	of	a	medication	to	be	taken	orally	(43),	and	is	a	particularly	important	determinant	of	medication	acceptability	in	children.			The	most	troubling	adverse	effects	are	related	to	the	second-line	injectable	medications	(amikacin,	kanamycin,	capreomycin).		These	medications	accumulate	in	cochlear	hair	cells,	eventually	resulting	in	cell	death	and	permanent	sensorineural	hearing	loss	that	progresses	from	higher	to	lower	frequencies	as	the	damage	increases	(44).		Long-term	treatment	(i.e.	for	4-6	months	duration)	with	these	injectable	drugs	has	been	reported	to	cause	hearing	loss	in	up	to	24%	of	children	(45).		Although	disastrous	at	any	age,	hearing	loss	is	particularly	devastating	in	young	children,	resulting	in	long-term	developmental	and	functional	challenges.		Additionally,	in	most	high	MDR-TB	burden	settings,	the	injectables	are	mainly	given	by	painful	daily	intramuscular	injections,	resulting	in	trauma	and	distress	for	patients,	their	caregivers	and	healthcare	providers.		This	also	contributes	to	the	need	for	long-term	hospitalization	of	children	with	MDR-TB	in	many	settings,	which	may	interrupt	education,	and	peer	and	family	bonds	in	older	children,	and	may	affect	attachment	in	younger	children.			Although	the	newly	WHO	recommended	9-12	month	shortened	regimen	has	the	advantage	over	conventional	regimens	of	a	reduced	treatment	duration,	safety	and	tolerability	continue	to	be	concerns,	with	limited	available	data	in	this	regard.		In	the	only	cohort	reported	to	date	of	children	with	MDR-TB	receiving	the	9-12	month	shortened	regimen,	75%	experienced	at	least	one	adverse	event,	including	41%	with	some	degree	of	hearing	loss	(40).		These	data	highlight	the	persistent	challenges	
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remaining	for	children;	even	with	this	newly	recommended	shortened	regimen,	an	injectable	drug	continues	to	be	required,	with	its	associated	pain	and	unacceptable	risk	of	permanent	hearing	loss,	adverse	events	remain	frequent,	and	the	duration	(minimum	of	9	months)	is	still	long.		This	is	ironic,	given	the	excellent	treatment	outcomes	and	low	bacillary	burden	in	most	children	with	MDR-TB,	in	whom	less	aggressive	shorter	regimens	are	likely	to	be	highly	successful.		Therefore,	as	treatment	outcomes	with	previously	and	currently	recommended	MDR-TB	regimens	are	good,	and	dramatically	better	than	reported	in	adults,	it	is	an	urgent	priority	to	develop	more	optimal	treatment	regimens	for	children	with	MDR-TB	that	retain	their	efficacy	but	are	shorter,	more	child-friendly,	better	tolerated,	safer	and	which	do	not	require	the	use	of	an	injectable	medication.			
1.3		Overall	approach	to	improving	MDR-TB	treatment	in	children	The	following	three-pronged	approach	will	inform	the	development	of	efficacious,	but	shorter,	more	child-friendly,	better	tolerated,	safer	and	injectable-sparing	treatment	regimens	for	children	with	MDR-TB.		
1)	Optimize	the	use	of	existing	second-line	antituberculosis	treatments:		This	aspect	has	formed	the	majority	of	this	doctoral	work,	given	the	paucity	of	data	in	this	regard,	and	is	discussed	in	detail	in	Section	1.4.	
2)	Study	currently	available	novel	TB	drugs	in	children	to	inform	their	effective,	safe	and	
acceptable	paediatric	use:		Paediatric	phase	1/2	for-registration	trials	to	establish	the	dose	and	safety	of	both	bedaquiline	and	delamanid	have	been	in	planning	or	implementation	during	the	course	of	this	doctoral	work,	but	were	beyond	its	scope.		However	some	aspects	of	the	paediatric	use	of	these	new	medications,	such	as	the	impact	of	formulation	manipulation	(i.e.	crushing	or	splitting	tablets),	have	not	traditionally	been	studied	in	such	trials	but	could	inform	the	practical	use	of	these	drugs	in	the	field	(see	1.4.3).	
3)	Combine	existing	and	novel	antituberculosis	drugs	into	shorter,	safer,	injectable-
sparing	regimens:		Once	the	optimal	dosing	and	safety	of	existing	second-line	and	novel	antituberculosis	drugs	have	been	established,	these	drugs	must	be	combined	into	short,	all-oral	regimens,	and	the	efficacy,	safety	and	acceptability	of	these	regimens	
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established.		Such	research	is	beyond	the	scope	of	this	doctoral	work,	but	is	being	informed	by	data	emerging	from	this	doctoral	research.		
1.4		Approach	to	optimizing	the	use	of	existing	second-line	antituberculosis	
treatments	Because	of	differences	in	the	pathophysiology	of	TB	in	children,	especially	regarding	the	disease	spectrum	and	paucibacillary	nature	of	the	majority	of	paediatric	TB,	and	the	difficulties	in	obtaining	sputum	specimens	in	young	children	(7,	8),	the	evaluation	of	the	efficacy	of	antituberculosis	drugs	or	regimens,	which	has	generally	relied	on	microbiologic	endpoints,	is	more	challenging	in	children	than	in	adults.		Additionally,	repeating	efficacy	studies	of	individual	antituberculosis	drugs	in	children	is	unnecessary.		There	is	clear	international	consensus,	including	from	regulatory	authorities,	that	efficacy	can	be	extrapolated	to	children	from	adult	studies,	as	it	is	reasonable	to	assume	that	antituberculosis	agents	shown	to	be	efficacious	in	adults	will	be	at	least	as	efficacious	in	children,	as	long	as	drug	exposures	are	similar	in	children	(46,	47).		Key	priorities	therefore	for	evaluating	and	optimizing	the	use	of	antituberculosis	drugs	in	children,	are	establishing	the	doses	in	representative	ages	that	result	in	exposures	similar	to	those	in	adults	receiving	doses	shown	to	be	efficacious,	and	rigorously	evaluating	safety	and	tolerability	in	children	at	those	doses	(48).		Development	of	appropriate	child-friendly	formulations,	especially	relevant	to	younger	children,	is	also	a	priority.	Prior	to	this	research,	the	pharmacokinetics,	safety	and	tolerability	of	most	of	the	second-line	antituberculosis	drugs	in	children	had	been	poorly	characterized	and	the	evidence	base	for	their	optimal	use	in	current	or	new	treatment	regimens	was	limited.			
1.4.1		Pharmacokinetics	and	optimal	doses	of	second-line	antituberculosis	drugs	in	
children	Doses	of	the	second-line	antituberculosis	medications	in	children	that	achieve	adult	target	concentrations	were	not	established	(42),	with	most	of	these	drugs	being	used	off-label	in	children,	with	mg/kg	doses	extrapolated	from	adult	data.		This	approach	does	not	take	into	account	the	known	effects	of	body	size	and	age	on	pharmacokinetics	(developmental	pharmacology).		Allometry,	the	study	of	how	biological	processes,	
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volumes	and	body	parts	scale	with	body	size,	can	help	describe	the	effect	of	body	size	on	pharmacokinetics	(49).		Drug	clearance,	a	key	determinant	of	total	drug	exposure,	scales	with	weight	at	a	less	than	proportional	rate,	meaning	that	the	same	mg/kg	dose	will	result	in	underexposure	of	drugs	in	children	relative	to	adults,	that	is	worse	in	small	children	(50).		The	relationship	of	clearance,	and	other	key	primary	pharmacokinetic	parameters,	with	body	size	can	be	accounted	for	mathematically	with	allometric	scaling	in	population	pharmacokinetic	modeling	that	utilizes	non-linear	mixed	effects	(NLME)	modeling	techniques	(50).		The	pharmacokinetics	of	drugs	are	also	affected	by	the	development	and	maturation	of	many	physiologic	processes,	including	changes	in	gut	structure	and	function,	metabolic	capacity	(enzyme	function),	renal	function	and	body	volumes	(51).		Maturation	of	these	processes	can	affect	drug	absorption,	distribution,	metabolism	and	elimination.		The	development	and	maturation	of	these	processes	depend	on	post-gestational	age	and	post-natal	age,	and	vary	from	process	to	process	in	how	rapidly	they	develop.		There	is	often	rapid	development	in	the	first	days	and	weeks	of	life,	and	then	more	slow	maturation	thereafter.		This	has	the	greatest	impact	on	pharmacokinetics	during	the	first	6	months	of	life,	and	by	2-3	years	of	age,	most	relevant	processes	have	matured	to	near	adult	levels	(51,	52).		The	effect	of	age	can	be	difficult	to	reliably	predict	and	must	be	evaluated	in	young	children,	and	for	each	relevant	drug.		It	is	therefore	important	to	include	a	substantial	number	of	young	children,	if	possible	of	different	racial	and	genetic	origins,	in	studies	of	antituberculosis	drug	pharmacokinetics	in	order	to	characterize	this	maturation	and	inform	dosing	across	the	age	spectrum.	Ensuring	that	paediatric	doses	of	the	existing	second-line	antituberculosis	drugs	are	used	that	achieve	target	exposures	will	ensure	that	these	agents	are	being	utilized	more	optimally.		This	will	help	maximize	their	efficacy	and	thus	potentially	allow	for	treatment	regimens	in	children	that	are	shorter	or	that	use	fewer	agents	(i.e.	could	allow	treatment	without	injectable	drugs).	
1.4.2	Safety	and	tolerability	of	existing	second-line	antituberculosis	drugs	in	children	Knowledge	of	the	safety	profile	of	key	second-line	antituberculosis	drugs	at	optimal	doses,	will	be	critical	to	inform	the	optimal	use	of	existing	drugs	in	current	regimens	and	in	combination	with	new	and	repurposed	drugs	in	novel	regimens.			
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The	safety	of	medications	in	children	can	be	informed	by	juvenile	animal	studies	and	adult	trials.		However	this	cannot	be	assumed	and	must	be	evaluated	carefully	in	paediatric	studies	that	include	children	across	the	age	spectrum	and	of	different	racial	and	genetic	origins.		Children	may	have	fewer	or	less	severe	adverse	effects	compared	to	animal	studies	or	adult	trials,	which	may	result	in	potentially	beneficial	medications	not	being	used	in	children	(53,	54).		An	example	is	the	fluoroquinolones	in	which	juvenile	animal	studies	showed	a	frequent	severe	arthropathy	which	has	not	been	seen	in	children	with	short-term	fluoroquinolone	use	(55).		Children	may	also	have	more	severe	or	unexpected	adverse	effects.		Chloramphenicol,	which	was	used	widely	in	adults	without	serious	concerns,	caused	“grey	baby	syndrome”	in	young	infants	due	to	immature	metabolic	pathways	(56).		The	safety	profile	of	current	MDR-TB	regimens	in	children	has	not	been	well	characterized	for	key	second-line	drugs,	such	as	the	fluoroquinolones	and	linezolid	(see	Sections	1.5.2,	1.5.3).		Safety	evaluations	of	existing	second-line	antituberculosis	drugs	should	also	proactively	consider	overlapping	toxicities	with	the	novel	medications	bedaquiline	and	delamanid,	as	this	will	inform	optimal	regimen	design.		The	key	adverse	effect	of	both	bedaquiline	and	delamanid	in	adults	is	QT-interval	prolongation	(33,	57).		Additional	considerations	are	the	study	of	these	drugs	in	HIV-infected	children	in	combination	with	appropriate	antiretroviral	therapy	(ART)	regimens.	Whereas	the	safety	of	a	medication	refers	to	the	medical	risk	it	poses	to	a	patient,	a	medication’s	tolerability	is	the	degree	to	which	its	adverse	effects	can	be	tolerated	by	a	patient	(58).		The	least	well	tolerated	second-line	antituberculosis	drugs	are	the	injectables.		In	addition	to	their	serious	safety	concerns,	the	need	for	these	medications	to	be	given	by	daily,	painful	injections	is	a	serious	problem	for	their	tolerability,	and	contributes	to	serious	distress	in	MDR-TB	patients.		These	injections	are	frequently	cited	as	one	of	the	worst	aspects	of	current	MDR-TB	treatment	and	likely	contribute	to	the	high	proportion	of	MDR-TB	regimens	not	completed	(59).		Ulimately,	the	goal	is	to	develop	regimens	which	do	not	include	the	injectables,	but	in	the	meantime,	strategies	to	improve	the	injectables’	tolerability	could	substantially	improve	current	regimens.	Understanding	the	appropriate,	safe	and	tolerable	use	of	the	existing	second-line	antituberculosis	drugs	is	a	priority	for	improving	MDR-TB	treatment	regimens		in	children.			
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1.4.3	Formulation	considerations	for	existing	second-line	antituberculosis	drugs	in	
children	The	impact	of	drug	formulation	on	the	pharmacokinetics	and	tolerability	of	medications	in	children	is	increasingly	being	recognized	(60,	61).		There	have	been	few	if	any	widely	available	child-friendly	formulations	of	the	second-line	TB	medications	(62),	and	the	routine	practice	of	manipulating	adult	formulations	by	crushing	or	splitting	tablets	can	affect	drug	exposures,	with	the	magnitude	and	the	direction	of	these	effects	difficult	to	predict	(60).		Formulation	manipulation	may	result	in	reduced	drug	exposures,	as	has	been	seen	with	rifapentine	in	children	(63),	potentially	increasing	the	risk	of	poor	treatment	response	and	theoretically	the	acquisition	of	additional	resistance,	or	may	increase	drug	exposures	with	a	higher	potential	risk	of	adverse	effects.		Work	is	ongoing	to	develop	child-friendly	dispersible	tablet	formulations	of	the	existing	second-line	and	novel	TB	drugs.	However	there	are	many	challenges	with	making	these	formulations	available	in	the	field,	including	financial,	technical,	market	and	regulatory	barriers	(62,	64).		To	improve	MDR-TB	treatment	in	children,	a	pragmatic	approach	to	formulation	development	is	needed,	which	in	parallel	seeks	data	on	the	optimal	dosing	of	new	child-friendly	formulations	in	children	and	characterizes	the	effects	of	formulation	manipulation	where	child-friendly	formulations	are	unlikely	to	be	readily	available.	
1.4.4		Summary		Addressing	critical	gaps	in	our	current	understanding	of	the	pharmacokinetics,	safety	and	tolerability	of	key	second-line	and	novel	TB	drugs	has	the	potential	to	substantially	improve	MDR-TB	treatment	strategies	in	children	in	the	immediate	future.		Understanding	the	effects	of	formulation	and	formulation	manipulation	effects	on	drug	pharmacokinetics	in	children	is	important	for	the	effective	and	safe	use	of	antituberculosis	drugs	and	regimens	in	children.		Improved	knowledge	in	these	areas	will	help	optimize	existing	treatment	regimens	that	utilize	currently	available	medications.		It	will	also	inform	future	paediatric	treatment	of	MDR-TB,	by	positioning	children	to	be	able	to	access	novel,	shorter	and	safer	regimens	currently	being	evaluated	and	even	recommended	in	some	adult	populations	in	the	rapidly	evolving	global	MDR-TB	treatment	landscape.				
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1.5	Key	existing	and	novel	second-line	antituberculosis	drugs:		the	
fluoroquinolones,	linezolid,	the	second-line	injectables	and	bedaquiline	
1.5.1		Priority	second-line	and	novel	antituberculosis	drugs	In	order	to	address	critical	knowledge	gaps	for	MDR-TB	treatment	with	high	potential	impact	on	MDR-TB	management,	this	PhD	work	has	focused	on	the	pharmacokinetics,	dosing,	safety	and	tolerability	of	key	existing	and	novel	antituberculosis	medications.		High	priority	medications	were	considered	to	be	those	that:	1)	were	critically	important	to	current	regimens	from	an	efficacy,	safety	or	tolerability	perspective;	2)	and/or	were	likely	to	be	important	in	future	treatment	regimens	(see	Table	1.3	for	list	of	ongoing	or	planned	trials	of	MDR-TB	treatment	or	prevention	in	adults	or	children);	3)	and	for	which	persistent	important	knowledge	gaps	had	remained.		Of	the	existing	second-line	antituberculosis	drugs,	the	fluoroquinolones,	linezolid,	the	second-line	injectables	and	bedaquiline	were	identified	as	priority	agents	for	this	doctoral	work	for	which	new	data	had	high	potential	to	improve	the	efficacy,	safety	or	tolerability	of	MDR-TB	treatment	in	children.	Research	on	delamanid	was	also	considered	a	high	priority,	but	was	collaboratively	pursued	beyond	the	scope	of	this	body	of	doctoral	research.	Pretomanid,	being	very	behind	in	its	paediatric	evaluation,	was	not	considered	an	immediate	priority.			
Table	1.3.		Planned	or	ongoing	Phase	2	or	3	trials	of	MDR-TB	treatment	or	preventive	
therapy	
MDR-TB	Treatment	trials	 MDR-TB	Preventive	therapy	trials	
Trial	
Components	of	intervention	
arm	 Trial	 Components	of	intervention	arm	NC005	 PZA,	BDQ,	PTA	 VQUIN	 LFX	Opti-Q	 LFX	+	standard	of	care	 TB-CHAMP	 LFX	STREAM	II	 BDQ,	CFZ,	EMB,	PZA,	LFX,	INH,	PTO	 PHOENIx	 DLM	NIX-TB	 LZD,	BDQ,	PTA	 	 	STAND	 PZA,	MFX,	PTA	 	 	NEXT-TB	 PZA,	LFX,	ETO/hdINH,	LZD,	BDQ	 	 	C208	 BDQ	+	standard	of	care	 	 	Trial	213	 DLM	+	standard	of	care	 	 	endTB	 Combinations	including	LZD,	
BDQ,	CFZ	 	 	PZA-pyrazinamide;	BDQ-bedaquiline;	PTA-pretomanid;	LFX-levofloxacin;	EMB-ethambutol;	MFX-moxifloxacin;	PTO-prothionamide;	CFZ-clofazimine;	hdINH-high	dose	isoniazid;	LZD-linezolid;	ETO-ethionamide;	DLM-delamanid;	BOLD	indicates	drugs	included	in	this	doctoral	research.	
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1.5.2	The	fluoroquinolones	for	treatment	of	MDR-TB	in	children	The	fluoroquinolones	inhibit	the	action	of	bacterial	DNA	gyrase,	resulting	in	disruption	of	DNA	synthesis	and	subsequent	cell	death	(65).		In	addition	to	broad-spectrum	activity	against	both	Gram-negative	and	-positive	organisms,	the	fluoroquinolones	have	potent	anti-mycobacterial	activity.		The	fluoroquinolones	most	commonly	used	for	TB	treatment	to	date	have	been	ofloxacin,	levofloxacin	and	moxifloxacin	(66).		Ofloxacin	was	one	of	the	first	quinolones	used	for	treatment	of	MDR-TB	and	because	of	its	low	cost	and	widespread	availability	became	the	fluoroquinolone	of	choice	for	TB	treatment	until	recently.		Levofloxacin,	the	l-isomer	and	the	active	component	of	the	ofloxacin	racemate	(67),	has	approximately	twice	the	activity	of	ofloxacin,	and	since	2012-2013	has	been	recommended	over	ofloxacin	for	MDR-TB	treatment	globally.		Moxifloxacin	is	the	most	potent	of	the	three	fluoroquinolones	against	M.	tuberculosis,	and	has	been	the	fluoroquinolone	of	choice	for	MDR-TB	treatment.		However	there	have	been	important	barriers	to	its	use	in	children,	including	limited	paediatric	pharmacokinetic	data	(68),	lack	of	a	child-friendly	formulation	(only	400	mg	unscored	tablets	available	in	most	settings),	and	very	poor	palatability	especially	when	crushed	(66).		Therefore	moxifloxacin	has	been	used	much	less	in	children.		Ofloxacin	(200	mg	and	400	mg	tablets)	and	now	levofloxacin	formulations	(250	mg	tablets),	although	imperfect,	are	in	strengths	that	allow	reasonably	accurate	dosing	in	children	and	are	less	bitter	than	moxifloxacin,	and	have	been	the	fluoroquinolones	of	choice	for	children	(66),	with	good	treatment	outcomes	documented	in	children	(23).	The	fluoroquinolones	are	the	most	important	component	of	current	MDR-TB	regimens	(16,	69,	70).		The	early	bactericidal	activity	(EBA)	of	levofloxacin	(1000	mg)	and	moxifloxacin	(400	mg),	defined	as	the	fall	in	colony	forming	units	per	mL	of	sputum	from	days	0	to	2	of	treatment	(71),	were	0.45	and	0.33	respectively,	approaching	that	of	300	mg	of	isoniazid	(0.67)	(72).		They	are	therefore	critical	for	rapidly	reducing	the	load	of	metabolically	active	mycobacteria	early	in	treatment	and	for	preventing	acquisition	of	resistance	to	companion	drugs.		In	addition	to	their	role	in	current	regimens,	the	fluoroquinolones	are	being	evaluated	as	components	of	multiple	novel	regimens	for	MDR-TB	treatment	(Table	1.3)	(73-75).		Recent	data	has	also	shown	that	levofloxacin	had	comparable	activity	to	isoniazid	in	a	mouse	model	of	latent	infection	with	M.	
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tuberculosis	(73),	and	appeared	effective	in	high	quality	observational	studies	of	MDR-exposed	children	and	adults	(76,	77).		Two	randomized	controlled	trials	comparing	levofloxacin	versus	placebo	for	the	prevention	of	TB	in	in	high-risk	children	(TB-CHAMP,	South	Africa, ISRCTN92634082)	and	adults	(VQUIN,	Vietnam,	ACTRN12616000215426)	exposed	to	MDR-TB	were	in	development	during	the	period	during	which	this	PhD	research	was	undertaken,	and	both	have	now	opened	and	are	enroling	(Table	1.3).			The	pharmacokinetics	and	safety	of	ofloxacin	and	levofloxacin	have	been	poorly	described	in	children	with	TB.		The	fluoroquinolones	are	well	absorbed	with	oral	bioavailability	of	85-95%	for	ofloxacin	and	>99%	for	levofloxacin;	neither	medication	has	significant	food	affects	and	both	are	primarily	eliminated	unchanged	in	the	urine	(66).		Clinically	significant	drug-drug	interactions	between	ofloxacin	or	levofloxacin	and	antiretrovirals	or	other	antituberculosis	drugs	have	not	been	described	and	are	not	expected	(66)	.	The	fluoroquinolones	are	concentration-dependent	antibiotics	with	the	area	under	the	concentration	time	curve	(AUC)	to	minimum	inhibitory	concentration	(MIC)	ratio	most	closely	tied	to	efficacy	(78);	exposures	in	children	should	be	targeted	to	approximate	the	AUC	in	adults	receiving	the	recommended,	efficacious	dose	(79-81).		Prior	to	this	PhD	research,	there	was	a	single	study	of	ofloxacin	pharmacokinetics	in	children	with	typhoid	fever	(82),	and	limited	published	data	on	levofloxacin	paediatric	pharmacokinetics	(83,	84).		In	previous	work,	we	described	a	small	cohort	of	23	children	receiving	levofloxacin	(15	mg/kg	daily)	or	ofloxacin	(20	mg/kg	daily)	for	MDR-TB	treatment	or	preventive	therapy,	and	documented	exposures	of	both	drugs	that	were	low	relative	to	adult	target	values.		However	this	study	was	small,	had	a	limited	ability	to	explore	the	impact	of	key	covariates,	such	as	age	and	HIV	infection,	on	pharmacokinetics	of	the	fluoroquinolones	(85),	and	primarily	used	non-compartmental	analysis	(NCA).		Data	on	levofloxacin	pharmacokinetics	in	50	children	treated	for	MDR-TB	exposure	or	disease	in	the	Federated	States	of	Micronesia	and	the	Republic	of	the	Marshall	Islands	suggested	a	dose	of	15-20	mg/kg	once	daily	would	be	appropriate,	but	few	young	children	and	no	HIV-infected	children	were	included	(86).	Although	the	fluoroquinolones	are	generally	well	tolerated,	they	are	known	to	cause	a	variety	of	adverse	effects.		Mild	gastrointestinal	effects	such	as	nausea,	vomiting,	diarrhoea	are	the	most	common	events	described	in	clinical	trials	(66).		A	variety	of	
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central	nervous	system	effects	have	been	described	with	the	fluoroquinolones,	including	dizziness,	headaches,	confusion,	psychosis,	and	seizures	(66).		Sleep	disturbance,	insomnia	and	hallucinations	(with	overdose),	have	been	well	documented	in	children	receiving	fluoroquinolones	(77,	87,	88).		QT	prolongation	is	also	a	classwide	effect	of	the	fluoroquinolones,	mediated	by	dose-dependent	inhibition	of	cardiac	potassium	rectifier	(HERG)	channels	(89).		Moxifloxacin	has	the	largest	QT	prolonging	effect	(89,	90),	while	even	at	doses	as	high	as	1500	mg	in	adults,	levofloxacin	results	in	minimal	clinically	important	QT	prolongation	(91).		The	QT	prolonging	effects	of	the	fluoroquinolones	in	children	have	not	been	well	described.		However	this	information	was	urgently	needed,	as	the	fluoroquinolones	will	increasingly	be	combined	in	novel	regimens	with	the	new	and	repurposed	drugs	bedaquiline,	delamanid	and	clofazimine,	all	of	which	cause	QT	prolongation	(33,	57).		This	was	also	important	for	understanding	the	expected	background	QT	interval	in	order	to	interpret	the	QT	effects	of	bedaquiline	and	delamanid	in	paediatric	trials,	in	which	the	drugs	will	be	added	to	an	optimized	background	regimen.		The	primary	limiting	factor	for	fluoroquinolone	use	in	children	to	date	has	been	a	concern	for	arthropathy	based	on	animal	data	(66).		Damage	to	the	weight-bearing	joints	induced	by	fluoroquinolones	was	demonstrated	in	all	juvenile	animal	models	tested,	with	juvenile	dogs	being	the	most	sensitive	(92).		However,	to	date	multiple	large	evaluations	have	not	demonstrated	a	significant	risk	of	serious	arthropathy	in	children	treated	with	fluoroquinolones	for	short	durations	(66).		One	non-blinded	long-term	follow-up	study	of	levofloxacin-treated	children	did	report	a	significant	increase	in	musculoskeletal	complaints,	primarily	subjective	arthralgia;	the	lack	of	blinding	may	have	biased	the	findings,	especially	given	the	subjective	nature	of	the	events	(55).		However	other	large	studies,	including	a	review	of	over	7000	children	and	another	including	6000	children,	did	not	identify	patients	with	severe	arthropathy	or	an	increased	risk	of	musculoskeletal	disorders	(92,	93).		However	there	is	limited	high	quality	prospective	data	on	fluoroquinolone	safety	for	the	long	durations	and	at	the	doses	in	use	for	MDR-TB	treatment	and	concerns	about	arthropathy	have	persisted.		Given	the	particular	importance	of	the	fluoroquinolones	in	current	and	future	MDR-TB	treatment	and	prevention,	it	was	critically	important	to	understand	the	pharmacokinetics,	impact	of	key	covariates	(including	the	effect	of	formulation	and	formulation	manipulation),	optimal	doses,	safety	and	tolerability	of	ofloxacin	(see	Section	1.8,	Chapter	2)	and	levofloxacin	in	children	with	MDR-TB	(Section	1.8,	Chapters	
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3,	4	and	5),	in	order	to	optimize	current	and	future	MDR-TB	treatment	regimens	in	children.	
1.5.3	Linezolid	for	the	treatment	of	MDR-TB	in	children	Linezolid	is	an	oxazolidinone	antibiotic,	that	binds	the	50s	ribosomal	subunit,	inhibiting	protein	synthesis	(94).		Linezolid	is	active	against	Gram-positive	bacteria	and	is	used	in	adults	and	children	for	the	treatment	of	skin	and	soft-tissue	infections	and	for	resistant	Gram-positive	organisms	(94).		Relatively	recently	it	has	also	been	identified	to	have	antimycobacterial	activity,	and	has	been	used	increasingly	and	very	effectively	in	difficult	to	treat	drug-resistant	TB	such	as	XDR-TB	for	which	there	are	very	few	effective	treatment	options	available	(95-97).		Its	excellent	cerebrospinal	fluid	(CSF)	penetration	makes	it	an	important	option	for	the	treatment	of	MDR-TB	meningitis	(98,	99).		Trials	in	adults	to	evaluate	the	best	dose	and	duration	of	linezolid	to	optimize	efficacy	while	minimizing	adverse	effects	have	been	in	planning	or	are	underway,	and	linezolid	is	a	component	of	a	number	of	novel	MDR-TB	regimens	under	evaluation	(Table	1.3).		As	in	adults,	linezolid	has	been	used	off-label	in	children	with	difficult	to	treat	forms	of	DR-TB,	however	the	evidence	for	this	was	limited	to	case	reports	and	case	series,	and	there	was	no	formal	guidance	on	its	use	or	dose	in	paediatric	MDR-TB.		During	the	course	of	this	PhD	research,	linezolid	has	become	an	even	more	important	treatment	option	for	MDR-TB.		The	Nix-TB	study	(NCT02333799),	an	open-label	single	arm	phase	3	study	that	opened	in	2015	is	evaluating	a	regimen	of	bedaquiline,	linezolid	and	pretomanid	for	6	months	among	adults	with	XDR-TB	or	with	MDR-TB	failure	or	intolerance	(100).		This	patient	population	has	very	poor	treatment	outcomes,	with	<25%	successfully	treated	in	some	studies	(101).	However	interim	results	of	the	trial	were	very	encouraging,	with	death	reported	in	only	4	of	61	and	all	surviving	patients	culture	negative	at	4	months	and	74%	culture	negative	at	8	weeks;	there	were	substantial	adverse	effects	mostly	attributed	to	linezolid	(100).		Final	results	are	pending	and	a	follow-up	study,	ZeNix	(NCT03086486)	that	aims	to	evaluate	different	linezolid	dosing	strategies	is	now	underway.			Linezolid	has	nearly	100%	oral	bioavailability,	and	food	does	not	significantly	affect	total	exposures	(94,	102).		Linezolid	has	complex	metabolism	with	formation	of	multiple	metabolites	and	undergoes	both	renal	and	non-renal	elimination	(102).		Linezolid	pharmacokinetics	has	been	studied	in	children	treated	short-term	(<28	days)	
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for	Gram-positive	bacterial	infections,	and	there	are	recommended	paediatric	doses	that	approximate	exposures	in	adults	receiving	600	mg	twice	daily	(103).		However	there	is	no	published	data	in	children	with	TB	with	or	without	HIV-infection,	and	it	is	not	clear	what	dose	in	children	will	result	in	exposures	that	approximate	the	600	mg	once	daily	dose	of	linezolid	most	commonly	in	use	for	adults	with	TB.			For	the	short	durations	that	are	recommended	for	treatment	of	Gram-positive	infections	(<28	days),	linezolid	has	been	shown	to	be	safe	and	well	tolerated	in	adults	and	children	(104).		However	linezolid	is	associated	with	dose	and	time-dependent	serious	adverse	effects,	including	peripheral	neuropathy,	optic	neuropathy,	myelosuppression	(anaemia,	thrombocytopaenia	and	leucopenia),	and	more	rarely	pancreatitis	and	lactic	acidosis	(105,	106).		These	have	been	described	to	occur	frequently	in	adults	treated	with	long	durations	of	linezolid	for	MDR-TB	(96,	107),	however	the	frequency,	severity,	and	risk	factors	for	these	serious	adverse	effects	in	children	treated	long-term	with	linezolid	for	MDR-TB	have	been	poorly	characterized.			Considering	the	importance	of	linezolid	currently	for	treatment	of	children	with	XDR-TB	or	MDR-TB	meningitis,	its	potential	to	substitute	for	the	second-line	injectable	agents,	and	its	likely	key	role	in	future	MDR-TB	treatment	regimens,	it	was	identified	that	there	was	insufficient	evidence	to	inform	its	use	in	children	with	MDR-TB	(see	Section	1.8,	Chapter	6).		Data	were	urgently	needed	on	linezolid	pharmacokinetics,	optimal	dose	and	safety	with	long	treatment	duration	in	children	with	MDR-TB	(Section	1.8,	Chapter	7).		
1.5.4	The	second-line	injectable	TB	medications	for	the	treatment	of	MDR-TB	in	children	The	aminoglycosides	amikacin	and	kanamycin	and	the	cyclic	polypepetide	capreomycin	are	often	referred	to	together	as	the	second-line	injectable	antituberculosis	drugs.		These	medications	have	similar	mechanisms	of	action,	pharmacology,	requirement	for	intravenous	(IV)	or	intramuscular	(IM)	route	of	administration,	and	adverse	effect	profiles.		All	three	bind	to	different	bacterial	ribosomal	subunits,	inhibiting	protein	synthesis	(108,	109).		Along	with	the	fluoroquinolones,	they	have	traditionally	been	considered	a	key	component	of	existing	MDR-TB	treatment	regimens.		This	has	begun	to	be	questioned,	as	these	agents	have	a	minimal	EBA	(110)	and	evidence	from	early	clinical	trials	with	streptomycin	suggests	that	they	have	minimal	if	any	sterilizing	effect	(111).	However,	for	now	they	remain	recommended	components	of	routinely	used	
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MDR-TB	treatment	regimens	for	most	adults	and	children	globally	(18).	The	second-line	injectables	are	rapidly	degraded	if	given	orally,	so	must	be	given	either	IV	or	IM,	and	are	eliminated	unchanged	in	the	urine	(108).		The	pharmacokinetics	of	amikacin,	kanamycin	and	other	aminoglycosides	have	been	studied	in	children	for	non-TB	indications	but	not	in	children	with	TB,	and	there	is	minimal	data	in	general	on	capreomycin	pharmacokinetics	in	children	(112).		The	most	important	concern	for	using	the	second-line	injectables	in	MDR-TB	treatment	regimens	is	the	high	risk	of	ototoxicity.		These	medications	cause	cochlear	hair	cell	death	resulting	in	permanent	sensory	neural	hearing	loss	(44).		The	most	important	risk	factor	for	this	ototoxicity	appears	to	be	cumulative	drug	exposure	(113,	114).		The	incidence	of	ototoxicity	with	long-term	second-line	injectable	treatment	varies	widely,	from	2.6-61%	in	adults,	but	is	likely	towards	the	higher	end	of	this	range	(115).		Paediatric	studies	have	reported	hearing	loss	in	up	to	24-41%	of	children	receiving	long-term	injectables	(17,	40,	45).		MDR-TB	treatment	regimens	that	avoid	the	use	of	the	injectables	are	thus	desperately	needed.		But	until	other	treatment	options	are	available,	improved	characterization	of	the	pharmacokinetics,	optimal	dose,	and	safety	(including	incidence	of	and	risk	factors	for	ototoxicity)	of	the	second-line	injectables	in	children	are	needed.		This	work	was	undertaken	but	was	outside	the	scope	of	my	PhD	research	thesis.			In	addition	to	the	serious	safety	concerns	regarding	ototoxicity,	the	daily	intramuscular	injections	of	the	injectable	agents	are	painful,	poorly	tolerated,	and	a	significant	source	of	distress	for	children,	caregivers	and	healthcare	workers.		This	has	not	been	well	documented	in	children,	but	in	adults	has	been	identified	as	one	of	the	worst	aspects	of	current	MDR-TB	treatment	regimens	(59).		As	the	second-line	injectables	continued	to	be	recommended	as	a	component	of	existing	MDR-TB	treatment	regimens	in	many	countries,	identifying	approaches	to	improve	the	tolerability	of	the	injectables	was	a	priority.		Strategies	to	reduce	the	pain	of	intramuscular	injections	could	substantially	improve	their	tolerability.	The	addition	of	local	anaesthetic	to	other	antibiotic	injections,	such	as	ceftriaxone	or	benzathine	penicillin,	has	been	shown	to	reduce	injection	pain	without	affecting	pharmacokinetics	(116,	117).		A	similar	strategy	had	not	been	evaluated	with	the	second-line	injectables,	but	had	the	potential	to	substantially	improve	the	tolerability	of	the	second-line	injectables	when	they	are	required	to	be	given	(see	Section	1.8,	Chapter	8).	Such	a	risk-reduction	strategy	would	be	a	
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temporizing	measure	until	other	medications	or	injectable-sparing	regimens	could	be	developed,	in	part	informed	by	work	in	this	PhD.	
1.5.5	Bedaquiline	As	described	in	Section	1.2.1,	the	novel	antituberculosis	drug	bedaquiline	received	accelerated	approval	in	2012	from	the	U.S.	FDA	for	adults	with	MDR-TB,	and	the	WHO	provided	recommendations	for	its	use	(28,	57).		Since	then	it	has	been	registered	in	many	countries,	and	is	becoming	widely	available	globally	(118).		In	South	Africa,	after	registration	in	2014,	aggressive	roll-out	in	routine	care	settings	has	provided	access	to	bedaquiline	for	thousands	of	adults	and	some	adolescents	with	good	treatment	outcomes	including	reduced	mortality	(119,	120).	Bedaquiline	is	also	being	evaluated	in	adults	as	a	component	of	many	novel,	shortened	regimens	for	MDR-TB	treatment	(Table	1.3).		Bedaquiline	is	clearly	a	critically	important	antituberculosis	medication	for	current	and	future	MDR-TB	treatment.		Paediatric	bedaquiline	trials	have	unfortunately	been	very	delayed,	and	were	in	planning	or	ongoing	during	this	PhD	research.	This	has	been	a	major	barrier	to	paediatric	access	to	bedaquiline.	The	Janssen-sponsored	C211	phase	1/2	trial	of	bedaquiline	pharmacokinetics	and	safety	in	HIV-uninfected	children	only	(NCT02354014),	only	opened	in	2016.		A	paediatric	bedaquiline	dispersible	tablet	formulation	was	developed	for	the	trial	and	will	be	studied	in	children	less	than	6	years	of	age	in	the	study.		The	IMPAACT	P1108	phase	1/2	trial	of	bedaquiline	pharmacokinetics	and	safety	(NCT02906007)	includes	HIV-infected	and	–uninfected	children	with	MDR-TB	and	opened	at	the	end	of	2017.		These	studies	will	characterize	the	pharmacokinetics,	optimal	dose	and	safety	of	bedaquiline	in	children,	and	should	lead	to	a	paediatric	indication.		However	access	to	the	paediatric	formulation	in	routine	care	settings	is	likely	to	be	very	delayed,	even	after	data	from	the	paediatric	trials	on	dosing	and	safety	in	young	children	is	available.		The	adult	formulation,	already	widely	available,	could	be	manipulated	through	crushing	or	suspending	in	water	for	administration	to	young	children,	but	it	is	unclear	if	and	how	this	would	affect	its	bioavailability.		This	question,	of	significant	practical	importance,	was	not	being	studied	in	the	paediatric	trials.		A	trial	characterizing	the	affect	of	suspending	adult	bedaquiline	tablets	in	water	on	its	bioavailability	would	inform	the	rational	use	of	the	adult	formulation	in	young	children,	greatly	improving	access	until	the	paediatric	formulation	is	more	widely	available	(Section	1.8,	Chapter	9).	
 21
Stellenbosch University  https://scholar.sun.ac.za
		
The	novel	TB	drug	delamanid	received	conditional	approval	from	the	EMA	in	2013	and	the	WHO	issued	recommendations	for	its	use	in	adults	with	MDR-TB	in	2014	(see	Section	1.2.1)	(32,	33).		Registration	of	delamanid	in	high	TB	burden	settings	has	been	very	slow,	however	the	paediatric	phase	1/2	trials	are	further	along	than	bedaquiline.		Otsuka-sponsored	phase	1	(242-12-232)	(NCT01856634)	and	phase	2	(242-12-233)	(NCT01859923)	paediatric	trials	of	delamanid	opened	in	2013,	including	in	South	Africa.		These	age	de-escalation	trials	aimed	to	characterize	delamanid	pharmacokinetics	and	safety	over	10	days	(trial	232)	and	6	months	of	dosing	(trial	233).	The	older	age	cohorts	(6	to	<18	years	of	age)	have	completed	the	trials,	and	the	WHO	issued	recommendations	for	delamanid	use	in	children	ages	6-17	years	with	MDR-TB	(121).		The	younger	cohorts	have	completed	enrolment,	with	only	long-term	follow-up	in	the	youngest	group	expected	to	be	completed	in	early	2019.		Two	paediatric	formulations	(5	and	25	mg	dispersible	tablets)	were	developed	for	and	studied	in	these	trials.		However,	similar	to	bedaquiline,	it	is	expected	that	access	to	these	paediatric	formulations	in	routine	settings	are	likely	to	be	very	delayed.		A	similar	pragmatic	approach	of	studying	the	effect	on	bioavailability	of	manipulating	the	adult	formulation	through	crushing	or	suspending	in	water	would	facilitate	rational	use	of	this	formulation	in	young	children	until	the	paediatric	formulation	is	available.		Such	a	study	would	be	very	useful,	but	was	not	included	in	the	scope	of	this	PhD	research,	partly	because	delamanid	was	not	registered	in	South	Africa,	so	access	to	the	adult	formulation	was	limited.	
	
1.6		Purpose	and	scope	of	proposed	research	The	purpose	of	this	PhD	research	was	to	address	critical	knowledge	gaps	in	paediatric	MDR-TB	treatment,	with	the	aim	of	informing	more	effective,	safer,	and	more	child-friendly	MDR-TB	treatment	strategies	in	children.		This	includes:		characterizing	the	pharmacokinetics	and	safety	of	currently	recommended	doses	of	key	second-line	antituberculosis	drugs	including	ofloxacin,	levofloxacin,	and	linezolid	in	children	with	MDR-TB,	investigating	the	impact	on	pharmacokinetics	and	pain	of	administration	practices	for	intramuscular	injections	of	amikacin	in	children	with	MDR-TB,	and	characterizing	the	effects	of	formulation	and/or	formulation	manipulation	on	the	pharmacokinetics	of	levofloxacin	and	bedaquiline.		Identifying	paediatric	doses	of	these	
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second-line	antituberculosis	drugs	that	better	approximate	target	exposures	will	ensure	that	the	efficacy	of	these	key	medications	is	optimized	and	will	allow	for	extrapolation	of	efficacy	to	children	from	adult	MDR-TB	regimens	under	evaluation.		Optimal	paediatric	dosing	may	also	facilitate	the	use	of	shorter,	safer	regimens	in	children	for	MDR-TB	prevention	and	treatment	compared	to	adults	in	future.				
1.7		Overall	objective	The	overall	objective	of	this	doctoral	research	was	to	characterize	the	pharmacokinetics,	including	the	effects	of	formulation,	optimal	dose,	safety,	and	tolerability	of	key	second-line	and	novel	antituberculosis	drugs	in	children	in	order	to	inform	the	safer	and	effective	treatment	of	children	with	MDR-TB.	
	
1.8		Hypotheses	and	proposed	studies	The	following	complementary	hypotheses	and	related	studies	were	proposed	to	address	the	key	knowledge	gaps	described	above:	
Hypothesis	1,	Study	1	(Chapter	2):		The	WHO-recommended	dose	of	ofloxacin	
(20mg/kg	once	daily)	is	safe	and	achieves	adequate	target	drug	concentrations	in	children	
with	MDR-TB	exposure	or	disease.			The	study	aim	was	to	characterize	the	pharmacokinetics	and	safety	of	ofloxacin	among	HIV-infected	and	uninfected	children	aged	0	to	<15	years	routinely	treated	for	MDR-TB	disease	or	exposure.		This	was	a	prospective	observational	intensive	pharmacokinetic	study.		Pharmacokinetic	measures	were	estimated	using	non-compartmental	analysis.	
Hypothesis	2,	Studies	2,	3,	4:		The	paediatric	dose	of	levofloxacin	(15-20mg/kg	once	
daily)	in	use	for	MDR-TB	exposure	or	disease	is	safe	and	achieves	target	drug	
concentrations	
Study	2	(Chapter	3)	aimed	to	characterize	the	pharmacokinetics	of	levofloxacin	15mg/kg	and	20mg/kg	oral	doses,	given	routinely	to	children	0	to	<15	years	of	age	for	prevention	or	treatment	of	MDR-TB.		In	this	prospective	observational	pharmacokinetic	study,	children	underwent	intensive	pharmacokinetic	sampling.		The	analysis	used	
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population	pharmacokinetic	modeling	techniques	and	clinical	trial	simulations	to	characterize	levofloxacin	pharmacokinetics	and	optimal	doses.			
Study	3	(Chapter	4)	characterized	levofloxacin	(15mg/kg	and	20mg/kg)	safety	in	children	with	MDR-TB	disease	in	this	same	cohort.		Clinical	and	laboratory	adverse	events	were	assessed	for	severity	according	to	standard	grading	and	for	attribution	to	levofloxacin.				
Study	4	(Chapter	5)	characterized	the	pharmacokinetics	and	short-term	safety	of	a	novel,	child-friendly	100	mg	scored	dispersible	tablet.		In	an	open-label	pharmacokinetic	study	as	a	lead-in	to	the	TB-CHAMP	phase	III	trial	(levofloxacin	vs.	placebo	for	MDR-TB	prevention),	children	0	to	<5	years	of	age	had	intensive	pharmacokinetic	sampling	following	weight-banded	doses	of	this	novel	levofloxacin	formulation.		NLME	modeling	was	used	to	compare	the	primary	pharmacokinetic	parameters	with	the	historical	cohort	evaluated	in	Study	2;	simulations	identified	optimized	weight-banded	dosing	for	this	formulation.	
Hypothesis	3,	Study	5,	6:		The	currently	used	dose	of	linezolid	for	MDR-TB	and	XDR-TB	
in	children	is	safe	and	achieves	target	concentrations.			The	aim	of	Study	5	(Chapter	6)	was	to	review	and	synthesize	the	literature	on	the	use	of	linezolid	for	the	treatment	of	MDR-TB	in	children.		This	scoping	review	undertook	a	sensitive	search	of	the	literature	for	all	evidence	that	could	inform	use	of	linezolid	in	children	with	MDR-TB,	including	pre-clinical	and	clinical	data	on	its	efficacy,	its	safety	in	adults	and	children	with	prolonged	use,	and	its	pharmacokinetics	in	adults	and	children.		Reports	of	linezolid	use	in	children	with	MDR-TB	were	combined	to	estimate	its	efficacy	and	safety	in	children,	and	other	results	were	synthesized	to	create	practical	recommendations	for	linezolid	in	children	with	MDR-TB.			
Study	6	(Chapter	7)	combined	data	from	two	prospective	observational	intensive	sampling	pharmacokinetic	studies	of	linezolid	in	children	with	MDR-TB.		Linezolid	pharmacokinetic	parameters	were	estimated	using	NLME	modeling	and	optimal	doses	were	identified	using	clinical	trial	simulations,	and	safety	described.			
Hypothesis	4,	Study	7	(Chapter	8):		Lidocaine	co-administered	with	intramuscular	
injections	of	amikacin	results	in	reduced	pain	and	similar	amikacin	plasma	concentrations	
in	children	with	MDR-TB.			
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This	study	assessed	the	effect	of	co-administering	lidocaine	with	intramuscular	amikacin	injections	on	injection-associated	pain	and	on	the	amikacin	pharmacokinetics	using	intensive	sampling.		This	was	a	randomized,	double-blind,	two-period	crossover	study	in	children	aged	8	to	<18	years	with	MDR-TB	routinely	receiving	amikacin	for	MDR-TB.		Children	received	a	standard	mg/kg	dose	of	amikacin	either	with	or	without	a	weight-banded	dose	of	lidocaine.		Pain	was	assessed	before,	and	then	immediately,	30	minutes	and	60	minutes	after	the	injection.		Pharmacokinetic	measures	were	estimated	using	non-compartmental	analysis.			
Hypothesis	5,	Study	8	(Chapter	9):		Bedaquiline	400	mg	administered	as	tablets	
suspended	in	water	is	bioequivalent	to	bedaquiline	400	mg	swallowed	as	whole	tablets	in	
healthy	adult	volunteers.			This	was	a	randomized,	open	label,	crossover,	bioequivalence	study	with	two	single	treatment	periods,	separated	by	a	14	day	washout	period.		Twenty-four	healthy	male	and	female	volunteers	with	similar	demographics	were	randomly	assigned	1:1	to	one	of	two	treatment	sequences	in	order	to	receive	either	first	the	crushed	form	of	bedaquiline,	as	the	experimental,	and	secondly	the	whole	tablet	as	the	approved	dosing	form,	or	vice	versa.		NLME	modeling	was	used	to	estimate	the	potential	difference	in	bioavailability	for	crushed	compared	to	whole	tablets.	95%	confidence	intervals	of	the	estimate	were	compared	to	formal	bioequivalence	criteria.					
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Chapter	2:	The	pharmacokinetics	and	safety	of	ofloxacin	in	children	
treated	for	drug-resistant	tuberculosis		
Rationale	The	fluoroquinolones	are	critical	components	of	treatment	regimens	for	MDR-TB.		Until	2013-2014	ofloxacin	was	the	most	widely	used	fluoroquinolone	for	TB	treatment	in	both	adults	and	children	globally.		The	WHO	recommended	a	dose	of	15-20	mg/kg	once	daily	in	children,	however	there	was	little	data	on	ofloxacin	use	in	children	to	inform	this	recommendation	and	it	was	unknown	if	this	dose	achieved	the	exposures	achieved	in	adults	after	the	standard	recommended	800	mg	dose	(median	AUC0-24	103	μg	·	h/ml)	(81).			
Study	aims	The	objective	of	this	study	was	to	characterize	the	pharmacokinetics	and	long-term	safety	of	ofloxacin	in	HIV-infected	and	-uninfected	children	routinely	receiving	ofloxacin	for	MDR-TB	disease	or	exposure.			
Methods	The	MDRPK1	study	(Pharmacokinetics	and	toxicity	of	second-line	antituberculosis	drugs	
in	HIV-infected	and	–uninfected	children,	PI	Hesseling,	Schaaf,	HD	069169-01)	was	an	NIH	RO1	funded	study	targeting	318	HIV-infected	and	uninfected	children	receiving	second-line	antituberculosis	drugs	for	pharmacokinetic	sampling	and	longitudinal	follow-up	for	safety	and	treatment	outcomes.		The	primary	objective	of	the	study	was	to	characterize	the	pharmacokinetics	of	the	second-line	antituberculosis	drugs	in	children;	other	objectives	were	to	characterize	the	safety	of	the	second-line	antituberculosis	drugs	and	any	potential	drug-drug	interactions	with	antiretrovirals	(ARVs)	in	HIV-infected	children.		The	study	was	open	from	2011-2015,	and	recruited	children	with	MDR-TB	disease	or	exposure	from	Tygerberg	Hospital	and	Brooklyn	Hospital	for	Chest	Diseases,	Cape	Town	as	well	as	Brewelskloof	Hospital,	Worcester.		Children	were	eligible	for	the	study	if	they	were	0	to	<15	years	of	age,	routinely	treated	with	second-line	antituberculosis	drugs	for	>2	weeks	but	<8	weeks	for	treatment	of	MDR-TB	disease	or	as	preventive	therapy	for	MDR-TB	exposure,	HIV-infected	or	–uninfected,	and	on	ART	for	>2	weeks	if	HIV-infected.		Exclusion	criteria	included	laboratory	documented	
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anaemia	(haemoglobin	<8	g/dL)	or	weight	<5	kg.		Local	guidelines	in	Cape	Town	used	a	three-drug	MDR-TB	preventive	therapy	regimen	composed	of	ethambutol,	high-dose	isoniazid	and	either	ofloxacin	(prior	to	2013)	or	levofloxacin	(from	2013)	to	children	<5	years	of	age	or	HIV-infected	and	<15	years	of	age	with	a	recent	documented	exposure	to	MDR-TB	but	no	evidence	of	TB	disease	at	the	time.		Children	enrolled	in	the	study	on	MDR-TB	preventive	therapy	had	cross-sectional	intensive	pharmacokinetic	sampling,	and	were	followed	in	the	routine	care	programme,	but	within	the	study	were	not	followed	for	safety	or	long-term	outcomes,	as	data	on	the	safety	of	this	regimen	had	already	been	documented	(77).		Children	in	the	study	who	were	receiving	treatment	for	MDR-TB	disease	had	intensive	pharmacokinetic	sampling	and	were	followed	longitudinally	for	safety	and	treatment	outcome.				Children	enrolled	in	MDRPK1	who	were	less	than	15	years	of	age	and	routinely	treated	with	ofloxacin	for	the	prevention	or	treatment	of	MDR-TB	were	included,	primarily	during	2011-2013,	prior	to	the	introduction	of	levofloxacin.		All	children	had	pharmacokinetic	sampling	between	2	and	8	weeks	of	treatment	with	ofloxacin	as	a	component	of	their	routine	treatment	regimens.		The	routinely	available	formulation	of	ofloxacin	was	used	(200	mg	tablets,	Sanofi	Aventis,	Midrand,	South	Africa).		On	the	day	of	pharmacokinetic	sampling,	an	exact	20	mg/kg	dose	of	ofloxacin	was	administered	by	the	study	team,	and	samples	taken	pre-dose	and	at	1,	2,	4,	8	and	either	6	or	11	hours	post-dose.		Ofloxacin	was	administered	either	as	whole	tablets,	or	as	crushed	tablets	either	orally	or	by	nasogastric	tube,	depending	on	what	the	child	was	able	to	tolerate.		Ofloxacin	plasma	concentrations	were	measured	using	a	validated	liquid	chromatography	tandem	mass	spectrometry	(LC	MS/MS)	assay	at	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology.		Key	pharmacokinetic	measures	were	calculated	using	NCA,	and	univariable	and	multivariable	linear	regression	used	to	assess	associations	between	pharmacokinetic	measures	and	clinical	and	other	covariates	of	interest	using	Stata	12.1	SE	software	(StataCorp.,	College	Station,	Texas).		Children	receiving	ofloxacin	as	a	component	of	a	treatment	regimen	for	MDR-TB	disease	had	1-2	monthly	safety	monitoring	until	the	completion	of	MDR-TB	treatment	(typically	12-18	months).		All	adverse	events	were	assessed	for	both	severity	using	standard	Division	of	AIDS	criteria	(DAIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	version	1.0,	December	2004,	updated	August	2009)	(122)	and	attribution	to	
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ofloxacin.	Frequency	and	rates	of	adverse	events	were	reported	by	grade	and	by	relation	to	ofloxacin.		
Results	Eighty-five	children,	median	(IQR)	age	3.4	years	(1.9	to	5.2),	were	included	in	this	study.		Eleven	(13%)	were	HIV-infected;	85%	received	ofloxacin	as	crushed	tablets	in	water	(as	opposed	to	tablets	swallowed	whole,	due	to	feasibility	reasons). The	mean	ofloxacin	(range)	Cmax,	AUC0–8,	and	t1/2	were	8.97	μg/ml	(2.47	to	14.4),	44.2	μg	·	h/ml	(12.1	to	75.8),	and	3.49	h	(1.89	to	6.95),	respectively.	The	mean	AUC0–24,	estimated	in	72	participants,	was	66.7	μg	·	h/ml	(range,	18.8	to	120.7).	In	multivariable	analysis,	AUC0–24	was	increased	by	1.46	μg	·	h/ml	for	each	1-kg	increase	in	body	weight	(95%	CI,	0.44	to	2.47;	p=0.006).	No	other	assessed	variable	contributed	to	the	model.	No	grade	3	or	4	adverse	events	at	least	possibly	attributed	to	ofloxacin	were	observed.	
Conclusions	and	recommendations	In	this	largest	study	of	ofloxacin	in	children	to	date,	ofloxacin	was	safe	and	well	tolerated	in	children	routinely	receiving	an	ofloxacin-containing	regimen	for	MDR-TB	treatment	or	prevention.	However,	ofloxacin	exposures	were	well	below	the	values	typically	achieved	in	adults.		The	long-term	safety	of	ofloxacin	demonstrated	in	this	study	is	reassuring,	as	historical	concerns	about	fluoroquinolone	adverse	effects	in	children	have	persisted	in	many	settings	despite	emerging	evidence	to	the	contrary.		Only	weight	was	associated	with	AUC0-24	in	multivariable	analysis.	Notably,	neither	HIV	co-infection	nor	ofloxacin	formulation	manipulation	(receiving	crushed	tablets	vs.	whole)	was	associated	with	ofloxacin	exposure.		The	study	identified	that	higher	doses	of	ofloxacin	than	currently	recommended	will	likely	be	needed	in	children	to	achieve	the	target	exposures	achieved	in	adults	receiving	an	800	mg	daily	dose.		Although	ofloxacin	was	no	longer	the	fluoroquinolone	of	choice	in	the	period	following	this	publication,	this	work	importantly	demonstrated	the	safety	of	long-term	fluoroquinolone	treatment	in	young	children	and	also	identified	that	the	recommended	dose	of	this	antituberculosis	drug	resulted	in	low	exposures	in	children,	raising	the	concern	that	there	may	be	similar	considerations	for	other	fluoroquinolones.	
Citation:		Garcia-Prats	AJ,	Draper	HR,	Thee	S,	Dooley	KE,	McIlleron	HM,	Seddon	JA,	Wiesner	L,	Castel	S,	Schaaf	HS,	Hesseling	AC.		The	pharmacokinetics	and	safety	of	
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Pharmacokinetics and Safety of Ofloxacin in Children with Drug-
Resistant Tuberculosis
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Baltimore, Maryland, USAc; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africad; Department of Paediatrics,
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Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Data on its pharmacokinetics and
safety in children are limited. It is not known whether the current internationally recommended pediatric dosage of 15 to 20
mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area
under the concentration-time curve from 0 to 24 h [AUC0–24], 103g · h/ml). We assessed the pharmacokinetics and safety of
ofloxacin in children<15 years old routinely receiving ofloxacin for MDR-TB treatment or preventive therapy. Plasma samples
were collected predose and at 1, 2, 4, 8, and either 6 or 11 h after a 20-mg/kg dose. Pharmacokinetic parameters were calculated
using noncompartmental analysis. Children withMDR-TB disease underwent long-term safety monitoring. Of 85 children (me-
dian age, 3.4 years), 11 (13%) were HIV infected, and of 79 children with evaluable data, 14 (18%) were underweight. The ofloxa-
cin mean (range) maximum concentration (Cmax), AUC0–8, and half-life were 8.97g/ml (2.47 to 14.4), 44.2g · h/ml (12.1 to
75.8), and 3.49 h (1.89 to 6.95), respectively. The mean AUC0–24, estimated in 72 participants, was 66.7g · h/ml (range, 18.8 to
120.7). In multivariable analysis, AUC0–24 was increased by 1.46g · h/ml for each 1-kg increase in body weight (95% confidence
interval [CI], 0.44 to 2.47; P 0.006); no other assessed variable contributed to the model. No grade 3 or 4 events at least possibly
attributed to ofloxacin were observed. Ofloxacin was safe and well tolerated in children withMDR-TB, but exposures were well
below reported adult values, suggesting that dosage modificationmay be required to optimize MDR-TB treatment regimens in
children.
Globally, in 2013 there were an estimated 480,000 new cases ofmultidrug-resistant tuberculosis (MDR-TB), defined asMy-
cobacterium tuberculosis resistant to isoniazid (INH) and rifampin
(RIF) (1). Precise incidence data in children are unavailable, but
modeling estimates suggest that there were 33,000 new pediatric
MDR-TB cases in 2010 (2). In addition, assuming an average of
two child contacts for each adult MDR-TB source case (3), there
may be as many as 900,000 children newly exposed to MDR-TB
globally each year. Fluoroquinolones are a key component of ex-
isting regimens for treatment (4) and prevention (5) of MDR-TB
in adults and children.
Ofloxacin, a fluoroquinolone, has potent activity againstM.
tuberculosis (6, 7) and has been routinely used in MDR-TB
treatment. The current World Health Organization (WHO)
recommended adult dose of ofloxacin for MDR-TB is 800 mg
daily. Ofloxacin is not metabolized; rather, it is excreted un-
changed in the urine (8). It is well absorbed after oral admin-
istration, and food intake does not affect its pharmacokinetics
appreciably (9–12).
There are limited data on ofloxacin pharmacokinetics in chil-
dren, particularly in children5 years of age, to guide appropriate
dose selection (11, 13). TheWHOrecommends a pediatric ofloxa-
cin dose forMDR-TB of 15 to 20mg/kg of body weight daily (14);
however, it is unknown if this dose achieves exposures in children
approximating those in adults after the recommended 800-mg
dose. Concerns regarding arthropathy (15, 16) had initially lim-
ited the use of fluoroquinolones in children. Although safe in
short courses (16–18), there are limited data on fluoroquinolone
safety in children with long-term use (5, 19).
The more potent fluoroquinolones levofloxacin and moxi-
floxacin (20, 21) are beginning to replace ofloxacin for MDR-TB
treatment. However, because of its low cost and widespread avail-
ability, ofloxacin is still used for MDR-TB in many settings, and
optimizing its use in children remains important.
The objective of this study was to evaluate the pharmacokinet-
ics and safety of ofloxacin among a large cohort of HIV-infected
and uninfected children of representative ages whowere routinely
receiving ofloxacin for the prevention or treatment of MDR-TB.
MATERIALS AND METHODS
Study design. This was a prospective observational pharmacokinetic
study.
Study setting.The study took place in theWesternCape, SouthAfrica,
where in 2010 the TB notification rate was 954.1 cases per 100,000 popu-
lation, and from 2009 to 2011 MDR-TB represented 7.1% of culture-
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confirmed cases in children 13 years old (22, 23). The diagnosis of
MDR-TBwas based on (i) culture ofM. tuberculosis from sputumor other
relevant specimens with drug susceptibility testing (DST) demonstrating
resistance to INH and RIF, (ii) clinical and radiologic evidence of TB and
contact with anMDR-TB source case, or (iii) failure of first-line TB treat-
ment. Treatment for MDR-TB in children was provided independent of
the study, according to local and international guidance, based on the
DST of the child’s isolate or the isolate of their most likely source case.
Treatment included at least four drugs likely to be active given for at least
12 to 18 months (14, 24).
In the study setting, child contacts of adultMDR-TB cases are referred
to a specialty clinic for preventive therapy. Children5 years of age and
those HIV infected without evidence of TB were prescribed 6months of a
three-drug preventive therapy regimen: ofloxacin, ethambutol, and high-
dose INH (5).
Study population. Children were recruited from a large provincial
referral hospital (Tygerberg Children’s Hospital) and two provincial TB
hospitals (Brooklyn Hospital for Chest Diseases and Brewelskloof Hospi-
tal). Children15 years of age routinely started on ofloxacin for preven-
tion or treatment of MDR-TB were eligible. Exclusion criteria were a
weight of 5 kg or hemoglobin of 8.0 g/dl. Children treated for
MDR-TB disease were followed longitudinally to assess safety and tolera-
bility during treatment. The safety of this preventive therapy regimen has
been previously documented; these children were followed independent
of the study (5).Data from23 children froma substudy of this cohortwere
previously published and are included in the present analysis (13).
Data collection. Children were categorized as receiving ofloxacin ei-
ther for MDR-TB treatment or prevention. TB was categorized as con-
firmed, probable, or possible according to international consensus defi-
nitions (25) and as pulmonary, extrapulmonary, or both. HIV status was
ascertained in all participants. Weight-for-age Z-score (WAZ) was calcu-
lated using the 1990 British growth reference (26).
All participants underwent intensive pharmacokinetic sampling 2 to 8
weeks after starting ofloxacin. Ofloxacin (200-mg tablets; Sanofi Aventis,
Midrand, South Africa) at a dose of 15 to 20 mg/kg once daily was rou-
tinely prescribed. On pharmacokinetic sampling days, an exact 20 mg/kg
dose of ofloxacin was weighed and administered by the study team after a
minimum 4-h fast with a small amount of water. Medications were given
either as whole tablets or were crushed and given bymouth or nasogastric
tube, depending on what the child would tolerate. Crushed tablets were
ground with amortar and pestle, mixed with a small amount of water in a
plastic cup along with any other crushed TB medications, and adminis-
tered immediately. Any residue in the cup was rinsed 1 to 2 times with
additional water and administered to the child. All other anti-TBmedica-
tions in the regimen were given together with the ofloxacin. One hour
after the TBmedications, antiretrovirals were administered (if applicable)
and a standard breakfast was offered. Samples for pharmacokinetic anal-
ysis were drawn predose and then at 1, 2, 4, 8, and either 6 or 11 h post-
dose.Whole-blood sampleswere collected in EDTA-containing tubes and
immediately centrifuged, and plasma was separated and frozen at80°C.
Ofloxacin concentrations were determined by high-performance liquid
chromatography coupled with triple quadrupole mass spectrometry (LC-
MS/MS) using a previously described method validated over a range of
0.0781 to 20.0 g/ml (27).
Children receiving ofloxacin for MDR-TB treatment had clinical
monitoringmonthly for the first 6months and then every 2months there-
after and laboratory monitoring (potassium, creatinine, alanine amino-
transferase [ALT], total bilirubin, thyroid functions) every 2months. Ad-
verse events were graded according to standardized Division of AIDS
(National Institute of Allergy and Infectious Diseases) criteria (28) and
were considered attributable to ofloxacin if they were (i) at least possibly
drug related and (ii) thought by the investigator to be likely related to
ofloxacin or if they were not otherwise attributed to another drug. The
person-time of observation began at the initial study visit and ended at
either the final study visit or the date of treatment completion; observa-
tion periods inwhich the child received an alternative fluoroquinolone for
part of the time (treatment guidelines changed during the study period)
were excluded from safety analyses.
Statistical analysis. Demographic and clinical characteristics were
summarized using descriptive statistics. Pharmacokinetic measures were
estimated using noncompartmental analysis (NCA). Observedmaximum
plasma drug concentration (Cmax) and time toCmax (Tmax) were recorded
directly from the concentration-time data. The area under the concentra-
tion time curve from 0 to 8 h (AUC0–8) was calculated using the linear
trapezoidal rule. Oral clearance (CL/F), half-life (t1/2), and AUC0–24 were
estimated in patients with at least 3 concentration data points in the elim-
ination phase, with the latter based on exponential extrapolation from the
final three time-concentration data points. Fifteen predose drug concen-
trations below the limit of quantification (0.078g/ml) were set to zero in
analyses.
TheCmax, AUC0–8, AUC0–24, and t1/2 were compared by age group (0
to2 years, 2 to5 years, and5 years), HIV status, nutritional status
(WAZ, 2 versus 2), and administration method (crushed versus
whole tablets).Using simple linear regression, theAUC0–24 andCmaxwere
analyzed separately for associations with age, weight, height, HIV status,
nutritional status, gender, ethnicity, disease status (receiving preventive
therapy versus treatment forMDR-TB), and administrationmethod. Co-
variates with a P of 0.05 in univariable analysis, and factors known to
affect drug disposition (age and weight) were included in multivariable
models. We also assessed whether body surface area (BSA) (29) or lean
body mass (LBM) (30) were better predictors than weight and height.
All analyses were performed using Stata 12.1 SE software (StataCorp,
College Station, TX).
Ethical considerations.Written informed consent was obtained from
the parents or legal guardian, and informed assent was collected from all
children 7 years of age. Ethical approval was provided by the Health
Research Ethics Committees of the Faculty of Medicine and Health Sci-
ences of Stellenbosch University and the Faculty of Health Sciences of the
University of Cape Town.
RESULTS
Baseline characteristics. Eighty-five children were included (Ta-
ble 1). All age groups were well represented. The median age was
3.4 years (interquartile range [IQR], 1.9 to 5.2 years). Eleven
(13%) participants were HIV infected. Fourteen of the 79 patients
with evaluable data (18%)were underweight for age (WAZ,2)
and 11 of these children were HIV infected (79%). Overall, 72 of
85 (85%) received crushed tablets on the day of pharmacokinetic
sampling (97% of those5 years old and 41% of those5 years
old).
Pharmacokinetics and determinants of drug exposures.
With a dose of 20mg/kg, themean AUC0–8 (n 85) was 44.2g ·
h/ml and AUC0–24 (n  72) was 66.7 g · h/ml; other summary
measures with reported adult values for comparison are shown in
Table 2. Pharmacokinetic values by age group, HIV status, WAZ
category, and type of administration are presented in Table 3.
Half-life was shorter in the youngest children, and there was a
trend toward a higher Cmax in children receiving crushed tablets.
In simple linear regression, no variables assessedwere significantly
associated with Cmax, and only weight was significantly associated
with AUC0–24. Inmultivariable analysis,Cmax was reduced by 0.44
g/ml for each 1-year increase in age (95% confidence interval
[CI],0.74 to0.13; P 0.005) andwas increased by 0.13g/ml
for each 1-kg increase in body weight (95% CI, 0.10 to 0.24; P
0.029). In multivariable analysis, AUC0–24 was increased by 1.46
g · h/ml for each 1-kg increase in body weight (95% CI, 0.44 to
2.47;P 0.006). Controlling for age andweight, no other assessed
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variables contributed to these models. Neither LBM nor BSA im-
proved the model fit over weight.
Safety. Forty-six children contributed a total of 23.8 years of
observation time on ofloxacin to the safety assessment, with a
median time per child of 4.9 months (IQR, 1.2 to 10.2 months)
(Table 4). Adverse events were mostly mild in severity; vomiting
and pruritus were the most frequent. Most adverse events were
not attributed to ofloxacin but represented known toxicities re-
lated to companion MDR-TB drugs. The only grade 3 or 4 events
were two episodes of asymptomatic ALT elevation due to con-
firmed acute hepatitis A, which resolved without complication
after brief interruptions of some TB medications while awaiting
the hepatitis A results.
DISCUSSION
Ofloxacin given at the WHO-recommended dose of 20 mg/kg to
children was safe and well-tolerated, but exposures in this sub-
stantial pediatric cohort were considerably lower than those
achieved in adults taking the standardMDR-TB treatment dose of
800 mg daily.
Although ofloxacin has been widely used for treatment and
prevention of MDR-TB in children, the appropriate dosage has
not been established. Indeed, only one other study evaluating the
pharmacokinetics of ofloxacin in children has been conducted to
our knowledge. In a study in Vietnam, 17 children (aged 5 to 17
years)with typhoid fever received a single oral dose of 7.5mg/kg of
ofloxacin (11). A Cmax of 5.73 g/ml and an AUC0–12 of 26.5
g/ml were achieved (11). The Cmax (8.97 g/ml) and AUC0–8
(44.1 g · h/ml) in our study are lower than would be expected
with a 2.5 higher dose given that ofloxacin exposures should be
dose proportional in the dosing range tested (8, 10). It is unclear if
this is because of differences in the study population or drug for-
mulation used, but our findings underline the importance of not
relying on a single study conducted in one geographic location to
inform global dosing recommendations in children.
The differing AUC0–8 and AUC0–24 trends by age in univari-
able analysis may be due to the fact that the proportion of the total
daily AUC that is captured in the first 8 h after dosing is greater in
younger children (data not shown) due to more rapid absorption
and clearance compared to older children. Children with slower
absorption and elimination, andmost likely a higher AUC, would
be more likely to be excluded from our estimates of AUC0–24.
Indeed, AUC0–24 was not estimated in a higher proportion of
older children (Table 3), suggesting we may have underestimated
theAUC0–24 in children5 years old. The differences in t1/2 by age
in univariable analysis and association of AUC0–24 with weight
are consistent with the principle of allometric scaling, in which
smaller body size is associated with more rapid clearance.
Our large sample allowed us to evaluate covariate effects on the
pharmacokinetics of ofloxacin. In multivariable analysis, age and
weight were associated with AUC0–8 and Cmax, and weight was
associated with AUC0–24. HIV and undernutrition are frequent
concomitant conditions among children with MDR-TB and have
been associated with failure to culture convert at 2 months and
death (31). HIV infection may affect concentrations of some TB
medications (32); however, we did not observe any significant
effect of HIV infection on ofloxacin pharmacokinetics. This is
consistent with the available adult literature (9, 10). Undernutri-
tion also did not have a clinically significant impact on ofloxacin
pharmacokinetics. These data suggest that worse outcomes
among children with HIV coinfection or undernutrition are not
likely due to reduced concentrations of ofloxacin, the key bacteri-
cidal drug in the regimen.
The lack of child-friendly formulations of second-line TB
medications is a major challenge for MDR-TB treatment in chil-
dren, and the impact of formulation manipulation, such as the
crushing or breaking of adult tablets, has not been evaluated fully.
TABLE 2 Summary statistics for ofloxacin pharmacokinetic measures in
children receiving treatment or prevention for multidrug-resistant
tuberculosisa
Parameterb
No. of
children
Values for
children in the
present study
Values for adults with
TB given an 800-mg
ofloxacin dosec
Cmax (g/ml) 85 8.97 (2.47–14.4) 10.5 (8.0–14.3)
Tmax (h) 85 2.0 (1.0–4.0) 1.03 (0.5–6)
t1/2 (h) 72 3.49 (1.89–6.95) 7.34 (3.53–28.3)
CL/F (liter/h/kg) 72 0.31 (0.11–1.06) 0.12 (0.02–0.32)
V (liter/kg) 72 1.45 (0.86–6.49) 1.28 (0.78–2.83)
AUC0–8 (g · h/ml) 85 44.2 (12.1–75.8)
AUC0–24 (g · h/ml) 72 66.7 (18.8–120.7) 103 (48–755)
a All values are presented as means (ranges), except for Tmax, CL/F, and V, which are
presented as medians (ranges); adult values are all reported as medians (ranges).
b Cmax, maximum serum concentration; Tmax, time to maximum serum concentration;
t1/2, half-life; CL, clearance; F, fraction absorbed; V, volume of distribution; AUC0–8,
area under the concentration time curve from 0–8 h; AUC0–24, area under the
concentration time curve from 0–24 h.
c n 11 (10).
TABLE 1 Baseline demographic and clinical characteristics of children
receiving ofloxacin for treatment or prevention of drug-resistant
tuberculosis
Characteristica
No. (%) with
MDR-TB
disease (n 55)
No. (%) receiving
MDR-TB preventive
therapy (n 30)
Age at enrollment
0 to2 yr 16 (29.1) 8 (26.7)
2 to5 yr 17 (30.9) 22 (73.3)
5 to15 yr 22 (40.0) 0 (0.00)
Male sex 32 (58.2) 15 (50.0)
Certainty of TB diagnosis
Bacteriological confirmation 20 (36.4)
Probable TB 32 (58.2)
Suspected TB 3 (5.5)
TB disease type (n 55)
PTB only 40 (72.7)
EPTB only 5 (9.1)
PTB and EPTB 10 (18.2)
HIV infected 11 (20.0) 0 (0.0)
Weight-for-age Z-score2.0
(n 79)b
11 (22.5) 3 (10.0)
Height-for-age Z-score2.0
(n 81)c
19 (35.9) 4 (14.3)
Weight-for-length Z-score
2.0 (n 60)c
2 (6.3) 1 (3.6)
a PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
b Weight-for-age Z-scores only available for patients aged10 years.
c The sample size is85 due to missing data.
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Many children in our study were unable to swallow whole ofloxa-
cin tablets and took them crushed. In univariable analysis, there
was a trend toward a higher Cmax with crushed tablets; however,
crushing did not contribute to the multivariable model, which
included age and weight. The associations of Cmax with age and
weight described here are somewhat unexpected and should be
interpreted cautiously, as crushing was highly associated with
younger age and less so with weight, and it may have been difficult
to separate these effects in the model. There was no association
between crushing and AUC0–8 or AUC0–24. Although this does
not replace a formal assessment of relative bioavailability of
crushed versus whole tablets, it suggests that crushing tablets does
not negatively impact drug exposures and crushing may, in fact,
increase the rate or magnitude of absorption.
When efficacy of a TB drug has been established in adults,
efficacy studies may not be required in children, but studies char-
acterizing a drug’s pharmacokinetics and safety in children are
essential. This allows the selection of dosages that achieve concen-
trations associated with treatment success in adults (9, 10). In a
study of ofloxacin pharmacokinetics after an 800-mg dose (me-
dian dose, 14.5 mg/kg) in adults with MDR-TB at two sites in
South Africa, estimated pharmacokinetic parameters were a t1/2 of
7.8 h and a Cmax of 8.8 to 10.4 mg/liter (9). In a U.S. study, 11
adults with TB (median age, 42 years [range, 22 to 57 years]; me-
dianweight, 64 kg [range, 50 to 86 kg]; 3HIV infected) underwent
intensive pharmacokinetic sampling on ofloxacin at steady state
with a median dose of 800 mg (range, 600 to 1,200 mg). Assays
were performed using high-performance liquid chromatography,
and data were analyzed using population pharmacokinetic mod-
eling (Table 2). Using simulations based on their population
model generated from these data and from an additional group in
this study having sparse pharmacokinetic sampling, estimated
pharmacokinetic parameters after an 800-mg once-daily dose
were anAUCof 100.7g · h/ml and aCmax of 9.35g/ml (10). The
Cmax in our children was only slightly below these reported adult
values, although the children received a higher milligram per ki-
logram dose (20mg/kg) compared to the adults (9). However, the
estimated AUC0–24 in our children of 66.7g · h/ml was far below
the adult value (103 g · h/ml) (10). This is likely related to the
more rapid clearance of ofloxacin in children; calculated t1/2 in
children in our study was 3.5 h compared to 7 to 8 h in the adult
studies. That currently recommended dosages of ofloxacin result
in AUCs in children well below those of adult targets has impor-
tant implications for MDR-TB treatment and prevention, partic-
ularly given the fluoroquinolones’ high bactericidal activity (33)
and their key role in current treatment regimens (34). The AUC is
believed to be themost important pharmacodynamicmeasure for
the fluoroquinolones against M. tuberculosis (35). As our data
were derived in an optimal setting with an exact 20-mg/kg dose,
drug exposures with unsupervised dosages closer to the lower end
of the recommended range (15 to 20 mg/kg) may be even lower.
Although additional studies corroborating the findings in our
study would be useful, it may not be prudent to wait on such
studies before reevaluating pediatric dosing. Population pharma-
cokinetic modeling can be used to predict dosages most likely to
achieve adult targets; this information is urgently needed, and
such an analysis is planned from this cohort. Higher dosages
should be introduced carefully, though, to assess their safety and
tolerability, particularly given that the Cmax may exceed the Cmax
in adults receiving 800 mg daily.
Ofloxacin was generally safe and well tolerated. The overall
person-time of observation for adverse events was more lim-
ited than expected, as many children were switched from
ofloxacin to levofloxacin or moxifloxacin during their treat-
ment, following a national treatment guideline change mid-
study. Adverse effects were of low grade, and there were no
ofloxacin-related grade 3 or 4 events. There was no evidence of
arthralgia or arthropathy in our cohort. Subtle arthralgia may
not have been reported, but it is unlikely clinically significant
arthralgia or arthritis would have been missed. There were two
reports of insomnia attributable to ofloxacin, a well-described
adverse effect of this medication (5, 36). Anecdotally, we have
seen self-limited, mild insomnia and nightmares attributable
to ofloxacin not infrequently; our data may underestimate the
TABLE 3 Pharmacokinetic measures for ofloxacin (20 mg/kg) in children receiving treatment or prevention for multidrug-resistant tuberculosis, by
age, HIV status, nutritional status, and administration methoda
Parameter
No. of
children Cmax (g/ml) P value
AUC0–8
(g · h/ml) P value
No. of
children
AUC0–24
(g · h/ml) P value t1/2 (h) P value
Age group
0 to2 yr 24 10.43 (1.96) 45.9 (8.8) 23 63.9 (15.3) 3.01 (0.53)
2 to5 yr 39 8.52 (2.37) 43.8 (12.0) 35 66.5 (20.9) 3.52 (0.75)
5 yr 22 8.18 (2.01) 0.001 43.1 (8.9) 0.632 14 71.7 (17.8) 0.473 4.18 (1.22) 0.001
HIV status
HIV infected 11 8.42 (1.51) 42.5 (9.0) 9 63.4 (16.4) 3.35 (0.59)
Not HIV infected 74 9.05 (2.44) 0.404 44.4 (10.6) 0.560 63 67.1 (19.0) 0.579 3.51 (0.93) 0.614
WAZ
2.0 18 8.94 (2.35) 42.7 (11.4) 15 61.0 (20.1) 3.06 (0.49)
2.0 67 8.98 (2.35) 0.953 44.6 (10.1) 0.498 57 68.2 (18.1) 0.190 3.60 (0.94) 0.004
Administration
Whole 11 7.87 (1.67) 42.2 (10.6) 8 72.4 (23.4) 4.32 (1.45)
Crushed 72 9.16 (2.40) 0.089 44.6 (10.4) 0.481 62 66.1 (18.1) 0.375 3.39 (0.76) 0.114
a HIV status, nutritional status, and administration method comparisons were generated using t tests; age group comparisons were generated using one-way analyses of variance
(ANOVAs); all values are presented as means (standard deviations). A total of 85 children participated in the study.
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incidence, as many children were admitted to hospital wards
early in their treatment and sleep disturbance may be less no-
ticeable by ward staff than by parents. Our safety assessment is
limited by the lack of a control group and by the difficulty in
attributing adverse effects to individual drugs in a multidrug
regimen that typically includes ethambutol, pyrazinamide,
amikacin, ethionamide, terizidone, and high-dose INH. Our
approach was, however, conservative and more likely to have
overestimated ofloxacin-related adverse effects. These data add
to a growing body of evidence that the fluoroquinolones are
safe in children, including in long-term use (37). The lack of
adverse effects may be related to the relatively low exposures,
and safety should continue to be monitored closely if dosages
are increased.
Treatment outcomes in this cohort were generally good and
will be reported elsewhere; however, one child had docu-
mented acquisition of ofloxacin resistance during treatment.
This HIV-infected child had a complicated course with large
recurrent tuberculous brain abscesses requiring the use of mul-
tiple immunosuppressant medications and was treated with
multiple fluoroquinolones prior to resistance development,
making it difficult to ascribe the resistance acquisition solely to
ofloxacin concentrations. Additionally, this child’s ofloxacinCmax
and AUC were each above the median. Despite generally good
outcomes, optimized dosing of the fluoroquinolones in children
remains an important priority and may potentially improve out-
comes further and facilitate the use of shorter, injectable sparing
MDR-TB treatment regimens.
In conclusion, in this large cohort of children receiving ofloxa-
cin, exposureswere lower than those in adults. Although ofloxacin
is being phased out of MDR-TB treatment regimens in favor of
more potent fluoroquinolones, it is still used inmany places and it
is likely underdosed in children. That ofloxacin was safe and well
tolerated is reassuring, particularly if higher dosages that will be
needed to reach adult reference exposure targets are to be evalu-
ated. A better understanding of the pharmacokinetics and safety
profiles of all second-line anti-TB drugs is essential to ensure the
provision of appropriate drugs at appropriate dosages to children
with MDR-TB to optimize treatment outcomes.
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Chapter	3:	Levofloxacin	population	pharmacokinetics	in	children	
treated	for	multidrug-resistant	tuberculosis		
Rationale	Levofloxacin	is	the	l-isomer	and	the	active	component	of	the	ofloxacin	racemate,	conferring	levofloxacin	with	nearly	twice	the	antimycobacterial	activity	of	ofloxacin.		Therefore	levofloxacin	became	favoured	over	ofloxacin	for	MDR-TB	treatment	and	prevention.		This	was	reflected	in	WHO	guidance,	which	recommended	phasing	out	ofloxacin	and	prioritizing	levofloxacin	or	moxifloxacin	for	MDR-TB	during	2012-2013,	during	the	time	field	research	contributing	towards	this	doctoral	dissertation	was	underway.		The	WHO	recommended	variable	doses	of	levofloxacin	for	children,	including:	7.5-10	mg/kg	once	daily	(15,	123)	and	15-20	mg/kg/day	divided	twice	daily	for	≤	5	years	of	age,	10-15	mg/kg	once	daily	for	>	5	years	of	age	(124).		However	the	optimal	levofloxacin	doses	in	children	that	achieve	target	concentrations	in	adults	after	a	750	mg	dose	(96.8	μg	·	h/ml)	(79)	had	not	yet	been	characterized.		This	routine	change	in	policy	recommendation	by	WHO	was	followed	by	a	South	African	National	TB	Programme	(SA	NTP)	recommendation	in	2012-2013	to	use	levofloxacin	in	children	below	8	years	of	age,	and	moxifloxacin	in	older	children	and	adults	with	MDR-TB	during	(125).		The	rationale	for	recommending	different	fluoroquinolones	in	children	was	primarily	due	to	formulation	considerations.		Moxifloxacin	was	only	available	as	an	unscored	400	mg	tablet,	making	accurate	dosing	in	young	children	very	difficult,	and	when	crushed	or	dissolved/suspended	in	water	it	is	very	bitter	and	poorly	palatable.		In	contrast,	levofloxacin	was	available	as	a	250	mg	tablet,	which	could	be	split	to	accurately	dose	most	children,	and	although	still	bitter	when	crushed	was	more	palatable	than	moxifloxacin.			
Study	aims	The	aim	of	this	prospective	observational	pharmacokinetic	study	was	to	characterize	the	pharmacokinetics	and	optimal	dosing	strategy	of	levofloxacin	in	children	routinely	treated	for	MDR-TB	disease	or	exposure.				
Methods	
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Children	in	this	evaluation	of	levofloxacin	were	enrolled	in	the	MDRPK1	study	(see	Chapter	2).		Similar	in	design	to	the	study	of	ofloxacin	in	Chapter	2,	children	<15	years	routinely	receiving	levofloxacin	for	MDR-TB	disease	or	exposure	at	one	of	the	three	study	facilities	in	Cape	Town	and	Worcester,	were	included	in	this	study,	primarily	from	2013-2015.		On	pharmacokinetic	sampling	days,	samples	were	taken	pre-dose	and	at	1,	2,	4,	8	and	6	or	11	hours	after	an	observed	exact	dose	of	15	mg/kg	or	20	mg/kg,	taken	as	either	whole	tablets,	or	crushed	tablets	either	swallowed	or	administered	via	nasogastric	tube.	The	routinely	available	levofloxacin	adult	250	mg	tablets	(Austell,	Johannesburg,	South	Africa)	were	used	throughout	the	study.		Levofloxacin	plasma	concentrations	were	measured	using	a	validated	LC	MS/MS	assay	at	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology.		Pharmacokinetic	parameters	were	estimated	using	NLME	modeling,	and	the	effect	on	the	model	fit	of	key	covariates	was	explored,	including	HIV	status,	MDR-TB	status	(disease	vs.	exposure),	undernutrition,	ethnicity,	and	administration	method	(whole	tablets	vs.	crushed	tablets	taken	orally	vs.	crushed	tablets	administered	via	nasogastric	tube).		Simulations	using	the	final	model	were	used	to	estimate	weight-banded	doses	achieving	the	adult	target	exposure.		This	optimized	dosing	regimen	was	targeted	to	achieve	a	median	AUC	in	each	weight	band	within	20%	of	the	target	exposure,	with	the	simulated	Cmax	not	exceeding	by	more	than	20%	that	observed	to	be	safe	in	adult	studies.		Safety	data	for	levofloxacin	are	reported	in	Chapter	4.		
Results	One-hundred	and	nine	children	were	included	in	the	study,	with	a	large	proportion	of	young	(median	age	2.1	years,	range	0.3	to	8.7)	and	small	(median	weight	12	kg,	range	6	to	22	kg)	children.		Levofloxacin	followed	two-compartment	kinetics	with	first-order	elimination	and	absorption	with	a	lag	time.		Inclusion	of	allometric	scaling	improved	the	model	fit,	and	clearance	in	a	typical	child	(weight	12	kg,	age	2	years)	was	4.7	liters/h;	HIV	infection	reduced	levofloxacin	clearance	by	16%.		Crushing	of	tablets	or	use	of	a	nasogastric	tube	did	not	significantly	affect	the	overall	bioavailability.		Levofloxacin	exposures	in	children	with	the	250	mg	adult	tablet	were	considerably	lower	than	reported	in	adults	receiving	a	similar	dose	on	a	mg/kg	basis	even	after	accounting	for	the	effect	of	body	size	with	allometric	scaling.		The	reason	for	this	is	not	clear,	but	possibilities	include	effects	of	the	formulation	used	in	the	study	or	effects	of	formulation	
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manipulation	(crushing	tablets).		To	achieve	exposures	in	children	equivalent	to	adult	target	exposure	values	with	the	routine	adult	formulation	studied,	higher	levofloxacin	doses	than	currently	recommended	would	be	required,	varying	from	18	mg/kg/day	for	younger	children	(3-4	kg)	up	to	40	mg/kg/day	for	older	children.		
Conclusions	and	recommendations	Currently	recommended	doses	of	levofloxacin	with	the	routine	adult	levofloxacin	formulation	studied	resulted	in	exposures	in	children	well	below	current	routine	target	values	in	adults.		Based	on	our	data,	the	largest	paediatric	levofloxacin	pharmacokinetic	study	to	date,	weight-banded	doses	in	children	that	would	be	expected	to	achieve	target	values	with	the	studied	formulation	were	proposed,	for	careful	prospective	evaluation	of	pharmacokinetics	and	safety.		Even	after	accounting	for	the	effects	of	body	size,	exposures	were	lower	in	this	study	than	has	been	previously	reported.		This	unexpected	difference	could	not	be	explained	by	our	data,	however	the	effects	of	formulation	or	formulation	manipulation	were	considered	possibilities.		The	effects	of	formulation	and	formulation	manipulation	on	levofloxacin	pharmacokinetics	need	further	evaluation.		As	pharmacokinetic	targets	evolve	in	adults	based	on	ongoing	trials,	paediatric	studies	would	be	required	to	evaluate	the	required	doses	to	achieve	these	new	exposures	and	safety	at	those	doses.			
Citation:		Denti	P*,	Garcia-Prats	AJ*,	Draper	H,	Wiesner	L,	Winckler	J,	Thee	S,	Dooley	K,	Savic	R,	McIlleron	H,	Schaaf	HS,	Hesseling	AC.	Levofloxacin	population	pharmacokinetics	in	South	African	children	treated	for	multidrug-resistant	tuberculosis.	
Antimicrob	Agents	Chemother	2018	Feb;	62(2).	*Contributed	equally			 	
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ABSTRACT Levoﬂoxacin is increasingly used in the treatment of multidrug-resistant tu-
berculosis (MDR-TB). There are limited pediatric pharmacokinetic data to inform dose se-
lection for children. Children routinely receiving levoﬂoxacin (250-mg adult tablets) for
MDR-TB prophylaxis or disease in Cape Town, South Africa, underwent pharmacokinetic
sampling following receipt of a dose of 15 or 20 mg/kg of body weight given as a
whole or crushed tablet(s) orally or via a nasogastric tube. Pharmacokinetic parameters
were estimated using nonlinear mixed-effects modeling. Model-based simulations were
performed to estimate the doses across weight bands that would achieve adult expo-
sures with 750-mg once-daily dosing. One hundred nine children were included. The
median age was 2.1 years (range, 0.3 to 8.7 years), and the median weight was 12 kg
(range, 6 to 22 kg). Levoﬂoxacin followed 2-compartment kinetics with ﬁrst-order elimi-
nation and absorption with a lag time. After inclusion of allometric scaling, the model
characterized the age-driven maturation of clearance (CL), with the effect reaching 50%
of that at maturity at about 2 months after birth and 100% of that at maturity by 2
years of age. CL in a typical child (weight, 12 kg; age, 2 years) was 4.7 liters/h. HIV infec-
tion reduced CL by 16%. By use of the adult 250-mg formulation, levoﬂoxacin exposures
were substantially lower than those reported in adults receiving a similar dose on a
milligram-per-kilogram basis. To achieve adult-equivalent exposures at a 750-mg daily
dose, higher levoﬂoxacin pediatric doses of from 18 mg/kg/day for younger children
with weights of 3 to 4 kg (due to immature clearance) to 40 mg/kg/day for older chil-
dren may be required. The doses of levoﬂoxacin currently recommended for the treat-
ment of MDR-TB in children result in exposures considerably lower than those in adults.
The effects of different formulations and formulation manipulation require further inves-
tigation. We recommend age- and weight-banded doses of 250-mg tablets of the adult
formulation most likely to achieve target concentrations for prospective evaluation.
KEYWORDS NONMEM, allometric scaling, dosing recommendations,
ﬂuoroquinolones, maturation, pediatric, population PK modeling
The ﬂuoroquinolones, with their potent antimycobacterial activity, are increasinglyimportant medications for tuberculosis (TB) prevention and treatment, particularly
for multidrug-resistant (MDR) TB (i.e., TB caused by Mycobacterium tuberculosis strains
resistant to both isoniazid and rifampin), against which the ﬂuoroquinolones are a key
component of current regimens. Levoﬂoxacin, the L-isomer and the more active com-
ponent of the oﬂoxacin racemate (1, 2), is the ﬂuoroquinolone most commonly used in
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young children with TB, partly due to the availability of smaller, child-friendly formu-
lations. Levoﬂoxacin also has the advantage of having a reduced QT-prolonging effect
compared to that of other ﬂuoroquinolones (like moxiﬂoxacin) (3), making it more
suitable for use in explorations of the effects of increased doses and its combined use
with the novel and repurposed anti-TB drugs bedaquiline, delamanid, pretomanid, and
clofazimine, all of which can cause QT interval prolongation (4). Levoﬂoxacin is also
increasingly used as a substitute for isoniazid in the treatment of isoniazid-resistant TB
and is being evaluated for the treatment of tuberculous meningitis. Data from an
animal model of latent TB infection and from observational studies in children suggest
a potential role for the ﬂuoroquinolones in MDR-TB-preventive therapy as well, and two
phase III clinical trials (the TB-CHAMP trial in South Africa [International Standard
Randomized Controlled Trial number ISRCTN92634082] and the V-QUIN trial in Vietnam
[trial identiﬁer, ACTRN12616000215426]) comparing levoﬂoxacin and placebo are on-
going (5, 6). Given these broad indications for the use of levoﬂoxacin against TB, it is
likely to be more widely used in children affected by TB (7, 8).
There are currently limited data on levoﬂoxacin pharmacokinetics (PK) in children
with TB. The ﬂuoroquinolones are concentration-dependent antibiotics, with the area
under the concentration-time curve (AUC) and maximum plasma concentrations (Cmax)
being considered the pharmacokinetic parameters most closely correlated with efﬁcacy
(9). Levoﬂoxacin is rapidly absorbed after oral administration with a bioavailability of
90% and is mainly renally eliminated (10). The doses of levoﬂoxacin in children that
result in exposures approximating those in adults receiving the current World Health
Organization (WHO)-recommended dose of 750 mg once daily for the treatment of TB
are not well deﬁned (11). The levoﬂoxacin dose currently recommended by WHO for
MDR-TB treatment in children is 15 to 20 mg/kg of body weight/day divided into two
doses daily in children aged 5 years and 10 to 15 mg/kg/day once daily in children
aged 5 years; however, published data supporting this recommendation are limited
(11). A small study of 22 South African children aged 0 to 8 years with MDR-TB disease
or exposure who received levoﬂoxacin at 15 mg/kg once daily showed lower exposures
(median Cmax, 6.79 mg/liter; median AUC, 32.9 mg · h/liter) than healthy adults after a
standard 750-mg dose (mean Cmax, 9.3 mg/liter; mean AUC, 101 mg · h/liter) (10, 12).
On the basis of data from a study of 50 children receiving levoﬂoxacin for MDR-TB
treatment or preventive therapy in the Federated States of Micronesia and the Republic
of the Marshall Islands, a 15- to 20-mg/kg once-daily dose was recently recommended
(13). However, few young children were included in that study, with the study including
only three children younger than 2 years of age, the age range during which renal
function is rapidly maturing (13). Data for HIV-infected children also remain limited.
The objective of this study was to describe the population pharmacokinetics of
levoﬂoxacin among children receiving levoﬂoxacin for MDR-TB and to use this infor-
mation in simulations to predict the dosing that would achieve the exposures seen in
adults receiving the currently recommended 750-mg dose.
RESULTS
Study population and pharmacokinetic samples. The study included 109 chil-
dren. The median age was 2.1 years (range, 0.3 to 8.7 years), and the median weight
was 12 kg (range, 6 to 22 kg); 16 were HIV infected and on antiretroviral therapy (ART)
containing either lopinavir-ritonavir (n 13) or efavirenz (n 3). Patient characteristics
are shown in Table 1. A total of 662 samples were available for analysis (3 participants
contributed data from more than one sampling occasion), with the levoﬂoxacin con-
centrations in 36 (5.4%) samples being below the limit of quantiﬁcation of the assay,
and all of these were observed in the predose sample.
Pharmacokinetic model. The pharmacokinetics of levoﬂoxacin was well described
using 2-compartment disposition kinetics (with respect to a 1-compartment model, the
change in the objective function value [ΔOFV] was 43.8; 2 degrees of freedom [df]; P 
0.001), ﬁrst-order elimination and absorption, and inclusion of an absorption lag time
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(ΔOFV, 68.5; 2 df; P  0.001). The ﬁnal parameter estimates of the model, along with
their precisions, are shown in Table 2.
After the inclusion of allometric scaling with total body weight, which substantially
improved the ﬁt (ΔOFV, 118), the model could characterize the effect of age, as shown
in Fig. 1 (ΔOFV, 18.5; 2 df; P  0.001): the model estimated that levoﬂoxacin clearance
(CL) reaches 50% maturity at about 2 months after birth and is nearly fully mature
around 2 years of age. The use of fat-free mass (14) for allometric scaling did not
provide meaningful improvements to the ﬁt.
The model estimated the typical value of CL in a 12-kg, 2-year-old child to be 4.7
liters/h. The use of a nasogastric tube (NGT) for drug administration was found to
increase the speed of absorption by shortening the absorption lag time (ΔOFV, 11.4; 1
df; P  0.001), but no signiﬁcant effect on bioavailability was detected when either the
tablet was crushed or an NGT was used. Additionally, HIV-infected children had a 16%
lower CL (ΔOFV, 9.3; 1 df; P  0.01) and, hence, higher exposure. This difference could
not be ascribed to a particular ART regimen, due to the small sample size of this
subgroup. Creatinine clearance was tested as an alternative to weight and age as a
predictor of CL in the subset for which serum creatinine concentration measurements
were available but did not provide a better model ﬁt. No signiﬁcant differences were
found between children receiving treatment for MDR-TB and those receiving preven-
tive treatment, and there was no effect of undernutrition or ethnicity.
After adjustment for all the predictors mentioned above, the model still identiﬁed a
moderate random between-subject variability (BSV) in CL, a large between-occasion
variability (BOV) in the absorption parameters, and a moderate BOV in bioavailability.
The model signiﬁcantly improved (ΔOFV, 51.4; 1 df; P 0.001) when the estimate of the
greater variability (4.5-fold) in the bioavailability of the unobserved doses was
allowed. This additional parameter was included to adjust for the greater uncertainty
TABLE 1 Characteristics of children with MDR-TB disease or exposure treated with
levoﬂoxacina
Characteristic Value
No. (%) of children of the following ethnicity:
Black 69 (63.3)
Mixed race 40 (36.7)
No. (%) of male children 56 (51.4)
Median (range) age (yr) 2.1 (0.32–8.65)
Median (range) wt (kg) 12.4 (5.88–21.8)
Median (range) wt-for-age Z-score (WHO) 0.39 (4.18–3.32)b
Median (range) ht-for-age Z-score (WHO) 1.31 (4.70–1.45)c
Median (range) wt-for-length Z-score (WHO) 0.60 (4.88–4.33)d
No. (%) of children with the following MDR-TB disease status:
MDR-TB disease (treatment) 71 (65.1)
MDR-TB exposure (preventive therapy) 38 (34.9)
Median (range) levoﬂoxacin total dose (mg) 212 (88.5–435)
Median (range) levoﬂoxacin dose (mg/kg) 15 (10–21.4)
Median (range) creatinine clearance (ml/min)e 119 (66.6–181)
No. (%) of children administered drug by the following procedure:
Whole tablet, orally 7 (6.4)
Crushed tablet, orally 12 (11)
Crushed tablet, nasogastric tube 90 (82.6)
No. (%) of children HIV infected 16 (14.7)
aData are for 109 children. WHO, World Health Organization.
bTwelve children had a Z-score of 2.
cThirty-three children had a Z-score of 2.
dTwo children had a Z-score of 2.
eThe revised formula of Schwartz et al. (47) was used; the serum creatinine concentration was measured only
in the patients treated for TB disease (n  71, 65.1%).
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expected to affect the information on the timing of doses and accurate dosing
procedures on the days prior to the day of the visit when the dose was observed to
have been given and samples were collected for pharmacokinetic analysis (Table 2).
The model ﬁt the data adequately, as shown in the visual predictive check (VPC) in
Fig. 2, which also highlights the differences between the pharmacokinetic proﬁles
obtained using different administration procedures and the effect of HIV infection.
Simulated exposures. The ﬁnal model was used to simulate the exposures
achieved in children with different weights and ages, and these were compared with
the values for adults. We ﬁrst explored the expected AUC and Cmax in children receiving
levoﬂoxacin at a 20-mg/kg dose (the high end of the currently used dosing range of 15
to 20 mg/kg). The resulting exposures (AUC and Cmax) across different weights are
shown in Fig. 3. These simulations show that the AUC achieved in children after dosing
of a 20-mg/kg dose using the 250-mg adult formulation was considerably lower than
TABLE 2 PK parameter values for levoﬂoxacin in children with MDR-TB disease or exposured
PK parameter Typical value (95% CI)
Variability as CV% (95% CI)
[eta shrinkage (%)]
CL (liters/h)a 4.70 (4.37, 5.00) for HIV BSV: 15.2 (10.6, 19.0) [24]
Vc (liters)a 19.2 (10.9, 21.8)
Q (liters/h)a 0.796 (0.332, 4.76)
Vp (liters)a 3.40 (2.53, 38.7)
Tlag (h) 0.242 (0.0385, 0.654) for oral dosing BOV: 130 (30.9, 303) [76]
ka (1/h) 1.61 (0.855, 2.78) BOV: 64.8 (43.4, 80.9) [43]
F 1 (ﬁxed) BOV: 21.8 (13.7, 28.4) [10]
HIV on CL (%) 15.9 (26.6, 5.93)
NGT on Tlag (%) 85.6 (99.3, 34.6)
Scaling of BOV in F for unobserved doses (fold)b 4.48 (3.31, 7.08)
PMAGE50 (mo) 10.6 (7.55, 12.9)
 3.39 (1.42, 4.98)
Additive error (mg/liter)c 0.0160, i.e., 20% of LLOQ (ﬁxed)
Proporational error (%) [epsilon shrinkage (%)] 11.6 (10.0, 12.7) [29]
aAll clearance and volume parameters have been scaled with allometric scaling. The typical values reported here refer to a 12-kg child aged 2 years. Age affects
clearance, since maturation was used. At 2 years after birth, maturation is predicted to be 97.9% complete.
bThis is a multiplicative factor increasing the BOV in bioavailability for all predose concentrations, which follow an unobserved dose.
cThe estimate of the additive error hit the stipulated lower boundary (20% of LLOQ), so it was ﬁxed to this value.
dValues in parentheses are empirical 95% conﬁdence intervals obtained with a 500-sample nonparametric bootstrap. The PK parameter variability was included either
as between-subject variability or between-occasion variability, assuming a lognormal distribution. It is reported here as the approximate coefﬁcient of variation (in
percent). CL, clearance; Vc, central volume of distribution; Q, intercompartmental clearance; Vp, peripheral volume of distribution; Tlag, absorption lag time;
ka, absorption rate constant; F, bioavailability; PK, pharmacokinetic; PMAGE50, postmenstrual age at which 50% maturation is reached; , shape factor for the
maturation function; BSV, between-subject variability; BOV, between-occasion variability; HIV and HIV HIV-infected and uninfected children, respectively; NGT, drug
administration with a nasogastric tube.
FIG 1 Maturation function of levoﬂoxacin clearance. The percent maturation achieved versus postnatal
age, assuming a standard duration of gestation (9 months), is shown.
Denti et al. Antimicrobial Agents and Chemotherapy
February 2018 Volume 62 Issue 2 e01521-17 aac.asm.org 4
 o
n
 M
ay 5, 2018 by Stellenbosch University
http://aac.asm
.org/
D
ow
nloaded from
 
 43
Stellenbosch University  https://scholar.sun.ac.za
the chosen target for all age groups. Additionally, a ﬁxed dose on a milligram-per-
kilogram basis achieved a progressively lower AUC as age and weight decreased down
to 9 kg (for children 1 year of age), at which point the effect of maturation
reversed this trend. Cmax was also lower than that previously reported in adults. We
then evaluated an alternative dosing scheme, shown in Table 3, designed to more
closely approximate the proposed target exposures in adults. To attain an AUC in
children similar to that in adults, our model predicts that children in the weight band
of between 8 and 11 kg may require considerably higher doses of this formulation of
up to almost 40 mg/kg on a milligram-per-kilogram basis compared with the dose in
adults. Children below 2 years of age, in whom the maturation of clearance is still
incomplete, would require a slightly lower dose on a milligram-per-kilogram basis
compared with the dose in adults, and the weight bands for very young children must
be narrow to provide appropriate doses, given the substantial impact of body size and
age on the pharmacokinetics of levoﬂoxacin in younger children.
DISCUSSION
Among children who routinely receive the standard adult formulation of levoﬂoxa-
cin for the treatment or prevention of MDR-TB at currently recommended doses,
exposures were substantially lower than those for adults receiving levoﬂoxacin at the
standard 750-mg dose for the same indication. This was true even in young children in
whom renal function is still immature (15). As ﬂuoroquinolones are considered the most
important component of MDR-TB regimens, underdosing of these drugs is particularly
concerning (16).
FIG 2 Visual predictive check of the levoﬂoxacin concentration versus time after dose, stratiﬁed by either the administration method (top) or HIV infection status
(bottom). The solid and dashed lines represent the 50th, 5th, and 95th percentiles of the observed data, while the shaded areas represent the model-predicted
95% conﬁdence intervals for the same percentiles. The dots are the observed concentrations.
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Our ﬁndings are generally consistent with those described in previous reports (13,
17) of the pharmacokinetics of levoﬂoxacin in children (also determined using a
standard 250-mg formulation), which showed lower exposures in children than in
adults when both groups were dosed at the same milligram-per-kilogram level. Only
part of the difference between the exposures in children and adults could be explained
by the nonlinear effect of differences in body size described by allometric scaling. After
standardizing the value of CL to a 70-kg individual with allometric scaling, our estimate
is higher than the values previously reported for pediatric populations (13, 17) and, in
keeping with the ﬁndings of other studies, is higher than the CL values reported in
studies with adults (Table 4) (15, 18, 19). Why the levoﬂoxacin concentrations in our
study were lower than expected after adjustment for body size is unclear. Compared to
other studies with pediatric populations, our CL values are greater than any of the
values previously reported and are closest to those reported by Chien et al. (17) for the
youngest cohorts in their study (2 years old). As differences in body composition
could play a role, we tested fat-free mass (FFM) as a descriptor of size for allometric
FIG 3 Simulated levoﬂoxacin steady-state AUC from time zero to 24 h (AUC0–24) (top) and Cmax (bottom) versus body weight. (Left) The concentrations achieved
with dosing at 20 mg/kg; (right) the suggested optimized dosing. The dashed lines for Cmax (15.55 mg/liter) are the median values observed by Peloquin et
al. (15) with dosing at 1,000 mg daily, while the dashed lines for AUC (96.8 mg · h/liter) represent the median exposure from the same study, after rescaling
of the dose from 1,000 mg to 750 mg daily, the dose currently recommended for the treatment of tuberculosis in adults.
TABLE 3 Suggested optimized weight-banded dosing of once-daily levoﬂoxacin in
children to approximate an adult 750-mg once-daily dosea
Wt band (kg) No. of 250-mg tablets Daily dose (mg) Median daily dose (mg/kg)
3-4 0.25 62.5 18
4-5 0.5 125 28
5-6 0.75 187.5 34
6-8 1 250 36
8-11 1.5 375 39
11-15 2 500 38
15-20 2.5 625 36
20-25 3 750 33
25-30 3.5 875 32
30-35 4 1,000 31
aThe target was a steady-state AUC0–24 of 96.8 mg · h/liter (rescaled from 1,000 mg to 750 mg from
Peloquin et al. [15]).
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scaling, but this did not signiﬁcantly improve the model. Although we did not identify
a signiﬁcant effect of the use of crushed tablets versus whole tablets in the model, our
study may have been underpowered to detect a difference, as only 7 of 109 children
received whole tablets. Differences in bioavailability between formulations are increas-
ingly recognized, and this is an important potential explanation for the variability in
exposures between those found in previous work and those found in our study. This
possibility should be evaluated in future work, as it has important practical implications.
Other explanations could be differences in the ethnicities of the patients evaluated,
differences between the drug formulations used our study and those used in previous
studies, or the concomitant use of other antituberculosis drugs. Novel dispersible
levoﬂoxacin formulations (e.g., a 100-mg scored dispersible pediatric formulation [Ma-
cleods, India]) which are currently undergoing prequaliﬁcation by WHO and which will
be used in several trials for the treatment of MDR-TB in children should be evaluated,
since bioavailability may vary substantially by formulation (20).
Our study was unique in that a large number of very young children were included,
and we were able to characterize the developmental pharmacokinetics of levoﬂoxacin.
Speciﬁcally, levoﬂoxacin CL was estimated to reach 50% of the value at maturity at
about 2 months after birth. Seventeen children in our cohort were younger than 1 year
of age. Since the youngest participants were about 4 months of age, the predicted
exposure for infants under age 4 months is a model extrapolation and should be
interpreted with caution. However, the parameter values for the maturation of levo-
ﬂoxacin clearance were estimated with reasonable precision and they are similar to
those reported for the maturation of glomerular ﬁltration rate (21). This is consistent
with the fact that levoﬂoxacin’s main route of elimination is renal excretion. It is
important to appropriately dose the youngest children, as these children are at the
highest risk of progression to TB disease following M. tuberculosis infection; have the
highest risk of disseminated TB in hard-to-reach compartments, such as the cerebro-
spinal ﬂuid (CSF); and have the highest rates of TB-related mortality (22).
HIV infection was associated with a lower clearance of levoﬂoxacin. The effect was
small and is unlikely to be clinically signiﬁcant. As all HIV-infected children were on ART,
we could not separate the effects of HIV infection and ART. The lower levoﬂoxacin
clearance could be related to a drug-drug interaction, possibly with ritonavir, which has
broad effects on metabolizing and transport enzymes. However, our study had an
insufﬁcient power to ascribe this ﬁnding to a single antiretroviral drug. Recently, high
levels of immune activation have been associated with reduced isoniazid clearance in
adults coinfected with M. tuberculosis and HIV (23). We did not routinely measure
markers of inﬂammation in the children to explore this hypothesis, which may deserve
further evaluation in the future. A previous study in adults failed to identify a signiﬁcant
TABLE 4 Comparison of scaled AUC and CL of levoﬂoxacin in South African children with MDR-TB treatment or exposure with previously
reported values in adults and children
Author (reference or
source)
No. of
patients Country
Median
wt (kg)
Median
and/or
range age
(yr)
Route of
administration
Dose
AUC
(mg · h/liter)
AUC scaled to
1,000 mg or
20 mg/kg
CL (liters/h)
scaled to a
70-kg adultamg mg/kg
Preston et al. (19) 272 USA 77.5 47 Oral 500 6.5 72.53 145 8.35
Thwaites et al. (18) 15 Vietnam 48 33 Intravenous 1000 20.8 155 155 8.56
Peloquin et al. (15) 10 Brazil 56 44 Oral 1000 17.9 129 129 9.16
Mase et al. (13) 50 Paciﬁc Islands 1–15 Oral gel 14 55 80 11.6
Chien et al. (17) 8 USA 11 0.5–2 Oral 7 25.8 13.7
8 USA 15.6 2–5 Oral 7 25.9 15.4
8 USA 26.1 5–10 Oral 7 29.0 13.7
8 USA 42.5 10–12 Oral 7 37.3 11.7
8 USA 60.7 12–16 Oral 7 41.1 12.2
Denti et al. (this study) 109 South Africa 12 2.4 (0.6–8.6) Oral 17.7 45 51 18.8
aAllometric scaling was applied with the exponent 3/4 to scale the value from the median weight in the original study to 70 kg.
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increase in levoﬂoxacin concentrations when levoﬂoxacin was given to HIV-infected
patients treated with efavirenz or nelﬁnavir, but that study had no HIV-infected control
group, and the comparison was instead made with historical data (24). The lack of an
effect of the drug administration method on the overall bioavailability of levoﬂoxacin
is reassuring, given the limited availability of child-friendly levoﬂoxacin formulations
and the frequent need to crush levoﬂoxacin tablets intended for use by adults for
administration to young children. However, only 7 of the 109 children in this study
received whole tablets, and those were the oldest children. This limits the power of our
analysis to investigate this effect. Conﬁrmation in other studies is necessary. Further-
more, the pharmacokinetics of a novel dispersible levoﬂoxacin formulation should be
evaluated in children, to inform the safe and effective dosing of levoﬂoxacin for the
treatment of MDR-TB.
The structure of our pharmacokinetic model, which has 2 compartments and
delayed ﬁrst-order absorption, differs from that of most previous models, which have
1 compartment and different models of absorption. These differences are likely due to
different sampling schedules: the beta phase of the pharmacokinetic proﬁle predicted
by our model did not affect the concentration during ﬁrst hours after the dose, but it
improved our description of the minimum concentration at 24 h postdosing.
To achieve exposures similar to those in adults receiving the routine daily 750-mg
dose used for the treatment of TB, the dose in children would need to be substantially
increased from the currently recommended doses. In general, small children may need
doses much higher on a milligram-per-kilogram basis (up to 40 mg/kg) than the 10- to
15-mg/kg dose used in adults. However, for infants (age, 1 year), who may have an
immature clearance function, the dose increase needed to achieve the pharmacokinetic
targets is more modest (18 to 28 mg/kg). Different formulations (e.g., dispersible
tablets) may, however, have different dosing requirements.
The use of higher doses of levoﬂoxacin in children may have implications for safety,
particularly if similar exposures produce more serious adverse effects in children than
in adults. Our most immediate concern would be for central nervous system (CNS)
toxicity. Hallucinations, serious sleep disturbances, severe headaches, and other clini-
cally signiﬁcant CNS events, such as intracranial hypertension, have been described in
children and adults receiving ﬂuoroquinolones. These have particularly been observed
with doses higher than those that were previously recommended but that were still
within the range of the doses required to achieve the target concentrations in adults
after the administration of 750-mg doses (25–28).
As can be seen from the simulations, if children are dosed once daily to target AUC
values similar to adults on the current 750-mg dose, this will also result in Cmax values
in children substantially higher than those in adults; the Cmax values in some children
will exceed those observed in adults on a 1,000-mg dose. The relationship between
Cmax and some adverse effects of concern (such as CNS side effects or muscle or joint
toxicity) is poorly characterized. As the Cmax values expected with the once-daily
simulated doses exceed what has been shown to be safe in adults to date, these doses
would need to be carefully assessed in children before they are recommended for
routine use for either the treatment or prevention of MDR-TB. For MDR-TB prevention,
the risk/beneﬁt ratio needs to be even more carefully considered, given the fact that
well children are treated to prevent future MDR-TB disease. Although the QT interval-
prolonging effect of levoﬂoxacin appears to be less of a concern, the very high peak
concentrations achieved with the simulated once-daily doses in children might still
pose a risk of QT prolongation that would need to be assessed carefully. Splitting of the
total daily dose into twice-daily doses would be a way to preserve the AUC without
producing such a high Cmax; however, in this situation, the balance between potentially
(but perhaps only modestly) improved safety and the burden to drug treatment
programs and/or the impact on adherence to the treatment regimen must be consid-
ered. The relationship between pharmacokinetic parameters (Cmax versus AUC) and
other toxicities, such as the CNS effects, has not been characterized. Therefore, splitting
of the daily dose to reduce the expected Cmax may not eliminate the risk of adverse
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effects if they are, in fact, more closely associated with the AUC. Exploration of the use
of higher doses of levoﬂoxacin would therefore need to be carried out thoughtfully
with careful safety monitoring. It should also be noted that the use of higher levo-
ﬂoxacin doses for the treatment of MDR-TB in adults is being explored in a phase II trial
(the Opti-Q trial; ClinicalTrials.gov registration number NCT01918397); depending on
the results from that study, target levoﬂoxacin exposures may be higher than the
current target exposures, which would impact dosing in the pediatric population.
Favorable outcomes are reported in 75 to 90% of children with MDR-TB (29, 30). This
is much better than that in adults with MDR-TB, where globally only 50% are success-
fully treated (31). However, there are a number of reasons for the further optimization
of levoﬂoxacin doses in children with MDR-TB disease. First, there is scope for improv-
ing successful MDR-TB treatment outcomes further in children beyond the current 75
to 90% rate. Second, increasing evidence shows that low drug exposures are associated
with poor TB treatment outcomes (including death and treatment failure) in children
(32, 33), and low drug exposures may increase the risk of acquired drug resistance (34).
Third, tuberculous meningitis is a relatively frequent form of TB in young children and
is associated with devastating morbidity and mortality. A recently published analysis
showed that doses of levoﬂoxacin considerably higher than those currently used in
children, approximately 19 to 33 mg/kg, are needed to obtain optimal concentrations
in the CSF (35). Lastly, revised WHO guidance provided in 2016 recommended avoid-
ance of the use of injectable medications in children with clinically diagnosed MDR-TB;
optimization of the exposures to the ﬂuoroquinolone in the regimen is especially
important to ensure the potency of injectable-sparing MDR-TB treatment regimens (16)
Additionally, the extrapolation of efﬁcacy to children from the results of ongoing or
planned trials of treatments for TB in adults, many of which contain levoﬂoxacin, is, in
principle, dependent on achieving similar drug exposures in children (36, 37).
There are limitations to the approach of using adult exposures as targets to deﬁne
pediatric doses for anti-TB drugs. However, in the absence of other more optimal, validated
approaches to deﬁning doses in children, we believe that it remains a useful strategy. The
use of pharmacokinetic (PK)/pharmacodynamic (PD) targets, such as the AUC/MIC, is an
option. However, exposures in plasma may not reﬂect exposures at the site of disease.
Differences in drug penetration into lesions or macrophages, which may not be reﬂected
in the levels of plasma exposure, may have important implications for efﬁcacy. These are
potentially important limitations to the targeting of PK/PD indices. Interesting work on the
development of hollow-ﬁber models of pediatric TB to establish drug targets has recently
been undertaken (38); however, in the absence of validation of the exposure targets
generated by these hollow-ﬁber models, we believe that it is premature to deﬁne doses on
the basis of that work. Therefore, despite the limitations, the use of exposures in adults
associated with efﬁcacy remains a reasonable approach to establishing pediatric doses for
anti-TB drugs. We would argue that TB disease in children differs from that in adults both
in severity and in type (extrapulmonary versus pulmonary). Although a small proportion of
children, mostly older children and adolescents, develop cavitating, adult-type TB, the
majority of children develop less severe, paucibacillary disease, which is likely to be more
responsive to treatment. It is therefore possible that children may be successfully treated
with less intense treatment. However, what less intense treatment means needs to be
carefully deﬁned. We can be conﬁdent that the doses in children resulting in exposures
approximating those seen with efﬁcacious doses in adults would be as efﬁcacious or more
efﬁcacious in children. It may be that exposures lower than those needed in adults with TB
may still be efﬁcacious in children; however, in the absence of a clear deﬁnition of “lower,”
targeting of adult exposures remains a reasonable approach. One approach would be to
maintain good exposures early in treatment to ensure a rapid response to treatment and
a rapid reduction in organism burden but then to reduce the intensity of treatment by
shortening the treatment duration in children. Such a strategy is being evaluated in the
SHINE trial (International Standard Randomized Controlled Trial number ISRCTN63579542),
which is a study of 4 versus 6 months of treatment for nonsevere intrathoracic TB in
children.
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A limitation of our study was the lack of older children, as moxiﬂoxacin was routinely
used in children 8 years of age and older in the local setting. However, pharmacoki-
netics is easier to predict in older children than in younger children. Another limitation
is the lack of clear documentation of previous dosing times prior to the day on which
samples were collected for pharmacokinetic analysis. Incomplete data on creatinine
values, which were not collected for all children, limited our ability to assess whether
renal function could explain some of the variability in clearance. Finally, we cannot
explain the differences between our data and those published previously, such as
higher values for clearance, and we cannot rule out the possibility of a contribution of
the formulation used. We were unable to include different levoﬂoxacin formulations in
this study. This may need further evaluation, and the levoﬂoxacin doses derived from
our simulations should not be used routinely in children before additional careful
evaluations have been completed.
In the large cohort of young South African children treated for MDR-TB described
here, levoﬂoxacin doses of 15 to 20 mg/kg resulted in exposures (Cmax and AUC) lower
than those seen in adults receiving the standard 750-mg daily dose for the same
indication, even in those very young children with immature renal function. Consider-
ably higher levoﬂoxacin doses will thus be needed for children. Model-derived dose
recommendations are provided and should be explored prospectively, with special
attention being given to safety.
MATERIALS AND METHODS
Study design. This was a prospective observational intensive pharmacokinetic study.
Setting and population. The study was performed in Cape Town, South Africa. Children were
eligible if they were 0 to 14 years of age, were routinely treated with levoﬂoxacin for the treatment of
pulmonary or extrapulmonary MDR-TB disease or exposure, had been on TB treatment and antiretroviral
therapy (ART) for at least 2 weeks if they were HIV infected, and provided written informed consent and
assent. Children with body weights of 5 kg or with hemoglobin concentrations of 8 g/dl were
excluded or enrollment was deferred. Children were diagnosed with conﬁrmed or probable TB on the
basis of signs, symptoms, microbiology, and radiography. In addition, the following was required:
isolation from the child of an M. tuberculosis strain with resistance to both isoniazid and rifampin (i.e.,
conﬁrmed MDR-TB disease), exposure to a case of infectious MDR-TB (probable MDR-TB), or clinical
evidence of the failure of adherent ﬁrst-line TB treatment (possible MDR-TB) (39). Children with MDR-TB
disease were treated according to local and international recommendations with at least four drugs
conﬁrmed or likely to be effective against the infecting strain plus pyrazinamide and ethambutol. Local
guidelines recommended the use of levoﬂoxacin for children8 years of age and moxiﬂoxacin for adults
and children8 years of age on the basis of the available drug formulations (250 mg levoﬂoxacin; Austel,
South Africa). In our setting, high-risk contacts of an infectious MDR-TB source case, including children
aged 5 years and HIV-infected children aged 14 years, without evidence of TB disease were
prescribed preventive therapy against MDR-TB consisting of levoﬂoxacin, ethambutol, and high-dose
isoniazid daily for 6 months. All children in the study were routinely tested for HIV by an HIV-speciﬁc
enzyme-linked immunosorbent assay if they are 18 months of age and by a PCR for HIV DNA if they
are 18 months of age. All HIV-infected children in the study received ART on the basis of local
recommendations, including lopinavir-ritonavir (children3 years of age) or efavirenz (children3 years
of age) in combination with two nonnucleoside reverse transcriptase inhibitors, usually lamivudine (3TC)
with abacavir or zidovudine.
Levoﬂoxacin dosing and pharmacokinetic sampling. Children received standard doses of 10 to 15
mg/kg once daily during the beginning of the study (2012 and 2013), according to the dose used for
routine care at the time. Following interim analyses showing low drug exposures with these doses, the
dose used for routine care was increased to 15 to 20 mg/kg once daily (2013 to 2017) (12). Pharmaco-
kinetic sampling was performed between 2 and 16 weeks after the start of the anti-TB treatment. On the
day of sampling, after an overnight fast, a levoﬂoxacin dose of 15 mg/kg (during 2012 and 2013) or 20
mg/kg (from 2013 to 2015) (exact milligram-to-kilogram dosing to 0.1 mg adjusted to body weight) was
administered by the study team together with all other anti-TB medications in the child’s MDR-TB
regimen. Medications were administered either as whole tablets (for older children able to swallow pills)
or as tablets crushed and dissolved in water and given either orally or via a nasogastric tube (NGT),
depending on what the child would tolerate. One hour after the anti-TB medication was dosed, a
standard meal was offered. For HIV-infected children, antiretrovirals were also administered at that time.
Blood samples were collected predose and then at 1, 2, 4, 6, and 8 h after levoﬂoxacin dosing.
Levoﬂoxacin assay. A method for the quantiﬁcation of levoﬂoxacin in plasma was validated and
consisted of protein precipitation using acetonitrile, followed by high-performance liquid chromatogra-
phy with tandem mass spectrometry (LC-MS/MS) detection. The calibration curve ﬁt a linear (weighted
by 1/concentration) regression over the range of 0.0781 to 5.00 mg/liter on the basis of the peak area
ratios for levoﬂoxacin. Levoﬂoxacin-d8 was used as the internal standard. The lower limit of quantiﬁca-
tion (LLOQ) was set at the concentration of the lowest validated standard for levoﬂoxacin, 0.0781
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mg/liter. Inter- and intraday coefﬁcients of variation were below 7% for all quality control samples.
Dilutions were performed using a validated dilution procedure for samples with concentrations greater
than the upper limit of the assay.
Population pharmacokinetic model development. The data were interpreted using nonlinear
mixed-effects modeling (NONMEM software, version 7.3) (40) and an algorithm with ﬁrst-order condi-
tional estimation with a eta-epsilon interaction. Summary statistics were calculated using the R program,
and model development was assisted and graphic diagnostics were generated using the R program (41)
and the Perl-Speaks-NONMEM, Xpose4, and Pirana programs (42). Several structural models were tested,
including models with 1- and 2-compartment dispositions with ﬁrst-order elimination and ﬁrst-order
absorption with and without the use of a lag time or a chain-of-transit compartment to model the onset
of absorption (43). Random between-subject variability (BSV) and between-occasion variability (BOV)
were assumed to have a lognormal distribution, and the error model included both an additive
component and a proportional component. Concentrations below the LLOQ of the assay were imputed
as LLOQ/2, as suggested in the M6 method of Beal (44), and the additive error component was
constrained to be at least 20% of the LLOQ. The effect of differences in body size on the pharmacokinetic
parameters was described using allometric scaling, with exponents ﬁxed to 3/4 for clearance parameters
and 1 for volumes of distribution (45), while the effect of growth and development was tested with a
maturation function using postmenstrual age (i.e., postnatal age plus the estimated gestational age) (46),
as shown in the following equation: maturation  PMAGE⁄PMAGE50
  PMAGE), where PMAGE
denotes postmenstrual age, PMAGE50 is the value of PMAGE at which 50% of the maturation is complete,
and  is a parameter changing the shape of the relationship. Since no information on the actual
gestational age of the children was available, the postmenstrual age was assumed to be the postnatal
age plus 9 months.
Additionally, other covariate effects were explored, including HIV infection status, MDR-TB disease
versus exposure status, ethnicity, undernutrition, the method of drug administration (crushed tablets via
an NGT, crushed tablets orally, whole tablets orally), and coadministration of antituberculosis or anti-
retroviral drugs (the regimens are shown in Table S1 in the supplemental material). Creatinine clearance
(estimated using the serum creatinine concentration and the revised formula of Schwartz et al. [47]) was
also explored as a covariate; however, it was available only for children receiving MDR-TB treatment and
not those receiving preventive therapy. Additionally, since administration of the dose 1 day prior to the
day of sampling for pharmacokinetic analysis was not observed by the study team and the exact time
and method (crushed versus whole tablets) of dose administration were not always accurately recorded,
the inclusion of a larger BOV for the absorption and bioavailability pharmacokinetic parameters was
tested for the pharmacokinetic proﬁles following a nonobserved dose (i.e., all the predose concentra-
tions) (Table 2). Model development was guided by the use of the change in the objective function value
(ΔOFV), considering decreases of 3.84 points to be signiﬁcant at a P value of 0.05 for the inclusion of
one additional parameter (denoted as the number of degrees of freedom [df]), by inspection of
goodness-of-ﬁt plots, and by the use of visual predictive checks (48). The precision of the ﬁnal parameter
estimates was evaluated using a nonparametric bootstrap with replacement (n  500).
Levoﬂoxacin dosing simulations. Simulations from the ﬁnal model were used to optimize the doses
across different weight bands. To account for the effect of age (in addition to weight), simulations were
performed using in silico patients with combinations of age and weight relevant for the population for
whom the dosing guidelines are designed. To increase the granularity of the simulations and reﬂect the
fact that children affected by TB generally have weights lower than those of children in the general
population, we used a model of weight for age developed with children with TB to generate in silico
patients: 100 males and 100 females at each 1-month age step from 0 to 18 years of age (49). Those in
the weight range of 4 to 35 kg were retained for the simulations. All in silico children were assumed to
be born at term, to be HIV uninfected, and to be dosed every 24 h with whole or crushed tablets without
an NGT. Values of AUC and Cmax were collected.
The pharmacokinetic target was the AUC expected in adults with normal renal function treated for
TB with levoﬂoxacin at the currently recommended 750-mg daily dose. The AUC target was set at 96.8
mg · h/liter, a value that was obtained after rescaling the median AUC reported by Peloquin et al. (15)
from 1,000 mg (reported in the study) to a 750-mg daily dose, since the pharmacokinetics of levoﬂoxacin
has been reported to be linear in this dose range (50). The study by Peloquin et al. (15) was chosen as
it provides the only current data on levoﬂoxacin pharmacokinetics in adults treated for TB. Reassuringly,
the AUC rescaled to 750 mg is similar to the value reported to be obtained with a 750-mg dose in healthy
adults without TB (mean AUC, 101 mg · h/liter) (10). As there may be implications for toxicity, we
compared the simulated Cmax levels with the original Cmax values from the same study (median Cmax,
15.55 mg/liter) (15), without any rescaling of the dose, since these adult TB patients received 1,000 mg
and levoﬂoxacin was reported to be well tolerated during a 7-day dosing period. The optimized dosing
regimen was designed to achieve a median AUC in each 1-kg weight band within a 20% tolerance of the
target while ensuring that the median Cmax would not exceed by 20% the value previously observed in
adults receiving the well-tolerated 1,000-mg dose. Finally, the doses in each weight band were adjusted
to account for the fact that levoﬂoxacin is currently available as a 250-mg tablet, which can be split in
half or into quarters, if needed.
Ethical considerations. Informed consent was provided by the parent(s) or legal guardian of all
participants, and assent was provided by all participants aged 7 years and older. Ethics approval for the
study was provided by the Health Research Ethics Committees of Stellenbosch University (N11/03/59)
and the University of Cape Town (397/2011).
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Chapter	4:	Clinical	and	cardiac	safety	of	long-term	levofloxacin	in	
children	treated	for	multidrug-resistant	tuberculosis		
Rationale	The	long-term	use	of	fluoroquinolones	for	TB	in	children	has	traditionally	been	limited	to	date	due	to	safety	concerns,	based	largely	on	studies	in	juvenile	animals	which	showed	that	fluoroquinolones	were	associated	with	a	destructive	arthropathy	(66,	92).		Extensive	experience	with	the	short-term	use	of	fluoroquinolones	in	children	has	however	not	found	a	meaningful	risk	of	similar	events	(55,	93),	and	the	fluoroquinolones,	including	levofloxacin,	are	routinely	recommended	for	use	in	children	for	specific	clinical	indications	such	as	MDR-TB	(126).		However,	persistent	concerns	among	healthcare	providers	remained	a	barrier	to	using	fluoroquinolones	in	children	with	MDR-TB	in	many	settings,	and	there	was	limited	safety	data	for	levofloxacin	at	the	doses	and	durations	currently	used	for	MDR-TB.		QT-interval	prolongation	is	a	class-wide	adverse	effect	of	the	fluoroquinolones	that	has	not	been	well	characterized	in	children.		Data	was,	however,	urgently	needed	as	novel	and	repurposed	antituberculosis	drugs	(clofazimine,	bedaquiline,	delamanid)	also	prolong	the	QT-interval.		Therefore,	in	addition	to	establishing	the	optimal	paediatric	dose	of	levofloxacin	for	children	with	MDR-TB,	its	long-term	safety	at	current	doses	should	also	be	demonstrated	to	inform	current	treatment	as	well	as	future	research	evaluating	levofloxacin	used	in	regimens	with	other	QT	prolonging	medications.	
	
Study	aims	The	aim	of	this	study	was	to	characterize	the	safety	of	levofloxacin	in	children	enrolled	in	the	previously	described	prospective	cohort	study	(Chapter	3).		
Methods	Children	were	enrolled	as	a	part	of	the	MDRPK1	study.		Children	who	were	a	part	of	the	previously	described	levofloxacin	pharmacokinetics	study	(Chapter	3,	aged	less	than	15	years	and	routinely	treated	with	levofloxacin)	and	who	received	levofloxacin	(10-20	mg/kg/day)	as	a	component	of	the	routinely	used	6-7	drug	treatment	regimen	for	MDR-TB	disease	had	longitudinal	follow-up	to	document	safety	(i.e.	not	those	treated	with	preventive	therapy	for	MDR-TB	exposure	who	only	contributed	cross-sectional	
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pharmacokinetic	data).		Standard	clinical	and	laboratory	monitoring	was	completed	1-2	monthly,	and	12-lead	electrocardiograms	(ECGs)	were	done	on	pharmacokinetic	sampling	days	pre-dose	and	at	2	hours	post-levofloxacin	dose	(expected	maximum	plasma	concentration)	and	QT-interval	estimated	using	the	Fridericia	correction	(QTcF)	by	one	of	two	paediatric	cardiologists.		ECGs	were	only	implemented	later	during	the	study,	based	on	emerging	data	from	adults,	so	not	all	children	contributed	to	the	analysis	on	the	QT-interval.		All	adverse	events	were	recorded,	assessed	for	attribution	to	levofloxacin,	and	graded	according	to	standard	criteria	and	summarized	using	descriptive	statistics.		Multivariable	linear	regression	was	used	to	characterize	the	association	between	QT-interval	and	levofloxacin	concentrations	(from	the	pharmacokinetic	study	in	Chapter	3).		
Results	Seventy	children	(median	age	2.1	years,	range	0.4	to	7.3)	were	included	in	this	analysis	and	were	observed	for	a	total	person	time	of	68.5	years	(median	11.6	months,	IQR	9.2	to	14.7);	41	children	contributed	ECG	data	(median	age	2.1	years,	range	0.2	to	4.8).		There	were	no	Grade	4	or	serious	adverse	events,	and	levofloxacin	was	not	permanently	discontinued	for	any	adverse	events.		There	were	few	and	only	mild	and	self-limited	musculoskeletal	events.		No	child	had	a	QTcF	>450	ms,	and	5	(13%)	and	1	(3%)	had	a	change	in	QTcF	from	pre-dose	to	2	hours	post-dose	of	30	to	60	ms	or	>60	ms	respectively.		In	multivariable	linear	regression,	only	age	(p=0.028),	and	not	change	in	levofloxacin	concentration,	was	associated	with	change	in	QTcF	from	pre-dose	to	2	hours	post-dose.		
Conclusions	and	recommendations	Levofloxacin	was	safe	and	well	tolerated	in	this	cohort	of	children	treated	for	MDR-TB.		Although	the	levofloxacin-associated	risk	of	some	events,	such	as	sleep	disturbance,	may	have	been	underestimated	and	the	risk	of	some	non-specific	events	such	as	vomiting,	alanine	aminotransferase	(ALT)	elevation,	overestimated,	this	study	provides	important	and	robust	evidence	on	the	safety	of	levofloxacin	with	currently	used	doses	and	for	long	durations.		The	lack	of	substantial	QT-interval	prolongation	in	these	children	is	reassuring	considering	plans	to	combine	levofloxacin	with	other	QT	
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prolonging	drugs	in	novel	MDR-TB	regimens.		This	study	provides	important	data	to	guide	current	and	future	MDR-TB	treatment	regimens	in	children.		
Citation	(this	study	was	accepted	for	publication	and	is	currently	in	press):		Garcia-Prats	AJ,	Draper	HR,	Finlayson	H,	Winckler	J,	Burger	A,	Fourie	B,	Thee	S,	Hesseling	AC,	Schaaf	HS.		Clinical	and	cardiac	safety	of	long-term	levofloxacin	in	children	treated	for	multidrug-resistant	tuberculosis.		Clin	Infect	Dis.	2018	May	16.	doi:	10.1093/cid/ciy416.	[Epub	ahead	of	print]		PMID:		29788331.		Reproduced	by	permission	of	Oxford	University	Press.		 	
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Abstract	Safety	concerns	persist	for	long-term	pediatric	fluoroquinolone	use.		Seventy	children	(median	age	2.1	years)	treated	with	levofloxacin	10-20	mg/kg	once	daily	for	multidrug-resistant	tuberculosis	(median	observation	time	11.8	months)	had	few	musculoskeletal	events,	no	levofloxacin-attributed	serious	adverse	events,	and	no	QTcF	>450	ms.		Long-term	levofloxacin	was	safe	and	well	tolerated.			 	
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Introduction	Levofloxacin	is	a	key	component	of	multidrug-resistant	tuberculosis	(MDR-TB)	treatment	regimens	in	children,	typically	for	9-18	months	duration	[1].		Levofloxacin	is	also	used	as	preventive	therapy	for	MDR-TB	in	children	in	some	settings	for	6	months	or	longer.		Fluoroquinolones	cause	a	destructive	arthropathy	in	juvenile	animals,	which	had	traditionally	limited	their	use	in	children	[2].		In	addition,	the	fluoroquinolones	may	cause	the	following:		Achilles	tendon	rupture;	nausea,	vomiting,	diarrhea;	central	nervous	system	effects	such	as	hyperactivity,	insomnia,	hallucinations,	and	raised	intracranial	pressure;	dysglycemia;	and	QT-interval	prolongation	[3].	Despite	these	historical	concerns,	accumulating	data	has	not	demonstrated	serious	arthropathy,	tendinopathy,	or	other	serious	safety	concerns	in	children	over	short	durations	(7-14	days)	[2,	4,	5].		Fluoroquinolones	are	now	recommended	by	the	World	Health	Organization	(WHO)	and	others	for	use	in	children	where	there	are	limited	treatment	options,	including	for	MDR-TB	[6].		However,	there	is	a	paucity	of	data	in	children	on	levofloxacin	safety	and	tolerability	over	long	durations	and	at	the	higher	doses	currently	used	for	MDR-TB	treatment.	Levofloxacin’s	QT-interval	prolonging	effects	in	children	have	also	not	yet	been	well	described,	however	this	information	is	needed	as	levofloxacin	is	increasingly	being	combined	in	treatment	regimens	with	novel	TB	drugs,	which	also	cause	QT-interval	prolongation	[7].		We	aimed	to	characterize	the	safety	and	tolerability	of	levofloxacin	in	children	routinely	treated	for	MDR-TB.		
Patients	and	Methods	
Study	design,	setting	and	population:		We	have	previously	described	the	design	of	this	prospective	observational	pharmacokinetics	study	in	Cape	Town,	South	Africa,	in	detail	[8].		Briefly,	children	were	included	in	this	study	if	they	were	<15	years	of	age,	>5	kg	body	weight,	and	routinely	treated	for	MDR-TB	with	levofloxacin.	In	this	setting,	children	with	MDR-TB	are	treated	with	6-7	drug	regimens,	which	usually	contain	a	fluoroquinolone,	amikacin,	ethionamide,	terizidone,	high-dose	isoniazid,	pyrazinamide,	ethambutol,	and	occasionally	para-aminosalicylic	acid,	linezolid	and	clofazimine.	Levofloxacin	(250	mg	tablets)	was	the	recommended	fluoroquinolone	for	children	with	
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MDR-TB	<8	years	of	age	due	to	challenges	with	administering	the	moxifloxacin	400	mg	tablet	formulation	used	in	children	>8	years	of	age	and	adults.		Levofloxacin	routine	dosing	in	our	setting	changed	from	10-15	mg/kg	once	daily	to	15-20	mg/kg	once	daily	during	the	study.	Children	are	often	hospitalized	for	1-6	months	at	the	beginning	of	MDR-TB	treatment,	and	then	complete	their	treatment	as	outpatients.	Parents	or	legal	guardians	provided	informed	consent.	The	Health	Research	Ethics	Committees	of	Stellenbosch	University	provided	study	approval	(N11/03/059).	
Data	collection:		Standard	clinical	and	laboratory	assessments	[alanine	aminotransferase	(ALT),	bilirubin,	creatinine,	potassium]	were	done	1-2	monthly	throughout	treatment.		All	adverse	events	were	recorded,	assessed	for	attribution	to	levofloxacin,	and	graded	for	severity	(DAIDS	Grading	Table,	Version	1.0,	August	2009)	[9].		Twelve-lead	electrocardiograms	(ECGs)	were	performed	in	triplicate	on	pharmacokinetic	sampling	days	just	prior	to	the	pharmacokinetic	blood	draws	pre-dose	and	at	2	hours	post-dose	(expected	maximum	levofloxacin	plasma	concentration).		ECGs	were	only	started	later	during	the	study	and	were	interpreted	by	one	of	two	pediatric	cardiologists;	the	measured	QT-interval	was	corrected	using	the	Fridericia	correction	(QTcF)	and	the	mean	of	the	triplicate	QTcF	values	used	for	analysis.		Pre-dose	and	2	hour	levofloxacin	concentrations	were	obtained	according	to	previously	described	methods	[8];	concentrations	below	the	limit	of	quantification	(BLQ)	were	assigned	a	value	of	zero	for	this	analysis.	
Analysis:		Demographic	and	clinical	characteristics,	and	QTcF	results	were	summarized	using	descriptive	statistics.		The	frequency	of	adverse	events	was	reported	by	grade	for	all	events,	and	also	for	events	that	were	possibly,	probably	or	definitely	related	to	levofloxacin.		Person	time	was	calculated	from	the	baseline	study	assessment	until	the	treatment	completed	or	the	last	available	study	visit.		Event	rates	were	reported	per	100	person-years.			Multivariable	linear	regression	was	done	to	characterize	the	association	between	the	change	in	QTcF	with	the	change	in	levofloxacin	concentration,	controlling	for	gender,	HIV	status,	and	age.		The	standard	errors	were	adjusted	to	account	for	one	patient	with	two	sets	of	levofloxacin	concentatration	and	ECG	data	from	different	days.			Stata/SE	14.0	was	used	to	analyze	the	data	(StataCorp.		2105.		Stata	Statistical	Software:	Release	
15.	College	Station,	TX:	StataCorp	LP).		
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Results	Seventy	children	(median	age:	2.1	years,	range	0.4,	7.3)	were	included	in	the	safety	analysis;	38	(54%)	were	male	and	12	(17%)	were	HIV-infected	(see	Supplemental	Table	1).		These	children	were	observed	for	a	total	duration	of	68.5	person-years	(median	11.6	months,	interquartile	range	[IQR]	9.2-14.7).		Table	1	shows	all	adverse	events	and	those	at	least	possibly	related	to	levofloxacin.		There	were	no	Grade	4	or	any	serious	adverse	events	attributed	to	levofloxacin,	and	no	adverse	event	resulted	in	permanent	levofloxacin	discontinuation.	ECG	results	were	available	in	41	children,	median	age	2.1	years	(range:	0.2-4.8	years);	20	(49%)	were	male	and	10	(24%)	were	HIV-infected.		All	HIV-infected	children	were	on	antiretroviral	therapy;	9	were	on	lopinavir/ritonavir	with	two	nucleoside	reverse	transcriptase	inhibitors	(NRTIs)	and	1	was	on	efavirenz	with	two	NRTIs.			Three	patients	had	one	ECG	at	2	hours	only	and	two	patients	had	one	ECG	at	both	0	and	2	hours.		There	were	38	pre-dose	(0	hour)	ECGs,	and	41	2-hour	ECGs,	with	37	children	contributing	38	paired	results.		The	mean	[standard	deviation	(SD)]	QTcF	was	359	ms	(21.0)	at	0-hours	and	365.4	ms	(26.6)	at	2-hours;	no	QTcF	was	>450	ms.		The	mean	(SD)	change	in	QTcF	from	0	to	2	hour	reading	was	4.7	ms	(27.3).		Five	(13%)	had	a	change	in	QTcF	of	30	to	<60	ms	from	0	to	2	hour	readings,	and	1	(3%)	had	a	change	>60ms.		For	the	children	with	paired	ECG	results,	the	mean	(SD)	levofloxacin	concentration	pre-dose	was	0.33	μg/mL	(0.61)	and	at	2	hours	was	8.57	μg/mL	(2.55);	11	(28.9%)	pre-dose	concentrations	were	BLQ.		Figure	1	shows	the	change	in	QTcF	vs.	change	in	levofloxacin	concentrations	from	0	to	2	hours.		In	multivariable	linear	regression,	only	age	(p=0.028)	was	significantly	associated	with	change	in	QTcF	from	0	to	2	hours,	with	every	1	year	increase	in	age	associated	with	a	7.36	ms	increase	in	QTcF	change	(Supplemental	Table	2).		The	one	patient	treated	with	clofazimine,	known	to	prolong	the	QT-interval,	had	a	QTcF	change	of	44	ms.			
Discussion	In	this	cohort	of	children	with	MDR-TB,	long-term	levofloxacin	treatment	was	safe	and	well-tolerated.		The	few	musculoskeletal	complaints	(pain,	arthralgia)	were	mild	and	
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self-limited.	Mild	musculoskeletal	complaints	and	those	in	young	children	may	have	been	underestimated,	however	it	is	unlikely	that	more	severe	events	were	missed,	such	as	those	having	objective	signs	of	arthritis	or	those	resulting	in	gait	abnormalities	or	failure	to	bear	weight.		This	should	be	reassuring	to	clinicians	and	TB	programs,	some	of	whom	are	still	hesitant	to	treat	children	affected	by	TB	with	fluoroquinolones.	Hyperactivity	and	sleep	disturbances	have	been	well	described	in	children	treated	with	fluoroquinolones	[10],	however	we	observed	few	such	events.		These	may	be	underestimated	due	to	children	being	admitted	early	in	their	treatment	to	the	TB	hospital	without	their	caregivers,	which	may	have	obscured	reported	changes	in	behavior	and	sleep	patterns.		The	most	common	events	overall	were	non-specific,	such	as	rash,	nausea,	vomiting,	and	ALT	elevation.	These	likely	represent	overestimates	of	the	rate	of	these	events	due	to	levofloxacin;	more	likely	these	were	due	to	other	medications	such	as	isoniazid,	pyrazinamide	(ALT	elevation)	and	ethionamide	(nausea,	vomiting).		We	erred	on	the	side	of	attributing	these	events	at	least	possibly	to	levofloxacin,	unless	there	was	strong	evidence	of	the	relationship	with	another	medication.		The	poor	palatability	of	levofloxacin	formulation,	especially	when	crushed,	may	have	contributed	to	some	of	the	nausea	and	vomiting.			No	child	had	a	QTcF	>450	ms,	and	few	had	a	change	>30	ms	from	pre-dose	to	2	hours.	We	did	not	observe	a	relationship	between	QTcF	and	levofloxacin	concentration.		Fluoroquinolone-associated	QT	prolongation	is	mediated	through	dose-dependent	inhibition	of	cardiac	potassium	channels	that	varies	by	agent,	with	moxifloxacin,	gatifloxacin	having	a	more	potent	effect	than	levofloxcin,	ciprofloxacin	and	ofloxacin	[11].	In	previous	adult	studies,	1000	mg	levofloxacin	resulted	in	a	mean	change	in	QTc	of	3.5-4.8	ms	compared	to	placebo	[12],	and	doses	as	high	as	1500	mg	in	adults	had	a	minimal	impact	on	QTc	[13].		This	is	consistent	with	our	findings.		The	association	of	older	age	with	QTcF	change	in	our	cohort	needs	further	evaluation.		A	limitation	to	our	study	is	that	these	children	did	not	have	true	pre-treatment	QTcF	values	for	comparison,	as	all	had	already	been	on	levofloxacin	for	atleast	one	week	at	the	time	ECGs	were	completed.		However,	the	pre-dose	concentrations	were	generally	low,	including	many	that	were	BLQ,	so	the	change	in	QTcF	from	pre-dose	remains	a	useful	evaluation.		This	data	therefore	also	provides	support	for	using	levofloxacin	in	
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combination	with	other	QT-prolonging	TB	medications	such	as	clofazimine,	bedaquiline	and	delamanid.	It	also	establishes	a	baseline	for	QT-intervals	in	children	treated	with	levofloxacin-containing	MDR-TB	regimens	for	interpreting	cardiac	safety	results	of	ongoing	pediatric	bedaquiline	and	delamanid	trials.	A	limitation	of	our	study	is	the	lack	of	children	>8	years	of	age	who	may	have	a	different	adverse	event	profile,	would	likely	be	able	to	report	subjective	symptoms	better,	and	may	have	different	QT	effects,	and	should	be	included	in	future	studies.	In	summary,	levofloxacin,	at	doses	up	to	20	mg/kg	once	daily,	was	safe	and	well-tolerated	and	should	remain	a	mainstay	of	pediatric	MDR-TB	treatment.		
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	Table	1.		Adverse	events	in	children	(n=70)	treated	for	multidrug-resistant	tuberculosis	with	levofloxacin	
	 All	adverse	event	by	grade	 Adverse	effects	possibly,	probably,	definitely	attributed	to	levofloxacin	by	grade	
Adverse	Event	 #	of	patients	with	event	 Grade	1	 Grade	2	 Grade	3	 Grade	4	
total	#	of	events	
Event	Rate																							(per	100	person-years)	
#	ofpatients	with	event	 Grade	1	 Grade	2	 Grade	3	 Grade	4	
total	#	of	events	
Event	Rate																							(per	100	person-years)	Arthralgia	 3	 3	 0	 0	 0	 3	 4.4	 2	 2	 0	 0	 0	 2	 2.9	Arthritis	 0	 0	 0	 0	 0	 0	 --	 0	 0	 0	 0	 0	 0	 --	Pain	other	than	trauma	 11	 11	 0	 0	 0	 11	 16.1	 4	 4	 0	 0	 0	 4	 5.8	Headache	 4	 4	 0	 1	 0	 5	 7.3	 2	 1	 0	 1	 0	 2	 2.9	Neurosensory	alteration	 1	 1	 0	 0	 0	 1	 1.5	 0	 0	 0	 0	 0	 0	 	--	Insomnia	 1	 0	 1	 0	 0	 1	 1.5	 1	 0	 1	 0	 0	 1	 1.5	Fatigue/malaise	 1	 1	 0	 0	 0	 1	 1.5	 0	 0	 0	 0	 0	 0	 	--	Nausea	 12	 13	 0	 0	 0	 13	 19.0	 8	 9	 0	 0	 0	 9	 13.1	Vomiting	 19	 23	 1	 0	 0	 24	 35.1	 14	 16	 0	 0	 0	 16	 23.4	Anorexia	 11	 8	 5	 0	 0	 13	 19.0	 7	 4	 3	 0	 0	 7	 10.2	Cutaneous	reaction	 12	 8	 6	 0	 0	 14	 20.4	 7	 3	 4	 0	 0	 7	 10.2	Pruritus	 13	 16	 1	 0	 0	 17	 24.8	 7	 7	 1	 0	 0	 8	 11.7	ALT	elevation	 22	 17	 3	 2	 5	 27	 39.4	 16	 16	 2	 0	 0	 18	 26.3	Bilirubin	elevation	 0	 0	 0	 0	 0	 0	 --	 0	 0	 0	 0	 0	 0	 --	Total	person	time	of	observation	=	68.5	years	
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Figure	1.		Change	in	QTcF	versus	change	in	levofloxacin	concentration	in	children	treated	
for	multidrug-resistant	tuberculosis	 	
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Supplemental	Table	1.	Demographic	and	clinical	characteristics	of	children	with	
multidrug-resistant	tuberculosis	treated	with	levofloxacin	(n=70)	Age	at	enrollment	(%)	 	0-2	years	 31	(44.3)	2-5	years	 35	(50.0)	6-15	years	 4	(5.7)	Male	sex	(%)	 38	(54.3)	Ethnicity	(%)	 	Black	 43	(61.4)	Mixed	race	 27	(38.6)	Certainty	of	TB	diagnosis	(%)		 	Bacterioloical	confirmation	 22	(31.4)	Probable	TB	 26	(68.6)	TB	disease	type	(%)	 	PTB	only	 54	(77.1)	EPTB	only	 4	(5.7)	PTB	and	EPTB	 12	(17.1)	HIV-infected		(%)	 12	(17.1)	If	HIV-infected,	ART	regimen	[n=12]	 	Efavirenz	+	2	NRTIs	 3	(25%)	Lopinavir/ritonavir	+	2	NRTIs	 9	(75%)	Weight-for-age-Z-score	<-2.0	(%)	[n	=	69]a	 16	(23.2)	Height-for-age-Z-score	<-2.0	(%)	[n	=	69]a	 24	(34.8)	aThe	sample	size	is	less	than	70	due	to	missing	data	NRTI	=	nucleoside	reverse	transcriptase	inhibitor	 	
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Supplemental	Table	2.		Univariable	and	multivariable	linear	regression	of	change	in	
QTcF	prior	to	and	2	hours	post-levofloxacin-dose	in	children	with	multidrug-resistant	
tuberculosis	(N=38)	
	 Univariable	 	 Multivariable	
		 Coefficient	β															(95%	CI)	 p-value	 	 Coefficient	β															(95%	CI)	 p-value	Change	in	levofloxacin	concentration	(μg/mL)	 -2.14		(-5.56	to	1.28)	 0.212	 	 -0.38		(-2.19	to	1.43)	 0.673	Age	in	years	 9.18		(3.60-14.77)	 0.002	 	 7.36		(0.86	-	13.87)	 0.028	HIV	status	 -20.01		(-40.03	to	0.04)	 0.050	 	 -12.15		(-36.53	to	12.23)	 0.319	Male	gender	 9.07		(-8.15	to	26.28)	 0.292	 	 4.54		(-11.47	to	20.54)	 0.569		*R2	=	0.238;	QTcF=	QT	interval	corrected	using	the	Fridericia	method	
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Chapter	5:	Pharmacokinetics,	safety	and	dosing	of	novel	levofloxacin	
dispersible	tablets	in	children	with	exposure	to	multidrug-resistant	
tuberculosis		
Rationale	The	TB-CHAMP	trial	(ISRCTN92634082)	is	a	phase	III	cluster	randomised	placebo-controlled	trial	to	assess	the	efficacy	of	levofloxacin	vs.	placebo	for	prevention	of	TB	in	child	household	contacts	of	adult	MDR-TB	source	cases.		For	the	trial,	a	levofloxacin	100	mg	dispersible	tablet	was	developed	for	the	trial	by	Macleods	Pharmaceuticals	(Mumbai,	India).		In	order	to	characterize	exposures	with	this	novel	formulation	in	the	target	population	(young	children	below	5	years	of	age)	prior	to	utilizing	it	in	this	large	phase	3	efficacy	trial	(n=1556),	a	lead-in	pharmacokinetic	study	was	designed.	Macleods	have	since	submitted	this	formulation	for	WHO	Prequalification	and	is	making	it	commercially	available,	so	this	study	would	potentially	inform	its	use	in	routine	care	in	addition	to	informing	its	use	in	the	TB-CHAMP	trial.		This	work	builds	directly	on	the	work	from	Chapter	3,	in	which	we	identified	questions	regarding	the	potential	effects	of	formulation	on	the	levofloxacin	exposures	observed	in	that	study.			
Study	Aims	The	aim	of	this	study	was	to	characterize	the	pharmacokinetics,	safety	and	optimal	dosing	of	a	novel	100	mg	dispersible	tablet	formulation	of	levofloxacin	in	children	with	MDR-TB	exposure,	to	inform	its	use	in	the	context	of	a	large	phase	3	preventive	therapy	trial.		
Methods	This	was	an	open-label	pharmacokinetic	lead-in	study	to	the	TB-CHAMP	trial.		Children	less	than	5	years	of	age	who	were	household	contacts	of	an	adult	MDR	pulmonary	TB	index	case	diagnosed	during	the	previous	6	months	were	eligible.		Exclusion	criteria	included	prevalent	TB	disease	at	enrolment,	receipt	of	preventive	therapy	with	isoniazid	or	a	fluoroquinolone	for	≥	16	weeks,	or	known	concurrent	exposure	to	an	isoniazid-susceptible	source	case.		Levofloxacin	100	mg	dispersible	tablets	were	prescribed	according	to	weight	bands	(15-20	mg/kg	once	daily).		Doses	were	dispersed	
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in	2.5-10	mL	of	clean	water	in	a	syringe	and	cup,	and	administered.		The	dosing	containiner	was	then	rinsed	with	clean	water	and	administered.	Pharmacokinetic	sampling	was	performed	7-14	days	after	starting	levofloxacin,	with	samples	taken	just	prior	to,	and	at	1,	2,	4,	6,	and	8	hours	after	an	observed	dose.		Assays	were	performed	at	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology	according	to	the	same	method	described	in	Chapter	3	(LC	MS/MS).		NLME	modelling	was	used	to	analyse	data	from	the	current	study	pooled	with	the	levofloxacin	data	reported	in	Chapter	3	of	this	dissertation	from	children	receiving	the	standard	adult	250	mg	tablet	formulation,	as	the	population,	site,	sampling	schema,	sampling	procedures	and	laboratory	assays	were	similar	to	this	study.		After	refitting	the	model	with	the	new	data,	pharmacokinetic	parameters	were	re-estimated.		Optimal	weight-banded	doses	for	the	100	mg	dispersible	tablet	were	estimated	using	clinical	trial	simulations	targeting	the	same	AUC	as	in	Chapter	3	(96.8	mg·h/L).		Any	adverse	events	occurring	during	the	time	the	child	was	on	the	study	drug	were	reported,	attribution	to	levofloxacin	assessed	and	graded	according	to	standard	Division	of	AIDS	(DAIDS)	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	(Corrected	version	2.1,	July	2017)	(127).		
Results	Twenty-four	children	(median	age	2.1	years;	IQR	1.2	to	2.7)	completed	the	study;	none	were	HIV-infected.		The	levofloxacin	pharmacokinetic	model	structure	was	the	same	and	the	parameter	values	not	significantly	different	from	the	previous	analysis,	except	for	the	bioavalability	of	the	new	dispersible	tablets.	When	the	new	dispersible	tablet	was	chosen	as	reference	for	biavailability	(F=1),	the	standard	250	mg	adult	tablets	used	in	the	previous	study	were	found	to	be	41%	less	bioavailable.		The	value	of	CL/F	for	a	typical	2-year	old,	12	kg	child	was	2.8	L/h.		After	adjusting	for	full	maturation	and	using	allometric	scaling	to	resize	to	a	70-kg	adult,	the	value	of	CL/F	from	this	study	for	a	typical	2-year	old	(2.8	L/h)	becomes	11.4	L/h,	which	is	much	more	consistent	with	scaled	values	from	published	adult	(CL/F	8.35-9.16)	and	pediatric	studies	(CL/F	11.6-15.4)	compared	to	the	value	from	the	study	in	Chapter	3	(18.8	L/h)	(128).		Optimal	weight-banded	doses	with	the	dispersible	tablet	formulation	were	simulated;	median	mg/kg	doses	for	weight	bands	varied	from	14.3	mg/kg	in	the	3	to	4	kg	weight	band	up	to	25	mg/kg	from	7	to	<11	kg	weight	band.		No	patients	had	any	grade	3	or	4	adverse	events	or	any	serious	advents.	
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Conclusions	and	recommendations	Exposures	in	children	receiving	this	novel	100	mg	dispersible	levofloxacin	tablet	formulation	were	much	higher	than	previously	observed	in	children	receiving	a	standard	250	mg	adult	tablet,	due	to	higher	bioavailability	of	the	new	formulation.	Our	proposed	weight-banded	dosing	can	be	used	for	this	novel	levofloxacin	formulation	for	the	TB-CHAMP	trial	and	also	by	TB	programmes	as	this	formulation	becomes	increasingly	available	and	used	in	routine	care	settings.		This	study	highlights	the	importance	of	carefully	investigating	formulation-related	factors	in	paediatric	antituberculosis	therapeutics.		
Citation:		Manuscript	has	been	submitted	to	Antimicrobial	Agents	and	Chemotherapy	and	is	under	review.				 	
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Abstract	
Background:	Levofloxacin	is	used	for	prevention	and	treatment	of	multidrug-resistant	tuberculosis	(MDR-TB)	in	children.		
Objectives:	To	characterize	the	pharmacokinetics,	optimal	paediatric	dosing	and	safety	of	a	novel	100	mg	scored	dispersible	levofloxacin	formulation	(Macleods	Pharmaceuticals)	in	children.	
Patients	and	methods:	In	this	open-label	pharmacokinetic	study,	children	aged	<5	years	with	household	MDR-TB	exposure	received	daily	weight-banded	doses	of	levofloxacin	15-20	mg/kg	using	100	mg	tablets	dispersed	in	water.	After	7-14	days,	children	were	sampled	pre-dose	and	at	1,	2,	4,	6	and	8	hours	post-dose.	Nonlinear	mixed-effects	modelling	was	used	to	analyse	data,	which	was	pooled	with	previously	published	data	from	109	children	with	MDR-TB	receiving	routinely	available	adult	(250	mg)	levofloxacin	tablets.	Weight-band	dosing	was	optimised	using	simulations	targeting	the	levofloxacin	adult	exposure	achieved	with	750	mg.	Adverse	events	were	systematically	recorded.			
Results:	24	HIV-uninfected	children	completed	pharmacokinetic	sampling,	median	(IQR)	age	2.1	years	(1.2	to	2.7).		Levofloxacin	pharmacokinetic	parameters	were	similar	to	those	previously	published,	except	for	41%	lower	bioavailability	of	standard	adult	250	mg	tablets	compared	to	the	novel	dispersible	tablets.	The	CL/F	for	a	typical	2-year	old,	12	kg	child	was	2.8	L/h,	consistent	with	previously	reported	adult	values,	after	adjusting	for	body	size	with	allometric	scaling.	There	were	no	grade	3	or	4	adverse	events,	nor	any	serious	events.			
Conclusions:	Exposures	in	children	receiving	the	100	mg	dispersible	levofloxacin	tablets	were	much	higher	than	previously	observed	due	to	higher	bioavailability	of	this	formulation.	Our	proposed	weight-banded	dosing	can	be	used	for	this	novel	levofloxacin	formulation.		 	
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Introduction	Levofloxacin	is	an	increasingly	important	medication	for	the	treatment	and	prevention	of	multidrug-resistant	(MDR)	tuberculosis	(TB)	in	adults	and	children.		Levofloxacin	is	well-absorbed	after	oral	administration	and	primarily	eliminated	unchanged	in	the	urine.1		Its	pharmacokinetics	in	children	have	now	been	evaluated	in	multiple	studies	with	somewhat	variable	results.2-5		A	major	barrier	to	its	use	in	young	children	to	date	has	been	the	lack	of	a	widely	available	child-friendly	formulation.			In	most	high	TB	burden	settings,	adult	250	mg	levofloxacin	tablets	are	administered	to	young	children	after	splitting	or	crushing	and	mixing	with	water	or	food.		In	addition	to	inaccurate	dosing	and	poor	palatability,	the	effect	of	this	formulation	manipulation	on	levofloxacin	exposures	is	unknown.		A	100	mg	scored	dispersible	taste-masked	tablet	has	been	developed	(Macleods	Pharmaceutical,	Ltd.,	Mumbai,	India)	and	has	now	received	World	Health	Organization	(WHO)	Pre-qualification,	with	an	expected	increase	in	routine	use	for	TB.		The	TB-CHAMP	trial	(ISRCTN92634082)	is	a	phase	III	cluster	randomised	placebo-controlled	trial	to	assess	the	efficacy	of	levofloxacin	vs.	placebo	for	prevention	of	TB	in	child	household	contacts	of	adult	MDR-TB	source	cases,	and	plans	to	use	this	novel	100-mg	levofloxacin	formulation.			As	part	of	the	TB-CHAMP	trial,	an	open-label	lead-in	study	was	undertaken	to	characterize	the	pharmacokinetics	and	short-term	safety	of	the	levofloxacin	100-mg	dispersible	tablet	in	children	less	than	5	years	of	age,	the	intended	target	population	for		the	TB-CHAMP	trial.				
Patients	and	Methods	
Study	design:		Prospective	descriptive	pharmacokinetic	and	safety	study.	
Setting	and	population:	The	study	was	undertaken	in	Cape	Town,	South	Africa.		Children	less	than	5	years	of	age	were	eligible	for	this	lead-in	study	if	they	were	a	household	contact	of	an	adult	MDR	pulmonary	TB	index	case	diagnosed	during	the	previous	6	months,	and	written	informed	consent	was	provided	by	the	parent	or	legal	guardian.	Exclusion	criteria	in	children	included	prevalent	TB	disease	at	enrolment,	receipt	of	preventive	therapy	with	isoniazid	or	a	fluoroquinolone	for	≥	16	weeks,	TB	treatment	in	
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the	previous	12	months,	known	concurrent	exposure	to	an	isoniazid-susceptible	source	case,	or	known	myasthenia	gravis	or	Guillain-Barré	syndrome.	
Levofloxacin	dosing	and	pharmacokinetic	sampling:	Levofloxacin	100	mg	dispersible	tablets	were	prescribed	according	to	weight-bands,	targeting	a	dose	of	15-20	mg/kg	(Supplemental	Table	5.1).		Doses	were	prepared	by	placing	the	tablets	in	a	plastic	dosing	cup	or	syringe,	adding	2.5-10	mL	of	clean	water,	swirling	the	cup	or	shaking	the	syringe	until	the	tablets	were	fully	dispersed,	and	then	it	was	administered.	An	additional	2.5-10	mL	of	clean	water	was	added	to	the	dosing	container,	swirled	or	shaken	to	suspend	any	remaining	medication	particles,	and	administered.		Pharmacokinetic	sampling	was	performed	7-14	days	after	starting	levofloxacin.		An	observed	levofloxacin	dose	was	given	after	an	overnight	fast,	and	samples	taken	just	prior	to,	and	at	1,	2,	4,	6,	and	8	hours	after	the	dose.	A	standard	breakfast	was	offered	1	hour	post-dose.		
Levofloxacin	assay:	Levofloxacin	concentrations	were	quantified	by	high	performance	liquid	chromatography	with	tandem	mass	spectrometry	(LC-MS/MS)	using	a	validated	method	as	previously	described.5		
Safety:		All	treatment	emergent	adverse	events,	i.e.	adverse	events	that	occurred	during	the	time	the	child	was	receiving	the	study	levofloxacin	formulation,	were	recorded,	assessed	for	attribution	to	levofloxacin,	and	graded	for	severity	according	to	standard	DAIDS	Grading.6	
Population	pharmacokinetic	model	and	dosing	simulations:	Nonlinear	mixed-effects	modelling	implemented	in	NONMEM	(version	7.4)7	was	used	to	analyse	data	from	the	current	study	pooled	with	our	previously	published	levofloxacin	data.5	The	previous	study	included	109	children	with	MDR-TB	receiving	the	routinely	available	standard	adult	250	mg	solid	tablet	formulation	(Austell,	Johannesburg,	South	Africa),	administered	either	as	tablets	crushed,	mixed	in	water	and	administered	orally	or	by	nasogastric	tube	if	the	child	refused	to	swallow	it,	or	swallowed	whole.		The	study	population,	site,	sampling	schema,	sampling	procedures	and	laboratory	assays	were	very	similar	to	the	current	study.		The	pharmacokinetic	model	from	the	previous	study	was	used	as	a	starting	point,	but	the	model	structure	was	revisited	and	the	model	parameters	re-estimated	when	fitting	the	new	data.		Improvements	in	objective	function	value	(ΔOFV)	and	goodness	of	fit	plots	were	used	for	model	development.	The	
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final	model	was	then	used	to	optimise	weight-band	dosing	targeting	the	levofloxacin	AUC	achieved	in	adults	with	TB	with	normal	renal	function	receiving	a	750	mg	daily	dose,	set	as	96.8	mg·h/L	based	on	rescaling	previously	reported	values	in	adults	with	TB	receiving	a	1000	mg	dose.5,	8		
Ethical	considerations:	Informed	consent	was	provided	by	the	parent/s	or	legal	guardians.	Ethics	approval	for	the	study	was	provided	by	the	Health	Research	Ethics	Committees	of	Stellenbosch	University	(M16/02/009).		
Results	
Study	population:		Twenty-eight	children	were	enrolled.	One	child	was	withdrawn	prior	to	pharmacokinetic	sampling;	27	children	contributed	to	safety	data,	however	3	children	were	unable	to	complete	pharmacokinetic	sampling	due	to	difficulties	with	phlebotomy,	resulting	in	24	completing	the	study.		The	median	age	of	children	completing	pharmacokinetic	sampling	(n=24)	was	2.1	years	(interquartile	range	1.2	to	2.7);	none	were	HIV-infected,	3	(13%)	had	a	WAZ	less	than	-2	(complete	baseline	characteristics	are	shown	in	Supplemental	Table	5.2).				
Pharmacokinetic	model:			A	total	of	144	levofloxacin	concentrations	were	available	for	analysis,	with	two	pre-dose	samples	below	the	limit	of	quantification.	The	levofloxacin	pharmacokinetic	model	structure	was	the	same	and	the	parameter	values	not	significantly	different	from	the	previous	analysis,	as	shown	in	Table	5.1,	except	for	the	bioavailability	of	the	new	dispersible	tablets.	When	the	new	dispersible	tablet	was	chosen	as	reference	for	biavailability	(F=1),	the	tablets	used	in	the	previous	study	were	found	to	be	41%	less	bioavailable	(ΔOFV=132,	1	extra	degree	of	freedom,	p<10-6).	Visual	predictive	checks	are	provided	in	Figure	5.1,	showing	how	the	model	suitably	fits	the	data	of	both	the	previous	and	the	current	study,	and	the	large	difference	in	exposure	due	to	the	change	in	bioavailability.	The	value	of	CL/F	for	a	typical	2-year	old,	12	kg	child	was	2.8	L/h.		After	adjusting	for	full	maturation	and	using	allometric	scaling	to	resize	to	a	70-kg	adult,	the	value	becomes	11.4	L/h,	which	is	more	consistent	with	scaled	values	from	published	adult	(CL/F	8.35-9.16)	and	pediatric	studies	(CL/F	11.6-15.4)	that	we	previously	summarised	compared	to	the	standard	250	mg	adult	tablet	we	previously	studied	(CL/F	18.8	L/h).5	Interestingly,	administration	with	nasogastric	tube	
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was	not	found	to	affect	the	speed	of	absorption	of	the	dispersible	tablets,	unlike	with	the	standard	250	mg	tablets	in	the	previous	study	for	which	the	absorption	lag	time	was	shortened	when	nasogastric	tube	was	used	for	drug	administration.		
Simulated	exposures:	Proposed	weight-banded	dosing	is	shown	in	Table	5.2.	Simulated	maximum	plasma	concentrations	(Cmax)	and	area	under	the	concentration	time	curve	(AUC0-24)	with	this	dosing	approach	are	shown	in	Figure	5.2.	
Safety:	Two	participants	had	three	adverse	events	that	were	at	least	possibly	related	to	levofloxacin,	including	vomiting	(grade	1),	difficulty	sleeping	(grade	1),	and	anorexia	(grade	2).		All	adverse	events	and	those	at	least	possibly	related	are	shown	in	Supplemental	Tables	5.2	and	5.3.		No	patients	had	any	grade	3	or	4	adverse	events,	any	serious	advents	and	none	discontinued	levofloxacin	because	of	potentially	drug-related	adverse	events.				
Conclusions	This	novel	pediatric	levofloxacin	dispersible	tablet	resulted	in	substantially	higher	exposures	in	children	relative	to	the	adult	250	mg	solid	tablets	used	in	previous	pediatric	pharmacokinetic	studies	by	our	group,5	with	bioavailability	primarily	accounting	for	this	difference.		Our	previously	published	work	included	children	receiving	levofloxacin	either	for	MDR-TB	treatment,	often	in	combination	with	at	least	five	other	TB	medications,	or	for	MDR-TB	preventive	therapy,	given	in	combination	with	isoniazid	and	ethambutol.		We	cannot	rule	out	an	interaction	with	other	TB	drugs	that	might	explain	the	difference	in	exposures	between	the	two	studies,	however	this	is	unlikely,	considering	no	such	interactions	have	been	previously	described.	This	may	be	worth	evaluating	in	future	studies.		The	difference	in	bioavailability	we	describe	is	likely	due	to	the	effect	of	formulation.			The	effect	of	formulation	is	increasingly	being	recognized	as	an	important	contributor	to	drug	exposure,	and	the	effect	of	formulation	may	differ	between	children	and	adults.9,	10	The	value	for	levofloxacin’s	apparent	oral	clearance	(CL/F)	with	the	100	mg	dispersible	tablets,	after	adjusting	for	body	size	with	allometric	scaling,	is	lower	than	we	described	previously	with	the	250	mg	immediate	release	tablets,	but	consistent	with	most	previously	published	values.5		Moreover,	when	choosing	the	bioavailability	of	the	new	formulation	as	reference	(value	of	1),	and	thus	
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rescaling	the	bioavailability	of	the	previous	study	to	0.587,	the	disposition	parameters	of	the	previous	analysis	also	become	consistent	with	the	historical	reports	on	levofloxacin	pharmacokinetics.	This	suggests	the	routinely	used	levofloxacin	formulation	used	in	our	previous	work	(and	in	routine	TB	care	in	South	Africa)	had	unexpectedly	low	bioavailability.		Additional	work	to	understand	potential	formulation	effects	are	warranted	given	the	widespread	global	use	of	the	250	mg	levofloxacin	tablets	in	children	with	TB.	The	lack	of	safety	concerns	in	this	study	is	reassuring	and	consistent	with	previous	reports.11		Careful	safety	monitoring	should	however	continue	in	children	receiving	levofloxacin,	particularly	with	longer	treatment	durations;	the	main	TB-CHAMP	trial	will	contribute	such	data.	The	levofloxacin	formulation	reported	on	here	is	expected	to	be	used	widely	by	national	TB	progammes	for	treatment	of	children	in	routine	settings.		Our	proposed	weight-banded	doses	can	be	adopted	by	programmes	for	dosing	in	children	with	this	formulation.		International	dosing	recommendations	for	children	with	TB	should	be	updated	for	levofloxacin	taking	into	consideration	emerging	data	and	new	formulations	for	levofloxacin,	as	is	needed	for	other	second-line	antituberculosis	medications.			
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Table	5.1.	Pharmacokinetic	parameter	values	of	levofloxacin	in	children	with	multidrug-resistant	
tuberculosis	disease	or	exposure	
PK	parameter	 Typical	value	(95%	CI)	 Variability	(95%	CI)		Current	pooled	analysis	(n=24	+	109)	 Previous	study*	(n=109)	 Current	pooled	analysis	(n=24	+	109)	 Previous	study*	(n=109)	
CL	(L/h)a	 HIV-:	2.80	(2.43,	3.19)	HIVd+:	-16.0%	(-26.3%,	-4.39%)	 HIV-:	2.76	(2.57,	2.94)	HIV+:	-15.9%	(-26.6%,	-5.93%)	 BSV:	14.3%		(10.3%,	16.3%)	 BSV:	15.2%		(10.6%,	19.0%)	
Vc	(L)a	 12.0	(10.1,	13.7)	 11.3	(6.40,	12.8)	 	 	
Q	(L/h)a	 0.227	(0.109,	0.616)	 0.467	(0.195,	2.79)	 	 	
Vp	(L)a	 2.08	(1.55,	15.2)	 2.00	(1.49,	22.7)	 	 	
Tlag	(h)	 Oral	Dosing:	0.183	(0.0114,	0.465)	NGTe:	-71.0%	(-99.3%,	-22.6%)	
Oral	dosing:	0.242	
(0.0385,	0.654)	
NGT:	-85.6%	
(-99.3%,	-34.6%)	
BOV:	116%		(44.3%,	349%)	 BOV:	130%		(30.9%,	303%)	
ka	(1/h)	 1.86	(1.45,	2.85)	 1.61	(0.855,	2.78)	 BOV:	66.4%		(54.9%,	79.5%)	 BOV:	64.8%		(43.4%,	80.9%)	
F	(-)	 Dispersible	tablet:	1	FIXED	(reference)	Standard	
tablet:	-41.3%	(-49.9%,	-33.3%)	
Standard	tablet:	0.587	
FIXED	
BOV:	23.2%		(16.5%,	29.4%)	 BOV:	21.8%		(13.7%,	28.4%)	
	
Other	parameters	(95%	CI)	
Current	pooled	analysis	 Previous	study*	 Other	parameters	(95%	CI)	 Current	pooled	analysis	 Previous	study*	
Scaling	of	BOV	in	F		
for	unobserved	doses	(-)b	 4.28-fold		(3.46,	6.02)	 4.48-fold	(3.31,	7.08)	 	 	 	
PMAGE50	(months)	 10.7		(8.20,	13.0)	 10.6	(7.55,	12.9)	 γ 	(-)	 3.53	(1.94,	4.99)	 3.39	(1.42,	4.98)	
Additive	error	(mg/	L)c	 0.0160	FIXED		(20%	of	LLOQ)	 0.0160	FIXED		(20%	of	LLOQ)	 Proportional	error	(%)		 12.7%	(11.2%,	14.2%)	 11.6%	(10.0%,	12.7%)	a	All	clearance	and	volume	parameters	have	been	scaled	with	allometric	scaling.	The	typical	values	reported	here	refer	to	a	12-kg	child,	aged	2	years.	Age	affects	clearance,	since	maturation	was	used.	At	2	years	after	birth,	maturation	is	predicted	to	be	97.9%	complete.	b	This	is	a	multiplicative	factor	increasing	the	BOV	in	bioavailability	for	pre-dose	concentrations	following	an	unobserved	dose	c	The	estimate	of	the	additive	error	was	hitting	the	stipulated	lower	boundary	(20%	of	LLOQ),	so	it	was	fixed	to	this	value.	dThe	effect	of	HIV	could	not	be	evaluated	in	the	children	in	the	current	study,	since	none	was	HIV-infected.	eThe	effect	of	nasogastric	tube	was	only	observed	with	standard	250	mg	tablet	formulation,	and	it	does	not	apply	to	the	new	dispersible	tablet	formulation.	*These	values	refer	to	the	previous	study	performed	with	standard	adult	250	mg	solid	dosage	formulation.	For	ease	of	comparison,	the	original	value	of	the	disposition	parameters	(CL,	Vc,	Q,	and	Vp)	has	been	rescaled	to	the	estimated	bioavailability	of	the	standard	250	mg	tablet	(0.587)	when	compared	to	the	one	used	on	the	current	study.		Values	in	parentheses	are	empirical	95%	confidence	intervals,	obtained	with	a	500-sample	nonparametric	bootstrap.		The	PK	parameter	variability	was	included	either	as	between-subject	(BSV)	or	between-occasion	(BOV)	variability,	assuming	a	lognormal	distribution.	It	is	reported	here	as	approximate	%CV.		The	estimate	of	the	additive	component	of	the	error	was	not	significantly	different	from	its	lower	boundary	of	LLOQ/2,	so	it	was	fixed	to	this	value.	CL:	clearance,	Vc:	central	volume	of	distribution,	Q:	inter-compartmental	clearance,	Vp:	peripheral	volume	of	distribution,	Tlag:	absorption	lag	time,	ka:	absorption	rate	constant,	F:	bioavailability,	PK:	pharmacokinetic,	PMA50:	Post-menstrual	age	at	which	50%	of	maturation	is	reached,	γ:	shape	factor	for	the	maturation	function,	BSV:	between-subject	variability,	BOV:	between-occasion	variability,	HIV+/-	HIV-infected	or	uninfected,	NGT:	drug	administration	with	naso-gastric	tube	
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Table	5.2.		Weight-banded	dosing	of	levofloxacin	100	mg	scored	dispersible	tablets	to	
approximate	exposures	in	adults	with	a	750	mg	dose	
Weight	band	(kg)	
Number	of	100	mg	
tablets	per	dose	 Daily	dose	(mg)	
Average	daily	dose	
(mg/kg)	3	–	<4	 0.5	 50	 14.3	4	-	<5	 0.75	 75	 16.7	5	-	<6	 1	 100	 18.2	6	-	<7	 1.5	 150	 23.1	7	-	<9	 2	 200	 25	9	-	<11	 2.5	 250	 25	11	-	<16	 3	 300	 22.2	16	-	<22	 4	 400	 21.1	22	-	<28	 5	 500	 20.0	28	-	<35	 6	 600	 19.1	
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Figure	5.1.	Visual	predictive	check	of	the	levofloxacin	concentration	versus	time	after	dose	for	the	historical	109	controls	receiving	adult	250	mg	standard	levofloxacin	tablets	(Denti	P,	et	al.	2018)	(left	panel)	vs.	the	24	patients	on	the	pediatric	100	mg	scored	dispersible	tablets	(right	panel).	The	solid	and	dashed	lines	represent	the	50th,	5th,	and	95th	percentiles	of	the	observed	data,	while	the	shaded	areas	represent	the	model-predicted	95%	confidence	intervals	for	the	same	percentiles.	The	dots	are	the	observed	concentrations.		 	
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Figure	5.2.		Simulated	steady	state	levofloxacin	Cmax	and	AUC0-24	versus	body	weight	using	weight-banded	dosing	of	pediatric	levofloxacin	100-mg	scored	dispersible	tablets.	The	dashed	line	for	Cmax	(15.55	mg/liter)	is	the	median	Cmax	from	adults	with	TB	receiving	1000	mg	daily	in	Peloquin	et	al.8	;	the	dashed	line	for	AUC	(96.8	mg.h/liter)	is	the	median	AUC	from	the	same	study	after	rescaling	the	dose	from	1000	mg	to	750	mg	daily.	
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Supplemental	Table	5.1.	Weight-banded	dosing	for	levofloxacin	100	mg	
dispersible	tablets	used	in	TB-CHAMP	lead-in	pharmacokinetic	study	
Weight	bands	 #	of	Levofloxacin		100	mg	tablets	 Range	of	mg/kg	doses	within	weight	bands	3.0-4.9	kg	 0.5	 10	 17	5.0-6.9	kg	 1	 14	 20	7.0-9.9	kg	 1.5	 15	 21	10.0-11.9	kg	 2	 17	 20	12.0-15.9	kg	 2.5	 16	 21	16.0-19.9	kg	 3	 15	 19	20.0-24.9	kg	 4	 16	 20	25.0-29.9	kg	 5	 17	 20	
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Supplemental	Table	5.2.		Demographic	and	clinical	characteristics	of	children	receiving	
levofloxacin	100	mg	dispersible	tablets	in	TB-CHAMP	lead-in	pharmacokinetic	study		
	 Participants	completing	PK	study	(n=24)	 Participants	contributing	safety	data	(n=27)	Median	age	at	enrollment	(IQR)	 2.1	(1.2,	2.7)	 2.1	(0.8,	2.7)	Male	gender	(%)	 15	(63)	 16	(59.3)	Ethnicity	(%)							Black						Mixed-race	 	7	(29)	17	(71)	 	8	(30))	19	(70)	Median	weight	in	kg	(IQR)	 12.3	(8.6,	13.5)	 12.2	(8.2,	13.3)	Median	height	in	cm	(IQR)	 87.2	(74.5,	93.3)	 87.0	(71.0,	92.4)	Weight-for-age	Z-score	<-2*	(%)	 3	(13)	 3	(11.1)	Height/length-for-age	Z-score	<-2*	(%)	 5	(21)	 5	(18.5)	HIV-infected	(%)	 0	(0.0)	 0	(0.0)	Received	levofloxacin	via	nasogastric	tube	on	pharmacokinetic	sampling	day	(%)	 4	(17)	 --	IQR=	interquartile	range;	*calculated	based	on	WHO	reference	values.	
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Supplemental	Table	5.3.		Summary	of	all	adverse	event	among	children	receiving	levofloxacin	100	mg	dispersible	tablets	in	TB-CHAMP	lead	in	
pharmacokinetic	study	(n=27)		 Grade	1														N	(%)	 Grade	2														N	(%)	 Grade	3														N	(%)	 Grade	4														N	(%)	 Total																			N	(%)	
Number	of	patients	with	any	Grade	1	or	Grade	2	AE	(%)*	 8	(28.6)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 8	(28.6)**	
Gastrointestinal	disorders	(%)	 2	(7.1)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 2	(7.1)	Constipation	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Diarrhoea	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Vomiting	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	
Metabolism	and	nutrition	disorders	(%)	 0	(0.0)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Anorexia	(%)	 0	(0.0)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 1	(3.6)	
Respiratory,	thoracic,		mediastinal	disorders	(%)	 2	(7.1)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 2	(7.1)	Upper	respiratory	tract	infection	(%)	 2	(7.1)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 2	(7.1)	
Skin	and	subcutaneous	tissue	disorders	(%)	 4	(14.3)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 4	(14.3)	Diaper	dermatitis	 2	(7.1)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 2	(7.1)	Rash	 2	(7.1)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 2	(7.1)		
General	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Difficulty	sleeping	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	*The	total	number	of	patients	equals	8	as	one	patient	reported	a	Grade	1	and	a	Grade	2	AE	AE=	adverse	event 
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Supplemental	Table	5.4.		Summary	of	adverse	events	possibly,	probably	or	definitely	study-drug	related,	among	children	receiving	
levofloxacin	100	mg	dispersible	tablets	in	TB-CHAMP	lead	in	pharmacokinetic	study	(n=27)	
	 Grade	1														N	(%)	 Grade	2														N	(%)	 Grade	3														N	(%)	 Grade	4														N	(%)	 Total																			N	(%)	
Number	of	patients	with	Grade	1	or	Grade	2	AE	possibly,	
probably	or	definitely	related	to	study	drug	(%)*	 2	(7.1)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 2	(7.1)**	
Gastrointestinal	disorders	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Vomiting	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	
Metabolism	and	nutrition	disorders	(%)	 0	(0.0)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Anorexia	(%)	 0	(0.0)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 1	(3.6)	
General	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	Difficulty	sleeping	(%)	 1	(3.6)	 0	(0.0)	 0	(0.0)	 0	(0.0)	 1	(3.6)	*The	total	number	of	patients	equals	2	as	one	patient	reported	a	Grade	1	and	a	Grade	2	AE	AE=	adverse	event	
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Chapter	6:	Linezolid	for	the	treatment	of	drug-resistant	tuberculosis	
in	children:	a	review	and	recommendations		
Rationale	Treatment	options	for	MDR-TB,	especially	with	additional	resistance	such	as	pre-XDR	and	XDR-TB,	are	limited.		At	the	time	this	review	was	undertaken	in	2013-14,	the	novel	TB	drugs	bedaquiline	and	delamanid	were	still	in	being	evaluated	in	adults	and	not	yet	available	for	use	outside	of	clinical	trials.		Other	existing	medications	were	being	explored	as	repurposed	treatments	for	use	in	MDR/XDR-TB.		Linezolid,	an	oxazolidinone	antibiotic,	had	shown	potent	antimycobacterial	activity	in	vitro	and	in	
vivo	(129,	130).		It	was	being	increasingly	used	in	adults,	especially	those	with	pre-XDR-	and	XDR-TB,	but	there	were	serious	concerns	about	its	safety	with	long-term	use.		Although	there	were	children	with	MDR/XDR-TB	who	stood	to	benefit	from	linezolid	treatment,	there	was	minimal	formal	paediatric	data	or	guidance	about	specific	indications,	doses,	and	safety	monitoring.				
Study	Aims	The	aim	of	this	study	was	to	systematically	review	the	literature	on	the	use	of	linezolid	in	adults	and	children	for	the	treatment	of	MDR-TB	in	order	to	formulate	practical	paediatric	guidance	and	to	identify	key	questions	for	future	research.		
Methods	A	structured	review	of	the	literature	on	linezolid	for	MDR-TB	was	undertaken.		Pubmed	was	searched	up	through	December	31,	2012	using	a	broad	search	strategy	to	identify	relevant	studies	of	the	efficacy	and	safety	of	linezolid,	and	a	second	specific	search	for	pharmacokinetic	data.		Key	evidence	on	linezolid’s	efficacy	for	TB	treatment,	safety	and	pharmacokinetics	was	summarized.		Data	on	children	treated	with	linezolid	for	MDR-TB	was	pooled	in	order	to	characterize	the	state	of	knowledge	on	its	efficacy	and	safety	for	this	indication.		Based	on	an	overall	assessment	of	the	data	from	the	review,	practical	recommendations	were	made	for	the	use	of	linezolid	in	MDR-TB	and	key	questions	for	future	research	identified.		
Results	
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Multiple	studies	were	identified	that	evaluated	linezolid	efficacy	against	M.	tuberculosis	in	different	in	vitro	and	in	vivo	conditions.		A	number	of	key	publications	were	identified	demonstrating	the	efficacy	of	linezolid	for	DR-TB.		Linezolid	had	a	modest	EBA0-2,	of	0.26	and	0.18	for	600	mg	twice	and	once	daily	respectively,	compared	to	0.67	for	isoniazid	300	mg	(131).		Two	systematic	reviews	primarily	including	observation	data	from	adults	routinely	treated	with	linezolid	for	MDR-	or	XDR-TB	reported	successful	outcomes	in	68%	and	82%	of	patients	(107,	132),	which	suggested	efficacy	of	linezolid	in	these	difficult	to	treat	patients.			A	single	clinical	trial	in	highly	treatment	experienced	adults	with	chronic	MDR-TB	who	were	randomized	to	immediate	or	delayed	(after	2	months)	linezolid	along	with	an	optimized	background	regimen	reported	culture	conversion	at	4	months	of	79%	in	the	immediate	group	vs.	35%	in	the	delayed	group;	a	remarkable	87%	of	patients	had	culture	converted	by	6	months	(97).	In	all	of	these	studies,	frequent	serious	and	treatment	limiting	dose	and	duration-dependent	adverse	effects	were	report.		Roughly	60%	of	those	included	in	each	of	the	above	systematic	reviews	experienced	a	linezolid-associated	adverse	effect,	with	the	most	common	being	anaemia	and	neuropathy	(96,	107).		In	one	of	these	reviews,	69%	of	events	required	linezolid	discontinuation	or	dose	adjustment	(96).			Three	studies	of	linezolid	pharmacokinetics	in	adults	with	TB	were	identified,	which	could	provide	target	exposures	for	paediatric	dose	selection	(133-135).		There	were	data	on	linezolid	pharmacokinetics	in	children,	but	none	in	children	with	TB	(103).		There	was	limited	published	experience	with	linezolid	use	in	children	with	MDR-TB.		Eight	reports	including	18	children	were	identified	(136).		Outcomes	were	good,	with	15	of	18	(83%)	having	successful	treatment	outcomes	despite	many	with	prolonged	previous	culture	positivity	and	extensive	resistance.		Nine	of	the	18	(50%)	had	a	reported	linezolid-related	adverse	event,	with	5	(28%)	requiring	a	dose-reduction	and	2	(11%)	permanently	discontinuing	linezolid.		Linezolid	should	be	used	in	children	with	XDR-TB,	or	who	are	failing	MDR-TB	treatment,	and	should	be	considered	in	those	with	MDR-TB	meningitis.		Linezolid	doses	of	10	mg/kg	twice	daily	for	those	<10	years	of	age	and	once	daily	for	those	>10	years	of	age	should	be	considered	for	MDR-TB	treatment	in	children	until	more	data	is	available.		Careful	monitoring	for	adverse	effects,	in	particular	anaemia	and	peripheral	neuropathy,	is	critically	important.		
Conclusions	and	recommendations	
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Linezolid	appears	to	be	an	effective	antituberculosis	drug	and	an	important	treatment	for	MDR-TB	considering	the	limited	options,	however	it	is	associated	with	frequent,	serious	dose	and	duration	dependent	adverse	effects.		Based	on	this	evidence	review,	practical	recommendations	for	linezolid	use	in	children	with	MDR-TB	were	made	and	future	questions	for	research	identified,	including:	identifying	the	optimal	dose	of	linezolid	in	adults	with	TB	(that	balances	efficacy	and	safety);	characterizing	the	pharmacokinetics	of	linezolid	in	children	with	TB	and	its	optimal	paediatric	dose;	describing	the	safety	of	long-term	linezolid	in	children	with	MDR-TB.				
Citation:			Garcia-Prats,	A.	J.,	P.	C.	Rose,	A.C.	Hesseling,	H.S.	Schaaf.		Linezolid	for	the	treatment	of	drug-resistant	tuberculosis	in	children:	A	review	and	recommendations.	
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Options for the treatment of children with drug-resistant tuberculosis (DR-TB) are limited. Emerging
evidence in adults from systematic reviews and a randomized trial has shown good efﬁcacy of linezolid
in difﬁcult cases of DR-TB but with frequent serious adverse effects. Published data in children are
limited and we are unaware of formal guidelines for linezolid in treatment of paediatric DR-TB, though it
will likely be an important component of DR-TB treatment for a growing number of children. We per-
formed a structured review of existing literature on the efﬁcacy, adverse effects, pharmacokinetics and
pharmacodynamics of linezolid in DR-TB, highlighting the key evidence from the adult literature and
systematically evaluating published paediatric data. Our search identiﬁed 8 reports of 18 children
receiving linezolid for difﬁcult to treat DR-TB. All 18 had culture conversion and 15 of 18 had successful
long-term treatment outcomes. Adverse events were reported in 9 of 18; a linezolid dose reduction was
required in 5 of 18, and 2 of 18 permanently discontinued linezolid because of adverse events. We make
speciﬁc recommendations for the use of linezolid in children with DR-TB, and identify priority questions
for future research. For children with multidrug-resistant (MDR)-TB with additional resistance or with
extensively drug-resistant (XDR)-TB, linezolid may make the difference between a successful or poor
outcome, and until newer antituberculosis agents with better efﬁcacy and safety become available in
children, linezolid will be an important component of treatment for children with the worst forms of
DR-TB.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Children account for an estimated 10e15% of the global burden
of disease caused by Mycobacterium tuberculosis (Mtb) with con-
servative estimates of 490,000 reported cases and 64,000 deaths
among HIV-negative children in 2011 [1,2]. Multidrug-resistant
tuberculosis [MDR-TB; i.e. Mtb resistant to at least both rifampicin
(R; RMP) and isoniazid (H; INH)] is increasing worldwide, with an
estimated 630,000 prevalent cases in 2011 [2]. There is a growing
recognition of the importance of drug-resistant TB (DR-TB) in
younger ages. A recent systematic review identiﬁed 8 cohorts with
318 children with MDR-TB and reported a pooled estimate forepartment of Paediatrics and
of Medicine and Health Sci-
erg, Cape Town, South Africa.
938 9793.
gmail.com (A.J. Garcia-Prats),
Hesseling), hss@sun.ac.za (H.
All rights reserved.treatment success of 81.7% [3]. Extensively drug-resistant TB (XDR-
TB; i.e. resistance to isoniazid, rifampicin, a ﬂuoroquinolone, and
one of the second-line injectable drugs) has been identiﬁed in 84
countries and accounts for 9.0% of MDR-TB cases globally [2,4]. A
systematic review reported successful outcomes in only 43.7% of
adults with XDR-TB [5]. There is little published data or guidance on
best management of children with XDR-TB.
The World Health Organization (WHO) categorizes linezolid in
Group 5, an antituberculosis agent with unclear efﬁcacy or con-
cerns regarding usage [6]. There is an increased interest in linezolid
for DR-TB treatment, especially in XDR-TB, and recent systematic
reviews and a randomized controlled trial have added substantially
to the adult literature. There is little published data about linezolid
use in children with DR-TB, though it will likely be an important
component of DR-TB treatment for a growing number of children
given the lack of availability of new TB drugs in children. This paper
reviews the existing knowledge about the efﬁcacy, adverse effects,
pharmacokinetics and pharmacodynamics of linezolid in DR-TB,
highlighting the key evidence from the adult literature and sys-
tematically evaluating published paediatric data. We also make 94
Table 1
Minimum inhibitory concentrations (MICs) (in mg/ml)*, epidemiologic cut-off (ECOFF), and proposed critical concentrations (in mg/ml) for linezolid against Mycobacterium
tuberculosis.
Mtb strains Middlebrook 7H10 Middlebrook 7H11 Bactec460 MGIT960
Published reports of MICs
Zurenko GE et al., 1996 [20] Clinical isolates, DS 0.5y e e e
Clinical isolates, DR 0.5e2.0z e e e
Rodriguez JC et al., 2002 [19] Clinical isolates, mostly DS e 0.5, 1.0 e e
Alcala L et al., 2003 [21] Clinical isolates, DS and DR 0.5, 1.0 e e e
Erturan Z et al., 2005 [22] Clinical isolates, DR e e 4.0, 8.0 e
Sood R et al., 2005 [23] Clinical isolates, DR e 1.0, 32.0 e e
Tato M et al., 2006 [24] Clinical isolates, DS and DR 0.25, 0.5 e e e
Yang C et al., 2011 [26] Clinical isolates, DS and DR 0.125, 0.5 e e e
Epidemiologic cut-off
Schon T et al., 2011 [30] e e 0.5 e e
Proposed critical concentrations
Rusch-Gerdes S et al., 2006 [25] e e e 1.0 1.0
WHO 2008 [28] e e e 1.0 1.0
WHO 2012 [29] e e e e 1.0
Mtb ¼ Mycobacterium tuberculosis; DS ¼ drug-susceptible; DR ¼ drug-resistant, to at least isoniazid or rifampicin, or both; WHO ¼ World Health Organization;
MGIT ¼ Mycobacterial Growth Indicator Tubes.
* Expressed as MIC50, MIC90, respectively, unless otherwise speciﬁed.
y Inhibited all strains.
z Range of MICs.
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and identify speciﬁc questions for future study.
2. Methods
2.1. Structure of review
Because the evaluation of antituberculosis drug efﬁcacy relies
on microbiologic endpoints, which are challenging to evaluate in
children, there are few trials of antituberculosis drug efﬁcacy in
children with TB disease, but no reason to presume that agents
efﬁcacious in adults will not also be in children, who typically have
paucibacillary TB [7,8]. Clinicians managing children with DR-TB
should be aware of the adult literature for drug efﬁcacy. There
may be considerable age-related variation in severity and fre-
quency of adverse effects of drugs, so the safety proﬁle of drugs
should be speciﬁcally evaluated in children [7e9]. We summarize
the key evidence on the efﬁcacy and safety of linezolid in adults
receiving the prolonged courses of linezolid used in DR-TB treat-
ment, and report all the paediatric experience identiﬁed in our
search.
The pharmacokinetics of many antituberculosis drugs differ in
children and adults [10e12] due mostly to age-related changes in
drug absorption, distribution, metabolism, and excretion [9,13,14].
Paediatric antituberculosis drug doses should be used that result in
the same drug exposure as that of efﬁcacious recommended doses
in adults [7,9]. We therefore also present studies of the pharma-
cokinetics of linezolid in adults with TB, and in children with TB or
other conditions.
2.2. Search
We searched Pubmed through December 31, 2012, using a broad
search strategy and a second speciﬁc search for pharmacokinetic
information, using the terms described in Supplemental Table 1.We
also reviewed the bibliographies of key articles and reviews, and
surveyed experts in the ﬁeld. We systematically extracted infor-
mation on the outcomes and adverse effects for all children treated
with linezolid for DR-TB. We used key articles from our search to
describe the efﬁcacy, adverse effects, and pharmacokinetics of
linezolid for DR-TB treatment in adults and children.3. Overview
Linezolid belongs to the oxazolidinone class of antibiotics,
which bind to the 50S ribosomal subunit, inhibiting formation of
the initiation complex and preventing translation and protein
synthesis [15e17]. This novel mechanism of action limits cross-
resistance with other protein-synthesis inhibitors and makes it
attractive for drug-resistant infections [15]. Linezolid has been
approved by the U.S. Food and Drug Administration for treatment of
susceptible strains of some microorganisms, most commonly
resistant Gram-positive bacteria, for nosocomial pneumonia, and
for skin and skin structure infections, but is used off-label for drug-
resistant TB [18]. Patent coverage of linezolid in the U.S. and other
countries, along with a lack of quality-assured alternative pro-
ducers, has resulted in prohibitively high costs of linezolid in many
settings [18]. Linezolid is available as 600mg tablets and as 100mg/
5 ml powder for suspension.
4. Efﬁcacy of linezolid against M. tuberculosis
4.1. Activity in vitro and in animals
The in vitro activity of linezolid against Mtb has been consis-
tently demonstrated, and minimum inhibitory concentrations
(MIC) from published studies are listed in Table 1 [19e26]. The
critical concentration of a drug is deﬁned as the ‘lowest concen-
tration of drug that will inhibit 95% of wild strains ofM. tuberculosis
that have never been exposed to drugs, while at the same time not
inhibiting clinical strains ofM. tuberculosis that are considered to be
resistant’ [6,27], and the epidemiological cut-off (ECOFF) is deﬁned
as the highest MIC among the wild-type MIC distribution [27].
Currently proposed [25] and WHO recommended critical concen-
trations [28,29], and a proposed ECOFF for linezolid are listed in
Table 1 [30]. A single study showed a trend towards higher linezolid
MICs in MDR isolates over 10 years despite a lack of linezolid
exposure, which was associated with resistance to the ﬂuo-
roquinolones (except levoﬂoxacin) and to kanamycin; the expla-
nation for these ﬁndings is not clear [31]. Using a test concentration
of 6 mg/ml linezolid on 295 MDR clinical isolates including 9 which
were XDR, only 2 isolates were found to be resistant [32]; however
the clinical relevance of that breakpoint is not clear.  95
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linezolid showed synergistic activity with rifampicin but not the
ﬂuoroquinolones [33]. Linezolid had intracellular activity against
Mtb in a murine macrophage model [23], but against non-
replicating Mtb in a latent growth phase only the highest concen-
trations showed any bactericidal activity, suggesting limited ster-
ilizing ability [34].
In one of the ﬁrst in vivo evaluations, linezolid showed dose-
dependent activity in a murine model of Mtb, based on lung and
spleen colony forming units (CFUs) in comparison to untreated
controls [35]. Subsequent studies in mice were less encouraging,
showing limited bactericidal activity at doses approximating the
clinically relevant exposure in humans [36], antagonistic activity
when it was added to isoniazid, rifampicin, and pyrazinamide, [37]
and no increased activity of linezolid and moxiﬂoxacin over mox-
iﬂoxacin alone [38]. We found no reports evaluating the combi-
nation of linezolid with pyrazinamide, although the related
compound PNU-100480 showed augmented activity when com-
bined with pyrazinamide [39].
4.2. Activity in adults
A single study reported a modest early bactericidal activity
(EBA) for linezolid at doses of 600mg once and twice daily [40]. The
EBA for days 0e2 (EBA0e2) was 0.26 for linezolid 600mg twice daily
and 0.18 for 600 mg once daily, compared to 0.67 for INH 300 mg
[40]. The values for the extended EBA for days 2e7 (EBA2e7) were
0.09 for twice daily and 0.04 for once daily linezolid, and 0.16 for
isoniazid [40]. The differences in EBA of linezolid 600 mg once and
600 mg twice daily were small and not statistically signiﬁcant [40].
There was no correlation between area under the concentration
time curve (AUC)/MIC or %T >MIC with linezolid EBA in this study,
which may be related to the relatively favourable pharmacody-
namics at both doses [40]. These data provide some evidence for
the effectiveness of once daily dosing, though the small sample size
limited the ability to detect small differences. The low EBA2-7 may
suggest minimal sterilizing activity, though this is an imperfect
marker of sterilizing activity, and pyrazinamide, which is known to
have potent sterilizing activity, also has a limited EBA2-7.
In one of the ﬁrst clinical studies of linezolid in DR-TB, three
adults with MDR-TB and resistance to other second-line agents had
successful outcomes with linezolid use [41]. Multiple other small
case series and observational studies reported similar results, with
good outcomes in patients with substantial drug resistance and
limited treatment options, but with frequent adverse effects [42e
56]. These and other reports were synthesized in two systematic
reviews published in 2012 evaluating the safety and efﬁcacy of
linezolid for DR-TB in adults [57,58]. The ﬁrst included 11 studies
representing 148 patients [57]. The pooled percentage of patients
with treatment success was 68.0% (95% CI 58.0e79.0) and culture
conversion was 97.9% (95% CI 95.2e100%) [57]. There was no sig-
niﬁcant difference in pooled treatment success in studies with a
mean duration of treatment >7 months versus 7 months, or for
studies that used >600 mg daily versus 600 mg daily [57]. The
second systematic review included 207 patients in 12 studies,
including many but not all the same studies as the ﬁrst review, and
reported similar ﬁndings [58]. Of 121 patients with deﬁnite treat-
ment outcomes, 82% (95% CI 74e88%) had successful treatment
outcomes, with 93% (95% CI 87e97%) having culture conversion
[58]. A subgroup analysis found no signiﬁcant differences in out-
comes between those receiving 600 mg daily versus >600 mg
[58].
A single clinical trial evaluated linezolid in 39 highly treatment-
experienced patients with chronic XDR-TB in which patients were
randomized to immediate versus delayed addition of linezolid totheir existing failed background regimen [59]. By 4 months, 79% in
the immediate group compared to 35% in the delayed group had
culture conversion (p ¼ 0.001), and by 6 months 87% of all the
patients had culture converted [59]. At the time of study publica-
tion, 8/38 patients had withdrawn from the study due to treatment
failure (n¼ 4), personal reasons (n¼ 1), and adverse events (n¼ 3),
while 17/38 were still receiving the study treatment [59]. Thirteen
had successfully completed treatment with no relapse to date,
suggesting sterilizing potential for linezolid [59]. Although the
numbers are small, these results are much better than existing
reported outcomes for XDR-TB and provide evidence for linezolid
efﬁcacy in these patients [59]. Of the 4 patients who did not have
culture conversion, all acquired linezolid resistance, with increased
MICs by a factor of 8e32 from baseline and known mutations
identiﬁed by gene sequencing [59]. This demonstrates that resis-
tance can emerge during treatment, despite a low mutant-
prevention concentration (MPC90 ¼ 1.2 mg/ml) comparable to that
of moxiﬂoxacin [60] and in vitro evidence that it is difﬁcult to
induce linezolid resistance in Mtb [34].
Only 5% [57] and 8.7% [58] of patients were HIV-infected in the
two systematic reviews, and HIV infectionwas an exclusion criteria
in the above clinical trial [59], so caution should be taken in
extrapolating these results to HIV-infected persons.
4.3. Activity in children
There is substantial evidence of the effectiveness of short
courses (less than 28 days) of linezolid in children for complicated
bacterial skin and soft tissue infections, nosocomial and
community-acquired pneumonia, and resistant Gram-positive in-
fections, including four clinical trials [61]. Experiencewith linezolid
in children with DR-TB is limited, and our search identiﬁed 8 re-
ports including 18 children [one patient was included in two re-
ports [62,63]] treated with linezolid for DR-TB [43,54,62e67], with
results summarized in Table 2. All 18 patients had culture conver-
sion, most within 1e3 months, and 15 of 18 (83%) had a successful
long-term outcome, with 1 lost-to-follow-up and 2 deaths. The
deaths were due to respiratory failure in one, and Stage 3 tuber-
culous meningitis and liver failure in a second, and both patients
were culture-negative at the time of death [43,67]. In many of these
patients, the good outcomes were despite extensive disease, sub-
stantial drug resistance, and prolonged culture positivity and failed
treatment with other second-line drugs prior to linezolid use for
periods as long as 9 months [54], 7 months [62], and 6e12 months
[63].
Despite the small numbers and all patients were identiﬁed from
case reports or small series, the outcomes described in children on
linezolid are good. The proportions of children with culture con-
version and successful treatment are similar to those reported for
adults. This provides some evidence for the utility of linezolid in
children with DR-TB, including those with XDR-TB.
4.4. Safety and tolerability
Although well tolerated in short courses, linezolid is associated
with important dose- and time-dependent adverse effects [68,69].
In general, adverse effects are reported less in linezolid treated
children than adults [61,70]. Inhibition of mitochondrial protein
synthesis by linezolid may be the cause of many of these adverse
effects [68].
4.5. Gastrointestinal adverse effects
Gastrointestinal adverse effects are commonly associated with
linezolid, but rarely require alteration or discontinuation of the 96
Table 2
Demographics and treatment outcomes for children (<18 years) treated with linezolid for drug-resistant tuberculosis.
Published report Age (yrs) and
gender
HIV TB resistance proﬁle Dose and duration of linezolid treatment Culture conversion Treatment outcome
Park IN et al., 2006 [43] 17 F Neg H, R, E, CS, KM, OFX, PAS, PTH 600 mg OD, 8 months Yes, 147 days Death (respiratory failure)
Condos R et al., 2008 [54] 10 F Pos H, R, E, Z, S, CIP, AM, AUG,
RB, PAS, CAP
600 mg OD, 25 months Yes, 29 days Successful
Schaaf HS et al., 2009 [62] and
Rose PC et al., 2012 [63]
0.9 F Neg H, R, E, OFX, AM 10e12 mg/kg BD, 19 months Yes, 23 days Successful
Pinon M et al., 2010 [64] 1.9 F Negy (H, R, E, Z, S, KM)* 10 mg/kg BD, 13 months Yes, 1 month Successful
0.9 M e (H, R, E, Z, S, ETH, PAS, CS)* 10 mg/kg BD, 3 months Yes, 2 months Lost-to-follow-up
Dauby N et al., 2011 [65] 14 F Neg H, R, RB, E, OFX, Z, AM, CS, PTH 600 mg OD, 8 months Yes, 11 weeks Successful
Kjollerstrom P et al., 2011 [66] 14 M Neg H, R, Z, E, S, RB, ETH, CAP, AM 600 mg BD, 9 months Yes, 12 weeks Successful
12 F Neg H, R, Z, S, RB, ETH, CS, PAS, KM, OFX 600 mg BD, 4 months;
300 mg OD 2 months
Yes, 6 weeks Successful
4 F Neg H, R, S, ETH 10 mg/kg BD, 1 month;
half dose for 5 months
Yes, 12 weeks Successful
17 M Pos H, R, Z, E, S 600 mg BD, 11 months Yes, 12 weeks Successful
Rose PC et al., 2012 [63] 13 M Neg H, R, AM 300 mg OD, 23 months Yes, 3 months Successful
10 M Pos H, R, E, AM, OFX 300 mg OD, 20 months Yes, 4 months Successful
13 F Neg H, R, E, AM, ETH, OFX 300 mg OD, 15 months Yes, 2.5 months Successful
0.6 M Neg H, R, E, AM, OFX 10 mg/kg BD, 15 monthsz Yes, 3 months Successful
10 F Pos H, R, E, ETH, KM, S 300 mg BD, 24 months;
200 mg BD, 3 monthsz
Yes, 18 months Successful
5 F Pos H, R, E, KM, S, OFX 300 mg OD, 7 months NA (negative
prior to linezolid)
Successful
Katragkou A et al., 2013 [67] 2.5 F Neg H, R, E, Z, LFX, AM, CAP 10 mg/kg TD, 7 months,
7 mg/kg TD 3 monthsz
NA (negative
prior to linezolid)y
Successful
1.5 M Negy H, R, Z, E, AM 10 mg/kg TD, 6 months Yes, 1 month Death (Stage 3 TBM, liver failure)
H ¼ isoniazid, R ¼ rifampicin, E ¼ ethambutol, Z ¼ pyrazinamide, ETH ¼ ethionamide, PTH ¼ prothionamide, PAS ¼ para-aminosalicylic acid, KM ¼ kanamycin, AM ¼ amikacin, CAP ¼ capreomycin, OFX ¼ oﬂoxacin,
LFX ¼ levoﬂoxacin, CIP ¼ ciproﬂoxacin, RB ¼ rifabutin, AUG ¼ augmentin, CS ¼ cycloserine, OD ¼ once daily, BD ¼ twice daily; TD ¼ thrice daily; F ¼ female; M ¼ male; NA ¼ not applicable; TBM ¼ tuberculous meningitis.
* Resistance proﬁle of source case reported.
y not in original publication, but provided by authors.
z Treatment ongoing at time of report.
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Table 3
Adverse events among children (<18 years) treated with linezolid for drug-resistant tuberculosis.
Published report Age (yrs)
and gender
HIV Dose and duration
of linezolid treatment
Adverse event/s Action and outcome
Park IN et al., 2006 [43] 17 F Neg 600 mg OD, 8 months None
Condos R et al., 2008 [54] 10 F Pos 600 mg OD 25 months None
Schaaf HS et al., 2009 [62]
and Rose PC et al., 2012 [63]
0.9 F Neg 10e12 mg/kg BD, 19 months None
Pinon M et al., 2010 [64] 1.9 F Negy 10 mg/kg BD, 13 months None
0.9 M e 10 mg/kg BD, 3 months None
Dauby N et al., 2011 [65] 14 F Neg 600 mg OD, 4 months,
300 mg OD, 4 months
Moderate peripheral
neuropathy after 4 months
Improved with dose
reduction to 300 mg
once daily
Kjollerstrom P et al., 2011 [66] 14 M Neg 600 mg BD, 9 months Severe progressive
peripheral neuropathy
after 9 months
Completely resolved
after discontinuation
of linezolid
12 F Neg 600 mg BD, 4 months;
300 mg OD 2 months
Peripheral neuropathy
after 4 months
Responded to dose
reduction to 300 mg
once daily
Severe anaemia
requiring transfusion
Anaemia attributed to
linezolid and comorbid
sickle cell disease;
linezolid continued
4 F Neg 10 mg/kg BD, 1 month;
half dose for 5 months
Urticarial rash Attributed to linezolid
hypersensitivity; resolved
after dose reduced to half
17 M Pos 600 mg BD, 11 months None
Rose PC et al., 2012 [63] 13 M Neg 300 mg OD, 23 months None
10 M Pos 300 mg OD, 20 months Pancreatitis at 8 months Attributed to d4T, anticonvulsant,
high-fat diet, and possibly
linezolid; linezolid continued
13 F Neg 300 mg OD, 15 months None
0.6 M Neg 10 mg/kg BD, 15 months* None
10 F Pos 300 mg BD, 24 months,
200 mg BD, 3 months*
Peripheral neuropathy
at 24 months
Linezolid dose reduced, d4T
changed to ABC, terizidone
dose reduced, pyridoxine
increased; symptoms resolved
Mild anaemia and
leukopaenia at 25 months,
Anaemia, leukopaenia
attributed to HIV
5 F Pos 300 mg once daily, 7 months Severe pancreatitis and
lactic acidosis requiring
ICU admission at 7 months
Attributed to linezolid
which was discontinued,
fully recovered
Katragkou A et al. (2013) [67] 2.5 F Neg 10 mg/kg TD, 7 months,
7 mg/kg TD 3mnths*
Mild neutropaenia after
7 m of linezolid
Attributed to linezolid, but
did not improve after
reduction of linezolid dose
1.5 M Negy 10 mg/kg TD, 6 months Liver failure, resulting
in death
Cause unknown, unlikely
related to linezolid
OD ¼ once daily, BD ¼ twice daily; TD ¼ thrice daily; F ¼ female; M ¼ male; NA ¼ not applicable.
* Treatment ongoing at time of report.
y Not in original publication, but provided by authors.
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drug-related adverse events were nausea (3.4%) and diarrhoea
(4.3%) [69]. In a review of clinical trials of short durations of line-
zolid in children, diarrhoea (3.8e9.1%) and vomiting (1.2e4.2%)
were the most common adverse effects, though there was no dif-
ference in frequency between linezolid and the comparators
(cefadroxil and vancomycin) [71].
4.6. Hematologic adverse effects
Both dose and time-dependent myelosuppressionwere noted in
pre-clinical evaluations of linezolid in animals [69]. A review of
adult clinical trial data of linezolid courses <28 days showed no
statistical difference in haematologic adverse effects between
linezolid and comparator groups, although there was a trend to-
wards increased mild anaemia and thrombocytopaenia in the
linezolid group for those treated for more than 2 weeks [69,72].Anaemia is more frequent in longer courses of linezolid, thought to
be related to a bone marrow suppression due to inhibition of
mitochondrial protein synthesis [69]. Studies have been variable in
adults, but suggest a slight risk of thrombocytopaenia that is
increased with longer duration of linezolid, but reversible with
drug cessation [69]. The exact mechanism of thrombocytopaenia is
unknown, but an immune-mediated phenomenon has been pro-
posed [69]. Reversible leukopaenia and pancytopaenia have been
described but are rare [69]. A single report of two adult patients
suggested that linezolid-associated cytopaenias may respond to
vitamin B6 (pyridoxine) supplementation [73], but was followed by
other observational studies in adults which showed no effect of
pyridoxine 125 mg daily [74] or 200 mg daily [75] on the risk of
anaemia or thrombocytopaenia. Pyridoxine supplementation
would not be expected to impact on the proposed mechanisms for
cytopaenias described above. The risk of cytopaenias with pro-
longed linezolid treatment in DR-TB is discussed below.  98
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showed a trend towards mild reversible thrombocytopaenia in
children treated >14 days but no statistical difference in hemato-
logic adverse events between the linezolid and comparator groups
[76].
4.7. Neurologic adverse effects
Peripheral neuropathy was not noted in clinical trials of line-
zolid, but has been well described during prolonged courses
[69,77]. It usually presents as paraesthesia and numbness in distal
extremities in a “stocking and glove” distribution, with lower ex-
tremities affected more commonly than upper [69]. In adults, pe-
ripheral neuropathy is not responsive to vitamin B6 [73], and is
usually not reversible, but may improve slowly in some cases after
linezolid discontinuation [69,77]. Linezolid also causes toxic optic
neuropathy, with painless, bilateral central vision loss, often of
sudden onset, and gradual progressive loss of colour vision and
visual acuity [69]. Onset of symptoms is from 3 to 12 months, and
existing evidence suggests optic neuropathy will improve with
discontinuation of linezolid, but can result in permanent visual
deﬁcits [69]. The risk of neuropathy with prolonged treatment is
discussed below.
In addition to the cases of peripheral neuropathy among
linezolid-treated children with DR-TB described below, a recent
review identiﬁed 8 cases of neuropathy in children e 5 with pe-
ripheral neuropathy alone, 1 with optic neuropathy, and 2 with
both peripheral and optic neuropathy [78]. Seven of 8 were on
prolonged courses with a range of 4 weeks to 7 months at the time
of onset [78]. As opposed to adults, 5 of 5 inwhich the outcomewas
reported had improvement or resolution of symptoms after
discontinuation of linezolid [78]. A single case of possible auditory
nerve neuropathy has been described in a neonate [79].
There is little information on the impact of co-treatment of
linezolid with isoniazid or cycloserine/terizidone on peripheral
neuropathy. High-dose isoniazid causes neuropathy due to Vitamin
B6 depletion, and pyridoxine supplementation greatly reduces this
risk [80]. Cycloserine and terizidone may also cause peripheral
neuropathy by a Vitamin B6 related mechanism, though this is
controversial [81,82]. Even though the likely mechanism of
linezolid-induced neuropathy by mitochondrial protein synthesis
inhibition is distinct from that of isoniazid or cyloserine and ter-
izidone, close monitoring of co-treated patients is warranted. The
nucleoside reverse transcriptase inhibitor (NRTI) class of anti-
retrovirals (ARVs) also causes peripheral neuropathy by mito-
chondrial protein synthesis inhibition [83] and there is a potential
for increased risk of neuropathy when used concomitantly with
linezolid in HIV-infected children, but little data reported to date.
With the exception of symptomatic management, the lack of
effective treatments for ARV-induced neuropathy makes it less
likely that pyridoxine or other existingmedications will be effective
for linezolid-induced neuropathy [84]. Additional evidence is
needed and close monitoring of such patients is indicated.
4.7.1. Other
Linezolid-associated hyperlactatemia and lactic acidosis have
been described, with a 2009 review identifying 9 adult cases [69].
Patients may be asymptomatic or have non-speciﬁc symptoms,
with nausea and vomiting commonly reported [69]. Hyper-
lactatemia resolves over the course of 1e2 weeks after linezolid
discontinuation [69]. Metabolic acidosis was reported in 2 of 79
(2.5%) children receiving linezolid in a randomized trial, though
both had other comorbidities [85]. Three additional cases were
described in children with liver disease and other comorbid ill-
nesses [86], and more recently a case was described in an HIV-infected child receiving ARVs and long-term linezolid for DR-TB
[63].
Rhabdomyolysis has been reported in an adult on linezolid for
DR-TB [87]. Linezolid is a weak monoamine oxidase inhibitor
(MAOI), and in combination with other drugs such as selective
serotonin reuptake inhibitors (SSRIs) may rarely precipitate sero-
tonin syndrome [69]. A single suspected case has been described in
a child [88].
4.8. Adverse events in DR-TB treatment regimens
In the ﬁrst systematic review of linezolid for DR-TB, the pooled
percentage of adverse events was 61.5% (95% CI 40.2e80.8%), with
pooled percentages of neuropathy of 36.1% (95%CI 19.1e53.2) and
bone marrow suppression of 28.5% (95%CI 14.8e42.1), and with
36.2% (95%CI 20.7e51.8) stopping linezolid because of adverse
events [57]. There was a trend towards increased risk of adverse
events for linezolid doses >600 mg [49.9% (37.3e62.4)] versus
600 mg [34.4% (95%CI 23.0e45.8)] (p ¼ 0.07), and a statistically
signiﬁcant difference in those discontinuing linezolid because of
adverse events for doses >600 mg [60.8% (95%CI 42.7e78.8)]
versus 600 mg [29.5% (95%CI 3.2e55.7)] (p ¼ 0.05) [57].
In the second systematic review, 59% (95% CI 49e68%) had an
adverse event, of which 69% (95% CI 58e79%) required linezolid
discontinuation or dose adjustment [58]. The most common
adverse events were anaemia (38.1%), peripheral neuropathy
(47.1%), gastrointestinal disorder (16.7%), optic neuritis (13.2%), and
thrombocytopaenia (11.8%) [58]. There was a statistically increased
risk of adverse events for those receiving >600 mg daily (74.5%)
versus those receiving 600 mg daily (46.7%) [58]. The higher dose
was also associated with statistically increased risk of some speciﬁc
adverse events, including anaemia (60% vs. 2.5%), leukopaenia
(17.1% vs. 2.0%), and gastrointestinal symptoms (29.4% vs. 8.0%)
despite a much shorter duration of treatment in the higher dose
group [58]. In the clinical trial of linezolid for chronic XDR-TB, 33 of
38 (87%) of the patients had a clinically signiﬁcant adverse event, of
which 31 were possibly or probably related to linezolid [59]. After a
second randomization in this study to continuation with 300 mg
versus 600 mg linezolid, the 600 mg group was 2.7 times (95% CI
1.1e6.5) more likely to experience an adverse event compared to
the 300 mg group, though adverse events were still common in the
300 mg group [59]. The lack of HIV-infected persons in these
studies makes extrapolation of these results to this important
subgroup difﬁcult.
Table 3 lists the adverse events among published reports of
children on linezolid for DR-TB. At least one adverse event was
reported for 9 of 18 children (50%) with 5 of 18 (28%) requiring a
linezolid dose reduction, and 2 of 18 (11%) permanently dis-
continuing linezolid. Peripheral neuropathy was themost common,
occurring in 4 of 18 (22%), but was reported to resolve after dose
reduction or discontinuation of linezolid in each case. The associ-
ation of linezolid with anaemia reported in 2 of 18 (11%) is unclear,
as one episode was attributed to linezolid and a vaso-occlusive
crisis in a child with comorbid sickle cell disease, and in the sec-
ond a bone marrow biopsy showed dyserythropoeisis possibly due
to HIV. The single life-threatening adverse event was a case of se-
vere pancreatitis and lactic acidosis [63]. Three of 5 (60%) known
HIV-infected children experienced adverse events, compared to 5
of 12 (42%) known HIV-uninfected. In our limited personal clinical
experience, 3/3 HIV-infected children had adverse events but 0/4
HIV-uninfected children [63]. As the NRTI class of ARVs also can
inhibit mitochondrial DNA, there is a theoretical basis for increased
risk of toxicity in HIV-infected persons taking NRTIs [89]. These
numbers are too small to draw any robust conclusions about
different risk between the two groups, but very close monitoring of 99
Table 4
Results of pharmacokinetic studies of linezolid in adults with tuberculosis, and children (concentrations in mg/mL, area under the concentration time curve (AUC) in mg h/mL, time in h).
Study Methods Age (in years
or speciﬁed)
N Dosage Tmax t1/2 Cmax Cmin AUC 0e24
Adults with tuberculosis (none known HIV-infected)
Dietze R et al., 2008 [40] * HPLC 45.0 (39.0e48.0) 9 600 mg twice daily 1.0 (1.0e4.0) 4.56 (2.1e7.0) 19.4 (11.8e24.9) e 232.9 (100.8e394.4)
33.5 (23.0e42.0) 10 600 mg once daily 1.5 (1.0e4.0) 3.20 (1.5e5.0) 15.0 (11.9e21.3) e 96.9 (47.8e143.7)
Koh WJ et al., 2009 [44] y HPLC e 10 300 mg once daily e e 11.6 (4.4) 2.1 (1.3) e
Alffenaar JW et al., 2010 [99] * LCMS/MS assay 28 (26e38)* 8 300 mg twice daily 1.2 (0.5e1.2) 5.6 (3.0e6.4) 9.5 (7.7e10.1) 1.9 (0.6e2.2) 115.2 (77.0e128.4){
8 600 mg twice daily 1.4 (0.8e1.4) 5.8 (4.7e6.0) 20.4 (16.3e21.9) 5.8 (2.7e6.8) 291.6 (202.4e321.8){
Children without tuberculosis (none known HIV-infected)
Jungbluth GL et al., 2003 [91] y HPLC Newborn, preterm,x
<1 week of age
9 10 mg/kg e 5.6 (2.4e9.8) 12.7 (9.6e22.2) e 108 (41e191)z
Newborn, full term,
<1 week of age
10 10 mg/kg e 3.0 (1.3e6.1) 11.5 (8.0e18.3) e 55 (19e103)z
Newborn, full term
1week 28 days
10 10 mg/kg e 1.5 (1.2e1.9) 12.9 (7.7021.6) e 34 (23e50)z
Infants >28 days to
<3 months
12 10 mg/kg e 1.8 (1.2e2.8) 11.0 (7.2e18.0) e 33 (17e48)z
Young children,
3 months to 11 years
59 10 mg/kg e 2.9 (0.9e8.0) 15.1 (6.8e36.7) e 58 (19e153)z
Adolescents
12e17 years
36 10 mg/kg or 600 mg e 4.1 (1.3e8.1) 16.7 (9.9e28.9) e 95 (32e178)z
Tmax ¼ Time to reach maximum concentration; t1/2 ¼ elimination half-life; Cmax ¼ maximum serum concentration; Cmin ¼ minimum serum concentration; AUC ¼ area under the concentrationetime curve; HPLC ¼ high-
performance liquid chromatography; LCMS/MS ¼ liquid chromatography-tandem mass spectrometry; TB ¼ tuberculosis; MDR ¼ multidrug-resistant; XDR ¼ extensively drug-resistant.
* All values in this study reported as median and interquartile range.
y All values in this study reported as mean and range.
z AUC 0 to N.
x Preterm considered<34 weeks gestation.
{ Originally reported as AUC 0e12, but values doubled here to generate AUC 0e24 to facilitate comparisons between studies.
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Table 5
Recommendations for the use of linezolid in children with drug-resistant tuberculosis.
Indications
XDR-TB Should be used routinely in all cases
Pre-XDR-TB, failed treatment with second-line drugs Should be used routinely in all cases
Pre-XDR-TB, meningitis Consider, depending on severity of illness,
extent of disease, other available drugs, response to treatment
Pre-XDR-TB, standard cases Consider, depending on severity of illness,
extent of disease, other available drugs, response to treatment
MDR-TB, failed treatment with second-line drugs Should be used routinely in all cases
MDR-TB, meningitis Consider, depending on severity of illness,
extent of disease and other available drugs
MDR-TB, standard cases Not routinely recommended
Dosing
<12 years of age 10 mg/kg twice daily
12 years of age 10 mg/kg once daily up to 300 mg
Monitoring
Full blood picture e monthly Dose reduction for cytopaenias
Active clinical monitoring for peripheral neuropathy Dose reduction for peripheral neuropathy;
discontinuation if no improvement
Monitoring visual acuity where able; challenge with
such monitoring in young children should not limit
linezolid use when otherwise indicated
Discontinuation if any signs of optic neuropathy
Monitoring for lactic acidosis, rhabdomyolysis, other
rare adverse effects only if clinically indicated
Dose reduction or discontinuation depending on severity
XDR-TB ¼ extensively drug-resistant tuberculosis; Pre-XDR-TB ¼ multidrug-resistant tuberculosis with additional resistance to either a ﬂuo-
roquinolone or a second-line injectable drug; MDR-TB ¼ multidrug-resistant tuberculosis.
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are available.
These data show a substantial number of children treated with
linezolid for DR-TBwill have adverse effects. Though this appears to
be less than in adult reports, the small number of paediatric cases
makes it difﬁcult to say with certainty. The majority of adverse
effects responded to dose reduction, including neuropathy. Chil-
dren on long-term linezolid should have close monitoring for any
toxicity, with a dose reduction for any non-life-threatening adverse
effects.
5. Pharmacokinetics and pharmacodynamics
5.1. Pharmacokinetics
Linezolid is well absorbed in both the oral suspension and tablet
formulation, with oral availability approaching 100% [15,90]. In
healthy volunteers the time to maximum concentration (Tmax) is
0.5e2 h. Co-administrationwith a high fat meal may delay the Tmax
and slightly reduce the maximum plasma concentration (Cmax), but
does not affect the (AUC) [90]. Protein binding is reported to be 31%
[15,90]. Linezolid has complex metabolism with two primary and
multiple minor metabolites [90]. The rate-limiting step in linezolid
clearance is the non-enzymic formation of the primary metabolite,
and both renal and non-renal routes are involved in elimination
[90], with non-renal elimination accounting for roughly 65% [91]. In
healthy volunteers the mean Cmax after steady state dosing with
600 mg varies from 16.3 to 21 mg/ml and the mean AUC0e12 from
107 to 138 mg h/ml [90]. Increased clearance, decreased AUC, and
substantial inter-patient variability have been noted in ill patients
relative to healthy volunteers [92,93]. Linezolid has good tissue
penetration [90,94], including into lung and epithelial lining ﬂuid
[95,96]. Penetration into cerebrospinal ﬂuid (CSF) is good, with
reported CSF-to-plasma ratios of 0.7 [90] and 0.66 [97] and PK
parameters in the CSF of adult neurosurgery patients [97] and
ventricular ﬂuid of children and adolescents [98] suggesting
excellent pharmacodynamics. Meningeal inﬂammation did not
appear to inﬂuence CSF penetration.Our search identiﬁed 3 studies of linezolid pharmacokinetics in
adults with TB, with results reported in Table 4 [40,44,99,100]. The
trial of linezolid for chronic XDR reported mean AUC0e24 of
91.1 mg h/ml for 300 mg once daily, and 180.4 mg h/ml for 600 mg
once daily [59]. In the same study, in all those taking 600 mg daily
the serum concentration exceeded the MIC for the entire dosing
period, but the trough was below the MIC for 9 of 16 taking 300 mg
once daily, including 2 patients who developed linezolid resistance
[59].
Our search did not identify any studies of linezolid pharmaco-
kinetics in children with TB. A review summarized the paediatric
pharmacokinetic data on linezolid from four clinical trials including
over 180 children (Table 4) [91]. In newborns linezolid clearance
approximates that in adults, but increases to 2e3 times adult values
by the ﬁrst week of life, gradually declining over time until around
12 years of age when it and other PK parameters approximate that
of adults [91]. The increased clearance results in shorter serum half-
life (t1/2) and smaller AUCs relative to adults [91]. It was recom-
mended that in order to approximate the adult dose of 600 mg
twice daily for Gram-positive infections, to give a dose of 10 mg/kg
8 hourly in children <12 years of age, and for adolescents  12
years of age to give adult doses [91].
Based on published pharmacokinetics, a dose of 10 mg/kg in
children 3 months to <12 years of age will approximate the Cmax of
a 600 mg dose in adults. Because of the increased clearance, the
exposure (AUC) of a 10 mg/kg dose in the same age group will
approximate that of a 300 mg dose in adults, so twice daily dosing
would be expected to provide similar coverage as a 600 mg adult
dose. A dose of 10 mg/kg twice daily for those <10 years, and
10 mg/kg once daily for those 10 years has been suggested [63],
and is the dose most commonly used in published linezolid-treated
paediatric DR-TB cases to date.
Clinicians should be aware of drug interactions with clari-
thromycin, also a WHO Group 5 antituberculosis drug which may
be given as part of a treatment regimen for XDR-TB patients. In
adults, co-administration with 500 mg clarithromycin increased
linezolid exposure by 44% [101], which theoretically could increase
the risk of adverse effects.  101
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Linezolid appears to have both time and concentration depen-
dent killing, with both the AUC/MIC ratio and percent time above
MIC (%T > MIC) correlated with linezolid activity against Gram-
positive bacteria [102,103]. Suggested targets for Gram-positive
bacteria are AUC/MICs>80e120 and %T > MIC of 100% [100,102].
Speciﬁc targets forMtb have not been established, though its much
slower doubling time relative to Gram-positive bacteria means
lower targets may still be effective [104]. A moderate post-
antibiotic effect for linezolid, reported to be 4 h in a single study
[105], would support maintaining concentrations above the MIC
throughout the entire treatment period, though the clinical
importance of this in Mtb is not known.
Excellent values have been reported for both free AUC/MIC and
%T>MIC for 600mg once and twice daily dosing, though therewas
no correlation between either of these measures and the EBA0e2 or
EBA2e7 in the study [40]. Favourable pharmacodynamic parameters
were also described for both linezolid 600 mg twice daily (AUC0-24/
MIC 243.2, and %T > MIC 100.0), and 600 mg once daily (AUC0-24/
MIC 116.2, and %T > MIC 62.8) [100]. A linezolid dose of 300 mg
twice daily resulted in an AUC0-24/MIC from 167 to 667 for 7 of 8
patients with a ratio >100 and %T > MIC of 100% for all patients,
suggesting that lower doses may maintain efﬁcacy while hopefully
limiting toxicity [99]. A higher %T>MIC of 100% for a 300mg twice
daily dose [99] compared to 62.8% for a 600 mg once daily dose
[100] may reﬂect differences between the two studies in both the
MICs of the Mtb isolates and in the reported linezolid pharmaco-
kinetics. The 300 mg twice daily dose resulted in higher exposures,
which may be related to differences in the pharmacokinetic assay
methodology between studies or to individual participant vari-
ability in these small samples, though real differences due to dose-
related alterations in linezolid elimination cannot be excluded. In
the single linezolid clinical trial for XDR-TB, neither Cmax nor trough
concentration was associated with time to culture conversion [59].
6. Recommendations for the use of linezolid in children with
DR-TB
TheWHO 2008 guidelines recommend the use of Group 5 drugs,
including linezolid, only when a regimen containing 4 drugs with
likely activity cannot be created from Groups 1e4, though no other
speciﬁc recommendations regarding linezolid were made [6]. The
recommended dosage is 600 mg twice daily for 4e6 weeks, then
600 mg once daily [6]. The WHO 2011 guidelines update did not
speciﬁcally address linezolid [106]. We are unaware of any other
formal recommendations for the use of linezolid in children with
DR-TB, in these or other documents [6,106].
In the absence of existing recommendations, Table 5 summa-
rizes our working recommendations for the use of linezolid in
children with DR-TB.
6.1. Indications for use in children with DR-TB
Because of the high cost, considerable toxicity, and good out-
comes with current treatment regimens, existing evidence does not
support the routine use of linezolid for children with MDR-TB. We
recommend linezolid for use in children with XDR-TB or for those
who have failed treatment for MDR-TB with or without additional
drug resistance. Linezolid is likely to be the most active drug for
such children and could make the difference between treatment
success and failure. Linezolid should be considered for children
with MDR-TB with additional ﬂuoroquinolone or second-line
injectable resistance (Pre-XDR-TB), especially those who have
extensive disease or meningitis. Linezolid should also beconsidered for children with MDR-TB meningitis, especially those
who have had a slow or poor response to standard treatment. The
good CSF penetration of linezolid makes it particularly useful for
DR-TB meningitis, as there are few second-line agents with potent
antituberculosis activity and good CSF penetration.
6.2. Dosage
There remains uncertainty about the optimal dose of linezolid in
adults with DR-TB, which balances efﬁcacy and toxicity [107e109].
Currently most adults will start with a dose of linezolid 600 mg
once daily for the intensive phase of treatment, though somewould
advocate for a 300 mg dose. In the continuation phase adults will
complete their treatment with either a dose of 600 mg or 300 mg
once daily, though many of those using 600 mg will switch to
300 mg due to adverse effects.
Generally children 12 years of age should receive the same
dose as adults, and we have had success using a dose of 10 mg/kg
once daily up to 300 mg for children 12 years of age, as in our
cases included in this report [62,63]. For children 3 months to 12
years we recommend a dose of 10 mg/kg twice daily. For children
with extensive disease or TB meningitis it may be advisable to use
up to a higher total daily dose of 600 mg, at least initially.
6.3. Monitoring
For children on linezolid we recommend monitoring of full
blood counts monthly. We also recommend active monitoring for
signs of peripheral neuropathy. Children who develop signs of pe-
ripheral neuropathy should initially have a linezolid dose reduc-
tion, as many will respond to this. The decision to reduce the
linezolid dose should be made considering the severity of the
adverse effects, severity of the TB disease, and other available
treatment options. Adults using 600 mg once daily usually reduce
the dose to 300 mg once daily when necessary. In children we
recommend reducing the dose by 1/3 or 1/2, however there is little
evidence for this, and close monitoring for persistence or wors-
ening of the adverse effects, or recrudescence or worsening of the
TB disease is important. Thrice weekly dosing of linezolid seemed
to reduce adverse effects in a small number of adult patients [110].
This is a potential approach for those with few other treatment
options, and further evaluation of this strategy in adults and chil-
dren would be useful. If peripheral neuropathy persists then line-
zolid may need to be discontinued. The cumulative evidence,
though of low quality, suggests no effect of vitamin B6 (pyridoxine)
supplementation on the risk of linezolid-related adverse effects,
and routine supplementation is not warranted; however patients
receiving high-dose INH or cycloserine/terizidone should receive
pyridoxine supplementation as currently recommended.
In settings where resources and expertise for ophthalmologic
assessments are available, routine eye exams in children on long-
term linezolid are warranted. Considering the challenges of
ophthalmologic assessments in young children, this is unlikely to
be feasible in resource-limited settings, and referral for ophthal-
mologic examination or discontinuation of linezolid for possible
optic neuropathy may be best indicated by any signs of decreasing
visual acuity. Because of the reported rarity of optic neuropathy, the
limited treatment options and the importance of linezolid to the
antituberculosis drug regimen in children with extensive resis-
tance, we strongly recommend that the inability to perform routine
eye exams in young children should not limit the use of linezolid
when it is otherwise indicated. Any signs of deteriorating visual
acuity without other explanation should prompt a thorough
ophthalmologic examination and discontinuation of linezolid.
Though routine monitoring for rare adverse effects such as lactic 102
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aware of the potential for these effects should patients develop
consistent signs or symptoms.
7. Questions for future study
The optimal dosing of linezolid in adults and children remains
unclear. Once an adult dose has been established, a more formal
recommendation can be made for paediatric dosing that gives a
similar drug exposure. We are unaware of published linezolid
pharmacokinetic data in children with TB, though such data would
be important for guiding appropriate dosing for this indication. An
ongoing study in Cape Town, South Africa is evaluating the phar-
macokinetics, safety, and tolerability of second-line antitubercu-
losis drugs in children, including linezolid, when used in children
with DR-TB.
Little data exist on linezolid use in HIV-infected adults or chil-
dren with DR-TB. Because of a potential increased risk of toxicity
related to co-administration with ARVs and limited published data
to date, additional information about the efﬁcacy and safety in HIV-
infected persons is needed. Additional evidence on the impact of
linezolid co-treatment with high-dose INH and cycloserine/ter-
izidone, as well as the impact of pyridoxine supplementation on
adverse effects in this context would be useful.
Biomarkers for treatment response or other improved surrogate
endpoints for trials in both adults and children with drug-
susceptible and drug-resistant tuberculosis are urgently needed
andwould greatly facilitate individualized management of children
with drug-resistant tuberculosis and the rational use of drugs like
linezolid.
Considering what appears to be potent activity of linezolid in
difﬁcult DR-TB cases, exploration of treatment intensiﬁcation with
a short course of linezolid in children with severe DR-TB disease
may be warranted. The second-line injectable agents (amikacin,
kanamycin, and capreomycin) are considered key drugs for DR-TB
treatment, but must be given by painful intramuscular injections
and are associated with permanent sensorineural hearing loss in as
many as 24% of childrenwhen given long term [111]. Substitution of
the second-line injectables by linezolid in the intensive phase of
treatment is an approach that warrants study.
A search of www.clinicaltrials.gov and the WHO International
Clinical Trials Registry Platform (http://www.who.int/ictrp/en/)
revealed no registered studies of linezolid in children with TB, and
future large trials of linezolid in children with DR-TB are unlikely.
Wewould encourage clinicians using linezolid for DR-TB in children
to systematically record key information about each case, doc-
umenting degree of drug resistance, dosing, treatment response
including culture conversion and outcome, and any adverse effects,
and to report these cases as widely as possible.
The oxazolidinone antibiotic PNU-100480 has shown better
efﬁcacy against Mtb than linezolid in pre-clinical studies [37], and
further study and development of it and other novel agents will be
important to improving treatment options for adults and children
with DR-TB. The inclusion of children with DR-TB in such trials is of
critical importance.
8. Conclusion
Despite modest activity of linezolid against Mtb in vitro and in
animal models, emerging data in adults have shown it to be
effective in difﬁcult cases of DR-TB. These beneﬁts are currently
offset by its high cost, and frequent and often severe time- and
dose-dependent toxicity. Though data are limited, the efﬁcacy and
adverse effects of linezolid in treatment of children with DR-TB
reported to date are similar to adults. For children with MDR-TBwith additional resistance or with XDR-TB, linezolid may however
make the difference between a successful or poor outcome, as
demonstrated in many of the paediatric cases described to date.
Because of its good CSF penetration, linezolid may also be an
important option for children with MDR-TB meningitis, for which
outcomes are often poor and other drugs with potent antituber-
culosis activity and good CSF penetration are limited. We would
support calls for lowering linezolid costs and making it available,
including in suspension form, for children with these indications
[18]. Until newer antituberculosis agents with better efﬁcacy and
safety become available, linezolid will be an important component
of treatment for children with the worst forms of drug-resistant
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Chapter	7:	Pharmacokinetics	and	safety	of	linezolid	in	children	
treated	for	multidrug-resistant	tuberculosis		
Rationale	As	identified	in	the	review	in	Chapter	6,	linezolid	has	potent	antimycobacterial	activity	and	is	an	increasingly	important	antituberculosis	drug	for	the	treatment	of	MDR-TB	in	adults	and	children.		There	are	no	linezolid	pharmacokinetic	data	available	yet	in	children	with	TB	and	there	is	limited	guidance	on	its	dose	for	long-term	treatment	of	MDR-TB.		Linezolid’s	dose	and	duration-dependent	adverse	effects	have	not	been	prospectively	and	systematically	described	in	children	treated	long-term	for	MDR-TB.		
Study	aims	The	objective	of	this	study	was	to	characterize	the	pharmacokinetics,	safety	and	optimal	dose	of	linezolid	in	HIV-infected	and	–uninfected	children	treated	for	MDR-TB.		
Methods	The	MDRPK2	study	(Optimizing	and	operationalizing	pediatric	drug-resistant	
tuberculosis	treatment,	PI	Garcia-Prats,	Savic	HD083047)	was	an	NIH	RO1	funded	study	targeting	100	HIV-infected	and	uninfected	children	receiving	one	of	three	key	second-line	antituberculosis	drugs	(levofloxacin,	moxifloxacin	or	linezolid)	for	pharmacokinetic	sampling	and	longitudinal	follow-up	for	safety	and	treatment	outcomes.		This	study	was	a	direct	follow-up	to	the	MDRPK1	study	(see	previous	chapters),	and	built	on	MDRPK1	study	methods	and	data.		The	primary	objectives	of	the	MDRPK2	study	were	to	characterize	the	pharmacokinetics	and	safety	of	levofloxacin,	moxifloxacin	and	linezolid	using	weight-banded	optimized	doses		based	on	data	from	MDRK1,	among	HIV-infected	and	–uninfected	children	routinely	treated	for	MDR-TB.		The	study	was	open	from	2016	and	enrollment	and	follow-up	are	ongoing.		As	for	MDRPK1,	children	with	MDR-TB	are	recruited	from	Tygerberg	Hospital	and	Brooklyn	Hospital	for	Chest	Diseases,	Cape	Town	as	well	as	Brewelskloof	Hospital,	Worcester.			Children	were	eligible	for	MDRPK2	if	they	were	0	to	<18	years	of	age,	HIV-infected	or	–uninfected,	routinely	treated	with	second-line	antituberculosis	drugs	including	at	least	one	of	levofloxacin,	moxifloxacin	or	linezolid	for	treatment	of	MDR-TB	for	<12	weeks.		Exclusion	criteria	included	laboratory	documented	anaemia	(haemoglobin	<8	g/dL),	
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other	serious	clinical	comorbidity,	or	weight	<2.5	kg.		Children	in	the	study	had	semi-intensive	pharmacokinetic	sampling	(pre-dose,	then	1,	4,	and	10	hours	post-dose),	and	were	followed	longitudinally	for	safety	and	TB	treatment	outcome.		Children	in	MDRPK2	not	receiving	linezolid	as	a	component	of	their	routine	treatment	regimen	were	prescribed	a	single	dose	on	the	day	of	pharmacokinetic	sampling,	and	so	contributed	cross	sectional	pharmacokinetic	data	but	not	long-term	safety	data.			As	linezolid	is	expensive	and	associated	with	frequent	adverse	events,	it	is	reserved	in	Cape	Town	for	children	with	MDR-TB	who	have	additional	resistance	to,	toxicity	or	intolerance	to	additional	second-line	antituberculosis	drugs,	so	relatively	few	children	receive	it	in	their	regimens.		Therefore,	children	from	both	MDRPK1	and	MDRPK2	who	received	linezolid	were	included	in	this	analysis.		All	children	had	pharmacokinetic	sampling	between	2	and	12	weeks	of	MDR-TB	treatment.		The	routinely	available	formulations	of	linezolid	were	used	(600	mg	tablets,	20	mg/mL	granules	for	suspension,	Pfizer,	Sandton,	South	Africa).		Children	receiving	linezolid	as	a	component	of	their	routine	treatment	regimens	were	generally	prescribed	10	mg/kg/dose	given	twice	daily	if	<10	years	of	age	or	once	daily	if	≥10	years	of	age	(maximum	daily	dose	of	600	mg).		On	the	day	of	pharmacokinetic	sampling,	linezolid	was	administered	as	an	exact	10	mg/kg	dose	in	MDRPK1,	and	as	a	weight	banded	dose	approximating	10	mg/kg	in	MDRPK2.		Linezolid	was	administered	either	as	whole	tablets,	suspension	or	occasionally	as	crushed	tablets,	and	either	orally	or	by	nasogastric	tube,	depending	on	what	the	child	was	able	to	tolerate.			Linezolid	plasma	concentrations	were	measured	using	a	validated	liquid	chromatography	tandem	mass	spectrometry	(LC	MS/MS)	assay	at	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology.		Linezolid	pharmacokinetic	parameters	were	calculated,	and	associations	with	covariates	of	interest	assessed,	using	non-linear	mixed	effects	modeling.		The	final	model	was	used	to	simulate	weight	banded	doses	resulting	in	exposures	in	children	across	ages	that	approximated	the	target	seen	in	adults	with	MDR-TB	receiving	600	mg	once	daily	(110	mg/L.h).		Children	receiving	linezolid	as	a	component	of	their	routine	treatment	regimen	had	1-2	monthly	clinical	and	laboratory	safety	monitoring.		All	adverse	events	were	reported,	and	assessed	for	severity	and	attribution	to	linezolid.		In	MDRPK1,	events	were	graded	for	severity	using	standard	Division	of	AIDS	criteria	(DAIDS	Table	for	Grading	the	Severity	of	Adult	and	
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Pediatric	Adverse	Events	version	1.0,	December	2004,	updated	August	2009)	(122).		In	MDRPK2,	events	were	graded	according	to	the	updated	DAIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	(Corrected	version	2.1,	July	2017)	(127).		Frequency	and	rates	of	adverse	events	were	reported	by	grade.		
Results	Forty-eight	children,	mean	(range)	age	5.9	years	(0.6	to	15.3),	were	included	in	this	study.		Three	were	HIV-infected.		Nine	children	were	from	MDRPK1,	and	39	from	MDRPK2,	the	majority	of	whom	(n=31)	received	single	dose	linezolid.	The	final	pharmacokinetic	model	consisted	of	a	one	compartment	model	characterized	by	clearance	(CL)	and	volume	(V)	parameters	which	included	allometric	scaling	to	account	for	weight.		No	other	evaluated	covariates	contributed	to	the	model.		Simulations	using	the	model	estimated	that	once	daily	doses	from	14.5	mg/kg	(children	5	to	<7	kg	body	weight)	down	to	8.2	mg/kg	are	needed	(children	43	to	<56	kg	body	weight)	to	achieve	target	exposures.		Ten	of	17	children	followed	long-term	had	a	linezolid-related	adverse	event,	including	5	with	a	Grade	3	or	4	event,	which	were	all	anaemia.		These	adverse	events	frequently	resulted	in	linezolid	dose	reductions	(n=4),	temporary	interruptions	(n=5)	or	permanent	discontinuations	(n=4).				
Conclusions	and	recommendations	In	this	first	clinical	study	of	linezolid	pharmacokinetics	and	safety	in	children	treated	for	MDR-TB,	linezolid	exposures	were	adequate,	and	higher	than	expected	considering	previous	linezolid	data	in	children	treated	for	non-TB	infections.		The	frequent,	serious	adverse	events	highlight	the	importance	of	careful	monitoring	for	children	receiving	linezolid.		Although	the	cumulative	incidence	of	events	increased	with	longer	treatment	durations,	events,	including	some	grade	3	and	4,	were	seen	even	in	the	first	two	months	of	treatment.		The	use	of	shorter	duration	of	linezolid	may	reduce	but	not	eliminate	the	risk	of	adverse	events,	and	careful	safety	monitoring	remains	important	regardless	of	the	duration.		Simulated	doses	achieving	target	exposures	were	lower	than	are	currently	being	used	in	many	routine	settings.		These	doses	may	reduce	the	risk	of	adverse	events.		The	impact	of	reduced	doses	on	efficacy	and	risk	of	acquired	resistance	should	be	considered,	especially	in	older	children,	although	a	600	mg	dose	in	adults	appears	to	be	efficacious	with	a	low	risk	of	acquired	resistance,	and	there	is	no	reason	to	expect	this	to	differ	in	children	achieving	the	same	exposures.		These	newly	proposed	
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linezolid	doses	should	be	evaluated	prospectively	in	children	to	characterize	the	pharmacokinetics,	safety	and	efficacy	of	these	doses.			
Citation:		This	study	has	been	prepared	as	a	manuscript	but	has	not	yet	been	submitted.		Author	contribution	is	as	described	in	Appendix	1.	
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Abstract	
Background:		Linezolid	is	an	increasingly	important	antituberculosis	drug	for	the	treatment	of	multidrug-resistant	tuberculosis	(MDR-TB)	in	adults	and	children.		However	there	are	no	linezolid	pharmacokinetic	data	in	children	with	TB,	and	its	adverse	effects	have	not	been	prospectively	described	in	children	treated	long-term	for	MDR-TB.		The	objective	of	the	study	was	to	characterize	the	pharmacokinetics,	safety	and	optimal	dose	of	linezolid	in	children	treated	for	MDR-TB.	
Patients	and	methods:		Data	from	two	observational	pharmacokinetic	studies	in	South	Africa	were	included.		Children	routinely	treated	for	MDR-TB	had	pharmacokinetic	sampling	after	either	a	single	dose	or	multiple	doses	of	linezolid	(at	steady	state).		Linezolid	pharmacokinetic	parameters,	and	associations	of	these	with	covariates	of	interest,	were	described	using	non-linear	mixed	effects	modelling.		Children	receiving	long-term	linezolid	as	a	component	of	their	routine	treatment	had	regular	clinical	and	laboratory	monitoring.		All	adverse	events	were	graded	for	severity	and	assessed	for	attribution	to	linezolid.		Simulations	with	the	final	pharmacokinetic	model	were	used	to	estimate	weight	banded	doses	resulting	in	exposures	in	children	that	approximate	those	in	adults	receiving	linezolid	600	mg	once	daily.	
Results:	Forty-eight	children	were	included	(mean	age	5.9	years,	range	0.6	to	15.3);	2	were	HIV-infected,	31	received	a	single	dose	of	linezolid	and	17	received	multiple	doses.		The	final	pharmacokinetic	model	consisted	of	a	one	compartment	model	characterized	by	clearance	(CL)	and	volume	(V)	parameters	which	included	allometric	scaling	to	account	for	weight;	no	other	evaluated	covariates	contributed	to	the	model.		Simulated	weight-banded	once	daily	doses	estimated	that	doses	from	14.5	mg/kg	(children	5	to	<7	kg	body	weight)	to	8.2	mg/kg	are	needed	(children	43	to	<56	kg	body	weight).		Ten	of	17	children	followed	long-term	had	a	linezolid-related	adverse	event,	including	5	with	a	Grade	3	or	4	event,	which	were	all	anaemia.		These	adverse	events	resulted	in	linezolid	dose	reductions	(n=4),	temporary	interruptions	(n=5)	or	permanent	discontinuations	(n=4).			
Conclusions:	Linezolid	exposures	were	satisfactory	in	this	cohort	of	children	with	MDR-TB,	compared	to	current	adult	target	exposures.		Linezolid-related	adverse	effects	were	frequent	and	occasionally	severe,	and	careful	safety	monitoring	is	required.		Compared	to	doses	currently	being	used	in	children	in	many	settings	for	MDR-TB	
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treatment,	lower	doses	may	approximate	target	exposures	and	should	be	evaluated	in	children.		 	
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Introduction	Multidrug-resistant	(MDR)	tuberculosis	(TB)	continues	to	threaten	global	TB	control,	with	an	estimated	490,000	incident	cases	worldwide	in	2016	[1].		Treatment	options	remain	limited,	especially	in	children.		Linezolid,	an	oxazolidinone	antibiotic	that	binds	to	the	50s	ribosomal	subunit	inhibiting	protein	synthesis	[2],	is	increasingly	being	used	for	MDR-TB	treatment,	particularly	when	there	is	additional	resistance	to	second-line	antituberculosis	medications,	such	as	for	extensively	drug-resistant	(XDR)	TB	(i.e.	MDR-TB	with	additional	fluoroquinolone	and	second-line	injectable	resistance).		In	routine	use	in	adults	with	MDR-TB,	linezolid	has	been	associated	with	good	outcomes,	with	68%	and	82%	of	patients	successfully	treated	in	two	systematic	reviews,	respectively	[3,	4].			Revised	2016	WHO	antituberculosis	drug	groupings	for	MDR-TB	treatment	have	given	a	higher	priority	to	linezolid,	moving	it	to	Group	C,	from	Group	5	in	the	older	grouping	[5,	6].		Interest	in	linezolid	has	grown	further	based	on	the	preliminary	results	of	the	Nix-TB	trial	(NCT02333799),	a	single-arm	open-label	phase	3	study	which	evaluated	adults	with	XDR-TB	or	MDR-TB	treatment	intolerance,	or	failure,	with	a	three-drug	regimen	of	bedaquiline,	pretomanid	and	linezolid	(1200	mg	given	once	daily)	for	six	months	[7].		At	the	time	of	interim	analysis,	61	adult	participants	had	been	enrolled	(49%	HIV-infected,	74%	with	XDR-TB)	[7].		Of	these	61,	4	had	died	and	of	the	surviving	patients,	45	(74%)	were	culture	negative	by	8	weeks	of	treatment.	By	4	months	of	treatment,	all	patients	were	culture	negative;	34	of	61	(56%)	had	completed	6	months	of	treatment,	20	(33%)	had	completed	6	month	post-treatment	follow-up	and	only	one	patient	has	had	microbiological	relapse	to	date	[7].		Linezolid	is	also	a	component	of	multiple	novel,	shortened	MDR-TB	treatment	regimens	currently	under	evaluation	in	adults	[8].	In	short	courses	(<28	days),	linezolid	is	safe	and	well	tolerated,	but	with	the	longer	treatment	durations	being	used	for	MDR-TB	treatment	(typically	6	months	or	longer	in	adults),	it	is	associated	with	frequent,	serious,	dose	and	duration-dependent	adverse	effects,	including	anaemia,	neutropaenia,	thrombocytopaenia,	peripheral	neuropathy,	and	more	rarely,	optic	neuropathy,	lactic	acidosis,	pancreatitis	and	rhabdomyolosis	[9].		In	the	same	systematic	reviews	of	linezolid-treated	adults	with	MDR-TB	described	earlier,	linezolid-related	adverse	events	were	reported	in	61%	and	59%	of	patients,	respectively	[3,	4],	with	69%	of	these	requiring	linezolid	dose-adjustment	or	
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discontinuation	in	one	review	[3].		A	linezolid	dose	of	>600	mg	daily	was	associated	with	an	increased	risk	of	adverse	effects	in	these	reviews	[3,	4].		In	the	Nix-TB	study,	27%	of	participants	experienced	a	serious	adverse	event;	71%	of	participants	had	at	least	one	linezolid	treatment	interruption,	due	mostly	to	myelosuppression	or	peripheral	neuropathy	[7].			There	is	a	substantial	burden	of	MDR-TB	in	children,	with	an	estimated	25,000-32,000	incident	cases	globally	each	year	[10,	11],	many	of	whom	could	benefit	from	linezolid	treatment	given	considerable	delays	in	the	evaluation	of	novel	effective	drugs	like	bedaquiline	in	children.		The	evidence	base	for	linezolid	use	in	children	with	MDR-TB	is	currently	limited.		A	2014	review	identified	only	case	reports	and	small	case	series	in	the	literature	that	described	18	children	with	MDR-TB	treated	with	linezolid	[9].		As	in	adults,	treatment	outcomes	were	good	with	15	of	18	children	(83%)	successfully	treated,	but	9	(50%)	experienced	a	linezolid-related	adverse	event,	with	5	(28%)	requiring	dose	adjustment	and	2	(11%)	discontinuing	linezolid	[9].		This	limited	early		data	was	also	retrospective,	and	had	variable	reporting	of	key	information.		High	quality	prospective	data	is	needed	to	better	characterize	the	incidence,	severity,	and	timing	of	adverse	events	among	children	with	MDR-TB	receiving	long-term	linezolid.	The	optimal	dose	of	linezolid	for	treatment	of	adults	with	MDR-TB	is	not	yet	certain.		However	600	mg	once	daily	is	currently	the	most	frequently	used	routine	dose	in	adults.		The	dose	of	linezolid	in	children	needed	to	approximate	target	exposures	in	adults	with	MDR-TB	receiving	a	600	mg	dose	has	not	been	characterized.		Linezolid	is	well	absorbed	after	oral	administration,	with	bioavailability	of	nearly	100%	[2,	12].		Linezolid	has	complex	metabolism	with	the	primary	metabolite	formed	through	a	non-enzymatic	mechanism,	with	the	major	pathway	of	excretion	being	the	urine	[12].		A	benefit	of	linezolid	is	its	good	penetration	into	tissues,	including	cerebrospinal	fluid,	where	its	exposure	is	70-98%	of	plasma	exposure	[12-14].		Linezolid	pharmacokinetics	have	been	studied	extensively	in	adults;	studies	to	date	have	shown	substantial	variability	between	patients,	patient	populations	and	studies	[15-17].			Linezolid	pharmacokinetics	have	been	studied	in	children	with	Gram-positive	infections	and	resulted	in	dosing	recommendations	of	10	mg/kg	three	times	daily	for	children	<10	years	of	age,	and	10	mg/kg	twice	daily	for	children	≥10	years	of	age	to	approximate	exposures	in	adults	receiving	600	mg	twice	daily	[18].		A	previous	attempt	at	linezolid	
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dose	selection	for	TB	treatment	in	children	used	simulations	with	this	paediatric	data	and	targeted	a	linezolid	area	under	the	concentration	time	curve	(AUC)	to	a	minimum	inhibitory	concentration	(MIC)	ratio	(AUC/MIC)	of	>62	mg/L.h	to	93.4	mg/L.h	[19].		The	suggested	doses	were	15	mg/kg	for	children	<3	months	and	10	mg/kg	for	children	3	months	to	11	years	of	age	[19].		However,	this	evaluation	was	limited	by	the	lack	of	clinical	studies	of	linezolid	pharmacokinetic	data	in	children	with	TB	and	requires	clinical	evaluation.		Dosing	guidance	should	ideally	be	based	on	data	from	the	target	population,	particularly	as	linezolid	pharmacokinetics	is	known	to	vary	considerably	across	disease	states	[17].		Additionally,	the	validity	of	the	proposed	targets	using	AUC/MIC	are	uncertain.		Understanding	the	optimal	dose	of	linezolid	for	MDR-TB	treatment	in	children	is	critical,	as	too	high	a	dose	may	increase	the	risk	of	serious	adverse	effects,	while	underdosing	may	reduce	the	efficacy	of	this	drug	that	is	often	playing	a	critical	role	in	regimens	where	treatment	options	are	very	limited,	such	as	resistance	(such	as	XDR-TB),	toxicity,	or	intolerance	to	other	second-line	antituberculosis	drugs,	and	may	also	lead	to	the	development	of	resistance	to	linezolid	[20,	21].		Practical,	weight-banded	paediatric	dosing	guidance	for	linezolid	based	on	its	pharmacokinetics	in	children	with	TB	is	urgently	needed.	The	objective	of	this	study	was	to	characterize	the	pharmacokinetics	and	safety	of	linezolid	in	children	routinely	treated	for	the	spectrum	of	MDR-TB,	and	to	estimate	optimal	weight-banded	doses	that	approximate	robust	adult	target	exposures	for	MDR-TB	treatment.		
Patients	and	Methods	
Study	design,	setting	and	population:		The	data	described	here	are	combined	from	two	prospective	observational	pharmacokinetic	studies	implemented	in	Cape	Town,	South	Africa,	which	used	standard	clinical	study	measures,	the	same	clinical	personnel,	identical	drug	formulations	and	laboratory	methods.		The	first	study	(MDRPK1)	enrolled	HIV-infected	and	-uninfected	children	from	0	to	<15	years	of	age	(n=173),	routinely	treated	with	second-line	antituberculosis	drugs	for	probable	or	confirmed	drug-resistant	TB,	who	were	followed	until	the	end	of	MDR-TB	treatment,	from	2011	to	2015.		Children	from	this	cohort	routinely	treated	with	linezolid	were	included	in	the	current	analysis.		The	second	study	(MDRPK2),	was	a	direct	follow-up	study	to	
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MDRPK1,	and	enrolled	HIV-infected	and	-uninfected	children	from	0	to	<18	years	of	age	(n=64),	routinely	treated	for	MDR-TB	with	levofloxacin,	moxifloxacin	or	linezolid,	in	the	same	setting,	from	2016.		Enrolment	and	follow-up	for	MDRPK2	are	ongoing.		In	MDRPK2,	children	not	prescribed	linezolid	as	a	component	of	their	routine	MDR-TB	care	received	a	single	dose	of	linezolid	on	the	day	of	pharmacokinetic	sampling	and	therefore	contributed	data	to	pharmacokinetic	analyses	only,	but	not	to	long-term	safety.			Children	with	MDR-TB	were	treated	according	to	national	and	international	guidelines	with	a	minimum	of	four	confirmed	or	likely	effective	drugs,	usually	with	the	addition	of	pyrazinamide	and	ethambutol,	generally	for	12-18	months’	duration	[6,	22,	23].		Due	to	its	cost	and	associated	adverse	effects,	linezolid	is	currently	reserved	in	Cape	Town	for	MDR-TB	patients	with:	1)	probable	or	confirmed	additional	fluoroquinolone	resistance,	including	those	with	XDR-TB;	2)	MDR-TB	meningitis;	3)	or	intolerance	to	other	second-line	antituberculosis	medications.		Management	of	linezolid-associated	adverse	events	were	individualized	depending	on	the	type	and	severity	of	the	event,	the	severity	of	the	child’s	TB	disease,	and	the	availability	of	other	treatment	options.		For	common,	non-severe	events	such	as	low	grade	anaemia,	linezolid	would	be	temporarily	interrupted	and	then	restarted	at	half	the	dose.		For	more	severe	events,	linezolid	may	have	been	permanently	discontinued,	depending	on	other	treatment	options,	and	the	child’s	clinical	status	including	their	response	to	TB	treatment	at	the	time.			
Linezolid	dosing	and	pharmacokinetic	sampling:		The	routinely	prescribed	dose	of	linezolid	in	the	study	setting	was	10	mg/kg/dose	twice	daily	for	children	<10	years	of	age	and	10	mg/kg/dose	once	daily	for	children	>10	years	of	age,	up	to	maximum	total	daily	dose	of	600	mg.		Linezolid	was	available	as	600	mg	unscored	tablets	and	as	a	20	mg/mL	suspension	(Pfizer,	Sandton,	South	Africa).		There	is	currently	no	global	evidence-based	dosing	recommendation	for	linezolid	for	TB	treatment	in	children.		In	the	MDRPK1	study,	on	pharmacokinetic	sampling	days,	an	exact	10	mg/kg	was	prepared	and	administered	along	with	other	antituberculosis	medications	in	the	regimen.		Samples	were	drawn	just	prior	to,	and	then	at	1,	2,	4,	8	and	either	6	or	11	hours	after	the	antituberculosis	medications’	dose.		In	MDRPK2,	a	weight-banded	dose	(approximately	10	mg/kg)	was	adminstered	on	pharmacokinetic	sampling	days	along	with	other	routine	antituberculosis	medications	in	the	regimen.		The	exact	linezolid	
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dose	given	on	the	day	was	documented.		Samples	were	drawn	just	prior	to,	and	at	1,	4	and	10	hours	after	the	observed	dose.		For	both	MDRPK1	and	MDRPK2,	whole	blood	samples	were	centrifuged,	and	plasma	separated	and	frozen	at	-80	C	within	30	minutes	of	phleobotomy.		For	both	studies,	medications	were	administred	on	an	empty	stomach	after	an	overnight	fast,	and	given	either	as	whole	tablets	if	the	child	was	able	to	swallow,	as	suspension	if	available,	or	crushed	tablets	mixed	in	the	smallest	volume	of	water	possible,	if	the	child	was	unable	to	swallow	and	the	suspension	was	unavailable.			On	occasssion,	all	antituberculosis	medications	were	adminstered	via	nasogastric	tube	on	pharmacokinetic	sampling	days	if	the	child	refused	to	swallow	them	orally	(e.g.	very	young	children).		One	hour	after	the	antituberculosis	medication	dose,	antiretrovirals	were	administered	if	relevant,	and	a	standard	breakfast	offered.		
Laboratory	assays:		Pharmacological	assays	were	performed	at	the	Unversity	of	Cape	Town	Division	of	Clincal	Pharmacology	using	a	validated	liquid	chromatography	tandem	mass	spectometry	(LC	MS/MS)	method.		This	LC	MS/MS	method	involves	a	simple	protein	precipitation	using	20	μl	of	plasma,	followed	by	isocratic	separation	on	a	Poroshell	120EC-C184.6	X	50mm,	2.7	um	column.		A	deuterated	internal	standard,	Linezolid-d3,	is	used	to	monitor	the	method	across	a	calibration	range	of	0.100	μg/ml	(LLOQ)	to	30	μg/ml	(ULOQ).	The	method	performed	well	over	the	period	of	analysis	with	an	accuracy	ranging	from	96.6-98.7%	and	a	precision	estimate	of	less	than	7.2%	(%	CV)	over	all	three	control	concentrations.	
Safety:		All	children	had	regular	clinical	and	laboratory	safety	assessments,	including	a	full	blood	count,	completed	at	the	National	Health	Laboratory	Services	(NHLS),	Cape	Town,	monthly	for	the	first	6	months,	then	every	two	months	or	as	clinically	indicated,	until	completion	of	treatment.		All	adverse	events	were	recorded,	assessed	for	attribution	to	linezolid,	and	graded	for	severity.		In	MDRPK1,	events	were	graded	according	to	standard	Division	of	AIDS	criteria	(DAIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	version	1.0,	December	2004,	updated	August	2009)	[24].		In	MDRPK2,	events	were	graded	according	to	the	updated	DAIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	(Corrected	version	2.1,	July	2017)	[25].	
Statistical	analysis:	Baseline	demographic	and	clinical	characteristics	were	presented	with	descriptive	statistics.		Weight-for-age	and	height-for-age	z-scores	were	calculated	
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using	British	Reference	values,	as	WHO	references	only	include	children	<10	years	of	age	[26].		Only	children	receiving	linezolid	as	a	component	of	their	routine	DR-TB	treatment	regimen	were	included	in	this	safety	analysis	(i.e.	not	children	only	receiving	single	dose	linezolid).		Adverse	events	at	least	possibly	related	to	linezolid	were	presented	by	grade	and	the	rate	of	events	per	person-time	of	observation	calculated.		The	median	(interquartile	range	[IQR])	time	without	linezolid-related	adverse	events	was	estimated	using	Kaplan-Meier	plots;	patients	were	censored	at	the	time	of	the	relevant	linezolid-related	event	or	when	linezolid	was	discontinued.	
Population	pharmacokinetic	model	and	dosing	simulations:	Pharmacokinetic	data	were	characterized	based	on	the	population	nonlinear	mixed	effects	modeling	approach	using	the	software	NONMEM	7.41	(ICON	Development	Solutions,	Ellicot	City).	The	method	of	estimation	used	was	FOCE	with	the	option	INTERACTION.	Regarding	the	statistical	part	of	the	model,	between	subject	variability	(BSV)	was	modeled	exponentially,	and	the	residual	error	was	described	using	a	combination	of	an	additive	and	proportional	error	model.		Model	building	was	performed	in	two	stages,	with	the	structural	model	developed	first	and	the	covariate	analysis	done	subsequently.		The	main	covariates	evaluated	during	the	analysis	were	weight,	height,	age,	sex	and	race.		HIV	status	,	linezolid	administration	method	(oral	vs.	nasogastric	tube),	formulation	(whole	vs.	crushed	vs.	suspension),	linezolid	given	as	single	dose	vs.	steady	state,	and	pharmacokinetic	interactions	with	concomitant	drugs.		Covariate	identification	was	done	using	the	stepwise	covariate	modeling	(SCM)	through	the	PsN	software	(v4.6.0).		This	method	consists	of	the	stepwise	testing	of	linear	and	non-linear	covariate-parameter	relationships	with	forward	inclusion	and	backward	exclusion	approaches	with	significance	levels	of	0.05	and	0.01,	respectively.	The	final	inclusion	of	the	identified	significant	covariates	was	done	taking	into	account	scientific	plausibility,	statistical	significance	and	clinical	relevance.		Both	stages	of	model	building	were	evaluated	by	the	likelihood	ratio	test,	goodness	of	fit	plots,	and	visual	predictive	checks	(VPC).	R	software	(version	1.1.383)	was	used	to	make	the	graphical	representation,	using	the	Xpose	package	(v4.6.1)	for	dataset	checkout	and	graphical	evaluation	of	the	results.			The	final	model	was	used	to	simulate	different	linezolid	doses	depending	on	children’s	weights.		The	target	linezolid	exposure	used	for	dosing	simulations	was	the	steady-state	
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AUC0-24		(AUC0-24,ss)	in	adults	with	TB	after	a	600	mg	once	daily	dose	(110	mg/L.h).		This	target	is	based	on	as-yet	unpublished	data	on	linezolid	pharmacokinetics	from	two	ongoing	adult	MDR-TB	trials	(personal	communication,	R.	Savic).		Doses	were	calculated	by	dividing	the	target	AUC	by	the	CL,	which	is	a	function	of	weight.		Two	hundred	simulations	of	the	pharmacokinetic	profile	of	a	paediatric	population	with	weights	ranging	from	5	to	56	kg,	receiving	the	calculated	weight-banded	dose	regimen,	were	performed	in	NONMEM,	and	their	AUCs	reported.	
Ethical	considerations:	Informed	consent	was	provided	by	the	parent/s	or	legal	guardians,	and	informed	assent	by	participants	≥7	years	of	age.		Ethical	approval	for	the	study	was	provided	by	the	Health	Research	Ethics	Committee	of	Stellenbosch	University	(N11/03/059	for	MDRPK1	and	N15/02/012	for	MDRPK2).		
Results	
Study	population:		Forty-eight	children	were	included	in	the	study,	9	from	MDRPK1	and	39	from	MDRPK2.		The	mean	(range)	age	overall	was	5.9	years	(0.6	to	15.3).		Three	patients	(6.3%)	patients	were	HIV-infected.		Baseline	clincial	and	demographic	characteristics	by	study	(MDRPK1,	MDRPK2)	are	shown	in	Table	7.1.			
Pharmacokinetic	model:	Of	the	48	children	included,	five	participants	contributed	data	from	more	than	one	pharmacokinetic	sampling	occasion.		Four	patients	from	MDRPK2	contributed	full	profiles	from	two	occassions,	and	one	patient	from	MDRPK1	contributed	one	full	profile	and	two	partial	profiles.		The	final	pharmacokinetic	model	consisted	of	a	one	compartment	disposition	model	characterized	by	clearance	(CL)	and	volume	(V)	parameters.		CL	and	V	included	allometric	scaling,	using	the	exponents	0.75	and	1,	respectively,	to	account	for	changes	in	weight.		The	rate	of	absorption	(Ka)	was	constrained	to	be	faster	than	the	rate	of	elimination	(CL/V)	in	order	to	avoid	flip-flop	kinetics	during	model	estimation.	BSV	was	estimated	on	both	CL	and	V.		No	covariates	significantly	improved	the	model	fit	for	any	of	the	pharmacokinetic	parameters,	after	accounting	for	the	effect	of	weight,	already	included	allometrically	in	CL	and	V.		Table	7.2	describes	the	final	model	parameters.		The	final	model	fit	the	observed	data	well,	as	shown	in	the	VPC	(Figure	7.1).		Calculated	AUC	and	maximum	plasma	concentrations	from	our	study	population	are	described	in	Table	7.3.	
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Simulated	exposures:		The	proposed	weight-banded	doses	across	weights	that	approximated	the	emerging	AUC	targets	reported	in	adults	with	MDR-TB	receiving	a	600	mg	once	daily	dose	are	shown	in	Table	7.4.		The	expected	linezolid	exposures	(AUC0-24ss)	across	weights	from	simulations	using	the	final	model	and	this	weight	banded	dosing	strategy	are	shown	in	Figure	7.2.	
Safety:		Seventeen	children	were	included	in	the	safety	analysis	(mean	age	6.1	years,	range	0.6	to	15.3)	and	followed	for	a	median	duration	of	17.7	months	on	linezolid	(IQR	7.5	to	19.7).		Ten	patients	(59%)	experienced	at	least	one	adverse	event	possibly	attributed	to	linezolid,	the	most	frequent	being	anaemia,	with	12	events	in	10	patients	(see	Table	7.5).		There	were	three	grade	3	and	two	grade	4	events	in	five	(23%)	participants,	all	anaemia.		The	linezolid	dose	was	adjusted	or	linezolid	was	temporarily	interrupted	and	restarted	after	4	(23.5%)	and	5	(29.4%)	events,	respectively,	and	4	(23.5%)	participants	permanently	discontinued	linezolid	due	to	adverse	events.		For	the	single	episode	of	peripheral	neuropathy,	linezolid	was	temporarily	interrupted,	and	the	patient	was	treated	with	gabapentin,	resulting	in	symptomatic	improvement.		The	linezolid	was	restarted	at	a	lower	dose	after	symptoms	resolved	with	no	sequelae	and	symptoms	did	not	recur	at	the	lower	dose.		We	did	not	identify	any	events	of	optic	neuropathy.	The	median	(IQR)	time	to	adverse	events	of	any	grade	at	least	possibly	related	to	linezolid	was	3.2	months	(1.8	to	13.9),	with	the	Kaplan	Meier	curve	shown	in	Figure	7.3.		The	median	(IQR)	time	to	grade	3	or	4	events	at	least	possibly	related	to	linezolid	was	2.4	months	(1.8	to	4.7),	with	the	Kaplan	Meier	curve	shown	in	Figure	7.4.		
Discussion	This	study	provides	the	first	data	on	the	pharmacokinetics	of	linezolid	in	children	with	TB,	and	the	first	prospective	data	on	the	safety	of	long-term	linezolid	in	children	treated	for	MDR-TB.			The	linezolid	plasma	AUCs	seen	in	our	cohort	were	higher	than	expected	compared	to	previously	published	values	in	children	(58	mg/L.h	for	children	3	months	to	11	years	of	age,	and	95	mg/L.h	for	12	to	17	years	of	age	after	a	10	mg/kg	dose)	[18].		This	could	be	related	to	previously	unidentifed	drug-drug	interactions	with	other	antituberculosis	
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drugs.		This	was	explored	in	the	analyses	and	no	association	was	found	between	any	pharmacokinetic	parameters	and	concomitant	drugs,	making	this	less	likely.		Other	causes	of	reduced	clearance	in	our	cohort	relative	to	previously	reported	studies	would	also	explain	these	differences.		Linezolid	has	complex	metabolism,	and	as	previously	noted,	there	is	substantial	variability	in	linezolid	pharmacokinetics	between	individuals	and	by	disease	state	[17,	27-29].		Differences	in	bioavailability,	including	formulation	effects,	should	be	considered.		However	the	previously	published	paediatric	data	reported	on	intravenous	doses	only.		The	formulations	used	in	our	study	were	all	non-generic	formulations	(Pfizer),	as	used	in	most	adult	studies	to	date,	and	no	differences	were	observed	in	pharmacokinetic	parameters	by	formulation	administration	(whole	vs.	crushed	vs.	suspension)	in	our	cohort,	making	this	less	likely.		Additional	data	on	linezolid	pharmacokinetics	in	children	treated	for	MDR-TB	would	be	useful	to	confirm	our	findings.			This	is	also	the	first	prospective	data	on	the	safety	of	long-term	linezolid	use	in	children	with	MDR-TB.		At	the	linezolid	doses	used	in	this	study,	10	of	17	children	treated	long-term	experienced	a	linezolid-related	adverse	event,	all	of	whom	had	anamia	in	addition	to	some	other	less	frequent	events,	approximately	similar	to	a	previous	summary	of	highly	variable	published	case	series	and	case	reports	in	which	9	of	18	children	had	a	linezolid-related	event	[9].		In	our	study,	regular	monitoring,	at	least	monthly,	was	able	to	identify	anaemia	at	relatively	mild	grades	in	most	children.		The	approach	of	temporarily	interrupting	the	linezolid	until	the	haemoglobin	had	improved,	followed	by	re-introduction	at	a	lower	dose	(usually	half	the	previous	dose),	was	generally	safe.	Five	children	experienced	a	grade	3	or	4	anaemia,	four	of	whom	permanently	discontinued	linezolid.		Although	all	patients	recovered	from	their	anaemia	without	sequelae,	the	frequency	and	severity	of	these	events	highlights	the	importance	of	careful	monitoring	of	haematological	parameters	during	long-term	linezolid	treatment.		In	our	study,	once	haemoglobin	values	began	to	drop,	they	often	fell	rapidly,	so	the	first	signs	of	a	falling	haemoglobin	should	prompt	more	frequent	testing	and	there	should	be	a	low	threshold	for	temporarily	interrupting	doses.		The	importance	of	the	contribution	of	the	linezolid	to	the	efficacy	of	the	regimen	must	also	be	considered.		The	cumulative	incidence	of	adverse	events	increased	with	longer	duration	of	treatment,	however	there	were	events	even	in	the	first	60	days,	including	grade	3	and	4	events.		Reducing	the	duration	of	linezolid	treatment	would	likely	reduce	but	not	eliminate	the	risk	of	adverse	events,	and	
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careful	safety	monitoring	will	be	necessary	in	future	studies	and	routine	care,		regardless	of	the	linezolid	duration.		We	identified	few	events	of	thrombocytopaenia,	and	it	was	difficult	to	rule	out	linezolid	as	a	potential	cause.		Only	one	child	experienced	peripheral	neuropathy,	which	improved	with	gabapentin	treatment	and	ultimatley	resolved	without	sequelae	after	reducing	the	linezolid	dose.		It	is	possible	other	peripheral	neuropathy	events	were	missed,	particularly	in	young	children	who	were	unable	to	report	subjective	symptoms	of	neuropathy,	but	we	did	not	find	other	children	with	objective	evidence	of	neuropathy.		We	did	not	identify	any	serious,	more	rare	events	such	as	optic	neuropathy	or	lactic	acidosis.		This	should	be	interpreted	cautiously,	as	the	number	of	children	included	here	is	small,	and	formal	ophthalmologic	examinations	were	not	feasible	to	perform.		Lactate	levels	and	pacreatic	enzymes	were	not	monitored,	which	is	also	a	limitation.		However,	no	children	had	clinical	symptoms	suggestive	of	optic	neuropathy,	lactic	acidoses	or	pancreatitis,	so	the	risk	is	low	that	clinically	significant	condtions	were	missed.		Using	the	final	model,	our	simulations	identified	weight-banded	doses	that	would	achieve	the	proposed	target	exposure,	based	on	emerging	data	in	adults	with	MDR-TB	receiving	a	600	mg	dose	(Figure	7.2,	Table	7.3).			These	proposed	doses	are	lower	than	those	used	in	this	study	and	in	routine	care	in	many	settings.		Lower	doses	in	children	would	likely	reduce	the	risk	of	adverse	events,	which	were	frequent	in	this	cohort,	although	this	would	need	to	be	confirmed	in	further	studies.		However,	lower	doses	in	children,	despite	paucibacillary	disease	in	many	children,	may	potentially	impact	negatively	on	the	efficacy	of	linezolid.		As	currently	used,	linezolid	is	most	often	used	in	regimens	where	there	is	MDR-TB	with	additional	resistance,	such	as	fluoroquinolone-resistance,	and	so	is	relied	on	heavily	in	these	regimens.		Lower	doses	of	linezolid	may	potentially	also	increase	the	risk	of	acquisition	of	drug	resistance,	as	has	been	previously	shown	in	adults	treated	with	300	mg	daily	doses	[21],	although	the	risk	of	this	would	likely	be	low	in	most	children,	who	usually	have	paucibacillary	TB.		Older	children	and	adolescents	however	frequently	develop	adult-type,	cavitating	pulmonary	TB,	where	both	efficacy	and	the	emergence	of	drug	resistance,	would	be	a	potential	concern.	Despite	these	limitations,	as	exposures	with	these	doses	in	children	would	be	expected	to	approximate	those	in	adults	after	a	600	mg	dose,	the	efficacy	would	be	
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expected	to	be	as	good	or	better	in	most	compared	to	adults	receiving	this	dose.		Whether	to	use	the	proposed	doses	in	the	routine	care	of	children	with	MDR-TB	should	be	considered	carefully,	weighing	the	potential	risks	and	benefits.		Careful	further	evaluation	of	the	pharmacokinetics,	safety	and	treatment	outcomes	in	children	treated	with	these	proposed	weight	banded	doses	of	linezolid	is	therefore	warranted.	There	were	few	young	and	small	children	included	in	this	analysis,	and	none	under	6	months	of	age.		There	is	data	in	neonates	and	young	infants	that	clearance	of	linezolid	is	associated	with	post-natal	age,	and	children	<8	days	of	age	had	lower	clearance	than	those	8	days	to	12	weeks	of	age	(i.e.,	clearance	rapidly	increased	in	the	first	week	of	life)	(137).		Gestational	age	was	a	predictor	of	volume	of	distribution	(Vd).		This	data	suggests	that	the	approach	to	dosing	for	infants	>7	days	post-natal	age	matched	that	for	older	infants	and	young	children,	but	differed	for	younger	infants.		Our	proposed	doses	for	smaller	children	should	therefore	be	interpreted	with	caution,	as	young	(<6	months)	and	small	children	did	not	contribute	to	the	model.		This	is	particularly	true	for	infants	<8	days	of	age,	for	whom	clearance	is	known	to	differ	from	older	children.		As	few	children	younger	than	6	months	of	age	are	treated	for	MDR-TB	it	is	difficult	to	generate	data	in	this	age	group.		However,	it	also	means	this	will	not	likely	impact	many	patients.		For	clinicians	in	the	field	responsible	for	caring	for	the	occasional	young,	small	child	with	MDR-TB,	some	practical	guidance	on	dosing,	even	with	inherent	limitations,	is	still	of	value.	The	exposure	targeted	clearly	has	an	impact	on	paediatric	dosing	studies	and	recommendations.		The	target	exposure	chosen	here	(110	mg/L.h)	is	based	on	as-yet	unpublished	data	from	two	adult	MDR-TB	trials.	The	target	was	chosen	as	it	was	taken	from	recent	studies	that	were	linked	to	efficacy	and	toxicity	data.		The	optimal	linezolid	target	exposure	is	not	yet	fully	established,	nor	is	the	optimal	dosing	strategy	for	linezolid	in	adults.		An	ongoing	phase	3	trial	(ZeNix,	NCT03086486)	is	evaluating	multiple	doses	and	durations	of	linezolid	in	combination	with	bedaquiline	and	pretomanid	in	adults	with	MDR-TB.		This	trial	will	provide	important	data	to	inform	linezolid	dosing	recommendations.		Proposed	pharmacokinetic-pharmacodynamic	targets	for	linezolid	and	Gram-positive	organisms	have	been	suggested	in	adults,	and	a	free-AUC/MIC	ratio	of	>100	has	been	proposed	for	efficacy	based	on	hollow	fibre	model	data	[30,	31].		A	linezolid	free-AUC/MIC	ratio	of	<96	or	a	trough	<2	mg/L	have	been	
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proposed	as	targets	to	reduce	the	risk	of	adverse	effects	[30-32].		However	more	data	is	needed	to	understand	how	relevant	these	targets	are	in	patients,	including	in	children	of	different	ages.		Additionally,	there	is	a	growing	awareness	of	the	importance	of	drug	exposures	at	the	site	of	disease,	which	is	influenced	by	penetration	of	drugs	into	different	areas	of	TB	lesions	[33].		Targeting	plasma	AUC/MIC	does	not	take	this	key	aspect	into	consideration.	Targeting	drug	exposures	that	are	linked	with	efficacy	in	TB	patients	with	the	spectrum	of		TB	disease	and	lung	pathology	does	incorporate	this	aspect,	and	in	our	estimation,	is	a	more	appropriate	target	given	the	current	state	of	knowledge.		Regardless,	paediatric	linezolid	dosing	recommendations	may	need	to	evolve	as	additional	data	on	optimal	dosing	in	adults	becomes	available.		
Conclusions	This	study	provides	the	first	data	on	linezolid	pharmacokinetics	and	prospectively	observed	safety	data	in	children	with	TB.		Linezolid	exposures	were	higher	than	expected,	and	adverse	events	were	common	and	frequently	severe.		Based	on	these	data,	we	have	proposed,	for	the	first	time,	paediatric	weight	banded	doses	approximating	a	600	mg	adult	dose	for	further	prospective	evaluation.		Clear	guidance	on	the	optimal	dose	of	linezolid	for	children	with	TB	is	urgently	needed	given	its	growing	importance	in	MDR-TB	treatment	regimens.	
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Table	7.1.		Baseline	demographic	and	clinical	characteristics	of	children	with	MDR-TB	
receiving	linezolid	in	two	observational	pharmacokinetic	studies		 MDRPK1																			(n=9)	 MDRPK2																			(n=39)	 Combined																						(n=48)	Mean	age	in	years	(range)	 5.0	(0.6	-	13.8)	 6.1	(1.2	-	15.3)	 5.9	(0.6	-	15.3)	Male	gender(%)	 6	(66.7)	 18	(46.2)	 24	(50.0)	Ethnicity	(%)	 	 	 	Black	 4	(44.4)	 21	(53.9)	 25	(52.1)	Mixed	race	 5	(55.6)	 18	(46.2)	 23	(47.9)	HIV-infected	(%)	 1	(11.1)	 2	(5.1)	 3	(6.3)	WAZ	<-2	(%)	 3	(33.3)	 6	(15.4)	 	9	(18.8)	Administration	on	day	of	PK	sampling	 	 	 	NGT	(%)	 6	(66.7)	 6	(15.8)	 12	(25.5)	Oral	(%)	 3	(33.3)	 32	(84.2)	 35	(74.5)	Formulation	(%)	 	 	 	Whole	tablet	(%)	 1	(11.1)	 5	(12.8)	 6	(12.5)	Crushed	tablet	(%)	 1	(11.1)	 8	(20.5)	 9	(18.8)	Suspension	(%)	 7	(77.8)	 26	(66.7)	 33	(68.8)	Single-dose	linezolid	only	(%)	 0	(0.0)	 31	(79.5)	 31	(64.6)	WAZ	=	weight-for-age	Z-score;	PK	=	pharmacokinetic;	NGT	=	nasogastric	tube	
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Table	7.2.		Parameter	values	for	modelled	linezolid	pharmacokinetics	in	children	
with	multidrug-resistant	tuberculosis	(n=48)	
Parameter	 Estimate	 RSE	(%)	Ka	(h-1)	θ_Ka+(CL	/V)	 θ_Ka	=0.77	 25	CL/F	(L/h)	=θ_CL×〖"(WT/70"	)〗^0.75	 θ_CL=4.73	 7	V/F	(L)	=θ_V×("WT/70")	 θ_V=54.8	 6	BSVCL/F	(%)	 37	 16	BSVV/F	(%)	 32	 23	Additive	error	(mg/L)	 0.78	 91	Proportional	error	(CV%)	 25	 25	Ka	=	absorption	rate	constant;	CL	=	clearance;	F	=	bioavailability;	θ	=	typical	parameter;	WT=	weight	in	kg;	V	=	volume	of	distribution;	BSV	=	between	subject	variability;	RSE	=	relative	standard	error;	CV	=	coefficient	of	variance	
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Table	7.3.		Proposed	weight-banded	once	daily	doses	of	linezolid	for	children	treated	for	
multidrug-resistant	tuberculosis	approximating	the	exposure	in	adults	with	MDR-TB	
receiving	a	600	mg	once	daily	dose	(AUC0-24ss	110	mg.h/L)	
Weight	band	(kg)	 Daily	dose	(mg)		 Daily	dose	(mg/kg)	5	to	<7	 80	 14.5	7	to	<9	 100	 13.3	9	to	<11	 120	 12.6	11	to	<15	 150	 12	15	to	<19	 180	 10.9	19	to	<25	 220	 8.9	25	to	<33	 270	 9.5	33	to	<43	 330	 8.8	43	to	<56	 400	 8.16	
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Table	7.4.		Calculated	linezolid	AUC0-24,ss	and	Cmax	from	children	with	multidrug-resistant	
tuberculosis	(n=48)	stratified	by	age	and	daily	dose	
Age	 Dose	 Number	of	children	
AUC0-24,SS	(mg/L.h)	 Cmax	(mg/L)	
Median	 [Min-Max]	 Median	 [Min-Max]	
	 <10	mg/kg	 16	 78.5	 56.63-158.09	 7.35	 5.49-9.16	<10	years	 10-20	mg/kg	 16	 127.52	 59.23-243.23	 10.1	 6.95-15.8	
	 >=20	mg/kg	 5	 189.8	 139.3-215.9	 11.193	 9.36-14.1		 <10	mg/kg	 7	 98.9	 75.27-321.90	 7.306	 5.10-21.2	
≥10	years	 10-20	mg/kg	 4	 113.7	 102.2-271	 11.175	 9.87-19.5	
	 >=20	mg/kg	 0	 -	 -	 -	 -	
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Table	7.5.		Adverse	events	in	children	treated	for	multidrug-resistant	tuberculosis	with	
linezolid	(n=17)	
	 Adverse	events	possibly,	probably	or	definitely	attributed	to	linezolid	by	grade	
Adverse	Event	
#	of	patients	with	event	 Grade	1	 Grade	2	 Grade	3	 Grade	4	 Total	#	of	events	 Event	Rate																							(per	100	person-yrs)	Peripheral	neuropathy	 1	 1	 0	 0	 0	 1	 4.8	Low	haemoglobin	 10	 5	 2	 3	 2	 12	 57.2	Low	platelets	 2	 1	 1	 0	 0	 2	 9.5	Low	white	blood	cell	count	 1	 1	 0	 0	 0	 1	 4.8	17	patients	followed	for	a	median	time	of	17.7	months	(IQR:	7.5	-	19.7	months);	total	person	years	=	21.0.	
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Figure	7.1.		Visual	predictive	checks	corresponding	to	final	linezolid	pharmacokinetic	
model.	Dots	represent	the	observed	linezolid	concentrations;	the	solid	lines	correspond	
to	the	5th,	50th	and	95th	percentiles	of	these	observations.		Shaded	areas	are	the	model-
predicted	95%	confidence	intervals	for	the	median	(blue),	and	5th	and	95th	(grey)	
percentiles	obtained	from	500	simulated	datasets.	
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	1	
	2	
Figure	7.2.		Simulated	linezolid	area	under	the	concentration	time	curve	from	0-24	hours	versus	body	weight	using	the	linezolid	doses	3	
listed.		The	red	hashed	line	indicates	the	adult	target	exposure	(AUC0-24ss	110	mg/L.h).		LNZ=linezolid;	AUC=area	under	the	concentration	4	
time	curve.5	
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Figure	7.3.	Kaplan-meier	estimates	of	the	time	(in	days)	on	linezolid	without	an	adverse	
event	of	any	grade	at	least	possibly	related	to	linezolid.	
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Figure	7.4.	Kaplan-meier	estimates	of	time	(in	days)	on	linezolid	without	a	Grade	3	or	4	
adverse	event	at	least	possibly	related	to	linezolid	
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Chapter	8:	Effect	of	coadministration	of	lidocaine	on	the	pain	and	
pharmacokinetics	of	intramuscular	amikacin	in	children	with	
multidrug-resistant	tuberculosis:	a	randomized	crossover	trial		
Rationale	Current	guidelines	continue	to	recommend	a	second-line	injectable	antituberculosis	medication	(amikacin,	kanamycin	or	capreomycin)	for	4-6	months	for	most	children	treated	for	MDR-TB	(18).		This	long	duration	of	second-line	injectable	treatment	is	associated	with	permanent	sensorineural	hearing	loss	in	up	to	24%	of	children	(45).		In	addition	to	this	high	risk	of	ototoxicity,	the	injectables	are	required	to	be	given	parenterally.		Long-term	indwelling	catheters	are	not	feasible	in	most	high	TB	burden	settings	and	pose	a	high	risk	of	infection,	so	the	majority	of	MDR-TB	patients	receive	these	medications	as	daily	intramuscular	injections,	which	are	very	painful	and	a	source	of	significant	distress	(59).		Treatment	regimens	that	no	longer	rely	on	injectable	medications	are	urgently	needed.		However,	in	the	meantime	temporizing	strategies	to	improve	the	tolerability	of	the	required	intramuscular	injections	would	greatly	benefit	MDR-TB	patients.		The	addition	of	the	anaesthetic	agent	lidocaine	(lignocaine)	to	intramuscular	injections	of	other	antibiotics	has	been	shown	to	reduce	the	associated	pain	without	affecting	the	medication’s	pharmacokinetics	(116,	117),	but	this	has	not	been	evaluated	with	the	second-line	injectables.			
Study	Aims	The	aim	of	the	study	was	to	evaluate	the	effect	of	coadministering	lidocaine	on	the	pain	and	pharmacokinetics	of	intramuscular	amikacin	in	children	with	multidrug-resistant	tuberculosis.		
Methods	This	randomized	double-blinded	two-period	crossover	study	was	a	sub-study	nested	in	the	MDRPK1	study.		Children	were	eligible	for	this	sub-study	if	they	were	enrolled	in	MDRPK1,	were	8	to	18	years	of	age,	were	routinely	receiving	amikacin	as	part	of	treatment	for	MDR-TB,	and	provided	informed	consent	and	assent	for	participation	in	this	sub-study.		Amikacin	was	routinely	given	as	part	of	the	recommended	MDR-TB	
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treatment	regimen	at	a	dose	of	15-20	mg/kg	once	daily	6	days	per	week,	for	2-6	months	duration.		As	part	of	the	study,	each	participant	received	two	treatments	on	a	single	occasion	each:		Treatment	A	–	amikacin	administered	with	lidocaine;	Treatment	B	–	amikacin	administered	without	lidocaine.		Participants	were	randomly	assigned	to	receive	Treatment	A	first	or	Treatment	B	first	(sequence	1	or	2	respectively).		Amikacin,	available	as	500	mg/2	mL	vials	(Fresenius,	Midrand,	South	Africa),	was	administered	as	an	exact	15	mg/kg	dose	on	pharmacokinetic	sampling	day	by	intramuscular	injection	(21	gauge,	1.5	inch	needle)	to	the	dorsogluteal	area	on	the	opposite	side	of	the	previous	day’s	injection.		Lidocaine,	available	as	2%	(20	mg/mL)	lidocaine	solution	for	injection	(Fresenius,	Midrand,	South	Africa),	was	drawn	up	with	the	amikacin	into	the	syringe	and	administered	at	a	pre-specified	weight-banded	dose	(within	a	range	of	0.2-0.4	mg/kg/dose).		The	randomization	was	generated	from	a	computer	generated	random	number	list,	in	blocks	of	four,	and	the	allocations	placed	in	consecutively	numbered,	sealed,	opaque	envelopes.		The	participants	and	all	team	members	were	blinded	to	the	allocation,	other	than	two	study	team	members	who	prepared	the	injections	but	did	not	otherwise	interact	with	the	participants.		On	study	days,	pharmacokinetic	sampling	was	done	just	before	and	1,	2,	4,	6,	and	8	hours	after	an	exact	15	mg/kg	amikacin	dose	with	or	without	lidocaine.		Amikacin	plasma	concentrations	were	measured	using	a	commercial	Particle	Enhanced	Turbidimetric	Inhibition	Assay	at	the	University	of	Cape	Town	Division	of	Clincial	Pharmacology.		Pharmacokinetic	measures	were	estimated	using	NCA.	Pain	was	assessed	using	the	validated	Wong-Baker	FACES	pain	scale,	just	prior	to	the	injection	and	then	immediately,	30	and	60	mins	after	the	injection.		All	adverse	events	were	reported	using	the	approach	described	in	previous	chapters.		The	median	and	IQR	for	each	pharmacokinetic	measure	and	for	adjusted	post-injection	pain	scores	were	reported	by	whether	lidocaine	was	given,	and	comparisons	made	using	the	Wilcoxon	matched-pairs	signed-rank	test.				
Results	Between	July	2103	and	August	2015,	12	participants	(median	age	11.5	years,	IQR	9.9	to	13.4)	were	enrolled	and	randomized.		The	median	adjusted	pain	score	immediately	after	the	injection	was	lower	when	administered	with	lidocaine	(1.0	[IQR	0.5-2.0]	vs.	2.5	[1.0-4.0]	without	lidocaine	(p=0.004);	scores	at	30	and	60	minutes	post-injection	were	not	significantly	different.		There	were	no	statistical	differences	in	AUC0-8,	AUC0-inf,	or	
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Cmax	when	administered	with	or	without	lidocaine.		No	adverse	events	were	reported	during	the	study	pharmacokinetic	sampling	days.		
Conclusions	and	recommendations	This	trial	demonstrated	that	the	coadministration	of	lidocaine	with	intramuscular	amikacin	injections	in	children	with	MDR-TB	was	safe,	reduced	immediate	post-injection	pain	and	did	not	significantly	affect	amikacin	pharmacokinetic	measures.			This	is	an	important,	simple,	inexpensive	strategy	to	improve	the	tolerability	of	second-line	injectable	treatment	until	effective	injectable-free	regimens	become	available.		
Citation	(this	study	was	accepted	for	publication	and	is	currently	in	press):		Garcia-Prats	AJ,	Rose	PC,	Draper	HR,	Seddon	JA,	Norman	J,	McIlleron	HM,	Hesseling	AC,	Schaaf	HS.		Effect	of	Co-Administration	of	Lidocaine	on	the	Pain	and	Pharmacokinetics	of	Intramuscular	Amikacin	in	Children	with	Multidrug-Resistant	Tuberculosis:	A	Randomized	Crossover	Trial.		Pediatr	Infect	Dis	J.	2018	Mar	14.	doi:	10.1097/INF.0000000000001983.	[Epub	ahead	of	print]		PMID:		29561515.		 	
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Abstract	
Background:		Currently	recommended	treatment	for	multidrug-resistant	(MDR)	tuberculosis	(TB)	includes	4-8	months	of	an	injectable	medication,	which	is	poorly	tolerated.		We	evaluated	the	impact	of	co-administering	lidocaine	on	pain	and	pharmacokinetics	of	intramuscular	injections	of	amikacin	in	children	with	MDR-TB.			
Methods:	Children	8-18	years	of	age,	receiving	amikacin	for	MDR-TB	treatment	in	Cape	Town,	South	Africa,	were	eligible	for	this	randomized	crossover	trial.		Participants	received	a	15	mg/kg	dose	of	intramuscular	amikacin	with	and	without	additional	lidocaine	(0.2-0.4	mg/kg)	on	different	days,	and	were	randomized	to	the	order	of	the	treatments	(the	sequence).	Participants	and	staff	completing	evaluations	were	blinded	to	sequence.		Samples	were	drawn	pre-dose,	and	at	1,	2,	4,	6	and	8	hours	post-dose	for	measurement	of	plasma	amikacin	concentrations.		Pain	was	assessed	by	participants	using	the	Wong	Baker	FACES	pain	scale	(0	to	5)	pre-dose,	immediately	after	the	injection	and	then	at	30	and	60	minutes.	Pharmacokinetic	measures	were	calculated	using	noncompartmental	analysis.		
Results:		Twelve	children	were	included,	median	age	11.5	years	(IQR	9.9-13.4y).	Participant-reported	pain	scores	immediately	after	the	amikacin	injection	were	lower	when	lidocaine	was	co-administered:	1.0	(IQR	0.5-2.0)	with	lidocaine	vs.	2.5	(1.0-4.0)	without	lidocaine	(p=0.004).		The	median	area	under	the	concentration	time	curve	(AUC)0-8	and	median	maximum	plasma	concentration	(Cmax)	of	amikacin	were	109.0	μg*h/mL	(IQR	84.7-121.3)	and	36.7	μg/mL	(IQR	34.1-40.5)	with	lidocaine	compared	to	103.3	μg*h/mL	(IQR	81.7-135.0;	p=0.814)	and	34.1	μg/mL	(IQR	35.6-46.4;	p=0.638)	without	lidocaine,	respectively.		
Conclusions:		The	co-administration	of	lidocaine	resulted	in	reduced	pain	immediately	after	the	injection	and	did	not	alter	amikacin	AUC	or	Cmax.		 	
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Introduction	Treatment	outcomes	for	children	with	multidrug-resistant	(MDR)	tuberculosis	(TB),	defined	as	resistance	to	at	least	both	isoniazid	and	rifampicin,	are	good,	with	more	than	80%	of	children	successfully	treated	(1).		However,	current	MDR-TB	treatment	regimens	are	long,	requiring	9	to	18	months	of	treatment,	are	poorly	tolerated,	and	are	associated	with	frequent	and	important	adverse	effects	(2).		The	second-line	injectable	antituberculosis	drugs,	including	amikacin,	kanamycin,	and	capreomycin,	have	been	considered	a	key	component	of	MDR-TB	treatment,	with	guidelines	recommending	4-8	months	of	an	injectable	agent	(3-5).		However	their	use	can	result	in	nephrotoxicity,	electrolyte	abnormalities,	and	is	associated	with	a	risk	of	permanent	sensorineural	hearing	loss,	in	up	to	25%	of	children	(6).		Recent	guidance	from	the	World	Health	Organization	(WHO)	opened	the	possibility	of	limiting	injectable	use	in	children	with	less	severe	TB.	However	the	newly	recommended	9-12	month	shortened	regimen	for	MDR-TB	includes	injectables	for	at	least	4	months,	indicating	that	they	will	likely	remain	in	use	for	the	near	future	(5).		In	addition	to	the	substantial	risk	of	adverse	effects	with	long-term	injectable	treatment,	their	use	is	complicated	by	the	requirement	for	parenteral	administration.		Long-term	indwelling	catheters,	such	as	portacaths	or	peripherally	inserted	central-venous	catheters	are	not	feasible	in	most	settings	with	a	high	burden	of	MDR-TB.	With	constrained	health	care	resources,	the	risk	of	catheter	infection	is	problematic,	and	access	to	rapid,	effective	treatment	of	such	infections	limited.	Hence,	the	vast	majority	of	children	with	MDR-TB	receive	these	agents	as	daily	intramuscular	injections.		The	injections	are	painful	for	adults	and	children,	and	have	been	cited	as	one	of	the	worst	aspects	of	MDR-TB	treatment	(7).		They	are	a	source	of	substantial	distress	for	children,	their	parents	and	caregivers,	as	well	as	for	health	care	workers	who	are	tasked	with	delivering	this	painful	intervention	for	months.		Strategies	to	reduce	this	injection	pain	and	improve	the	tolerability	of	the	injectables	are	urgently	needed.	Lidocaine,	also	known	as	lignocaine,	is	a	local	anaesthetic	agent,	which	blocks	nerve	conduction,	producing	rapid	local	anaesthesia	lasting	1-3	hours,	with	a	maximum	effect	within	minutes	(8).		Adverse	effects	are	generally	mild.		However	serious	systemic	adverse	effects	may	rarely	occur	if	there	is	inadvertent	intravascular	injection,	including	central	nervous	system	effects	(paraesthesias,	visual	disturbance,	seizures)	and	
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cardiovascular	effects	(hypotension,	bradycardia,	arrhythmia,	cardiovascular	collapse)	(8).		When	co-administered	with	intramuscular	injections	of	ceftriaxone	(9,	10)	and	penicillin	(11)	lidocaine	reduced	injection	pain	without	affecting	the	antibiotics’	pharmacokinetics.		However	this	strategy	has	not	been	evaluated	with	the	second-line	injectable	antituberculosis	medications.		The	injectables	are	rapidly	absorbed	after	intramuscular	injection	and	are	renally	eliminated	unchanged	(12,	13).		Compared	to	intravenous	injection,	there	may	be	increased	variability	in	the	rate	and	degree	of	absorption	of	intramuscularly	injected	aminoglycosides	(14).		The	impact	of	lidocaine	on	the	pharmacokinetics	of	the	injectables	needs	to	be	considered,	as	these	injectable	medications	have	concentration-dependent	activity	against	Mycobacterium	tuberculosis,	with	the	maximum	plasma	concentration	most	closely	associated	with	efficacy	(15).	Ototoxicity	is	associated	with	cumulative	drug	exposure	(16).	The	objective	of	this	study	was	to	evaluate	the	impact	of	co-administering	lidocaine	on	the	pain	and	pharmacokinetics	of	intramuscular	injections	of	amikacin	in	children	and	adolescents	routinely	treated	for	MDR-TB.				
Materials	and	methods	
Trial	design	This	was	a	randomized	double-blinded	two-period	crossover	trial.			
Participants	Children	were	eligible	to	the	study	if	they	were	8	to	18	years	of	age,	routinely	treated	for	MDR-TB	with	a	regimen	including	amikacin,	and	had	received	amikacin	for	at	least	14	days.		Exclusion	criteria	included	acute	illness	(enrolment	could	be	deferred),	neurologic	disability	that	may	have	prohibited	reporting	of	pain,	or	a	haemoglobin	<	8	g/dL.	Consecutively	eligible	children	were	recruited	from	the	Brooklyn	Chest	Hospital,	a	provincial	TB	hospital	that	provides	long-term	care	of	children	with	drug-resistant	and	other	complicated	forms	of	TB	in	Cape	Town,	South	Africa.		A	sample	size	of	12	participants	was	primarily	based	on	pragmatic	considerations	of	the	expected	number	of	eligible	children.		The	treatment	of	MDR-TB	was	consistent	with	local	and	international	guidance,	and	generally	included	6-7	antituberculosis	medications	given	for	12-18	months	duration.		Amikacin,	a	second-line	injectable	antituberculosis	
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medication,	was	included	in	the	regimen	of	most	children	with	MDR-TB,	and	was	given	as	an	intramuscular	injection	6	days	each	week	for	2-6	months.		Amikacin	is	recommended	for	MDR-TB	treatment	in	adults	and	children,	but	is	used	off-label	for	this	purpose.	
Interventions	Each	participant	received	two	treatments,	each	on	a	single	occasion.		In	treatment	A,	amikacin	was	administered	without	lidocaine;	in	treatment	B,	amikacin	was	administered	with	lidocaine.		Participants	were	assigned	1:1	to	receive	treatment	A	or	treatment	B	first	(sequence	1	or	sequence	2,	respectively).		Amikacin	was	available	in	2	mL	vials	as	a	500	mg/2	mL	solution	for	injection	(Fresenius,	Midrand,	South	Africa),	and	was	administered	as	an	exact	15	mg/kg	dose	on	the	day	of	sampling.		A	pre-specified	weight-banded	dose	of	lidocaine	(2%	lidocaine	solution	for	injection	[20	mg/mL],	Fresenius,	Midrand,	South	Africa),	within	the	range	of	0.2-0.4	mg/kg/dose	was	drawn	up	into	a	syringe	along	with	the	amikacin,	to	be	co-administered	(see	Table	1);	this	is	well	below	the	maximum	safe	dose	of	lidocaine	for	anaesthesia	of	3-4	mg/kg.		Intramuscular	injections	were	administered	with	a	21	gauge	1.5	inch	needle	in	the	dorsogluteal	area	on	the	opposite	side	as	the	previous	day’s	injection,	according	to	standard	local	practice.		
Randomisation	and	blinding	The	randomization	was	generated	by	the	study	statistician	using	a	computer-generated	list	of	random	numbers	with	a	permutated	fixed	block	randomization	having	a	block	size	of	4	to	assign	the	order	of	injections.		Allocations	were	placed	in	consecutively	numbered,	sealed,	opaque	envelopes	(17).		Upon	enrolment	of	a	participant,	two	unblinded	study	team	members	reviewed	the	allocation,	and	on	the	days	of	pharmacokinetic	sampling,	they	prepared	the	amikacin	injections	with	or	without	lidocaine	according	to	the	allocation.			Only	these	two	study	team	members	responsible	for	preparing	the	injections	and	the	study	statistician	were	unblinded.		None	of	these	unblinded	team	members	participated	in	administration	of	the	injections	or	in	pain	assessments.		After	preparation	of	the	injections,	opaque	tape	was	placed	around	the	syringe	to	ensure	that	small	differences	in	volume	of	the	injection	would	not	be	visible,	to	further	ensure	integrity	of	the	
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blinding.		The	study	participant	and	caregivers,	and	the	remainder	of	the	study	team	were	blinded	to	the	allocation.		
Pharmacokinetic	sampling	Pharmacokinetic	sampling	was	completed	from	2-16	weeks	after	starting	treatment.	On	the	day	of	sampling	the	amikacin	dose	was	administered	by	the	study	team	together	with	all	the	other	oral	TB	medications	in	the	child’s	MDR-TB	regimen.		One	hour	after	TB	medication	was	dosed	HIV-infected	children	were	given	their	antiretroviral	drugs.	Blood	samples	were	collected	pre-dose	and	then	at	1,	2,	4,	6,	and	8	hours	after	amikacin	dosing	into	an	EDTA-containing	tube	and	placed	on	ice.	Blood	samples	were	centrifuged	and	plasma	separated	and	frozen	at	-80	degrees	Celsius	within	30	minutes.	Amikacin	plasma	concentrations	were	measured	using	a	commercial	Particle	Enhanced	Turbidimetric-Inhibition	Immunoassay	(PETINIA)	(Architect	ci4100,	Abbott	Laboratories,	Diagnostics	Division,	Abbott	Park,	IL.).	The	assay	was	valid	over	the	range	2.0	–	50	µg/ml	and	quality	controls	were	run	daily	to	monitor	the	assay	performance.	
Data	collection	Pain	was	assessed	using	the	Wong-Baker	FACES	pain	scale,	a	5-point	hedonic	scale,	which	has	been	extensively	validated	for	assessing	pain	in	children	older	than	7	years	of	age	(18,	19).		The	pain	scale	was	translated	into	Afrikaans	and	Xhosa,	the	most	frequently	used	local	languages.		Using	this	scale,	the	children	were	asked	by	a	study	team	member	to	rate	the	pain	in	the	dorsogluteal	area	on	the	side	of	the	day’s	IM	injection.		This	was	done	before	the	injection,	to	account	for	pre-existing	pain	from	previous	injections,	immediately	after	the	injection,	and	then	at	30	and	60	minutes	post-injection.		In	order	to	account	for	pre-existing	pain	from	previous	daily	injections,	adjusted	pain	scores	were	calculated	by	subtracting	the	pain	score	taken	just	prior	to	the	injection,	from	the	pain	score	immediately	after	injection,	and	from	the	scores	at	30	and	60	minutes	after	the	injection.		HIV	status	was	determined	by	HIV	ELISA	testing	in	children	>18	months	of	age,	and	HIV	DNA	PCR	in	those	<18	months.		Weight-for-age	z-scores	were	calculated	using	the	1990	British	growth	curves	(20).		The	study	team	monitored	for	adverse	events	related	to	the	injections	during	the	60	minutes	post-injection.		Adverse	events	were	graded	according	to	standard	grading	criteria	(21)	and	attribution	assessed	by	the	study	investigator.	
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Statistical	methods	Demographic	and	clinical	characteristics	were	summarized	using	descriptive	statistics.				Pharmacokinetic	measures	were	estimated	using	non-compartmental	analysis	(NCA).		Observed	maximum	plasma	concentration	(Cmax)	and	time	to	Cmax	(Tmax)	were	recorded	directly	from	the	concentration-time	data.		The	area	under	the	concentration	time	curve	from	0-8	hours	(AUC0-8)	was	calculated	using	the	linear	trapezoidal	rule.		The	AUC(0-∞)	was	calculated	using	an	exponential	extension	to	the	AUC(0-8).		Half-life	(t1/2)	was	denoted	as	ln(2)/kel,	where	kel	(elimination	rate	constant)	was	the	negative	slope	of	the	log-linear	regression	of	the	three	final	data	points	of	the	concentration-time	curve.	Pre-dose	drug	concentrations	below	the	lower	limit	of	quantification	(BLQ)	(2.0	µg/mL)	were	set	to	zero	in	the	analysis.		For	post-dose	concentrations	that	were	BLQ,	the	first	was	set	to	½	of	the	lower	limit	of	quantification	(LLOQ),	and	any	subsequent	were	set	to	zero.		The	primary	outcome	was	adjusted	pain	scores	post-injection.		Secondary	outcomes	were	Cmax,	AUC(0-8),	AUC(0-∞)	and	the	number	of	adverse	events	at	least	possibly	related	to	the	injection.			The	median	and	interquartile	range	(IQR)	for	adjusted	pain	scores	immediately,	30	and	60	minutes	after	injection	and	pharmacokinetic	parameters	(Cmax,	AUC(0-8),	AUC(0-∞),	Tmax,	and	t1/2)	were	reported	by	whether	lidocaine	was	given.		Comparisons	for	each	variable	(adjusted	pain	scores	and	pharmacokinetic	measures)	by	lidocaine	status	were	made	using	the	Wilcoxon	matched-pairs	signed-ranks	test.		Geometric	means,	the	exponentiated	arithmetic	means	of	log-transformed	values,	are	often	better	estimators	for	comparing	pharmacokinetic	parameters,	which	are	frequently	positively	skewed	and	log-normally	distributed.	Geometric	mean	ratios	(GMR)	were	reported	with	90%	confidence	intervals	and	p-values	to	determine	if	treatment	status	was	associated	with	Cmax,	AUC(0-8),	AUC(0-∞)	or	Tmax.	A	test	drug	is	considered	to	be	bioequivalent	to	a	reference	drug	if	the	90%	confidence	interval	of	the	GMR	of	the	AUC	and	Cmax	between	the	test	and	reference	fall	within	80%-125%.		Carryover	effects	for	pain	and	pharmacokinetic	measures	were	assessed	statistically	using	accepted	methods,	by	comparing	the	mean	and	median	values	for	the	pharmacokinetic	parameters	and	the	adjusted	pain	score	outcomes	between	the	two	sequences	(AB	vs.	BA)	using	t-tests	and	Wilcoxon	rank	sum	tests,	respectively	(22).	Pharmacokinetic	parameters	and	other	data	
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analysis	were	performed	using	Stata	14.1	(StataCorp,	2015.		Stata	Statistical	Software	
Release	14.	College	Station,	TX:	StataCorp	LP.)		This	study	was	approved	by	the	Health	Research	Ethics	Committee	of	Stellenbosch	University	(M12/08/043)	and	the	University	of	Cape	Town.		Informed	consent	was	provided	by	the	parent	or	legal	guardian	and	informed	assent	by	the	participant.		The	trial	was	registered	with	the	Pan-African	Clinical	Trials	registry,	registration	number	PACTR201401000670381.	
	
Results	Between	July	2013	and	August	2015,	18	participants	were	screened,	with	12	enrolled	and	randomized	(see	Figure,	Supplemental	Digital	Content	1).		Overall,	the	median	age	was	11.5	years	(IQR:	9.9	–	13.4);	other	baseline	characteristics	are	shown	by	sequence	in	Table	2.		All	randomized	participants	successfully	completed	the	trial.		Adjusted	pain	scores	are	shown	in	Table	3.		The	median	adjusted	pain	score	immediately	after	the	injection	was	lower	when	administered	with	lidocaine	added:	1.0	(IQR	0.5-2.0)	with	lidocaine	vs.	2.5	(1.0-4.0)	without	lidocaine	(p=0.004);	no	significant	carryover	effects	were	detected.	The	median	adjusted	pain	scores	30	and	60	minutes	after	the	injection	with	lidocaine	added	were	zero,	however	this	was	not	statistically	different	compared	with	injections	without	lidocaine.			Summary	pharmacokinetic	measures	are	shown	in	Table	4	and	Figure	1.		All	24	pre-dose	concentrations	were	BLQ,	and	sixteen	8-hour	concentrations	were	BLQ.		One	participant	had	both	6-hour	and	8-hour	concentrations	that	were	BLQ.		There	were	no	statistical	differences	in	AUC0-8,	AUC0-∞	or	Cmax	when	administered	with	or	without	lidocaine	(Table	3);	no	significant	carryover	effects	were	detected.	GMRs	for	pharmacokinetic	measures	of	interest	are	shown	in	Table	5.	The	90%	confidence	intervals	(CIs)	for	the	GMRs	are	outside	of	what	would	be	considered	bioequivalence	(0.80-1.25).		Two	participants	had	amikacin	exposures	that	were	statistical	outliers	(one	for	Cmax,	one	for	AUC0-8);	there	was	no	clinical	or	laboratory	explanation	for	these	extreme	values.	No	adverse	events	during	the	two	pharmacokinetic	sampling	days	were	reported.		
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Discussion	In	this	trial	we	have	shown	that	the	addition	of	lidocaine	to	amikacin	injections	in	children	and	adolescents	reduced	immediate	injection	pain,	was	safe,	and	did	not	have	substantial	effects	on	amikacin	pharmacokinetics.	Given	previous	research	with	lidocaine	co-administered	with	ceftriaxone	and	penicillin,	it	is	not	surprising	that	pain	was	reduced	with	the	addition	of	lidocaine.		In	those	previous	studies,	however,	lidocaine	was	used	as	a	diluent	to	powder	for	injection,	so	the	final	volume	for	injection	was	not	altered.		The	amikacin	formulation	routinely	available	in	our	study	setting	comes	as	a	prepared	solution	for	injection,	so	the	volume	for	injection	was	larger	when	lidocaine	was	added.		Although	these	additional	volumes	were	relatively	small,	this	may	have	reduced	the	anaesthetic	effect,	as	larger	volumes	would	be	expected	to	be	associated	with	increased	pain.	When	lidocaine	is	used	as	a	diluent	instead,	it	may	be	that	the	pain	would	be	reduced	even	further.		Some	of	the	reported	pain	is	likely	related	to	the	needle	penetrating	the	skin.		In	this	study	we	did	not	use	a	topical	anaesthetic	agent,	however	it	is	possible	that	this	would	further	reduce	pain	and	would	be	an	additional	measure	to	improve	the	tolerability	of	these	intramuscular	injections.		Although	we	did	not	include	children	aged	<8	years	in	this	study,	there	is	no	specific	reason	to	believe	that	the	addition	of	lidocaine	to	amikacin	injections	would	not	also	reduce	pain	in	younger	children.	Pain	at	30	and	60	minutes	post-injection	was	not	statistically	different	with	lidocaine.		It	may	be	the	study	was	under-powered	to	detect	a	difference.		However,	it	is	notable	that	the	median	adjusted	pain	score	at	these	time	points	was	zero	on	the	occasion	when	administered	with	lidocaine,	meaning	that	pain	was	no	different	than	prior	to	the	injection,	and	that	in	a	proportion	of	the	patients	the	adjusted	pain	score	was	less	than	zero,	meaning	that	after	the	injection	pain	was	lower	than	before.			It	may	be	that	the	local	anaesthetic	reduced	the	pre-existing	pain	related	to	past	injections.	There	were	no	significant	differences	between	either	the	Cmax	or	AUC	with	or	without	lidocaine.		Establishing	amikacin	bioequivalence	between	the	two	treatments	was	not	a	pre-specified	aim	and	the	study	was	not	powered	to	formally	assess	this.		The	90%	CIs	for	the	GMRs	did	not	fall	between	the	targets	for	bioequivalence,	which	may	be	due	to	the	disproportionate	effect	of	a	few	outlier	concentrations.	Substantial	between	occasion	variability	of	the	rate	and	extent	of	absorption	of	injectable	medications	has	
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been	described	(23,	24),	and	may	explain	some	of	the	differences	we	observed	between	the	two	treatments	in	our	small	sample.	Additional	work,	powered	to	demonstrate	bioequivalence,	would	confirm	more	definitively	that	the	addition	of	lidocaine	does	not	significantly	affect	amikacin	pharmacokinetics.		However	it	is	reassuring	that	there	was	not	a	statistical	difference	in	key	pharmacokinetic	measures	in	our	study.	Carryover	effects	were	expected	to	be	minimal	both	for	pharmacokinetics,	as	amikacin	is	rapidly	absorbed	and	eliminated,	and	for	pain,	as	injections	were	always	given	on	the	alternate	side	as	the	previous	day’s	injection	and	lidocaine	has	only	an	intermediate	duration	of	action	(hours).	There	were	no	adverse	effects	noted	on	the	two	study	days	related	to	the	injections.		As	severe	systemic	adverse	effects	are	associated	with	intravascular	injection,	careful	adherence	to	IM	injection	administration	practices	is	important.		This	includes	choosing	an	appropriate	injection	site	and	ensuring	that	the	needle	is	not	in	a	vascular	structure	after	penetration	of	the	needle	through	the	skin	and	prior	to	injection.		The	study	was	not	designed	to	evaluate	the	safety	of	long-term	daily	intramuscular	lidocaine	administration.	However	to	our	knowledge	there	is	no	reason	to	suspect	such	adverse	effects.	Based	on	these	results,	we	would	argue	that	the	co-administration	of	lidocaine	should	become	routine	practice	with	intramuscular	injections	of	the	second-line	antituberculosis	drugs	in	both	children	and	adults	with	MDR-TB.	Lidocaine	should	be	widely	available,	as	it	is	used	routinely	for	local	anaesthesia	and	is	included	in	the	WHO	Model	List	of	Essential	Medicines.	This	is	likely	to	be	a	minimal	additional	expense	for	TB	programs,	particularly	given	the	potential	of	the	intervention	to	reduce	patients’	pain	and	improve	the	tolerability	of	this	treatment.	Although	elimination	of	the	need	for	injectable	treatment	remains	a	longer-term	priority,	this	is	a	safe,	feasible	and	clinically	impactful	intervention	that	could	immediately	be	implemented,	which	substantially	reduces	the	pain	associated	with	these	very	large	number	of	injections,	and	could	potentially	improve	the	tolerability	of	MDR-TB	treatment.		
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Table	1.		Weight-banded	doses	and	volumes	of	lidocaine	co-administered	with	amikacin	
intramuscular	injections	in	children	with	multidrug-resistant	tuberculosis	
Body	
weight	
2%	lidocaine	
volume	(mg)	
added	
Lidocaine	mg/kg	
dose,	range	
Amikacin	(15	
mg/kg)	volume,	
range	
Volume	of	
combined	
injection,	range	10	-	<20kg	 0.2	mL	(4	mg)		 0.2	–	0.4	mg/kg	 0.6	–	1.2	mL	 0.8	–	1.4	mL	20	-	<30kg	 0.3	mL	(6	mg)		 0.2	–	0.3	mg/kg	 1.2	–	1.8	mL	 1.5	–	2.1	mL	30	-	<	40kg	 0.4	mL	(8	mg)	 0.2	–	0.27	mg/kg	 1.8	–	2.4	mL	 2.2	–	2.8	mL	40	-	<50kg	 0.5	mL	(10	mg)	 0.2	–	0.25	mg/kg	 2.4	–	3	mL	 2.9	–	3.5	mL	≥50kg	 0.5	mL	(10	mg)	 <0.2	mg/kg	 3	mL	 3.5	mL				 	
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Table	2.		Baseline	characteristics	by	sequence	for	children	routinely	treated	with	
amikacin	for	multidrug-resistant	(MDR)	tuberculosis	(TB)		
Sequence	1	
(Without	lidocaine	
then	with	lidocaine)	
(n=6)	
Sequence	2	
(With	lidocaine	then	
without	lidocaine)	
(n=6)	
Median	age	at	enrolment	(IQR)	 10.3	(9.8-11.4)	 13.4	(11.7-14.5)	
Male	gender	(%)	 6	(100)	 2	(33)	
HIV-infected	(%)	 3	(50)	 0	(0)	
WAZ	<	-2	(%)	 3	(50)	 1	(17)	
Median	weeks	on	MDR-TB	treatment	(IQR)	 6.4	(3.0-15.9)	 9.5	(5.9-11.7)	IQR=interquartile	range,	WAZ=weight-for-age	z-score			 	
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Table	3.		Adjusted	pain	scores	among	children	with	multidrug-resistant	tuberculosis	
(n=12)	receiving	amikacin	injections	with	and	without	added	lidocaine		 Treatment	A		(without	added	lidocaine)	 Treatment	B	(with	added	lidocaine)	 p-value*	Median	adjusted	pain	score,	immediately	after	injection	(IQR)	 2.5	(1	to	4)	 1	(0.5	to	2)	 0.004	Median	adjusted	pain	score,	30	minutes	post-injections	(IQR)	 1	(0	to	1.5)	 0	(-0.5	to	0.5)	 0.107	Median	adjusted	pain	score,	60	minutes	post	injections	(IQR)	 1	(0	to	1)	 0	(-1	to	0.5)	 0.075	IQR	=	interquartile	range	*	Wilcoxon	matched-pairs	signed-ranks	test				 	
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Table	4.	Summary	statistics	for	amikacin	(15	mg/kg)	pharmacokinetic	parameters	
with	and	without	lidocaine	among	children	with	multidrug-resistant	tuberculosis	
(n=12)	
Pharmacokinetic	
parameter	
Treatment	A	
Without	lidocaine,	
median	(IQR)	
Treatment	B	
With	lidocaine,	
median	(IQR)	 p-values*	
AUC0-8	(µg*h/mL)	 103.3	(81.7-135.0)	 109.0	(84.7-121.3)	 0.814	
AUC0-∞	(µg*h/mL)	 107.5	(83.8-136.8)	 111.3	(86.8-126.4)	 0.754	
Cmax	(µg*h/mL)	 34.1	(25.6-46.4)	 36.7	(34.1-40.5)	 0.638	
t1/2	(h)	 1.28	(1.14-1.49)	 1.50	(1.27-1.62)	 0.182	
Tmax	(h)	 1	(1.0-1.0)	 1	(1.0-1.0)	 0.157	*Wilcoxon	matched-pairs	signed-ranks	test	AUC=area	under	the	concentration	time	curve,	Cmax=maximum	plasma	concentration,	t1/2=half-life,	Tmax=time	to	Cmax			 	
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Table	5.		Geometric	means	with	and	without	lidocaine,	geometric	mean	ratio	and	
90%	confidence	interval	for	amikacin	(15	mg/kg)	pharmacokinetic	parameters	
(n=12)	
Pharmacokinetic	
parameter	
Geometric	mean	(GM)	 	
Treatment	A	
Without	lidocaine	
Treatment	B	
With		
lidocaine	
GM	Ratio	(90%	CI)*	
AUC0-8	 93.8	 110.6	 1.18	(0.89-1.56)	
AUC0-∞	 96.2	 114.3	 1.19	(0.90-1.57)	
Cmax	 31.8	 37.6	 1.18	(0.92-1.52)	*	Treatment	B/Treatment	A	AUC=area	under	the	concentration	time	curve;	Cmax=maximum	plasma	concentration;	CI=confidence	interval			 	
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Figure	1.	Concentration-time	profiles	of	intramuscular	amikacin	with	and	without	
lidocaine	among	children	(n=12)	treated	for	multidrug-resistant	tuberculosis			
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Chapter	9:	The	relative	bioavailability	of	adult	bedaquiline	tablets	
suspended	in	water:	implications	for	dosing	in	children		
Rationale	The	novel	antituberculosis	drug	bedaquiline	is	increasingly	important	for	the	treatment	of	MDR-TB.		Following	on	its	accelerated	approval	from	the	U.S.	FDA	in	2012,	it	is	being	rolled	out	globally	for	adults	with	MDR-TB	and	is	being	evaluated	in	multiple	clinical	trials	in	adults	as	a	component	of	shortened	treatment	regimens	(57,	118).		The	Janssen	Pharmaceutical	sponsored	trial	(C211)	and	the	U.S.	NIH	(NIAID,	NICHD)	sponsored	trial	(IMPAACT	P1108)	have	been	very	delayed,	opening	only	in	2016	and	2017	respectively.		These	trials	are	expected	to	identify	the	optimal	dose	and	safety	of	bedaquiline	in	HIV-infected	and	-uninfected	children.		Although	a	paediatric	formulation	has	been	developed	for	the	C211	trial,	it	was	not	clear	whether	this	formulation	would	be	available	for	the	IMPAACT	P1108	trial	or	when	it	would	be	accessible	for	routine	use	in	high	TB	burden	settings.		The	adult	formulation	is	widely	available	and	could	be	manipulated	(crushed,	suspended	in	water)	for	administration	to	young	children.	However	it	is	unclear	whether	or	how	this	formulation	manipulation	might	affect	bedaquiline’s	bioavailability.				
Study	Aims	The	aim	of	the	study	was	to	evaluate	the	relative	bioavailability,	short-term	safety,	acceptability	and	palatability	of	suspended	bedaquiline	tablets	compared	to	whole	tablets,	in	order	to	explore	the	possibility	of	using	the	existing	tablet	formulation	in	young	children.		
Methods	This	randomized,	open-label,	two-period	crossover	study	was	conducted	in	Cape	Town,	South	Africa.		As	bedaquiline	and	its	M2	metabolite	accumulate	in	cells	and	tissues,	resulting	in	long	terminal	elimination	half-lives	(bedaquiline	164	days,	M2	159	days),	a	crossover	study	using	a	traditional	non-compartmental	analysis	would	have	required	an	exceedingly	long	washout	period	to	avoid	carryover	into	the	second	period.		Alternatively	a	parallel	design	could	be	employed,	but	would	require	a	much	larger	sample	size.		Therefore	a	model-based	analytic	approach	was	utilized	for	the	study,	
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which	is	able	to	account	for	the	carryover	effect,	allowing	a	more	efficient	crossover	design.	The	sample	size,	length	of	the	washout	period	and	sampling	schema	were	selected	using	an	existing,	published	bedaquiline	population	pharmacokinetic	model	and	clinical	trial	simulations	(138).		With	the	selected	design	(24	participants	receiving	two	single	doses	separated	by	a	14	day	washout	period),	the	trial	had	87%	power	to	demonstrate	bioequivalence.		Healthy	adult	volunteers,	ages	18-55	years	were	eligible	for	the	study.		All	participants	received	two	single	doses	of	400	mg	bedaquiline,	including	one	dose	administered	as	4	x	100	mg	tablets	swallowed	whole	with	240	mL	water,	and	one	dose	administered	as	a	bedaquiline	suspension,	prepared	by	adding	4	x	100	mg	tablets	to	30	mL	clean	water	in	a	plastic	dosing	cup,	using	a	metal	spoon	to	stir	and	break	up	the	tablets	over	2	minutes	and	followed	by	two	small	rinses.		Participants	were	randomized	1:1	to	the	order	of	the	treatments.		The	randomization	was	generated	using	a	computer	generated	random	numbers	in	a	single	block,	and	allocations	were	concealed	using	sealed,	consecutively	numbered,	opaque	envelopes.		Pharmacokinetic	samples	were	drawn	just	before	and	at	1,	2,	3,	4,	5,	6,	8,	12,	24,	48	and	336	hours	after	each	dose.		All	adverse	events	were	recorded	and	assessed	for	attribution	to	the	study	medication	and	for	severity	using	the	Division	of	AIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	(DAIDS	AE	Grading	Table),	Version	2.0,	dated	November	2014.		A	palatability/acceptability	questionnaire	was	administered	to	each	participant	within	one	hour	of	each	dose.		Bedaquiline	and	M2	plasma	concentrations	were	measured	using	a	validated	LC	MS/MS	assay	at	the	University	of	Cape	Town,	Division	of	Clinical	Pharmacology.		Non-linear	mixed	effects	models	were	used	to	estimate	the	pharmacokinetic	parameters,	and	secondary	pharmacokinetic	metrics	(area	under	the	concentration	curve	until	48	and	336	hours	after	dose,	i.e.	AUC0-48h	and	AUC0-336h,	and	time	and	magnitude	of	peak	concentrations,	i.e.	Tmax	and	Cmax)	were	derived	from	the	final	model.		The	bioequivalence	of	bedaquiline	tablets	swallowed	whole	vs.	suspended	in	water,	based	on	the	primary	pharmacokinetic	parameter	affecting	the	extent	of	absorption,	i.e.	the	bioavailability,	would	be	assessed.			
Results	Twenty-four	adult	volunteers	were	enrolled,	randomized	and	all	completed	the	study.		The	existing	bedaquiline	model	described	the	data	well.			The	difference	in	bioavailability	between	suspended	and	whole	tablets	was	not	statistically	significant	
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(p=0.92).	The	nonparametric	95%	confidence	interval	(CI)	of	the	relative	bioavailability	of	suspended	bedaquiline	tablets	was	94-108%	relative	to	that	of	whole	bedaquiline	tablets;	hence	the	predefined	bioequivalence	criteria	(80-125%)	were	fulfilled.	The	mean	absorption	time	was	slightly	longer	for	suspended	tablets,	+23%	(95%	CI	2.1-48%,	p=0.03).	There	were	no	Grade	3	or	4	or	serious	treatment	emergent	adverse	events.		The	majority	of	participants	were	either	neutral	to	or	liked	most	individual	aspects	of	acceptability,	and	twenty-three	of	24	participants	(96%)	reported	the	suspension	to	be	acceptable	overall.				
Conclusions	and	recommendations	Bedaquiline	tablets	suspended	in	water	were	bioequivalent	to	bedaquiline	tablets	swallowed	whole,	and	were	acceptable	to	this	group	of	healthy	adult	volunteers.		This	suggests	that	the	bedaquiline	formulation,	increasingly	widely	available,	could	be	used	to	treat	MDR-TB	in	children,	to	bridge	the	gap	between	when	paediatric	dosing	regimens	have	been	established	and	when	a	paediatric	dispersible	formulation	becomes	routinely	available,	improving	access	for	children	to	this	much	needed	treatment	in	the	near	future.		This	should	not	be	used	to	delay	or	negatively	affect	timely	roll-out	of	the	paediatric	formulation	as	soon	as	possible.		Replication	of	this	pragmatic	approach	should	be	considered	for	other	medications,	such	as	delamanid	and	other	antituberculosis	drugs	where	access	to	child-friendly	formulations	is	unlikely	in	the	short-term.		Additionally,	this	study	demonstrated	the	value	of	pharmacometric	methods,	which	were	critically	important	for	this	crossover	study	with	a	long	half-life	drug,	but	which	is	also	valuable	in	the	design	and	analysis	of	other	paediatric	trials.		
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Abstract	
Objectives:	Bedaquiline	is	an	important	novel	drug	for	treatment	of	multidrug-resistant	tuberculosis,	but	no	paediatric	formulation	is	yet	available.	This	work	aimed	to	explore	the	possibility	of	using	the	existing	tablet	formulation	in	children	by	evaluating	the	relative	bioavailability,	short-term	safety,	acceptability	and	palatability	of	suspended	bedaquiline	tablets	compared	to	whole	tablets.		
Methods:	A	randomized,	open-label,	two-period	cross-over	study	was	conducted	in	24	healthy	adult	volunteers.	Rich	pharmacokinetic	sampling	over	48	hours	was	conducted	at	two	occasions	14	days	apart	in	each	participant	after	administration	of	400	mg	bedaquiline	(whole	or	suspended	in	water).	The	pharmacokinetic	data	were	analysed	with	nonlinear	mixed-effects	modelling.	A	questionnaire	was	used	to	assess	palatability	and	acceptability.	
Results:	There	was	no	statistically	significant	difference	in	the	bioavailability	of	the	suspended	bedaquiline	tables	compared	to	whole.	The	nonparametric	95%	confidence	interval	of	the	relative	bioavailability	of	suspended	bedaquiline	tablets	was	94-108%	of	that	of	whole	bedaquiline	tablets;	hence	the	predefined	bioequivalence	criteria	were	fulfilled.	There	were	no	Grade	3	or	4	or	serious	treatment	emergent	adverse	events	recorded	in	the	study	and	no	apparent	differences	between	whole	tablets	and	suspension	regarding	taste,	texture	or	smell.	
Conclusions:		The	bioavailability	of	bedaquiline	tablets	suspended	in	water	was	the	same	as	for	tablets	swallowed	whole	and	the	suspension	was	well	tolerated.	This	suggests	that	the	currently	available	bedaquiline	formulation	could	be	used	to	treat	MDR-TB	in	children,	to	bridge	the	gap	between	when	paediatric	dosing	regimens	have	been	established	and	when	a	paediatric	dispersible	formulation	is	routinely	available.	
Keywords:	bedaquiline,	paediatric	dosing,	bioavailability,	suspended	tablets,	population	PK	
What	is	already	known	about	this	subject	
• There	is	currently	no	paediatric	formulation	available	of	the	novel	anti-tuberculosis	drug	bedaquiline	
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• Important	absorption	properties	such	as	the	bioavailability	can	be	altered	if	a	drug	formulation	is	manipulated	to	enable	administration	to	children,	for	example	through	crushing	or	suspending	the	tablets	
What	this	study	adds	
• A	precise	estimate	of	the	relative	bioavailability	of	bedaquiline	tablets	suspended	in	water	compared	to	when	administered	whole	
• Support	for	the	use	of	suspended	bedaquiline	tablets	as	an	option	for	treatment	of	multidrug-resistant	tuberculosis	in	children	 	
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Introduction	Bedaquiline,	the	first	novel	antituberculosis	drug	developed	in	decades,	is	increasingly	used	for	treatment	of	multidrug-resistant	(MDR)	tuberculosis	(TB).		Based	on	phase	II	trial	data	it	received	accelerated	approval	from	the	U.S.	Food	and	Drug	Administration	in	2012	and	is	included	on	the	World	Health	Organization	(WHO)	list	of	essential	medicines.	Bedaquiline	is	being	rolled	out	for	programmatic	use	globally	(1).	Janssen	Pharmaceuticals	has	developed	a	paediatric	dispersible	formulation	of	bedaquiline	and	paediatric	bedaquiline	trials	are	now	underway	(Janssen	C211,	NCT02354014	and	IMPAACT	P1108,	NCT02906007).	However,	considerably	more	time	is	needed	for	this	formulation	to	become	available	for	widespread	routine	care,	limiting	bedaquiline’s	immediate	potential	for	use	in	young	children.		Bedaquiline	is	a	diarylquinoline	that	inhibits	mycobacterial	ATP-synthase,	resulting	in	potent	antimycobacterial	activity	(2).	The	recommended	adult	dose	is	400	mg	daily	for	two	weeks,	then	200	mg	thrice	weekly	for	22	weeks.	In	adults,	the	time	to	maximum	bedaquiline	serum	concentrations	is	4-6	hours,	with	2.0-2.4	fold	increased	absorption	when	administered	together	with	food	(3).	Absolute	bioavailability,	i.e.	the	fraction	of	the	total	dose	administered	which	is	absorbed	to	the	systemic	blood	circulation,	for	bedaquiline	is	not	known	(4).	Bedaquiline	is	primarily	metabolized	by	CYP3A4	to	M2	(3).	This	leads	to	drug-drug	interactions	with	several	antiretroviral	and	anti-TB	compounds	which	induces	or	inhibits	CYP3A4	(5–7).	Both	bedaquiline	and	its	M2	metabolite	have	cationic	amphiphilic	properties.	They	bind	to	phospholipids	and	accumulate	in	cells	and	tissues,	resulting	in	long	terminal	elimination	half-lives	(bedaquiline	164	days;	M2	159	days)	due	to	the	slow	release	from	tissues	(3).		Bedaquiline	100	mg	tablets	are	increasingly	available	for	the	treatment	of	adults	with	MDR	TB,	with	global	access	improving	rapidly	(8,9).	These	tablets	could	potentially	be	used	for	treatment	of	children.	However	administration	of	these	tablets	to	young	children	who	cannot	swallow	tablets	may	require	suspending	or	crushing	the	adult	formulation.	Such	formulation	manipulation	for	paediatric	administration,	which	is	commonly	done	for	most	second-line	TB	drugs	given	in	children,	may	affect	the	bioavailability	(10).	Characterizing	the	effect	of	suspending	bedaquiline	tablets	on	the	bioavailability	would	inform	the	safe	and	effective	use	of	this	formulation	in	young	
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children,	potentially	accelerating	access	to	this	much	needed	medication,	given	limited	treatment	options	and	availability	of	child-friendly	formulations	in	children.		The	primary	objective	of	this	study	was	to	evaluate	the	bioequivalence	of	bedaquiline	tablets	swallowed	whole	vs.	suspended	in	water,	based	on	the	primary	pharmacokinetic	parameter	affecting	the	extent	of	absorption,	i.e.	the	bioavailability.	Secondary	objectives	were	to	determine	the	impact	of	suspending	the	tablets	on	the	time-course	of	absorption,	and	to	describe	the	palatability,	acceptability	and	safety	of	whole	vs.	suspended	bedaquiline.			
Methods	
Study	design	and	participants	This	was	a	randomized,	open-label,	two-period	cross-over	study.		Healthy	male	and	female	adults	were	eligible	if	they	were	18-55	years	of	age	and	weighed	between	40-90	kg.	Exclusion	criteria	included	a	history	or	clinical	evidence	of	any	of	the	following:	QT	prolongation,	dysrhythmia,	or	other	significant	cardiac	conditions;	other	serious	comorbid	illness	including	but	not	limited	to	liver	disease,	kidney	disease,	HIV	infection,	Hepatitis	B	or	C	infection,	hypothyroidism;	use	of	QT	prolonging	medications	or	CYP3A4	inducers	or	inhibitors;	suspected	or	documented	current	active	tuberculosis	or	recent	household	tuberculosis	exposure.		The	study	was	conducted	in	Cape	Town,	South	Africa,	from	November	to	December	2016.	The	sample	size,	the	length	of	the	washout-period	and	the	number	and	timing	of	pharmacokinetic	samples	were	selected	with	help	of	clinical	trial	simulations.	These	were	conducted	with	stochastic	simulation	and	re-estimation	(SSE)	procedures,	using	a	published	population	model	of	bedaquiline	and	M2	pharmacokinetics	developed	on	data	from	healthy	volunteers	(5).	The	designs	evaluated	included	washout-periods	between	2	and	28	days	long,	and	11	to	17	samples	per	dosing	occasion.	One	hundred	virtual	trials	were	simulated	for	each	design,	assuming	no	difference	in	absorption	characteristics	for	whole	and	suspended	tablets.	Model	parameters	were	re-estimated	including	factors	allowing	for	differences	in	bioavailability,	and	delay	and	rate	of	absorption,	between	whole	and	suspended	tablets.	Effects	on	distribution-	and	elimination-related	parameters	were	not	evaluated,	as	these	cannot	be	affected	by	the	
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drug	formulation.	The	power	to	show	bioequivalence	under	the	suggested	design	given	that	the	two	forms	are	truly	equal,	were	evaluated	by	calculating	in	how	many	of	the	100	trials	the	95%	confidence	interval	of	the	factors	describing	a	difference	between	whole	and	suspended	tablets	were	fully	contained	within	the	bioequivalence	criteria,	defined	as	80-125%	of	the	expected	value	(11).	The	selected	design	(described	below)	was	estimated	to	have	an	87%	power	(95%	confidence	interval	80-94%)	to	fulfil	the	formal	bioequivalence	criteria	for	bioavailability.		
Intervention	and	randomization	The	selected	design	included	24	participants	who	received	a	single	dose	of	each	treatment	(formulation),	with	a	washout	period	of	14	days	between	the	two	dosing	occasions.		Each	bedaquiline	tablet	(Sirturo™,	Janssen	Pharmaceuticals)	contains	120.89	mg	of	bedaquiline	fumarate	drug	substance,	which	is	equivalent	to	100	mg	of	bedaquiline.	As	tablets,	400	mg	bedaquiline	was	administered	as	4	x	100	mg	tablets	swallowed	whole	with	240	mL	water.	A	bedaquiline	suspension	was	prepared	by	adding	4	x	100	mg	tablets	to	30	mL	clean	water	in	a	plastic	dosing	cup,	using	a	metal	spoon	to	stir	and	break	up	the	tablets	over	2	minutes.	The	suspension	was	administered	within	5	minutes	of	adding	the	tablets	to	the	water.	An	additional	20	mL	of	water	was	added	to	the	dosing	cup	to	rinse	any	residual	medication	from	the	cup	and	stirrer,	and	administered	to	the	participant.	Lastly,	another	10	mL	of	water	was	added	to	the	cup	for	a	final	rinse	and	then	administered	to	the	participant.	All	doses	were	administered	within	30	minutes	after	a	standardized	breakfast	consisting	of	approximately	670	kcal	with	at	least	33%	fat	content.	Participants	were	randomized	1:1	to	having	bedaquiline	administered	as	whole	tablets	at	the	first	occasion,	and	then	as	tablets	suspended	in	water	on	the	second	occasion,	or	the	reverse.		The	randomisation	scheme	was	created	using	computer	generated	random	numbers	in	a	single	block	to	ensure	equal	numbers	of	participants	were	assigned	to	each	treatment	sequence.	Consecutively	numbered,	sealed,	opaque	envelopes	were	prepared	by	the	study	pharmacist	and	stored	in	a	secure	location	at	the	site.	After	enrolment	of	a	participant,	the	research	pharmacist	opened	the	next	consecutively	numbered	envelope	in	order	to	determine	the	participant’s	allocation.	
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Data	collection	Pharmacokinetic	samples	were	drawn	just	before	and	at	1,	2,	3,	4,	5,	6,	8,	12,	24,	48	and	336	hours	after	each	dose	(the	336	hour	sample	for	the	first	occasion	also	serving	as	the	predose	sample	for	the	second).	Whole	blood	samples	were	drawn	into	EDTA-containing	tubes	and	immediately	placed	on	ice.	Samples	were	centrifuged	at	1500-2000g	within	one	hour,	plasma	was	separated	and	stored	at	-80	C	until	bioanalysis	was	performed.			All	treatment	emergent	laboratory	and	clinical	adverse	events	were	recorded	by	the	study	team,	and	assessed	for	attribution	to	the	study	medication	and	for	severity	using	the	Division	of	AIDS	Table	for	Grading	the	Severity	of	Adult	and	Pediatric	Adverse	Events	(DAIDS	AE	Grading	Table),	Version	2.0,	dated	November	2014	by	the	site	investigators.	Twelve-lead	electrocardiograms	(ECGs)	were	done	at	screening	and	on	dosing	days,	just	prior	to	the	dose	and	at	4	hours	post-dose.	The	QT	interval	was	calculated	using	the	Frederica	correction	and	captured	along	with	other	clinically	significant	abnormalities.	Safety	lab	monitoring	included	haematology,	liver	function	tests,	and	lactate.		A	palatability/acceptability	questionnaire	was	administered	to	each	participant	within	one	hour	of	each	dose.		The	questionnaire	utilized	a	5-point	facial	hedonic	scale	to	assess	taste,	smell,	visual	appearance,	texture,	size/volume,	and	overall	acceptability	of	both	treatments.		
Bioanalysis	Bedaquiline	and	M2	concentrations	were	determined	using	a	validated	LC-MS/MS	assay	developed	in	the	Division	of	Clinical	Pharmacology,	University	of	Cape	Town,	South	Africa,	validated	according	to	FDA	and	EMA	guidelines,	as	previously	described	(12)	and	further	detailed	in	the	online	supplementary	material.	The	assay	was	validated	over	the	concentration	range	of	0.01	–	5	µg/ml	for	BDQ	and	0.01	–	0.5	µg/ml	for	M2	(lower	and	upper	limit	of	quantification).	During	sample	analysis,	the	accuracies	(%	Nom)	for	bedaquiline	were	102.6%,	102.0%	and	99.3%	at	the	high	(4	µg/ml),	medium	(2	µg/ml)	and	low	(0.024	µg/ml)	QC	levels	respectively	with	precision	(%	CV)	less	than	10%	across	all	three	levels.		The	accuracies	for	M2	were	99.1%,	99.3%	and	96.7%	at	the	high	
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(0.40	µg/ml),	medium	(0.20	µg/ml)	and	low	(0.024	µg/ml)	QC	levels,	respectively,	with	precision	(%	CV)	less	than	7%.	
Pharmacokinetic	analysis	Nonlinear	mixed-effects	models,	able	to	characterize	both	typical	parameter	values	and	distributions	of	random	inter-individual	and	inter-occasion	variability	(IIV	and	IOV),	as	well	as	unexplained	residual	variability,	were	employed	for	the	analysis.	The	previously	developed	population	pharmacokinetic	model	utilized	in	the	clinical	trial	simulations	was	used	as	a	starting	point	(5).	This	model	included	three	distribution	compartments	for	bedaquiline	and	two	for	M2.	Each	bedaquiline	dose	was	defined	as	a	separate	occasion.	IIV	and	IOV	were	implemented	with	log-normal	distributions.		A	correlation	between	the	residual	errors	for	observations	at	the	same	time	point	was	included.	Concentration	measurements	below	the	limit	of	quantification	were	excluded	from	the	analysis.	Model	selection	was	based	on	maximum	likelihood	ratio	test	(95%	significance	level)	and	goodness-of-fit	plots,	including	visual	predictive	checks	based	on	simulations	from	the	final	model	(n=1000).	Secondary	PK	metrics	(area	under	the	concentration	curve	until	48	and	336	hours	after	dose,	i.e.	AUC0-48h	and	AUC0-336h,	and	time	and	magnitude	of	peak	concentrations,	i.e.	Tmax	and	Cmax)	were	derived	from	the	final	model.	Data	management,	post	processing	of	results	and	plotting	were	performed	in	R	(R	Foundation	for	Statistical	Computing,	Vienna,	Austria)(13).	The	modelling	and	simulations	were	performed	in	NONMEM	7.3	(Icon	Development	Solutions,	Ellicott	City,	MD,	USA)(14),	aided	by	PsN	(Department	of	Pharmaceutical	Biosciences,	Uppsala	University,	Uppsala,	Sweden)	and	Pirana	(Pirana	Software	&	Consulting,	San	Francisco,	CA,	USA)(15).	Parameter	uncertainty	was	obtained	from	the	covariance	step	in	NONMEM.	Additionally,	log-likelihood	profiling	(as	implemented	in	PsN)	was	used	to	obtain	non-parametric	confidence	intervals	for	the	parameters	describing	potential	effects	of	suspending	tablets.	
Ethics	This	study	was	approved	by	the	Pharma-Ethics	Independent	Research	Ethics	Committee	of	South	Africa	(#141110730).		All	participants	provided	written	informed	consent.		The	trial	was	registered	at	clinicaltrials.gov	with	identifier	NCT03032367.		
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Results	
Study	participants	and	data	All	24	participants	completed	the	study.	A	summary	of	the	demographic	characteristics	can	be	found	in	Table	1.	Study	investigators	noted	that	the	tablets	did	suspend	in	this	volume	of	water	over	2	minutes,	although	some	amount	of	stirring	and	breaking	up	the	tablets	with	the	spoon	handle	were	required.		Some	visual	particles	usually	remained,	which	were	successfully	suspended	by	the	described	rinses.		There	were	552	concentration	observations	each	for	bedaquiline	and	M2	available.	All	predose	observations	at	the	first	sampling	occasion	as	well	as	five	postdose	bedaquiline	and	81	postdose	M2	observations	were	below	the	limit	of	quantification.	The	average	concentration	of	bedaquiline	and	M2	per	nominal	time	point	is	shown	in	supplemental	figure	S1.	
Pharmacokinetic	analysis	The	starting	model	generally	described	the	data	well,	and	only	a	few	modifications	were	required.	A	six	hour	maximum	limit	for	the	mean	absorption	time	(i.e.	the	typical	time	to	when	90%	of	the	dose	is	absorbed)	was	added	to	the	flexible	transit	compartment	model	describing	absorption,	consistent	with	another	recently	published	model	of	bedaquiline	pharmacokinetics	(16).	The	absorption	model	was	simplified	without	a	statistically	significant	loss	of	fit	by	making	the	rate	of	absorption	from	the	last	transit	compartment	the	same	as	the	rate	of	transfer	between	the	transit	compartments.		The	difference	in	bioavailability	between	suspended	and	whole	tablets	was	not	statistically	significant	(p=0.92).	The	nonparametric	95%	confidence	interval	(CI)	of	the	relative	bioavailability	of	suspended	bedaquiline	tablets	was	94-108%	relative	to	that	of	whole	bedaquiline	tablets;	hence	the	predefined	bioequivalence	criteria	(80-125%)	were	fulfilled.	Inter-individual	variability	in	bioavailability	was	not	significantly	different	between	whole	and	suspended	tablets.	The	mean	absorption	time	was	slightly	longer	for	suspended	tablets,	+23%	(95%	CI	2.1-48%,	p=0.03).	In	the	final	model,	only	the	formulation	effect	on	mean	absorption	time	was	included.	Parameter	estimates	with	uncertainty	are	reported	in	Table	2,	and	the	NONMEM	control	stream	detailing	the	parametrization	is	included	in	the	online	supplementary	material.	The	fit	of	the	model	to	the	observed	data	per	formulation	and	sequence	are	shown	in	Figure	1	and	2	for	
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bedaquiline	and	M2,	respectively.	The	typical	pharmacokinetic	profile	after	a	single	400	mg	dose	bedaquiline	administered	either	as	whole	or	suspended	tablets	are	demonstrated	in	Figure	3.	Secondary	PK	metrics	(AUC0-48h,	AUC0-336h,	Cmax	and	Tmax)	are	reported	in	Table	3	and	Supplemental	Table	S1	to	facilitate	comparison	with	other	clinical	studies.		
Safety,	palatability	and	acceptability	There	were	no	Grade	3	or	4	or	serious	treatment	emergent	adverse	events,	nor	any	treatment	adverse	events	leading	to	withdrawal	from	the	study.		All	adverse	events	and	all	potentially	bedaquiline-related	treatment	emergent	adverse	events	are	shown	in	Supplemental	Tables	S2	and	S3	by	grade	of	severity.	The	most	frequent	event	(n=7)	was	mild	or	moderate	headache.	No	participant	had	a	QTcF	>450	ms	at	any	point	during	the	study.	No	lactate	levels	above	3	mmol/L	were	found.	Table	4	shows	results	of	the	acceptability	and	palatability	questionnaire	by	formulation	(whole	tablets	vs.	suspension).		The	large	majority	of	participants	(88-100%)	were	either	neutral	to	or	liked	most	aspects	of	the	bedaquiline	suspension	palatability,	such	as	taste,	smell,	texture.	Twenty-three	of	24	participants	(96%)	reported	the	suspension	to	be	acceptable	overall.			
	
Discussion	This	study	demonstrates	that	a	400	mg	dose	of	bedaquiline	given	as	100	mg	tablets	suspended	in	a	small	volume	of	water	had	equivalent	bioavailability	to	bedaquiline	administered	as	100	mg	tablets	swallowed	whole.	The	suspended	bedaquiline	tablets	were	considered	by	the	majority	of	participants	to	be	palatable	and	acceptable.	The	mean	absorption	time	for	suspended	bedaquiline	was	found	to	typically	be	23%	longer	for	suspended	tablets.	This	translates	to	a	delay	in	the	time	to	peak	bedaquiline	concentrations	from	4.3	to	5.2	hours,	and	a	decrease	in	typical	maximal	concentrations	of	5%,	but	no	change	in	the	average	concentration.	Given	that	average	rather	than	peak	concentrations	have	been	linked	to	bedaquiline	efficacy	(17),	we	do	not	expect	the	effect	of	suspending	on	mean	absorption	time	to		be	clinically	relevant.	The	bedaquiline	exposures	observed	in	this	study	(see	Table	3)	were	somewhat	lower	compared	to	other	studies	in	healthy	volunteers	with	similar	design	and	the	same	dose.	Dooley	et	al.	
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reported	bedaquiline	AUC0-336h	of	58200	(42200–78200)	ng/mL*h	(18),	and	Winter	et	
al.	reported	67200	(standard	deviation	20200)	ng/mL*h	(19),	while	the	median	in	this	study	was	44000	ng/mL*h.	This	might	be	explained	by	the	larger	proportion	of	black	subjects	included	here	(88%)	compared	to	in	the	studies	by	Dooley	and	Winter	(22%	and	6%,	respectively),	since	black	race	has	been	associated	with	higher	bedaquiline	clearance	(16).	Our	findings	have	important	implications	for	the	clinical	use	of	bedaquiline	100	mg	tablets	in	young	children,	who	will	likely	not	have	access	to	paediatric	bedaquiline	formulations	in	routine	care	settings	in	the	near	future.	Data	on	the	safety	and	dosing	of	bedaquiline	from	paediatric	trials	across	the	age	range	(0-17	years)	is	expected	to	be	available	long	before	the	paediatric	formulation	used	in	the	studies	is	registered	and	widely	available,	as	there	are	many	barriers	preventing	access	to	TB	medications	in	children	(20),	including	the	development,	manufacture,	licensure,	procurement	and	uptake	of	paediatric	drug	formulations.	Given	no	other	choice	due	to	the	lack	of	child	friendly	formulations,	adult	formulations	manipulated	either	by	splitting,	crushing,	dissolving	or	suspending	are	frequently	used	in	paediatric	TB	care,	especially	for	MDR-TB	(10).	However	the	impact	of	such	manipulation	on	drug	exposures	or	formulation	acceptability	is	often	unknown.	Data	from	our	study	addresses	these	questions	for	bedaquiline	and	will	facilitate	the	use	of	bedaquiline	in	children	with	the	already	widely	available	adult	100	mg	tablets,	once	paediatric	dosing	and	safety	is	established,	and	until	the	paediatric	formulation	becomes	widely	available	in	the	field.	It	is	reassuring	that	the	vast	majority	of	adults	found	the	suspended	tablets	to	be	palatable	and	acceptable,	a	critical	consideration	for	children’s	medication	and	adherence	to	long-term	treatment.	Although	children	may	have	different	perceptions	of	palatability	and	acceptability,	the	data	suggests	that	poor	palatability	or	acceptability	are	unlikely	to	be	major	barriers	to	use	of	suspended	bedaquiline	tablets	in	children.	The	design	of	this	study	was	supported	by	clinical	trials	simulations	to	ensure	adequate	statistical	power.	The	data	was	analysed	with	a	model-based	approach	to	handle	the	extremely	long	terminal	half-life	of	bedaquiline	and	M2	and	expected	carry-over	between	the	sampling	occasions,	avoiding	the	risk	of	bias	associated	with	non-compartmental	analysis	in	such	cases	(21).	However,	the	final	model	has	some	limitations.	Individual	bedaquiline	profiles	showed	a	tendency	towards	having	dual	
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peaks.	This	is	not	accounted	for	in	the	structure	of	the	final	model,	but	simply	handled	by	the	larger	residual	error	estimated	for	the	absorption	phase	(first	6	hours	after	dose).	An	expanded	structural	model	including	enterohepatic	circulation	linked	to	meal	times	was	evaluated,	but	did	not	improve	the	model	fit	to	the	data.	Furthermore,	concentration	observations	below	the	limit	of	quantification	were	excluded	in	this	analysis.	For	bedaquiline,	the	proportion	of	samples	below	limit	of	quantification	was	very	low	(<1%),	hence	the	exclusion	is	not	expected	to	impact	our	results.	For	M2,	the	proportion	of	samples	below	the	limit	of	quantification	was	larger	(15%)	and	95%	of	occurred	within	the	first	4	hours	after	dose	administration.		This	may	have	influenced	the	M2	parameter	estimates.	However,	predictions	from	the	final	model	at	the	time	points	of	samples	with	below	limit	of	quantification	results	were	in	77	of	81	cases	below	two	times	the	quantification	limit,	indicating	a	reasonable	description	also	at	low	concentration	levels.	This	study	demonstrating	bioequivalence	of	100	mg	bedaquiline	tablets	suspended	in	water	vs.	swallowed	whole	will	support	the	use	of	bedaquiline	for	MDR	TB	in	children.	Similar	work	would	be	beneficial	for	other	novel	TB	medications	in	the	future.		While	this	data	addresses	an	immediate	gap	in	medication	formulation	availability	for	children,	it	should	not	result	in	delays	or	limit	the	development	and	availability	of	an	affordable	child-friendly	formulation	of	bedaquiline,	preferably	a	palatable	dispersible	scored	formulation.		Equitable	access	to	child-friendly	formulations	of	life-saving	medications	must	continue	to	be	a	priority	for	the	TB	community.		 	
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Table	1.	Summary	of	the	demographic	characteristics	of	the	study	participants.		Characteristics	
[unit]	
All	participants	
Median	(range)/n	
(%)	
Whole	tablets	first		
Median	(range)/n	
(%)	
Suspension	first	
Median	(range)/n	
(%)	N	 24	 12	 12	Weight	[kg]	 63.4	(45.6,	88.5)	 66.15	(45.6,	84.7)	 61.85	(53.3,	88.5)	Age	[years]	 23.5	(19,	37)	 22	(19,	26)	 24.5	(20,	37)	Female	sex		 15	(62.5%)	 8	(66.7%)	 7	(58.3%)	Race					Black				Mixed	race	
	21	(87.5%)	3	(12.5%)	
	11	(91.7%)	1	(8.3%)	
	10	(83.3%)	2	(16.7%)	
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Table	2.	Parameter	estimates	for	the	final	model	including	uncertainty.	
Structural	parameters	 Parameter	
value	
Relative	
standard	
error	MAT	[h]	 2.63	 5.0%	NN	 4.00	 10.9%	CLBDQ/F	[L/h]	 5.67	 10.1%	VBDQ/F	[L]	 130	 6.1%	QBDQ,1/F	[L/h]	 6.33	 9.6%	VPBDQ,1/F	[L]	 3020	 28.0%	QBDQ,2/F	[L/h]	 4.83	 15.5%	VPBDQ,2/F	[L]	 64.5	 13.1%	CLM2/F/fm	[L/h]	 17.2	 11.8%	VM2/F/fm	[L]	 1380	 9.2%	QM2/F/fm	[L/h]	 126	 12.9%	VPM2/F/fm	[L]	 3450	 11.7%	Weighting	residual	error	samples	0-6h	 1.67	 5.6%	Effect	of	suspending	on	MAT	[%]	 23	 43.0%	
Variability	between	individuals	and	
occasions	
	 	
IOV	F	 9.1%	 23.8%	IIV	F	 22.6%	 12.8%	IOV	MAT	 66.3%	 9.4%	IIV	CLBDQ	 17.1%	 23.2%	Correlation	IIV	CLBDQ-CLM2	 8.5%	 5.4%	IIV	CLM2	 20.5%	 23.4%	IIV	VBDQ	 28.3%	 15.5%	IIV	QBDQ,1	 17.3%	 25.7%	IIV	VM2	 26.3%	 25.3%	IIV	VPM2	 22.3%	 35.6%	
Residual	variability	 	 	Proportional	error	BDQ	 23.1%	 4.0%	Correlation	error	BDQ-M2	 53.1%	 11.7%	Proportional	error	M2	 11.4%	 3.7%	Abbreviations:	BDQ,	bedaquiline;	M2,	metabolite	M2;	MAT,	mean	absorption	time;	NN,	number	of	transit	compartments;	CL,	clearance;	V,	volume	of	distribution	central	compartments;	Q,	intercompartmental	clearance;	VP,	volume	of	distribution	peripheral	compartments;	F,	bioavailability;	IOV,	inter	occasion	variability;	IIV,	inter	individual	variability		
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Table	3.	Summary	of	secondary	PK	metrics	after	two	single	doses	of	400	mg	bedaquiline	
administered	14	days	apart.	The	numbers	represent	geometric	mean	and	range	of	
individual	exposure	estimates	from	the	final	model.		 First	dose,	whole	
(n=12)	
First	dose,	
suspended	(n=12)	
Second	dose,	
whole	(n=12)	
Second	dose,	
suspended		
(n=12)	
Bedaquiline	AUC0-48h	[ng/mL*h]	 31900		(18600,	51600)	 32900		(25600,	43800)	 35900		(29600,	49100)	 34700		(20700,	54000)	AUC0-336h	[ng/mL*h]	 43500		(24900,	69300)	 45900		(34300,	60700)	 56700		(44600,	75400)	 53400		(31100,	89700)	Cmax		[ng/mL]	 2400		(1410,	3660)	 2260		(1750,	3280)	 2500	(2030,	3820)	 2460	(1490,	3910)	Tmax		[h]	 4.3		(2.8,	5.6)	 4.9		(2.8,	6.9)	 4.1		(2.8	,6.7)	 4.9		(3.3,	7.3)	
M2	metabolite	AUC0-48h	[ng/mL*h]	 1650		(818,	3110)	 1780		(1270,	2580)	 2800		(1990,	4140)	 2520		(1360,	4380)	AUC0-336h	[ng/mL*h]	 8450		(4520,	15400)	 9340		(6480,	13600)	 14900		(10400,	22000)	 13400		(7750,	22300)	Cmax		[ng/mL]	 44.3		(22.0,	81.2)	 47.9	(33.4,	72.2)	 69.5		(50.7,	106)	 63.6		(33.9,	109)	Tmax		[h]	 14.4		(10.1,	19.6)	 14.8		(11.4,	18.1)	 14.0		(10.9,	17.3)	 14.8		(11.0,	20.0)	Abbreviations:	AUC,	area	under	the	concentration	curve;	Cmax,	maximal	concentration,	Tmax,	time	of	maximal	concentration	
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Table	4.		Results	of	palatability	and	acceptability	assessments	in	healthy	adults	receiving	
suspended	vs.	whole	bedaquiline	tablets	(n=24)		 Whole		
formulation	
Suspended	
	formulation		 Dislike	
very	
much	or	
dislike	
Neutral,	
Like	or	Like	
very	much	
Dislike	
very	much	
or	dislike	
Neutral,	
Like	or	Like	
very	much	How	did	you	feel	about	the	visual	
appeal	of	the	formulation?	(did	the	formulation	look	acceptable	to	you?)																																																																																																																													1	(4%)	 23	(96%)	 3	(13%)	 21	(88%)	How	did	you	feel	about	the	smell	of	the	formulation?																																																																																																													0	(0%)	 24	(100%)	 1	(4%)	 23	(96%)	How	did	you	feel	about	the	taste	of	the	formulation?																																																																																																													3	(13%)	 21	(88%)	 3	(13%)	 21	(88%)	How	did	you	feel	about	the	texture	of	the	formulation?		(how	did	the	formulation	feel	in	your	mouth?)																																																																																																																																		5	(21%)	 19	(79%)	 2	(8%)	 22	(92%)	How	did	you	feel	about	the	size/amount	of	the	formulation	(volume	of	liquid	or	size	of	tablet)?																																																																																																																																							5	(21%)	 19	(79%)	 0	(0%)	 24	(100%)	How	did	you	feel	about	the	OVERALL	
acceptability	of	the	formulation?																																																																																													0	(0%)	 24	(100%)	 1	(4%)	 23	(96%)	If	a	child	is	required	to	take	this	formulation,	how	do	you	think	they	would	feel	about	the	taste	of	the	formulation?																																																																																																																			5	(21%)	 19	(79%)	 2	(8%)	 22	(92%)	If	a	child	is	required	to	take	this	formulation,	how	do	you	think	they	would	feel	about	the	size/amount	of	the	formulation	(volume	of	liquid	or	size	of	tablet)?																																																																																																																																																																																																6	(25%)	 18	(75%)	 1	(4%)	 23	(96%)	If	a	child	is	required	to	take	this	formulation,	how	do	you	think	they	would	feel	about	the	OVERALL	
acceptability?																																																																																																																						3	(13%)	 21	(88%)	 3	(13%)	 21	(88%)		
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Figure	1.	Visual	predictive	check	showing	the	5th,	50th,	and	95th	percentiles	(lines)	of	
observed	bedaquiline	concentrations	(open	circles)	over	time	after	dose,	per	formulation	
(whole	or	suspended	tablets)	and	dose.	The	shaded	areas	represent	the	90%	confidence	
intervals	for	the	same	percentiles	calculated	from	model-simulated	data.	
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Figure	2.	Visual	predictive	check	showing	the	5th,	50th,	and	95th	percentiles	(lines)	
of	observed	M2	concentrations	(open	circles)	over	time	after	dose,	per	
formulation	(whole	or	suspended	tablets)	and	dose.	The	shaded	areas	represent	
the	90%	confidence	intervals	for	the	same	percentiles	calculated	from	model	
simulated	data.	
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Figure	3.	Typical	pharmacokinetic	profile	after	a	single	400mg	dose	bedaquiline	
administered	either	as	whole	(solid	line)	or	suspended	(broken	line)	tablets,	based	on	
final	model	parameters.	
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Chapter	10:	Discussion	
	
10.1	Discussion	The	overall	objective	of	this	doctoral	research	was	to	characterize	the	pharmacokinetics,	including	the	effects	of	formulation,	the	optimal	dose,	safety,	and	the	tolerability	of	key	second-line	and	novel	antituberculosis	drugs	in	children,	in	order	to	inform	their	use	in	the	safer	and	effective	treatment	of	children	with	MDR-TB.		As	currently	recommended	treatment	regimens	for	MDR-TB	in	children	are	long,	toxic	and	poorly	tolerated,	the	ultimate	goal	of	this	research	was	to	inform	the	development	of	treatment	regimens	for	children	with	MDR-TB	that	are	highly	effective,	shorter,	child-friendly	(their	use	is	child-friendly	and	formulations	are	acceptable),	safer	and	better	tolerated	(specifically	avoiding	the	use	of	injectable	medications).		The	three-pronged	approach	used	to	achieve	this	goal	was	to	optimize	the	use	of	1)	existing	and	2)	novel	antituberculosis	drugs	in	children	by	characterizing	their	pharmacokinetics,	optimal	dose,	and	safety,	including	consideration	of	formulation,	and	3)	to	combine	these	medications	into	better	regimens.		Not	all	issues	could	be	addressed	in	this	doctoral	dissertation.		However,	I	identified	the	following	priority	questions:	characterizing	the	pharmacokinetics	and	safety	of	currently	recommended	doses	of	key	“second-line”	antituberculosis	drugs	including	ofloxacin,	levofloxacin,	and	linezolid	in	children	with	MDR-TB,	investigating	the	impact	on	pharmacokinetics	and	pain	of	administration	practices	for	intramuscular	injections	of	amikacin	in	children	with	MDR-TB,	and	characterizing	the	effects	of	formulation	and/or	formulation	manipulation	on	the	pharmacokinetics	of	levofloxacin	and	bedaquiline.		Below,	I	discuss	the	results	of	this	doctoral	research	in	relation	to	its	objective,	how	this	research	is	influencing	policy	and	practice	of	paediatric	MDR-TB	care	(Section	10.2),	and	future	research	that	is	emerging	and	is	building	on	research	from	my	doctoral	dissertation	(Section	10.3),	and	other	considerations	(Section	10.4).	
10.1.1	Fluoroquinolone	studies	(Chapters	2,	3,	4,	and	5)	In	Chapter	2,	I	described	a	prospective	observational	study	of	the	pharmacokinetics	and	safety	of	ofloxacin	in	children	routinely	treated	for	MDR-TB	disease	or	exposure	(139).		At	the	time	the	study	was	conceived	and	implemented,	ofloxacin	was	the	only	
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recommended	fluoroquinolone	for	MDR-TB	treatment	in	children.		Although	this	is	no	longer	true,	as	levofloxacin	and	moxifloxacin	have	now	become	the	fluoroquinolones	of	choice	for	MDR-TB	treatment,	this	study,	the	largest	study	of	ofloxacin	pharmacokinetics	in	children	to	date,	made	a	number	of	valuable	contributions.		It	importantly	identified	that	at	the	recommended	dose	of	ofloxacin	for	children	(15-20	mg/kg),	drug	exposures	were	well	below	the	target	exposure	in	adults	receiving	the	recommended	800	mg	once	daily	dose.		Although	ofloxacin	is	unlikely	to	be	used	frequently	for	MDR-TB	treatment	in	the	future,	this	finding	has	a	number	of	important	implications.		It	confirms	that	mg/kg	extrapolation	of	doses	from	adults	to	children	should	not	be	relied	on,	as	has	been	done	for	many	second-line	antituberculosis	drugs.		This	limitation	of	mg/kg	extrapolation	and	the	concept	of	allometric	scaling	and	its	importance	for	drug	dosing	in	children	is	well	known	among	clinical	pharmacologists,	but	not	well	enough	among	general	TB	clinicians	and	policy	makers.		However,	it	is	important	for	this	concept	to	be	better	known	and	better	communicated,	as	it	has	critical	impact	on	policy	and	clinical	practice.		Well-designed	pharmacokinetic	studies	of	antituberculosis	drugs	should	be	undertaken	in	children	across	the	age	spectrum	to	identify	paediatric	doses	that	achieve	target	exposures.			Additionally,	it	is	interesting	to	note	that	despite	exposures	of	ofloxacin	that	were	well	below	target	levels,	children	in	the	same	setting	as	this	study,	treated	with	these	doses	of	ofloxacin,	expected	to	be	the	key,	most	bactericidal	drug	in	the	treatment	regimen,	had	excellent	outcomes	in	observational	studies	(17).		In	a	prospective	cohort	study	of	137	children	with	probable	or	confirmed	MDR-TB	treated	in	Cape	Town	between	January	2009	and	December	2010,	96.4%	were	treated	with	ofloxacin	at	recommended	doses,	and	92%	of	children	were	successfully	treated	(cure	or	probable	cure)	(17).		As	children	with	MDR-TB	in	this	cohort	had	excellent	outcomes	even	with	a	fluoroquinolone,	the	most	important	drug	in	the	regimen,	which	was	less	potent	than	fluoroquinolones	currently	in	use	and	that	was	likely	underdosed,	there	may	be	scope	for	treating	children	with	less	intensive	treatment	regimens	in	future.		Optimizing	the	dose	of	fluoroquinolones,	given	its	critical	role,	could	make	such	an	approach	even	more	likely	to	be	effective.		Additionally,	the	study	documented	that	ofloxacin	at	the	recommended	doses	was	safe	and	well	tolerated	for	the	long	durations	required	for	MDR-TB	treatment.		Despite	clear	recommendations	for	the	use	of	fluoroquinolones	in	children	for	some	indications,	including	for	MDR-TB,	some	clinicians	and	TB	programmes	remain	hesitant.						
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Although	ofloxacin	is	unlikely	to	be	widely	used	in	the	future,	and	there	may	be	variations	in	the	safety	profile	of	different	fluoroquinolones,	this	is	reassuring	for	long	duration	fluoroquinolone	use	in	children.		There	were	few	musculoskeletal	events	in	this	cohort.		It	is	possible	that	mild,	subjective	musculoskeletal	complaints	were	under-reported,	especially	in	young	children.		However,	it	is	unlikely	that	overt	arthritis	or	more	serious	arthralgia	events	that	would	have	affected	weight-bearing	or	functional	activities	were	missed.		As	described	in	the	publication,	sleep	disturbance	and	hyperactivity	are	well	described	with	fluoroquinolones	in	children	(87,	88)	but	were	reported	infrequently	in	this	cohort.		These	events	may	have	been	underreported	as	most	children	in	the	cohort	were	hospitalized	early	in	treatment,	potentially	obscuring	these	types	of	behavioural	changes.		Future	studies	among	children	treated	primarily	as	outpatients	should	be	certain	to	observe	carefully	for	these	events.		As	these	children	were	on	multidrug	regimens,	with	at	least	5-7	other	antituberculosis	drugs,	assessing	the	attribution	of	events	to	individual	medications	was	challenging,	and	should	be	interpreted	cautiously.		It	is	likely	that	many	of	the	non-specific	events	reported	in	the	study	as	possibly	related	to	ofloxacin	were	more	likely	related	to	other	drugs	in	the	regimen,	such	as	vomiting	with	ethionamide.			Although	the	safety	profile	of	ofloxacin	in	this	study	was	reassuring,	it	must	be	considered	in	the	context	of	the	low	drug	exposures	shown.		Should	ofloxacin	paediatric	doses	be	increased	to	more	closely	approximate	adult	target	exposures,	then	safety	should	be	carefully	reassessed.			In	Chapter	3,	I	reported	on	the	results	of	the	largest	study	of	the	pharmacokinetics	of	levofloxacin	in	children	to	date.		Similarly	to	the	study	of	ofloxacin,	levofloxacin	exposures	were	well	below	targets	with	the	formulation	studied	(the	formulation	routinely	available	in	the	TB	programme	in	Cape	Town)	with	the	doses	most	widely	used	currently	for	MDR-TB	(15-20	mg/kg	once	daily).		This	has	important	implications	considering	that	the	fluoroquinolones	are	the	most	important	component	of	existing	MDR-TB	treatment	regimens.		Optimizing	their	bactericidal	activity	is	important	for	rapidly	reducing	the	burden	of	metabolically	active	mycobacteria	early	in	treatment,	and	for	protection	against	acquisition	of	resistance	in	companion	drugs.		Doses	that	are	likely	to	achieve	target	exposures	with	the	formulation	studied	were	estimated	from	the	resultant	model	using	clinical	trial	simulations.		These	doses	were	much	higher	than	currently	recommended,	up	to	nearly	40	mg/kg	in	some	weight	bands.		Additionally	the	estimated	doses	varied	substantially	across	weights,	from	nearly	40	mg/kg	down	to	18	
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mg/kg	at	the	lowest	weights	(youngest	ages),	clearly	demonstrating	the	problem	with	recommending	a	single	mg/kg	dose	to	be	used	across	children	of	all	sizes	and	ages.		The	formulation	used	is	an	important	consideration	for	paediatric	medicines,	and	in	this	study	the	effect	of	formulation	manipulation	was	assessed.		Administration	of	levofloxacin	by	nasogastric	tube	was	associated	with	an	increased	speed	of	absorption,	but	had	no	effect	on	overall	bioavailability.		Nasogastric	tubes	are	rarely	used	in	routine	practice	as	this	is	not	feasible.		However	in	this	study	it	was	at	times	necessary	to	ensure	the	medication	doses	were	completely	ingested	in	a	short	amount	of	time	in	young	children,	many	of	whom	would	refuse	due	to	the	large	pill	burden	(most	were	taken	with	5-7	other	antituberculosis	drugs)	and	poor	palatability	of	many	of	the	second-line	antituberculosis	drugs.		The	bioavailability	of	levofloxacin	administered	as	crushed	tablets	did	not	differ	from	whole	tablets.	This	finding	was	limited	by	the	small	number	of	children	in	this	study	who	were	able	to	swallow	whole	tablets,	and	also	that	the	administration	method	(crushed	vs.	whole)	was	highly	associated	with	age.		Nevertheless,	this	is	reassuring,	as	until	very	recently	this	was	the	only	option	for	administering	levofloxacin	to	young	children	in	most	settings.		Interestingly,	when	scaling	the	clearance	(CL/F)	from	this	study	and	other	published	levofloxacin	studies,	it	can	be	seen	as	clearly	higher	than	both	previous	adult	and	paediatric	studies	(Chapter	3,	table	4).		The	published	manuscript	describes	the	scaled	value	as	CL,	rather	than	as	CL/F,	in	error.		Regardless,	the	explanation	for	this	difference	is	not	clear,	however	it	was	hypothesized	that	this	was	related	to	the	formulation	studied.		Formulation	would	not	be	expected	to	affect	CL,	but	could	plausibly	affect	bioavailability	(F)	and	thus	CL/F.	This	appears	to	be	likely	considering	the	findings	from	the	study	in	Chapter	5.		It	may	be	that	this	was	an	issue	with	the	individual	formulation	studied	in	Chapter	3,	or	it	may	be	an	issue	more	broadly	with	adult	formulations	administered	to	children.		As	young	children	may	continue	to	receive	adult	levofloxacin	tablets	in	many	settings,	this	question	has	high	practical	importance	and	deserves	future	study.	In	Chapter	4,	I	reported	on	the	clinical	and	cardiac	safety	of	levofloxacin	among	a	subset	of	the	cohort	reported	on	in	Chapter	3.			I	reported	a	very	similar	safety	profile	as	for	the	ofloxacin-treated	children	in	Chapter	2,	which	adds	to	the	confidence	in	these	findings.		Again,	the	study	may	have	underestimated	some	levofloxacin-associated	events	such	as	mild	musculoskeletal	complaints,	sleep	disturbance,	mild	behavioural	changes,	and	overestimated	the	contribution	of	levofloxacin	to	non-specific	events	such	as	nausea,	
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vomiting,	and	ALT	elevation.		Overall	however,	this	is	reassuring	for	the	safety	of	levofloxacin	at	these	doses	and	resulting	exposures.		Although	not	reported	in	this	cohort,	a	child	with	MDR-TB	in	a	separate	concurrent	study	was	incidentally	noted	to	have	papilloedema	on	an	ophthalmologic	exam	and	a	high	opening	pressure	on	lumbar	puncture	(>50	cm	H2O)	and	was	subsequently	diagnosed	with	levofloxacin-associated	intracranial	hypertension	(140).		This	has	been	previously	but	very	rarely	described	with	levofloxacin	and	other	fluoroquinolones	(141-143)	and	highlights	the	importance	of	ongoing	vigilance	when	evaluating	the	safety	of	antituberculosis	drugs	in	children.		A	concern	for	intracranial	hypertension	should	not	limit	fluoroquinolone	use	in	children	where	it	is	needed,	however	future	studies	may	consider	more	comprehensive	ophthalmologic	assessments	to	ascertain	whether	intracranial	hypertension	is	more	frequent	than	previously	understood.			The	report	of	QT-interval	prolongation	in	this	study	was	one	of	the	first	detailed	assessments	of	this	fluoroquinolone	class-wide	adverse	effect	in	children	with	MDR-TB.		A	previous	study,	which	I	contributed	to,	showed	that	among	children	(n=23)	treated	for	MDR-TB	disease	or	exposure	with	ofloxacin	(20	mg/kg)	or	levofloxacin	(15	mg/kg)	the	mean	QTcFs	were	361	ms	(SD	37)	and	369	ms	(SD	22)	respectively,	and	no	child	had	a	QTcF	>450	ms	(85).		This	study	was	limited	by	its	size,	lower	levofloxacin	dose	than	currently	in	use	and	limited	ability	to	evaluate	associations	between	levofloxacin	concentration	and	QT-interval	because	of	the	timing	of	ECGs	(85).		The	study	in	Chapter	
4	again	reported	minimal	QT-interval	prolongation,	with	mean	QTcFs	of	359	(SD	21.0)	just	prior	to	the	levofloxacin	dose	and	364	(SD	26.6)	at	2	hours	post-levofloxacin	dose,	with	no	QTcF	>450	ms.		This	provides	important	evidence	to	support	the	use	of	levofloxacin	in	combination	with	other	QT-interval	prolonging	drugs,	such	as	bedaquiline,	delamanid	and	clofazimine.		Additionally,	this	data	provides	a	benchmark	for	QT-interval	among	children	treated	with	levofloxacin-containing	regimens,	with	which	to	contextualize	findings	on	QT	prolongation	in	the	paediatric	trials	of	bedaquiline	and	delamanid,	which	do	not	have	control	groups.		The	lack	of	association	seen	between	levofloxacin	concentration	and	QT-interval	is	slightly	different	than	what	is	reported	in	adults,	where	there	is	a	relationship	between	levofloxacin	concentration	and	QT	interval.		However,	this	paediatric	data	is	consistent	with	what	has	been	published	in	adults	in	which	there	was	little	clinically	important	QT	prolongation	(i.e.	significantly	prolonged	QT	interval	that	would	be	a	risk	for	arrhythmia)	even	with	
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levofloxacin	doses	as	high	as	1500	mg	(91).		The	effect	on	QT-interval	should	still	be	carefully	assessed	if	higher	levofloxacin	doses	or	exposures	are	evaluated	in	future.		Additionally,	the	study	was	limited	by	the	lack	of	children	>8	years	of	age,	who	may	have	a	different	adverse	event	profile	and	different	effects	of	levofloxacin	on	the	QT-interval	compared	to	younger	children.		Older	children	should	be	included	in	future	levofloxacin	studies.	In	Chapter	5,	I	reported	on	the	pharmacokinetics	of	a	novel	levofloxacin	100	mg	dispersible	tablet	in	children	with	MDR-TB	exposure.		When	pooled	together	in	a	model	with	the	data	from	the	study	in	Chapter	3,	models	parameters	were	unchanged,	except	for	bioavailability,	with	the	standard	adult	250	mg	tablet	studied	in	Chapter	3	having	41%	lower	bioavailability	compared	to	the	dispersible	tablet.		When	the	typical	CL/F	from	these	studies	was	scaled	to	a	70	kg	adult,	values	for	the	dispersible	tablet	formulation	(11.6	L/h)	were	much	more	consistent	with	published	adult	and	paediatric	literature	compared	to	the	standard	adult	250	mg	tablet	studied	in	Chapter	3	(18.8	L/h).		This	highlights	the	importance	of	evaluating	the	effects	of	formulation	and	formulation	manipulation	on	pharmacokinetics	in	children.		Differences	in	bioavailability	for	different	formulations	have	been	well	described	for	other	antituberculosis	drugs,	notably	rifampicin	(61).		Different	excipients	can	affect	bioavailability,	and	these	effects	can	differ	between	adults	and	children	(60).		It	is	not	clear	whether	the	lower	bioavailability	in	the	standard	adult	250	mg	tablet	studied	in	Chapter	3	is	inherent	to	this	specific	formulation	(formulation	quality)	or	may	be	seen	with	other	formulations.	Although	we	did	not	find	an	effect	on	overall	bioavailability	of	crushing	the	adult	tablet	in	Chapter	3,	that	analysis	had	some	limitations	(confounding	by	age,	few	children	swallowing	whole	tablets).		As	there	currently	are	few	child-friendly	formulations	of	second-line	antituberculosis	drugs,	off-label	use	of	the	adult	formulations	in	children	requires	crushing	or	splitting	tablets.		This	practice	is	routine	and	the	assumption	is	that	this	has	minimal	effects	on	bioavailability,	however	this	is	not	always	true,	and	the	effects	of	this	manipulation	should	be	studied	if	the	expectation	is	that	children	will	be	using	adult	formulations.		It	is	of	clear	practical	importance	to	understand	these	formulation	effects	for	levofloxacin	given	the	magnitude	of	the	difference	in	exposures	for	this	key	medication	for	MDR-TB	treatment	and	preventive	therapy,	and	follow-up	studies	are	planned	(see	Section	10.3).			
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There	are	a	number	of	other	overarching	issues	raised	by	the	studies	in	Chapters	2-5	together.		Selection	of	targets	for	establishing	paediatric	doses	is	challenging.		The	current	approach	of	approximating	the	AUCs	observed	in	adults	receiving	the	efficacious,	safe,	recommended	doses	of	the	drug	of	interest	may	still	be	the	best	approach,	but	has	a	number	of	limitations.		One	challenge	is	that	the	optimal	adult	dose	has	not	been	established	for	several	key	drugs.		At	the	time	ofloxacin	was	the	recommended	fluoroquinolone	for	MDR-TB,	the	sufficiency	of	the	recommended	800	mg	dose	in	adults	was	already	being	questioned.		Based	on	data	from	South	African	adults	with	MDR-TB,	the	probability	of	attaining	the	pharmacodynamic	target	for	ofloxacin	(AUC/MIC	of	at	least	100)	was	only	0.45,	which	is	clearly	not	optimal	(144).		Although	levofloxacin	is	more	likely	to	attain	pharmacodynamics	targets	with	the	currently	used	750-1000	mg	dose,	the	optimal	doses	has	similarly	not	been	well	established.		The	Opti-Q	trial	(NCT01918397)	is	a	phase	2	trial	in	adults	with	MDR-TB	evaluating	four	doses	of	levofloxacin,	up	to	20	mg/kg,	in	combination	with	an	optimized	background	regimen	to	determine	the	AUC/MIC	that	achieves	the	shortest	time	to	sputum	culture	conversion,	the	highest	AUC	that	is	safe	and	well	tolerated,	and	the	dose	that	achieves	the	targeted	AUC.		Preliminary	pharmacokinetic	results	from	this	study	demonstrated	that	higher	doses	of	levofloxacin	resulted	in	higher	exposures,	up	to	a	median	AUC0-24	(IQR)	of	207	mg/L*h	(143	to	534)	with	a	20	mg/kg	levofloxacin	dose	(145).		The	safety	and	efficacy	of	these	doses	have	not	yet	been	reported	from	this	trial,	but	the	pharmacokinetic	data	may	provide	target	exposures	to	be	evaluated	in	children	should	higher	doses	be	safe	and	efficacious	in	adults	(145).		It	is	thus	possible	that	the	optimal	levofloxacin	dose	in	adults	with	MDR-TB	may	be	changing.		Doses	of	levofloxacin	and	other	antituberculosis	drugs	in	children	need	to	adapt	as	targets	evolve	over	time	based	on	new	data.		Population	pharmacokinetic	models	can	be	used	to	simulate	doses	that	will	result	in	similar	exposures	to	new	adult	targets,	however	actual	drug	exposures	and	careful	safety	evaluations	would	need	to	be	performed	in	children.		Other	novel	approaches	to	establish	dosing	targets	for	childhood	TB	are	being	investigated,	including	with	hollow	fiber	models	(146).	However,	these	remain	exploratory	and	would	need	validation	before	being	applied	to	clinical	dose	selection.		The	mutant	prevention	concentration	(MPC),	defined	as	the	concentration	that	is	able	to	suppress	the	growth	of	the	least	susceptible	single-step	mutant,	has	also	been	proposed	as	a	way	to	select	target	exposures	for	TB	drugs	(147).		Achieving	this	concentration	
 196
Stellenbosch University  https://scholar.sun.ac.za
		
would	ensure	that	growth	of	even	resistant	mutants	would	be	suppressed,	so	acquisition	of	resistance	during	treatment	would	be	unlikely.		One	current	limitation	to	using	the	MPC	as	targets	for	dose	selection	is	that	the	MPC	has	not	been	well	characterized	for	most	antituberculosis	drugs,	and	for	those	drugs	for	which	it	has	been	studied,	there	is	up	to	10-fold	variability	across	studies	(147).		It	is	additionally	not	clear	whether	exceeding	the	MPC	or	maintaining	concentrations	above	the	MPC,	as	suggested	by	animal	data,	is	required	for	preventing	mutation	amplification,	which	would	result	in	very	different	dosing	requirements	(148).		The	value	of	achieving	the	MPC	for	a	single	drug	in	strong	multidrug	regimens	is	also	not	clear,	as	companion	drugs	protect	other	drugs	in	the	regimen	against	resistance	acquisition.		Lastly,	for	children	who	usually	have	paucibacillary	TB	and	thus	a	low	risk	of	acquisition	of	resistance,	the	importance	of	achieving	concentrations	above	the	MPC	is	not	clear.		Nonetheless,	the	MPC	may	still	contribute	to	choices	of	target	concentrations	for	paediatric	dose	selection	as	additional	information	about	its	value	becomes	available.			Although	not	discussed	at	length	in	the	studies	in	this	dissertation,	this	body	of	research	on	the	fluoroquinolones	has	highlighted	the	importance	of	acceptability	and	palatability	in	paediatric	therapeutic	research.		The	fluoroquinolones	are	bitter	compounds,	and	the	very	poor	palatability	of	moxifloxacin	is	an	important	reason	why	levofloxacin	has	been	the	fluoroquinolone	of	choice	for	young	children.		Acceptability	and	palatability	can	impact	on	children’s	and	their	caregivers’	experience	of	treatment	(149),	and	can	significantly	affect	adherence	(150),	an	important	factor	for	the	success	of	TB	treatment.		As	such,	considerations	of	the	acceptability	and	palatability	are	increasingly	a	component	of	ongoing	and	future	studies	informed	by	this	doctoral	research	(see	10.3).			The	research	in	this	thesis	has	focused	on	ofloxacin	and	then	levofloxacin,	which	was	and	remains	the	fluoroquinolone	of	choice	for	children	with	TB,	primarily	due	to	its	ease	and	feasibility	of	use	(i.e.	tablet	strength	and	palatability)	relative	to	moxifloxacin.		As	previously	noted,	moxifloxacin	is	the	most	potent	fluoroquinolone	against	M.	
tuberculosis	(66),	and	is	used	as	the	first	choice	in	adults	and	older	children	with	MDR-TB.			Moxifloxacin	may	have	advantages	over	levofloxacin	related	to	increased	uptake	into	macrophages	and	higher	bactericidal	activity	that	may	confer	it	improved	overall	efficacy	for	TB	treatment	(151).		Levofloxacin	may	have	safety	advantages	over	moxifloxacin	related	to	reduced	QT	prolongation	(68,	89),	which	may	allow	for	
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levofloxacin	to	be	both	used	at	higher	doses	relative	to	moxifloxacin	and	used	more	safely	in	combination	with	other	key	antituberculosis	drugs	that	also	prolong	the	QT	interval,	such	as	bedaquiline,	delamanid	and	clofazimine.			There	have	been	few	head-to-head	comparisons	of	the	two	medications	to	date	to	better	understand	their	relative	importance	in	MDR-TB	treatment.		As	currently	it	is	unclear	whether	levofloxacin	or	moxifloxacin	may	ultimately	be	the	fluoroquinolone	of	choice	for	TB	treatment,	or	whether	both	may	have	a	role,	it	is	important	to	ensure	the	dosing	and	safety	are	well	characterized	for	both	medications.		I	have	previously	contributed	to	a	study	of	moxifloxacin	in	children	with	MDR-TB	which	characterized	its	pharmacokinetics	and	safety	in	23	children	8	years	of	age	and	older,	and	I	am	involved	with	ongoing	research	on	moxifloxacin	in	children	(see	Section	10.3).	An	additional	highly	instructive	aspect	of	this	research	was	the	value	of	pharmacometrics	as	a	tool	for	the	design	and	analysis	of	paediatric	pharmacokinetic	studies.		Pharmacometrics	is	the	application	of	mathematical	models	to	physiology,	pharmacology	and	disease	to	understand	the	interactions	of	drugs	and	patients	(152).			The	non-linear	mixed	effects	modeling	techniques	employed	can	more	easily	account	for	the	known	effects	of	size	on	drug	pharmacokinetics	using	allometric	scaling,	and	can	better	characterize	the	effects	of	age	(153).		In	addition	to	other	analytical	benefits,	clinical	trial	simulations	using	these	models	can	be	used	for	selecting	optimal	doses	in	children	of	different	age	and	weights	(152,	153),	as	was	done	in	Chapters	3	and	5.		Limitations	to	pharmacometrics	are	that	it	is	highly	specialized	and	less	accessible	and	understandable	to	the	general	clinician	than	traditional	non-compartmental	analysis,	and	that	it	requires	specialized	expertise	that	is	in	limited	supply.		However,	these	challenges	are	outweighed	by	the	benefits,	and	the	technique	is	being	increasingly	used	in	both	design	(see	Section	10.1.4)	and	analysis	in	paediatric	studies	of	antituberculosis	drugs,	as	evidenced	in	this	dissertation.		
10.1.2		Linezolid	(Chapters	6,	7)	In	Chapter	6,	I	performed	a	scoping	review	of	the	literature	on	linezolid	for	use	in	MDR-TB	treatment.		The	review	highlighted	that	the	data,	although	of	relatively	low	quality,	suggested	that	linezolid	was	a	highly	effective	antituberculosis	drug,	but	associated	with	frequent	serious	dose	and	duration	dependent	adverse	effects.		It	also	highlighted	the	
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paucity	of	data	on	linezolid	in	children	with	TB.		The	review	guided	our	approach	to	using	linezolid	in	children	with	MDR-TB	at	the	time,	and	also	identified	priority	research	questions	that	informed	the	work	in	Chapter	7.	In	Chapter	7,	I	describe	the	results	of	an	analysis	combining	linezolid	pharmacokinetic	and	safety	data	from	two	similar	observational	studies	(MDRPK1	and	MDRPK2)	of	children	routinely	treated	for	MDR-TB.		To	my	knowledge,	this	is	the	first	linezolid	pharmacokinetic	data	in	children	with	TB.		At	the	time	these	studies	were	ongoing,	linezolid	was	important	as	one	of	the	few	highly	effective	antituberculosis	medications	for	children	with	highly	resistant	forms	of	MDR-TB,	such	as	XDR-TB.		Currently,	linezolid	may	have	an	even	more	important	role	in	the	rapidly	evolving	MDR-TB	treatment	landscape.		The	Nix-TB	trial	(NCT02333799)	has	demonstrated	the	excellent	efficacy	of	linezolid	(1200	mg	once	daily)	in	adults	with	very	difficult	to	treat	MDR-TB	in	a	6-month	three-drug	regimen	(100).		Although	the	risk	of	frequent	serious	linezolid-related	adverse	events	in	this	trial	is	not	acceptable	for	children	with	MDR-TB,	who	generally	have	good	outcomes	already,	these	were	generally	manageable	in	adults	in	this	trial	(100).		A	follow-up	study,	ZeNix	(NCT03086486),	is	evaluating	alternative	linezolid	dosing	approaches,	including	lower	doses	and	shorter	durations,	in	combination	with	bedaquiline	and	pretomanid	treatment	in	adults	with	MDR-TB,	and	will	likely	inform	linezolid	dosing	for	MDR-TB	in	future.		Other	adult	trials	are	also	evaluating	other	regimens	that	include	linezolid	in	multiple	other	combinations	(152).		More	information	on	the	optimal	use	of	linezolid	for	MDR-TB	is	expected	in	the	future.		The	reduced	doses	of	linezolid	in	our	proposed	weight	banded	dosing	compared	to	the	most	commonly	used	dosing	currently,	would	almost	certainly	reduce	the	risk	of	linezolid-related	adverse	effects	that	were	described	in	our	paediatric	study,	although	this	would	need	to	be	confirmed.		There	is	however	a	concern	that	the	lower	linezolid	doses	would	reduce	its	efficacy	and	increase	the	risk	of	resistance	acquisition,	which	has	been	seen	with	lower	doses	in	adults	(300	mg	once	daily)	(97).		However	there	are	a	number	of	reasons	to	think	this	will	not	be	the	case.		First,	the	proposed	weight	banded	doses	should	achieve	exposures	that	approximate	those	seen	in	adults	receiving	a	600	mg	once	daily	dose.		This	dose	is	the	most	commonly	used	dose	in	routine	care	in	adults,	and	has	been	shown	to	be	highly	effective	and	to	have	a	minimal	risk	of	resistance	acquisition	(97,	154).		There	is	thus	no	reason	to	think	that	children,	who	tend	to	have	paucibacillary	disease	and	which	should	respond	to	treatment	as	well	as	or	better	than	
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in	adults,	would	not	respond	to	these	doses.		Secondly,	linezolid	is	increasingly	being	combined	with	other	effective	antituberculosis	drugs,	such	as	clofazimine,	bedaquiline,	and	delamanid,	that	were	not	available	until	recently,	but	that	now	provide	additional	efficacy	to	the	regimen	and	potentially	protection	of	other	companion	drugs	in	the	regimen	(including	the	linezolid)	from	acquisition	of	resistance.			There	is	currently	a	strong	interest	in	moving	away	from	the	use	of	the	injectable	drugs	to	all-oral	regimens	for	MDR-TB	treatment	for	adults	and	children.		South	Africa	has	recently	announced	a	change	to	national	MDR-TB	treatment	guidelines	that	will	now	recommend	substitution	of	bedaquiline	for	the	injectable	drug	in	most	regimens	for	patients	aged	12	years	and	older	(see	Section	10.3)	(155).		Due	to	the	lack	of	paediatric	data	on	the	dosing	and	safety	of	bedaquiline	and	delamanid,	younger	children	would	still	need	to	use	other	medications	as	substitutes	for	the	injectable	in	order	to	benefit	from	all-oral	regimens.		Linezolid	is	an	option	for	this	strategy.	However,	safety	concerns	in	addition	to	cost	considerations,	have	led	to	caution	in	using	linezolid	routinely	as	a	substitute	for	the	injectable.		However,	the	lower	doses	proposed	in	our	study	would	likely	result	in	fewer	adverse	events	and	preserve	substantial	efficacy,	making	linezolid	a	more	attractive	option	for	use	as	a	substitute	for	the	injectable	in	MDR-TB	treatment	regimens.		Even	with	the	proposed	lower	doses,	the	ability	to	carefully	monitor	safety,	especially	haematologic	indices,	should	be	a	requirement	for	long-term	linezolid	use.		The	current	reality	is	that	access	to	linezolid	remains	limited	in	most	settings,	due	its	high	cost.		Although	a	suspension	exists,	availability	in	routine	settings	is	lower	than	for	the	tablet	formulation.		The	adult	600	mg	tablet	formulation	is	unscored,	and	difficult	to	manipulate	for	use	in	children.		A	reasonably	priced	generic	linezolid	dispersible	tablet	formulation	is	urgently	needed	to	improve	access	for	children	to	this	increasingly	important	medication	for	MDR-TB	treatment.	
10.1.3	Second-line	injectables	(Chapter	8)	In	Chapter	8,	I	described	a	small	randomized	blinded	two-period	crossover	study	that	demonstrated	that	adding	lidocaine	to	amikacin	injections	was	safe	and	reduced	early	post-injection	pain	without	significantly	affecting	amikacin	pharmacokinetics	or	causing	additional	adverse	effects.		A	recently	published	study	evaluating	a	comparable	strategy	in	adults	with	MDR-TB	treated	with	kanamycin	reported	similar	findings	(156).		The	
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priority	is	to	develop	MDR-TB	treatment	regimens	that	do	not	require	the	second-line	injectable	drugs,	and	the	other	studies	in	this	doctoral	research	aim	to	contribute	to	this	goal.		However,	in	the	meantime,	the	injectables	remain	components	of	most	current	MDR-TB	treatment	regimens,	and	the	study	in	Chapter	8	identifies	a	feasible,	inexpensive	and	safe	strategy	for	improving	the	tolerability	of	the	injectables.		The	results	of	the	study	support	the	practice	of	routinely	adding	lidocaine	to	intramuscular	injections	of	the	second-line	injectable	drugs	when	they	are	required	to	be	used	(Section	10.2).		In	addition	to	the	specific	findings,	the	study	was	an	excellent	learning	opportunity	for	me	to	be	involved	with	the	design,	implementation,	analysis	and	write-up	of	a	small	randomized	crossover	study	such	as	this.		I	was	able	to	think	carefully	about	design	elements	to	reduce	bias	in	trials,	such	as	the	details	of	the	randomization,	allocation	concealment,	blinding,	and	others,	and	how	to	report	the	results	of	a	trial	consistent	with	international	consensus	for	trial	reporting	(CONSORT)	(157).		Addtionally,	the	trial	provided	an	opportunity	to	better	understand	the	concept	of	bioequivalence.		Although	the	study	was	not	powered	to	demonstrate	bioequivalence	of	amikacin	with	and	without	lidocaine,	this	was	evaluated	in	the	study.		The	analysis	followed	the	accepted	approach	to	establish	average	bioequivalence,	in	which	the	measure	of	interest	(AUC,	Cmax)	is	log	transformed,	means	are	obtained,	and	the	means	antilogged,	to	then	generate	the	geometric	mean	ratios	with	90%	confidence	intervals.		Bioequivalence	is	demonstrated	when	these	90%	confidence	intervals	fall	within	80-125%.	This	was	especially	valuable	experience	for	subsequent	trials	I	have	been	involved	with	(e.g.	Chapter	9	and	others	outlined	in	Section	10.3).		
10.1.4		Bedaquiline	(Chapter	9)	In	Chapter	9,	I	described	a	randomized	two-period	crossover	study	in	healthy	adult	volunteers	in	which	it	was	demonstrated	that	100	mg	(adult	formulation)	bedaquiline	tablets	administered	suspended	in	water	was	bioequivalent	to	100	mg	(adult	formulation)	tablets	swallowed	whole.		The	suspended	tablets	were	also	found	to	be	acceptable	and	palatable	to	the	majority	of	participants,	an	important	finding	considering	that	crushing	or	suspending	some	tablets,	such	as	the	fluoroquinolones,	reduces	their	acceptability	substantially.			
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State	of	the	art	pharmacometrics	was	critical	to	the	design	and	analysis	of	this	study,	as	bedaquiline	and	its	primary	metabolite,	M2,	have	very	long	half-lives	(bedaquiline	164	days,	M2	159	days)	(158).		This	traditional	approach	to	assessing	bioavailability	uses	a	crossover	design	and	non-compartmental	analysis	to	compare	pharmacokinetic	measures	(AUC,	Cmax)	in	individuals	receiving	both	treatments	separated	by	a	washout	period	(159).		However,	the	long	half-life	of	bedaquiline	complicates	this	approach,	as	even	with	a	long	washout	period	there	is	likely	to	be	some	carryover	(138,	159,	160).		An	option	is	to	utilize	a	parallel	group	design,	but	this	requires	a	larger	sample	size	and	is	less	efficient.		A	modeling	approach	is	able	to	handle	the	carryover	effect	and	characterizes	the	primary	bioavailability	parameter,	allowing	the	more	traditional,	efficient	crossover	approach	(159).		This	is	a	relatively	new	statistical	approach	to	evaluating	bioequivalence,	and	there	is	less	familiarity	and	guidance	from	regulatory	authorities	in	this	regard.		However,	for	long	half-life	drugs	it	is	a	critical	tool	to	evaluating	bioequivalence.		Modeling	and	simulations	in	this	study	also	informed	the	sample	size	calculations	and	the	sampling	schema,	as	described	in	Chapter	9,	to	ensure	the	most	efficient	study	design	while	preserving	the	study’s	precision	for	key	parameters.		As	a	clinical	trials	investigator	in	therapeutics,	it	is	increasingly	important	to	understand	the	benefits	and	limitations	of	pharmacometrics	in	order	to	work	with	pharmacometricians	to	optimally	design	and	analyze	trials	relevant	to	children.	The	study	was	originally	envisioned	to	support	the	P1108	trial,	which	evaluates	the	pharmacokinetics	and	safety	of	bedaquiline	in	HIV-infected	and	–uninfected	children,	and	which	may	not	have	access	to	the	paediatric	formulation.		However,	it	was	also	informed	by	an	improved	understanding	of	the	barriers	and	challenges	to	making	a	paediatric	formulation	accessible	for	treatment	of	children	in	routine	care	settings,	given	the	expectation	that	paediatric	bedaquiline	and	delamanid	formulations	are	not	likely	to	be	widely	available	for	some	time.		Research	gaps,	such	as	a	lack	of	data	on	the	pharmacokinetics,	optimal	dose	and	safety	of	medications,	are	critical	and	are	being	addressed	by	phase	1/2	trials.		However,	there	are	multiple	other	barriers	to	access	much-needed	medications	in	children,	including	both	downstream	(pre-approval)	and	upstream	(post-approval)	barriers	(161,	162).		In	addition	to	research	gaps	that	are	described	in	this	dissertation,	other	downstream	barriers	include	policy	gaps	such	as	a	lack	of	consensus	prioritization	of	TB	formulations	for	children	and	lack	of	evidence-based	antituberculosis	medication	dosing	guidance,	development	(formulation)	gaps	
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such	as	poor	acceptability	of	existing	key	second-line	antituberculosis	drugs	and	persistent	critical	gaps	in	available	child-friendly	formulations,	and	challenges	with	
regulatory	approvals	by	stringent	regulatory	authorities	(64,	161,	162)	and	production	of	formulations.		Upstream	barriers	include	challenges	with	national	regulatory	
approvals,	such	as	South	Africa,	and	issues	with	procurement,	introduction	and	
pharmacovigilance	(161,	162).		The	very	small,	fragmented	market	for	second-line	antituberculosis	drugs,	exacerbated	by	the	small	proportion	(<5%)	of	children	with	MDR-TB	globally	each	year	who	are	diagnosed	and	treated	(163),	further	complicates	these	problems.		Pragmatic	solutions,	such	as	this	study,	which	will	allow	for	the	rational	use	of	the	widely	available	adult	formulation	to	accelerate	paediatric	access,	are	an	important	part	of	the	response	and	can	temporarily	address	issues	around	formulation	development.		However,	these	barriers	must	be	addressed	by	a	broad	array	of	partners	and	advocates,	often	at	the	level	of	national	and	international	policy.		This	work	has	stimulated	an	interest	in	broader	paediatric	drug	development	issues	and	has	resulted	in	collaborations	with	other	groups	and	partners	outside	of	the	traditional	paediatric	TB	research	community	(see	Section	10.5).			
	
10.2		Impact	on	policy	and	practice	As	the	studies	in	this	doctoral	thesis	were	designed	to	answer	therapeutic	questions	that	are	currently	directly	relevant	to	the	clinical	care	of	children,	they	have	already	had	substantial	impact	on	current	policy	and	practice	of	caring	for	children	with	MDR-TB	in	the	study	setting	and	beyond.		Although	fluoroquinolones	are	recommended	for	use	in	children	with	MDR-TB,	there	is	hesitance	to	use	them	among	many	clinicians	due	to	persistent	concerns	about	safety.		The	data	on	ofloxacin	and	levofloxacin	safety	in	Chapters	2	and	4	should	provide	reassurance	to	clinicians	and	programmes	providing	paediatric	MDR-TB	care	and	should	improve	the	uptake	of	fluoroquinolone-containing	treatment	or	preventive	therapy.	Formal	WHO	guidance,	which	is	currently	under	review	again,	still	recommends	levofloxacin	to	be	given	at	15-20	mg/kg	daily	divided	into	two	doses	in	children	<5	years	and	10-15	mg/kg	once	daily	for	children	>5	years	(124).		This	is	likely	to	underexpose	many	children.	The	levofloxacin	pharmacokinetic	data	presented	in	Chapter	3	has	already	influenced	local	practice	in	Cape	Town,	where	levofloxacin	is	now	being	dosed	at	15-25	mg/kg	once	daily	for	MDR-TB	treatment	in	
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children.		Data	from	this	research	is	hoped	to	influence	ongoing	and	future	WHO	and	other	international	dosing	recommendations.		Given	concerns	about	the	levofloxacin	formulation	studied	and	the	much	higher	doses	of	levofloxacin	estimated	by	this	study	needed	to	meet	target	exposures,	further	evaluation,	especially	of	safety	at	higher	doses,	should	be	undertaken	before	these	doses	are	recommended,	especially	in	healthy	children	who	are	at	risk	of	developing	future	MDR-TB.		However	this	data,	along	with	that	from	Chapter	5,	and	other	previously	published	data	certainly	call	into	question	currently	recommended	levofloxacin	doses.		As	previously	described,	the	levofloxacin	dispersible	tablets	studied	in	Chapter	5,	and	which	development	was	supported	by	the	TB-CHAMP	trial,	have	now	been	WHO	prequalified,	are	available	through	the	Global	Drug	Facility	for	procurement	and	will	begin	to	be	used	in	eligible	TB	programmes.		The	weight	banded	dosing	in	Chapter	5	will	directly	inform	dosing	of	this	formulation	for	routine	programmatic	use.			Given	that	there	was	little	formal	guidance	on	linezolid	use	in	children	with	MDR-TB,	the	review	in	Chapter	6	provided	a	suggested	practical	approach,	that	considered	the	available	evidence	despite	its	relatively	low	quality,	and	was	directed	at	clinicians	and	TB	programmes.		The	dosing	guidance,	despite	its	limitations,	has	informed	local	practice	and	what	has	been	advised	by	other	partners	such	as	the	Sentinel	Project	in	its	weight	banded	dosing	chart	(http://sentinel-project.org/2014/06/21/dosing-chart-second-edition-2/),	to	which	I	contributed.		However,	higher	quality	data	on	the	optimal	linezolid	dose	in	children	for	MDR-TB	and	its	long-term	safety	was	clearly	needed.			This	has	been	addressed	in	part	in	Chapter	7,	where	I	showed	that	at	current	linezolid	doses	used	most	commonly	in	routine	care	for	MDR-TB	treatment	in	children,	drug	exposures	were	good,	but	that	there	were	frequent,	serious	adverse	events,	primarily	anaemia.		Weight	banded	doses	achieving	target	exposures	in	adults	after	a	600	mg	once	daily	dose	were	proposed,	and	were	lower	than	the	most	commonly	used	doses	currently.		This	data	has	the	potential	to	inform	international	paediatric	dosing	guidelines	for	linezolid	for	MDR-TB	treatment,	as	there	is	currently	minimal	formal	dosing	guidance.		The	choice	to	recommended	the	proposed	weight	banded	doses	for	routine	care	of	children	with	MDR-TB	would	need	to	carefully	consider	the	implications	of	the	lower	doses	for	efficacy	and	risk	of	acquisition	of	drug	resistance.		These	weight	
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banded	doses	will	inform	the	design	of	future	paediatric	trials	(see	IMPAACT	2020,	Section	10.3.3)			Chapter	8	demonstrated	that	co-administration	of	lidocaine	with	IM	injections	of	amikacin	reduces	injection	pain,	did	not	significantly	affect	amikacin	concentrations,	and	was	safe.		These	findings	provided	evidence	for	what	was	already	the	practice	at	the	Brooklyn	Chest	Hospital	paediatric	wards,	where	the	majority	of	children	with	MDR-TB	in	the	Cape	Town	area	are	cared	for.		The	City	of	Cape	Town	TB	programme	is	reviewing	this	evidence	and	will	consider	whether	to	make	this	a	policy	for	the	DR-TB	programme,	including	for	adults.		The	results	of	the	study	have	already	been	disseminated	through	organization	such	as	the	Sentinel	Project	and	Treatment	Action	Group’s	annual	Pipeline	Report,	with	the	intent	to	influence	policy	and	practice	at	an	international	level.			The	results	of	the	data	from	Chapter	9	demonstrating	bioequivalence	of	bedaquiline	tablets	suspended	in	water	compared	to	tablets	swallowed	whole,	has	already	had	important	impacts.		The	ongoing	IMPAACT	P1108	paediatric	bedaquiline	trial	may	not	have	access	to	the	paediatric	bedaquiline	dispersible	tablet	formulation,	so	adult	tablets	suspended	in	water	will	be	used	in	the	younger	age	cohorts	(less	than	6	years	of	age),	informed	by	this	research.		The	results	from	Chapter	9	will	also	have	important	implications	for	policy	and	practice.		As	widespread	access	to	the	paediatric	bedaquiline	formulation	(which,	like	delamanid,	is	still	a	trial	formulation	and	not	licensed)	is	expected	to	lag	far	behind	data	on	the	dosing	and	safety	of	bedaquiline	in	children	of	all	ages,	the	data	from	Chapter	9	will	allow	the	rational	use	of	the	manipulated	adult	100	mg	tablet	formulation	in	young	children	(and	older	children	and	adults)	who	are	unable	to	swallow	tablets	whole.		This	will	accelerate	access	to	bedaquiline	for	young	children,	a	much	needed	treatment	option.		Emerging	data	and	recent	policy	changes	have	made	access	to	bedaquiline	an	even	greater	priority.		Recently	published	evidence	from	a	South	African	bedaquiline	access	programme	for	adults	with	MDR-TB	reported	that	bedaquiline-treated	patients	with	MDR-TB	and	XDR-TB	had	reductions	in	all-cause	mortality	by	65%	and	74%	respectively	compared	to	standard	regimens	(120).		On	the	strength	of	this	evidence,	the	South	African	National	Department	of	Health	announced	that	national	MDR-TB	treatment	guidelines	would	now	recommend	that	bedaquiline	be	given	to	all	patients	12	years	of	age	and	older	with	MDR-TB	as	a	substitute	for	the	second-line	injectable	drug	in	an	injectable-free	regimen	in	all	MDR-TB	cases	(155).		
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Children	under	12	years	of	age,	however,	cannot	currently	benefit	from	this	policy	due	to	the	lack	of	bedaquiline	dosing	and	safety	data.		This	policy	change	highlights	the	importance	of	rapid	access	to	bedaquiline	for	children,	and	the	practical	importance	of	the	results	from	Chapter	9.	In	addition	to	impact	on	current	policy	and	practice,	the	data	has	also	impacted	substantially	on	the	research	agenda	in	children	with	MDR-TB,	as	discussed	in	Section	10.3	
	
10.3	Other	related	research	and	future	directions	This	doctoral	research	has	made	important	direct	contributions	towards	the	goal	of	developing	effective,	shorter,	safer,	better	tolerated	and	child-friendly	regimens	for	MDR-TB	treatment	in	children.		It	has	also	informed	and	complemented	other	ongoing	or	planned	research	across	the	three-pronged	approach	to	achieve	this	goal,	as	described	below.	
10.3.1	Optimizing	the	use	of	existing	second-line	TB	medications	My	research	has	focused	on	levofloxacin	and	linezolid	as	key	existing	second-line	medications	requiring	additional	optimization.		The	study	MDRPK2	(see	Chapter	9)	of	which	I	am	the	Co-Principal	Investigator,	is	building	on	the	levofloxacin	data	described	here,	and	is	evaluating	the	pharmacokinetics	and	safety	of	higher	doses	of	levofloxacin	(20-25	mg/kg)	in	children	using	the	routinely	available	standard	adult	250	mg	levofloxacin	formulation.		Other	priority	second-line	drugs,	not	evaluated	in	this	thesis,	include	moxifloxacin	and	clofazimine	(see	Section	1.5,	Table	3).		Building	on	moxifloxacin	research	from	MDRPK1,	the	MDRPK2	study	is	also	evaluating	the	pharmacokinetics	and	safety	of	higher	doses	(10-15	mg/kg)	of	moxifloxacin,	including	in	young	children	<8	years	of	age,	which	is	a	major	gap	(68).		Clofazimine,	a	rhiminophenazine	antibiotic	that	disrupts	the	mycobacterial	respiratory	chain	(164)	and	may	destabilize	the	mycobacterial	membrane	(165),	has	been	used	for	decades	in	leprosy	treatment,	but	has	only	recently	been	explored	for	MDR-TB	because	of	the	severely	limited	treatment	options.		It	is	an	increasingly	important	antituberculosis	medication	as	it	is	a	component	of	the	newly	WHO-recommended	shortened	regimen	now	being	widely	used	in	adults	and	children	with	MDR-TB	(18).		However,	there	is	no	
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available	paediatric	pharmacokinetic	data,	and	the	existing	soft-gel	capsule	formulation	is	inflexible	and	problematic	for	young	children.		The	enrollment	of	children	into	MDRPK2,	who	are	now	being	routinely	treated	with	clofazimine,	represents	an	opportunity	to	generate	much	needed	paediatric	data	on	this	medication.		Stored	samples	from	MDRPK2	will	have	clofazimine	assays	done	at	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology,	and	analysis	is	planned	with	MDRPK2	Co-Principal	Investigator	Rada	Savic	(University	of	California	San	Francisco)	during	2018.		In	addition,	I	have	contributed	to	a	proposal	for	a	prospective	study	of	the	pharmacokinetics	and	safety	of	clofazimine	in	children	with	MDR-TB	that	Novartis,	the	manufacturers	of	clofazimine,	has	agreed	to	fund.			The	studies	in	this	thesis	have	highlighted	the	importance	of	formulation	for	the	pharmacokinetics	and	acceptability	of	antituberculosis	drugs	in	children	(see	Section	10.4)	and	future	planned	research	will	include	careful	consideration	of	formulation.		MDRPK2	also	includes	a	crossover	component	in	which	children	able	to	swallow	whole	tablets	will	have	an	additional	pharmacokinetic	sampling	occasion	on	which	they	will	received	crushed	tablets,	to	better	characterize	the	effect	of	formulation	manipulation	on	the	pharmacokinetics	of	levofloxacin	and	moxifloxacin.		This	added	crossover	component	of	the	study	design	will	address	some	of	the	limitations	in	analyses	on	formulation	effects	described	in	Chapters	2	and	3,	including	the	small	number	of	children	swallowing	whole	tablets	and	the	difficulty	in	separating	the	effect	of	age	from	crushing	of	tablets.		In	addition,	I	have	led	the	development	of	a	recently	submitted	proposal	that	among	other	activities	aims	to:	1)	characterize	the	effects	of	formulation	and	formulation	manipulation	on	levofloxacin	pharmacokinetics	(following	on	the	results	described	in	Chapters	3	and	5;	2)	characterize	the	pharmacokinetics,	safety	and	acceptability	of	other	novel	second-line	dispersible	tablet	formulations	developed	by	Macleods,	including	moxifloxacin;	3)	partner	with	the	TB	Alliance,	a	product	development	partnership,	to	develop	paediatric	formulations	of	key	second-line	antituberculosis	drugs	that	are	not	yet	available	(linezolid,	clofazimine).		MDRPK1	is	evaluating	the	pharmacokinetics	and	safety	of	all	the	existing	second-line	antituberculosis	drugs	in	children,	and	I	am	contributing	to	ongoing	analyses	of	ethionamide,	terizidone,	high-dose	isoniazid,	amikacin,	and	PAS.	
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Along	with	the	research	presented	in	this	thesis,	the	ongoing	and	planned	research	described	here	will	substantially	contribute	to	optimizing	our	use	of	these	key	existing	second-line	antituberculosis	drugs	in	children.	A	finding	across	these	studies	was	the	high	degree	of	variability	in	pharmacokinetics	within	the	study	population.		It	is	worth	considering	whether	individualization	of	doses,	which	may	reduce	some	of	this	variability	may	be	beneficial.		Therapeutic	drug	monitoring	(TDM)	is	one	approach	that	has	the	potential	to	reduce	the	variability	of	drug	exposures	between	patients.		It	remains	to	be	seen	whether	such	a	strategy	will	be	valuable	or	feasible	for	paediatric	MDR-TB	treatment.		Characteristics	of	individual	drugs	that	make	them	good	candidates	for	TDM	include	substantial	interindividual	variability,	limited	interoccasion	variability,	well	characterized	exposure	or	concentration	targets	for	efficacy	and/or	safety,	narrow	therapeutic	window,	and	stability	and	type	of	samples	required	for	drug	assays.		Few	drugs	used	in	the	context	of	MDR-TB	treatment	in	children	meet	these	criteria.		Linezolid	may	be	an	exception,	as	it	is	associated	with	clinically	important	adverse	events	that	are	clearly	dose	and	duration	related.		TDM	may	provide	an	opportunity	to	individualize	drug	doses	to	maintain	sufficient	concentrations	for	efficacy	but	to	limit	high	exposures	and	reduce	the	risk	of	adverse	events.		This	may	be	a	topic	for	further	exploration,	particularly	as	linezolid	becomes	more	widely	used	for	MDR-TB.		However,	constrained	TB	programmes	in	high	burden	settings	may	not	have	the	capacity	to	implement	TDM	and	individualized	drug	dosing.		It	would	be	important	to	evaluate	the	feasibility	and	cost-effectiveness	of	such	a	strategy	before	implementing	it	at	scale.		
10.3.2	Optimizing	the	use	of	novel	TB	drugs	Novel	regimens	for	MDR-TB,	and	also	potentially	drug-susceptible	TB,	will	almost	certainly	rely	on	novel	antituberculosis	medications.		The	paediatric	trials	to	characterize	the	pharmacokinetics,	optimal	dose	and	safety	of	bedaquiline	and	delamanid	were	beyond	the	scope	of	this	doctoral	research.		However,	they	have	been	ongoing	in	parallel	and	I	have	made	meaningful	contributions	to	some	of	these	studies.			IMPAACT	P1108	is	the	NIH-sponsored	phase	1/2	trial	of	the	pharmacokinetics	and	safety	of	bedaquiline	in	HIV-infected	and	-uninfected	children	with	MDR-TB	treated	
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with	an	optimized	background	regimen.		The	results	from	the	study	in	Chapter	9	on	suspended	bedaquiline	tablets	directly	informed	the	design	of	P1108,	which	will	be	evaluating	suspended	tablets	in	the	younger	cohorts.		The	trial	opened	in	Quarter	4	of	2017,	and	I	have	been	giving	input	as	a	member	of	the	core	protocol	team.		As	the	Medical	Director	of	the	Desmond	Tutu	TB	Centre’s	site	at	Brooklyn	Chest	Hospital,	a	site	for	P1108	and	the	NIH-funded	IMPAACT	network,	I	have	been	overseeing	our	day-to-day	implementation	of	the	trial.			The	Otsuka-sponsored	phase	1	(242-12-232)	(NCT01856634)	and	phase	2	(242-12-233)	(NCT01859923)	trials	of	delamanid	in	children	with	MDR-TB	are	age	de-escalation	trials	that	aim	to	characterize	delamanid	pharmacokinetics	and	safety	over	10	days	(trial	232)	and	6	months	of	dosing	(trial	233).		These	trials	opened	in	2013,	and	enrolled	at	two	sites	–	one	in	the	Philippines	and	the	second	at	the	Desmond	Tutu	TB	Centre	site	in	Cape	Town.		Since	2016,	I	have	been	the	site	Principal	Investigator,	overseeing	the	site’s	implementation	of	the	trial,	providing	support	as	needed	to	the	protocol	team,	and	giving	input	on	interpretation	of	trial	results.		Group	1	(ages	12-17	years,	n=7),	Group	2	(ages	6-11	years,	n=6)	and	Group	3	(ages	3-5	years,	n=12)	completed	enrolment	and	long-term	follow-up.		Group	4	(ages	0-2	years,	n=12)	has	completed	enrolment	and	long-term	follow-up	is	expected	to	complete	in	early	2019.		Based	on	preliminary	results	from	these	trials,	the	WHO	issued	recommendations	for	delamanid	use	in	children	ages	6-17	years	with	MDR-TB	and	limited	treatment	options	(121).		Data	from	these	trials	is	critical	for	informing	delamanid	use	in	children	and	ultimately	ensuring	it	is	accessible	to	children	in	the	field.			I	am	also	the	protocol	Co-Chair	of	the	NIH-sponsored	IMPAACT	2005	protocol,	a	phase	1/2	open-label	single-arm	multi-centre	study	to	evaluate	the	pharmacokinetics,	safety	and	tolerability	of	delamanid	with	an	optimized	background	regimen	in	HIV-infected	and	–uninfected	children	with	MDR-TB	(NCT03141060).		The	trial	will	include	up	to	48	HIV-infected	and	–uninfected	children	0	to	<18	years	of	age	with	MDR-TB.		The	primary	objectives	of	the	study	are	to	evaluate	the	1)	pharmacokinetics	and	2)	safety	of	delamanid	when	added	to	an	optimized	background	regimen	at	doses	determined	most	likely	to	achieve	exposures	achieved	in	adults	receiving	100	mg	twice	daily.		Data	from	the	232/233	trials	will	be	modeled	and	optimized	doses	estimated	and	then	evaluated	in	this	trial.		Key	secondary	objectives	include	to	characterize	the	impact	of	HIV-
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coinfection	and/or	cotreatment	on	delamanid	drug	disposition,	to	characterize	delamanid	acceptability,	and	to	characterize	treatment	outcomes,	as	children	in	the	trial	will	be	receiving	an	injectable-sparing	regimen.		As	the	protocol	Co-Chair	I	have	led	the	protocol	development,	will	oversee	its	overall	implementation	and	lead	the	interpretation	and	dissemination	of	the	trial	results,	as	well	as	leading	the	trial	implementation	on-site.		This	trial	will	further	contribute	to	the	optimal	use	of	delamanid,	including	in	HIV-infected	children,	and	will	provide	preliminary	evidence	on	the	efficacy	of	an	injectable-sparing	delamanid-containing	regimen.	As	described	above,	the	delamanid	paediatric	trials	are	nearing	completion	and	there	will	soon	be	dosing	and	safety	information	across	ages.		Although	Otsuka	has	developed	two	paediatric	delamanid	formulations	(5	mg	and	25	mg	dispersible	tablets),	these	were	trial	formulations	and	it	is	likely	that	these	formulations	would	not	be	commercially	available	for	some	time	(possibly	years).		The	adult	formulation	is	becoming	much	more	widely	available,	and	could	be	used	in	young	children.		However	the	effect	of	formulation	manipulation	(crushing	or	suspending	the	adult	tablets	in	water)	on	its	bioavailability	is	not	known.		This	key	question	could	be	addressed	by	a	study	similar	in	design	to	that	in	Chapter	9	with	bedaquiline.		I	have	led	a	funding	proposal	for	such	a	study.		As	for	the	study	of	the	relative	bioavailability	of	suspended	bedaquiline	tablets,	such	a	study	with	delamanid	would	inform	the	rational	use	of	the	adult	formulation	in	young	children,	accelerating	access	to	this	much	needed	treatment.			The	novel	antituberculosis	medication	pretomanid,	a	nitroimidazole	antibiotic	like	delamanid,	is	being	evaluated	in	multiple	novel	regimens	in	adults,	however	safety	concerns	have	delayed	its	evaluation	in	children,	and	paediatric	trials	are	only	at	the	earliest	stages.	I	have	been	contributing	to	initial	work	to	develop	a	paediatric	investigational	plan	(PIP)	for	the	EMA	for	pretomanid,	which	TB	Alliance	is	leading.		
10.3.3		Combining	existing	and	novel	TB	drugs	into	effective	shorter,	safer	and	child-
friendly	treatment	regimens	in	children	As	referred	to	in	Section	1.4,	traditionally,	the	efficacy	of	TB	treatment	regimens	has	been	extrapolated	to	children	from	adult	studies.		Therefore	pharmacokinetics	and	safety	of	individual	TB	drugs	have	been	considered	the	priority	research	area	in	children	(166).		However,	children	tend	to	have	paucibacillary	TB	(approximately	30-40%	culture-confirmed	and	<10%	sputum	smear-positive	for	acid-fast	bacilli	in	
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pediatric	pulmonary	TB	under	well	investigated	conditions)	and	could	reasonably	be	expected	to	respond	to	TB	treatment	better	than	adults.		This	is	consistent	with	the	much	better	treatment	outcomes	in	children	with	MDR-TB	(75-90%	successfully	treated)	(17,	23)	compared	to	adults	(50%	successfully	treated)	(167).		Additionally,	children	may	suffer	more	damaging	consequences	of	adverse	effects	of	these	drugs	like	permanent	hearing	loss,	separation	from	caregivers	during	critical	periods	of	attachment	and	interruption	of	education,	all	of	which	have	drastic	implications	for	neurodevelopment	and	long-term	functioning	when	TB	occurs	in	early	childhood.		Taken	together,	children	with	MDR-TB	may	suffer	disproportionately	more	from	some	adverse	effects,	and	are	also	more	likely	than	adults	to	respond	to	shorter,	less	intensive	treatment	for	MDR-TB.			With	this	rationale,	and	considering	the	availability	of	novel	oral	drugs	like	delamanid	and	repurposed	oral	drugs	like	clofazimine	and	linezolid,	a	phase	3	efficacy	trial	of	a	shortened,	all-oral	treatment	regimen	for	children	with	at	least	rifampicin-resistant	TB	has	been	considered	a	high	priority	(168).		I	am	chairing	this	protocol	called	IMPAACT	2020,	sponsored	by	the	U.S.	NIH	through	the	IMPAACT	network,	which	has	been	in	development	since	late	2017.		As	initially	envisioned,	this	partially	randomized	multicentre	phase	3	trial	would	enroll	HIV-infected	and	–uninfected	children	<15	years	of	age	with	probable	or	confirmed	at	least	rifampicin-resistant	TB	(including	RMR-,	MDR-,	preXDR-	and	XDR-TB)	pulmonary	or	extrapulmonary	TB	(other	than	TB	meningitis	or	osteoarticular	TB).		Children	with	rifampicin	resistance	without	additional	injectable	or	fluoroquinolone	resistance	would	be	randomized	to	the	primary	intervention	arm	(Arm	1,	26	weeks	of	bedaquiline,	delamanid	and	levofloxacin	with	addition	of	linezolid	to	the	first	8	weeks)	or	to	the	control	arm	(Arm	2,	the	WHO	9-12	month	shortened	regimen).		Children	with	additional	injectable	or	fluoroquinolone	resistance	would	be	assigned	to	intervention	arms	depending	on	their	resistance	patterns	(Arms	3	or	4).		In	addition	to	a	number	of	secondary	and	exploratory	objectives,	the	primary	objectives	of	the	trial	were	to	evaluate	whether	the	primary	intervention	arm	(Arm	1)	had	non-inferior	efficacy	(Objective	1)	and	superior	safety	(Objective	2)	compared	to	the	control	arm	(Arm	2).		My	doctoral	research	presented	here,	specifically	Chapters	2-5	on	levofloxacin,	Chapters	7-8	on	linezolid,	and	potentially	Chapter	9	on	bedaquiline,	was	directly	informing	the	design	of	the	intervention	arm	and	other	aspects	of	the	trial.	
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Considering	the	recent	policy	change	in	South	Africa	to	substitute	bedaquiline	for	the	injectable	drug	in	MDR-TB	treatment	regimens,	it	is	no	longer	acceptable	to	randomize	children	to	an	injectable-containing	control	arm.		The	trial	is	now	being	reconsidered	as	a	smaller	phase	2	study,	with	the	objectives	to	characterize	the	safety,	pharmacokinetics	and	treatment	outcomes	among	children	with	probable	or	confirmed	rifamipicin-resistant	TB	treated	with	two	intervention	regimens:	Arm	1	for	fluoroquinolone-susceptible	rifampicin-resistant	TB	cases	(Arm	1,	26	weeks	of	bedaquiline,	delamanid	and	levofloxacin	with	addition	of	linezolid	to	the	first	8	weeks);	Arm	2	for	fluoroquinolone-resistant	rifampicin-resistant	TB	cases	(Arm	1,	26	weeks	of	bedaquiline,	delamanid	and	clofazimine	with	addition	of	linezolid	to	the	first	8	weeks).		This	is	still	informed	by	my	doctoral	research,	and	the	trial	may	still	eventually	inform	a	future	phase	3	trial	in	children,	depending	on	evolving	data	from	the	adult	trial	landscape.		Data	from	this	doctoral	dissertation	remains	critical	to	informing	the	IMPAACT	2020	trial	design.	
10.3.4		Cross-cutting	issues	Medication	acceptability	and	palatability	is	a	cross-cutting	issue	highlighted	by	this	doctoral	research,	and	is	an	area	of	ongoing	and	future	research.		This	is	often	accomplished	using	a	mixed	methods	approach,	utilizing	both	quantitative	and	qualitative	methods.		As	part	of	the	TB-CHAMP	lead-in	pharmacokinetics	study	(Chapter	5),	assessments	were	done	of	the	acceptability	of	the	novel	levofloxacin	formulation,	for	which	the	analysis	and	write-up	are	ongoing.		Characterizing	the	acceptability	of	the	second-line	antituberculosis	drugs	is	one	of	the	aims	of	the	MDRPK2	study	and	will	involve	quantitative	observations	and	survey	questions	paired	with	in-depth	interviews	performed	by	qualitative	researchers.	Objectives	to	assess	acceptability	are	also	included	in	Otsuka	232/233	paediatric	and	IMPAACT	2005	delamanid	trials.				
10.4		Other	relevant	considerations	The	doctoral	research	presented	here	has	contributed	to	the	strengthening	or	initiation	of	numerous	local,	national	and	international	collaborations.		I	have	worked	closely	with	the	University	of	Cape	Town	Division	of	Clinical	Pharmacology	on	multiple	studies	described	here	including	laboratory,	pharmacology	and	pharmacometrics	experts.		I	
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worked	closely	with	pharmacometricians	at	the	University	of	California	San	Francisco	(Rada	Savic)	and	Upssala	University	(Elin	Svensson),	both	of	whom	I	am	collaborating	with	now	on	multiple	other	projects.			During	the	time	of	my	doctoral	research	I	have	had	many	opportunities	to	provide	leadership,	contribute	to	capacity	building,	and	give	input	on	policy	on	MDR-TB	treatment	in	children,	at	local,	regional	and	international	levels.		I	am	involved	with	and	have	contributed	to	a	number	of	policy	statements	from	the	Sentinel	Project.		I	am	a	Paediatric	Expert	for	the	WHO-European	Respiratory	Society	TB	Consilium,	in	which	capacity	I	provide	expert	clinical	advice	on	difficult	paediatric	MDR-TB	cases	through	the	WHO-ERS	on-line	consultation	platform.		I	have	lectured	and	contributed	to	multiple	capacity	building	efforts	through	the	Desmond	Tutu	TB	Centre,	including	at	the	annual	International	Child	TB	Training	Course,	and	through	other	partners	including	Médecins	Sans	Frontières	(MSF),	the	KNCV	Tuberculosis	Foundation	(KNCV),	the	International	Union	Against	Tuberculosis	and	Lung	Diseases	(IUTLD),	and	the	WHO	Africa	Regional	Office	(AFRO).		I	have	regularly	contributed	to	local	MDR-TB	policy	for	the	City	of	Cape	Town	and	the	Western	Cape	Department	of	Health.		I	am	a	member	of	the	WHO	AFRO	Childhood	TB	Task	Force	(2016-current).		I	am	an	investigator	within	the	TB	Scientific	Committee	of	the	IMPAACT	network,	where	I	am	leading	or	involved	with	multiple	protocols	(see	Section	10.3),	and	am	helping	shape	the	TB	Scientific	Committee’s	agenda.		I	am	an	Associate	Editor	for	the	journals	Public	Health	Action	(2017-current)	and	BMC	Infectious	Diseases	(2018-current).		I	have	represented	the	childhood	TB	community	at	international	forums	on	paediatric	drug	development,	including	at	meetings	of	the	WHO’s	Paediatric	Antiretroviral	Drug	Optimization	(PADO)	group	and	the	Global	Accelerator	for	Paediatric	Formulations	(www.gap-f.org).		I	look	forward	to	continuing	to	leverage	the	skills	and	experience	I	have	developed	during	the	time	of	this	doctoral	research	to	have	a	global	impact	on	childhood	TB	and	MDR-TB	treatment.	
	
10.5		Conclusions		In	conclusion,	this	doctoral	research	has	addressed	a	number	of	important	key	knowledge	gaps	related	to	the	optimal	paediatric	MDR-TB	treatment.		This	research	has	raised	a	number	of	follow-up	questions	that	in	addition	to	other	key	knowledge	gaps,	discussed	above,	myself	and	colleagues	are	working	to	address	in	order	to	continuing	
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advancing	the	field	towards	a	goal	of	effective,	safe,	shorter	MDR-TB	treatment	for	children.					 	
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Abstract
Background
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobac-
terium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the
optimal treatment for these children.
Methods and findings
To inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB
treatment guidelines, we performed a systematic review and individual patient data (IPD)
meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify
eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, Psy-
chINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished
data, we reviewed conference abstracts, contacted experts in the field, and requested data
through other routes, including at national and international conferences and through organi-
zations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a mini-
mum of three children (aged <15 years) who were treated for bacteriologically confirmed or
clinically diagnosed MDR-TB, and if treatment outcomes were reported. The search yielded
2,772 reports; after review, 33 studies were eligible for inclusion, with IPD provided for 28 of
these. All data were from published or unpublished observational cohorts. We analyzed
demographic, clinical, and treatment factors as predictors of treatment outcome. In order to
obtain adjusted estimates, we used a random-effects multivariable logistic regression (ran-
dom intercept and random slope, unless specified otherwise) adjusted for the following
covariates: age, sex, HIV infection, malnutrition, severe extrapulmonary disease, or the
presence of severe disease on chest radiograph. We analyzed data from 975 children from
18 countries; 731 (75%) had bacteriologically confirmed and 244 (25%) had clinically diag-
nosed MDR-TB. The median age was 7.1 years. Of 910 (93%) children with documented
HIV status, 359 (39%) were infected with HIV. When compared to clinically diagnosed
patients, children with confirmed MDR-TB were more likely to be older, to be infected with
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HIV, to be malnourished, and to have severe tuberculosis (TB) on chest radiograph (p <
0.001 for all characteristics). Overall, 764 of 975 (78%) had a successful treatment outcome
at the conclusion of therapy: 548/731 (75%) of confirmed and 216/244 (89%) of clinically
diagnosed children (absolute difference 14%, 95% confidence interval [CI] 8%–19%, p <
0.001). Treatment was successful in only 56% of children with bacteriologically confirmed
TB who were infected with HIV who did not receive any antiretroviral treatment (ART) during
MDR-TB therapy, compared to 82% in children infected with HIV who received ART during
MDR-TB therapy (absolute difference 26%, 95% CI 5%–48%, p = 0.006). In children with
confirmed MDR-TB, the use of second-line injectable agents and high-dose isoniazid (15–
20 mg/kg/day) were associated with treatment success (adjusted odds ratio [aOR] 2.9, 95%
CI 1.0–8.3, p = 0.041 and aOR 5.9, 95% CI 1.7–20.5, p = 0.007, respectively). These find-
ings for high-dose isoniazid may have been affected by site effect, as the majority of patients
came from Cape Town. Limitations of this study include the difficulty of estimating the treat-
ment effects of individual drugs within multidrug regimens, only observational cohort studies
were available for inclusion, and treatment decisions were based on the clinician’s percep-
tion of illness, with resulting potential for bias.
Conclusions
This study suggests that children respond favorably to MDR-TB treatment. The low success
rate in children infected with HIV who did not receive ART during their MDR-TB treatment
highlights the need for ART in these children. Our findings of individual drug effects on treat-
ment outcome should be further evaluated.
Author summary
Why was this study done?
• Treatment for multidrug-resistant tuberculosis (MDR TB) affects 32,000 children per
year, requires longer treatment with much more toxic medications than drug-suscepti-
ble tuberculosis. Unfortunately, little is know about the optimal treatment for children
with MDR TB.
• This study reviewed treatment and outcome data from children around the world in
order to better understand the management of MDR-TB in children.
• This study also sought to understand the risk factors for poor treatment outcomes in
children with MDR-TB.
• This study informed the World Health Organization guidelines on treatment of MDR-
TB in children.
What did the researchers do and find?
• We performed a systematic review and individual patient data meta-analysis on clinical
characteristics and treatment outcomes on 975 children from across 18 countries.
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• Children were analyzed in two separate groups, those with bacteriologically confirmed
MDR-TB and those who were clinically diagnosed with MDR-TB.
• We found that, in general, children do well when treated with the second-line MDR-TB
medications (78% overall had successful treatment outcomes), despite the fact that there
was a high burden of severe disease.
• Malnutrition and not being treated for HIV (if the child was HIV-positive) during TB
treatment significantly increased the risk of poor outcomes.
• Second-line injectable agents and high-dose isoniazid were associated with treatment
success. However, a high proportion of children with non-severe disease who received
no second-line injectable agents still did well; therefore, children with non-severe dis-
ease may be able to be spared from these toxic medications.
What do these findings mean?
• Consideration should be given to using high-dose isoniazid in treatment regimens, and
if children have non-severe disease, the possibility of excluding second-line injectable
agents from the treatment regimen should be considered.
• HIV treatment should be started as soon as is possible, and malnutrition should be
aggressively treated.
Introduction
Almost 500,000 people developed multidrug-resistant tuberculosis (MDR-TB) (defined as
Mycobacterium tuberculosis with resistance to at least isoniazid and rifampin) in 2015 [1].
Despite the fact that as many as 32,000 children younger than 15 years of age develop
MDR-TB globally each year, little is known about the optimal treatment for children with
MDR-TB [2]. The diagnosis and treatment of MDR-TB in children is challenging: it can be dif-
ficult to bacteriologically confirm the diagnosis because of difficulties in collecting respiratory
samples in younger children and in children who frequently have paucibacillary (smear- or
culture-negative) disease [3].
Treatment of MDR-TB is difficult as well, requiring the use of second-line medications in
regimens much longer (often lasting 18–20 months) than those for drug-susceptible disease
[4]. These regimens are frequently hard to tolerate, particularly in children, due to the length
of treatment, drug toxicity, and the lack of child-friendly formulations. However, unlike adults,
children have a wide spectrum of tuberculosis (TB) disease, from limited disease with low
bacillary burden, to more severe adult-type disease (e.g., cavitating pulmonary TB) with a
higher bacillary load [3]. Children with less severe disease may not require a treatment regi-
men as intensive as children with more severe disease or adults. Therefore, they may be able to
be spared from these long, toxic regimens [5].
A previous systematic review of 315 children from eight cohorts from five countries
reported successful treatment outcomes in 82% of children with clinically or bacteriologically
diagnosed MDR-TB [6]. Clinical or treatment factors associated with outcomes in children
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with MDR-TB have been evaluated in a few individual studies but have not been well charac-
terized in large, geographically diverse cohorts. The small size of individual published cohorts
limits the precision in assessing the impact of clinical factors on outcomes, and their lack of
geographic diversity restricts the generalizability of findings. Study-level meta-analyses limit
the useful inferences that may be drawn on the associations between outcomes and the treat-
ment, and limit the adjustment for confounding or interaction that would be possible from the
analysis of individual patient data (IPD). A more rigorous evidence base is needed to help
guide the management of MDR-TB treatment in children globally. Given the paucibacillary
nature of TB in most children and the potential for certain children to receive less intensive
and less toxic treatment regimens, an understanding of risk factors for poor outcomes across
settings is important for designing future treatment regimens.
In order to provide this stronger evidence base and to inform the revised 2016 World
Health Organization (WHO) MDR-TB treatment guidelines, we undertook a systematic
review and IPD meta-analysis to describe treatment outcomes among children with confirmed
or clinically diagnosed MDR-TB, and to characterize demographic, clinical, and treatment fac-
tors associated with treatment outcomes [4].
Methods
Eligibility criteria
A cohort was eligible for inclusion in this IPD meta-analysis if it included a minimum of three
children (aged<15 years) within a defined treatment cohort who were treated for bacteriologi-
cally confirmed (“confirmed”) or clinically diagnosed pulmonary or extrapulmonary
MDR-TB, and for whom treatment outcomes were reported, using standard 2014 WHO
MDR-TB outcome definitions (Table 1) [7,8]. All cohorts containing children included in a
previous, largely adult systematic review and IPD meta-analysis of MDR-TB were also consid-
ered eligible; those data were accepted as one data set, even if that data set contained fewer
than three children from a defined geographic area [9]. In order to be defined as having “con-
firmed” MDR-TB, there needed to be bacteriological confirmation with documented resis-
tance to both isoniazid and rifampicin on genotypic or phenotypic testing. The basis for a
clinical diagnosis of TB is described in Table 1. Eligibility criteria were applied at the individual
level, so that studies reporting on both adults and children could be considered eligible if they
otherwise met the specified criteria. Both published and unpublished data were included, with-
out date restrictions. Eligible study designs included controlled and noncontrolled retrospec-
tive and prospective studies and case series. Reports written in English, Spanish, French,
Dutch, and Russian were included. Studies that used only combinations of rifampin, isoniazid,
pyrazinamide, ethambutol, or streptomycin to treat MDR-TB were excluded, as this is consid-
ered inadequate therapy.
Identifying primary reports
In order to identify eligible reports, we searched PubMed, LILACS (Latin American and
Caribbean Health Sciences Literature), Embase, The Cochrane Library, PsychINFO, and Bio-
MedCentral databases through 1 October 2014, with a search strategy using a combination of
the search terms “tuberculosis,” “multidrug resistance,” “MDR-TB,” “multidrug-resistant,”
and “children,” both as exploded MeSH (Medical Subject Headings) headings and free-text
terms, and without language restriction. The specific search strategies for Pubmed and Embase
are presented in S1 Table. We also reviewed conference abstracts from the annual World Lung
Health Conferences of the International Union Against Tuberculosis and Lung Diseases (The
Union).
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To identify additional published and unpublished data, we contacted experts in the field of
pediatric MDR-TB. We also requested data through other routes, including at national and
international conferences and training events, and through international and in-country orga-
nizations working in pediatric MDR-TB, including the Sentinel Project on Pediatric Drug-
Resistant Tuberculosis, the WHO Childhood TB Sub-Group, Me´decins Sans Frontières
(MSF), the United States Centers for Disease Control and Prevention (CDC) and European
Centre for Disease Prevention and Control (ECDC), The Union, and the National Institutes of
Health (NIH).
Report selection and review
All abstracts were screened by EPH and a researcher with Cochrane South Africa to select full
text reports to review. All full text reports were reviewed independently by two reviewers
(EPH, AJGP, HSS, JF, ACH) to assess for eligibility, except reports in Russian, French, Dutch,
Table 1. Tuberculosis case definitions and treatment outcome definitions.
TB case definitions
Bacteriologically
confirmed TB
A case of TB in a patient from whom a biological specimen was positive by smear
microscopy1, culture, or WHO-approved rapid diagnostics (including GeneXpert
MTB/RIF).
Clinically diagnosed TB A case of TB in a patient who does not fulfill the criteria for bacteriological
confirmation but who has been diagnosed with TB disease by a clinician or other
medical practitioner who has decided to give the patient a full course of TB treatment.
This definition includes cases diagnosed on the basis of radiographic abnormalities or
suggestive histology and extrapulmonary cases without laboratory confirmation.
TB source case A case of infectious TB (usually sputum smear- or culture-positive) in a person who
transmits infection to one or more other individuals.
MDR-TB outcome definitions
Cured Treatment completed as recommended by the national policy without evidence of
failure, and three or more consecutive cultures taken at least 30 days apart are negative
after the intensive phase of treatment.
Treatment completed Treatment completed as recommended by the national policy without evidence of
failure, but no record that three or more consecutive cultures taken at least 30 days
apart are negative after the intensive phase of treatment.
Treatment failed Treatment terminated or need for permanent regimen change of at least two anti-TB
drugs because of
• lack of conversion by the end of the intensive phase,
• bacteriological reversion in the continuation phase after conversion to negative,
• evidence of additional acquired resistance to fluoroquinolones or second-line
injectable drugs, or
• ADRs.
Died A patient who dies for any reason during the course of treatment.
Lost to follow-up A patient whose treatment was interrupted for two consecutive months or more.
Not evaluated A case of TB in a patient for whom no treatment outcome is assigned. This includes
patients “transferred out” to another treatment unit and whose treatment outcome is
unknown.
Treatment success The sum of cured and treatment completed.
Adapted from: Guidance for national tuberculosis programmes on the management of tuberculosis in children:
second edition. WHO, 2014 [7].
1For this study, participants had to have MDR-TB confirmed by culture or WHO-approved rapid diagnostics; smear
microscopy was not sufficient to be classified as bacteriologically confirmed.
Abbreviations: ADR, adverse drug reaction; MDR-TB, multidrug-resistant tuberculosis; MTB/RIF, Mycobacterium
tuberculosis/rifampin; TB, tuberculosis; WHO, World Health Organization.
https://doi.org/10.1371/journal.pmed.1002591.t001
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and Spanish, which were reviewed by a single reviewer (AT, EPH, ACH, and JF, respectively).
Disagreements about study selection were resolved by a third reviewer. If eligibility was
unclear because of missing information, two attempts were made to contact authors of the pri-
mary report. After two unsuccessful attempts, reports were excluded.
The quality of individual studies was described using a modified version of the Newcastle-
Ottawa approach for cohort studies adapted for use in pediatric MDR-TB [10]. An example of
our grading approach is provided in S2 Table, followed by the grading of the individual
studies.
Data sharing and abstraction
The authors of all eligible studies and cohorts were contacted to request IPD. De-identified
IPD were included following written agreement from the original authors, or the lead clinical
physician in the case of unpublished data.
Data were requested on factors that could influence treatment decision and outcome,
including:
Participants: age, sex, nutritional status, HIV status and antiretroviral treatment (ART),
adult MDR-TB source case information, bacteriologically confirmed versus clinical diagnosis
(Table 1), disease site (pulmonary or extrapulmonary), severity of disease on chest radiograph,
drug susceptibility test (DST) results, and history of previous TB episodes.
Intervention: use of individual drugs and the duration of drug use in the treatment
regimen.
Outcomes: acid-fast bacilli (AFB) smear microscopy (smear) and culture conversion,
adverse events, and WHO-defined treatment outcomes, including cure, treatment completion,
treatment failure, loss to follow-up, not evaluated, and death (see Table 1 for definitions) [7].
Severity of TB disease on the chest radiograph was graded independently by two reviewers
(EPH, ACH) as either severe or non-severe, based on the reported chest radiographic findings
using adapted Wiseman criteria [11]; disagreements were arbitrated by a third reviewer (HSS).
Malnutrition was defined as being severely underweight for age (weight-for-age-adjusted z-
score of less than −3) or malnourished, as per attending clinician’s clinical assessment, includ-
ing the presence of nutritional edema. Severe extrapulmonary TB was defined as TB meningi-
tis, miliary TB, abdominal, osteoarticular, or “disseminated TB disease” (this diagnosis was
given in 11 children, without further details). The primary authors of all included reports were
contacted to resolve any queries.
Although we collected information on adverse effects, we were unable to complete formal
analyses given the limitations in the data.
Statistical analysis
Data from children with confirmed pre-extensively drug-resistant (pre-XDR)-TB (MDR-TB
with additional resistance to either a fluoroquinolone or a second-line injectable agent) were
combined with those from children with MDR-TB. Children with confirmed extensively drug-
resistant TB (XDR-TB, defined as MDR-TB with additional resistance to both a fluoroquino-
lone and a second-line injectable agent) were excluded from analysis and will be reported on
separately. This was done because patients with XDR-TB generally have very different treat-
ment requirements, such that their outcomes would not be representative of the MDR-TB and
pre-XDR-TB cohorts. When analyzing the association between individual drug use and treat-
ment success, treatment outcomes were dichotomized as either successful or unsuccessful and
stratified by confirmed versus clinically diagnosed MDR-TB. Successful treatment outcome
was defined as cure or treatment completion (Table 1). Unsuccessful outcome was defined as
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treatment failure or death. Children who were lost to follow-up or not evaluated were excluded
from analyses.
With respect to the analysis of the estimates of the association between individual antituber-
culosis medications (used as part of a multidrug regimen) and treatment success, in order to
obtain adjusted estimates, we used a random-effects multivariable logistic regression (random
intercept and random slope, unless specified otherwise) with adaptive quadrature approxima-
tion. Our models for predictors of drug effect on TB treatment outcome only included those
children with bacteriologically confirmed MDR-TB. Patients were considered to be clustered
within cohorts such that intercepts and slopes of the main exposure variables were allowed to
vary across cohorts. This was done to account for unmeasured differences in patient popula-
tions and other site-specific characteristics. Estimates were adjusted for the following covari-
ates: age (as a continuous variable), sex, HIV infection, malnutrition, severe extrapulmonary
disease, or the presence of severe disease on chest radiograph. There were nine sites that did
not report any information on patients’ nutritional status (n = 44 children) and one site that
did not report on the severity of extrapulmonary disease (n = 2 children). For the patients at
sites that had no data from which to estimate a mean value, their missing values were replaced
in the analysis by the mean value of the variable in the entire sample. At sites where most
patients had these values reported, for individual patients who had missing data on HIV status
(n = 65), sex (n = 3), severe extrapulmonary disease (n = 68), and malnutrition (n = 43), miss-
ing values were replaced by their respective site’s mean value of the variable. Children from
countries with very low HIV prevalence who did not have an HIV test were assumed to be
HIV uninfected following consultation with site investigators. A p-value of 0.05 was taken as
the limit of statistical significance. All statistical analyses were performed using SAS software
(version 9.3, SAS Institute, Cary, NC).
Ethical considerations
A protocol prespecified the study rationale and methods (S2 Text). Ethics approval was pro-
vided by the Health Research Ethics Committee of the Faculty of Medicine and Health Sci-
ences, Stellenbosch University (reference number X14/09/020). The collection of the original
data and sharing of those data was approved by the appropriate oversight body at each contrib-
utor’s local institution, including the use of unpublished data, prior to release of data to the
team.
For IPD contributed by the US CDC, Atlanta, GA, Institutional Review Board approval was
obtained from the South African Medical Research Council Ethics Committee and the Human
Research Ethics Committee of University of the Witwatersrand in Johannesburg and was
determined to be routine disease surveillance by the US CDC.
Results
Search results and report selection
The search results and report selection are summarized in Fig 1 (see S1 Text for PRISMA
checklist). The search yielded 2,772 reports; after screening of abstracts and review of the full
texts, 33 studies were eligible for inclusion, with IPD provided for 28 of these [9,12–33] (Fig 1).
Overall, the studies were noted to be of low quality, given the lack of any randomized con-
trolled trials (see S3 Table for overview of studies). Although we are unable to quantify the
pediatric data that were not included, we believe they were minimal. The largest group of stud-
ies from which data were excluded were the studies in which there was no reply from the
authors, so it is unknown exactly how many children may have been excluded. However, these
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Fig 1. Study selection. IPD, individual patient data; XDR-TB, extensively drug resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.g001
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were almost all studies with mainly adult patients, but inclusion of children could not be ruled
out with certainty based on reading these articles.
Report characteristics
Data sets were received from sites in 18 countries with a broad geographic distribution (Fig 2),
with the majority from Africa. Nine countries (Belarus, India, Pakistan, Peru, Russian Federa-
tion, South Africa, Tajikistan, Ukraine, Uzbekistan) were among the 30 high-burden MDR-TB
countries [1]. Details of published and unpublished cohorts included are presented in S3
Table. Eight percent of children were treated between 1990 and 2004, 67% of children were
treated between 2005 and 2009, and 25% were treated from 2010 and later.
Summary patient data and outcomes
The 28 cohorts included data from 1,012 patients. All data were from observational studies in
which children were treated with the local standard of care. Thirty-seven children with con-
firmed XDR-TB were excluded from analyses; therefore, data from 975 children were ana-
lyzed. Of the 975 children, 731 (75%) had confirmed MDR-TB by DST and 244 (25%) had
clinically diagnosed MDR-TB. Most data predated the rollout of GeneXpert MTB/RIF; the
vast majority of confirmed patients were diagnosed using culture. Of the 731 children with a
confirmed diagnosis, 68 (9.3%) had pre-XDR-TB (36 with MDR-TB with additional fluoro-
quinolone resistance, and 32 with additional second-line injectable resistance). It should be
noted that 68% of confirmed patients had no additional information regarding resistance to
fluoroquinolones and/or second-line injectable agents. Of the 244 children with a clinical diag-
nosis of MDR-TB, 164 (67%) had clinical TB with a known close source case with DST-con-
firmed MDR-TB, 14 (6%) had failure of first-line therapy (first-line oral anti-TB drugs are
isoniazid, rifampin, ethambutol, pyrazinamide, rifabutin, and rifapentine [34]) despite docu-
mented good adherence, and one child had a clinical diagnosis of TB with a known MDR-TB
source case, in addition to treatment failure on first-line TB drugs despite good adherence.
The basis for the clinical diagnosis of MDR-TB was not specified in 65 patients (27%).
Key demographic and clinical characteristics, stratified by confirmed versus clinically diag-
nosed MDR-TB, are shown in Table 2. The median age was 7.1 years (IQR 2.6–11.7); 429
(44%) were males. HIV status was documented in 910 (93%) children, of whom 359 (39%)
were infected with HIV. Children with confirmed MDR-TB were more likely to be older, to be
infected with HIV, to be malnourished, and to have severe TB on chest radiograph.
TB treatment outcomes are summarized in Table 3. Overall, 764 of 975 (78%) had a success-
ful treatment outcome, with successful treatment outcomes in 548/731 (75%) of bacteriologi-
cally confirmed children and 216/244 (89%) in clinically diagnosed children. Treatment
success rates did not differ among those children with pre-XDR, although numbers were
small. Across all sites, most children had successful treatment outcomes, particularly those
with a clinical diagnosis (Fig 3). There was considerable heterogeneity between sites with
regard to treatment outcomes among confirmed cases, and less heterogeneity among clinical
cases. Treatment outcomes among children infected with HIV assessed by the time of initia-
tion of ART relative to MDR-TB therapy initiation are shown in Table 4. These data are pre-
sented by site in Fig 4. Treatment outcomes were worse in children infected with HIV who
were never on any ART during their MDR-TB therapy, compared to children who received
ART (either started before or concurrent with MDR-TB treatment). Among children with
confirmed MDR-TB, treatment was successful in 56% (15/27) of children infected with HIV
who did not receive any ART during MDR-TB therapy, compared to 82% (149/182) in
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children who received ART during MDR-TB therapy. Among children not infected with HIV,
93% with confirmed MDR-TB had successful treatment outcomes.
In multivariable analysis, among children with confirmed MDR-TB, HIV infection
(adjusted odds ratio [aOR] 0.3, 95% CI 0.2–0.6) and malnutrition (aOR 0.3, 95% CI 0.2–0.6)
were associated with reduced odds of successful treatment outcome versus treatment failure or
death (Table 5). Malnutrition was an independent risk factor from HIV infection for poor
treatment outcome. This analysis did not adjust for the regimen used or individual drugs used.
Among children with clinically diagnosed MDR-TB, no assessed covariates predicted treat-
ment outcome.
Treatment outcomes and specific drug therapy
We also conducted analyses to assess estimates of the association between individual antituber-
culosis medications, used as part of a multidrug regimen, and treatment success (Table 6) to
inform the WHO treatment guideline process. This analysis was restricted to patients with
bacteriologically confirmed MDR-TB. Although children who were lost to follow-up were
excluded from the analysis, among children with confirmed MDR-TB, there were no differ-
ences in the following key variables between children who were lost to follow-up versus those
with a known outcome: age, HIV status, sex, the presence of severe TB or severe extrapulmon-
ary TB, previous TB treatment, or nutritional status (S4 Table). In children with confirmed
MDR-TB, the second-line injectable agents and high-dose isoniazid (15–20 mg/kg/day) were
associated with treatment success. Ninety-eight percent (130/133) of these children treated
Fig 2. Geographic distribution of patients. Locations of patients included in the individual patient data meta-analysis. The number indicates the number of
participants included from each location.
https://doi.org/10.1371/journal.pmed.1002591.g002
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Table 2. Demographic and clinical characteristics among children with MDR-TB.
Characteristic All children
n = 975 (%)
Bacteriologically confirmed MDR or Pre-XDR-TB
n = 731 (%)
Clinically diagnosed
MDR-TB
n = 244 (%)
p-valued
Age (years)
<5 399 (41) 240 (33) 159 (65) <0.001
5 to <10 234 (24) 178 (24) 56 (23)
10 to <15 342 (35) 313 (43) 29 (12)
Median age 7.1, IQR 2.6–11.7 8.5, IQR 3.4–12.2 3.6, IQR 1.9–7.0
Sex
Female 543 (56) 414 (57) 129 (53) 0.570
Male 429 (44) 315 (43) 114 (47)
Unknown 3 (0.3) 2 (0.3) 1 (0.4)
HIV status
Infected with HIV 359 (37) 323 (44) 36 (15) <0.001
Not infected with HIV 551 (57) 356 (49) 195 (80)
Unknown 65 (7) 52 (7) 13 (5)
Malnourisheda
Yes 332 (34) 276 (38) 56 (23) <0.001
No 556 (57) 381 (52) 175 (72)
Unknown 87 (9) 74 (10) 13 (5)
Severe disease on chest radiograph
Yes 474 (49) 407 (56) 67 (28) <0.001
No 294 (30) 168 (23) 126 (52)
Unknown 207 (21) 156 (21) 51 (21)
Severe extrapulmonary diseaseb 127 (13) 103 (14) 24 (10) 0.031
Site of disease
Pulmonary only 710 (73) 526 (72) 184 (75) 0.002
Extrapulmonary only 99 (10) 67 (9) 32 (13)
Both extrapulmonary and pulmonary 152 (16) 130 (18) 22 (9)
Unknown 14 (1) 8 (1) 6 (3)
Extrapulmonary disease sitesc
Meningitis 34 (14) 23 (12) 11 (20)
Miliary 34 (12) 29 (15) 5 (9)
Bone/joint (including spine) 25 (10) 20 (10) 5 (9)
Pleural 19 (8) 15 (8) 4 (7)
Urogenital 1 (0.4) 1 (0.5) 0
Abdominal 53 (21) 48 (24) 5 (9)
Skin 1 (0.4) 1 (0.5) 0
Disseminated disease not otherwise specified 11 (4) 10 (5) 1 (2)
aMalnourished was defined as being underweight or malnourished by clinical diagnosis, having nutritional edema, or having low weight for age (weight-for-age-
adjusted z-score of less than −3).
bSevere extrapulmonary disease was defined as meningitis, miliary, abdominal, osteoarticlar, and disseminated disease not otherwise specified.
cDisease sites are not mutually exclusive; one child could have multiple disease sites. Denominator is children with only extrapulmonary and with both pulmonary and
extrapulmonary disease sites.
dp-value represents differences in characteristics between clinically diagnosed and bacteriologically confirmed cohorts.
Abbreviations: MDR-TB, multidrug-resistant tuberculosis, pre-XDR-TB, pre-extensively drug-resistant tuberculosis; XDR-TB, extensively drug resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.t002
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Table 3. Summary of treatment outcomes for children treated for MDR-TB.
MDR-TB treatment outcome Bacteriologically confirmed MDR-TB
n = 731 (%)
Clinically
diagnosed MDR-TB
n = 244 (%)
Absolute difference (95% CI)a p-value All children
n = 975 (%)
Cured/completed treatment 548 (75) 216 (89) 14% (8%–19%) <0.001 764 (78)
Death 77 (11) 8 (3) 8% (4%–11%) <0.001 85 (9)
Failed treatment 16 (2) 0 2% (0%–4%) 0.044 16 (2)
Lost to follow-up/not evaluated 90 (12) 20 (8) 4% (0%–9%) 0.100 110 (11)
aThe overall chi-squared p-value treatment outcomes between clinically diagnosed and bacteriologically confirmed cohorts is <0.001.
Abbreviation: MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.t003
Fig 3. Proportion of patients achieving successful treatment outcomes, stratified by method of diagnosis, by site.
Excludes lost to follow-up and cases that did not have an outcome. Results estimated via random effects modeling to
account for clustering by cohort. The 95% confidence limits were estimated using exact (Clopper-Pearson) method.
Unpublished data.
https://doi.org/10.1371/journal.pmed.1002591.g003
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with high-dose isoniazid were from South Africa. When the association of individual drugs
with treatment success was examined in South African data only, the CI widened but the point
estimate remained the same (S5 Table). Among clinically diagnosed children, multivariable
models were too unstable to provide reliable estimates.
Among the clinically diagnosed children (who tended to have less severe disease on chest
radiograph and lower rates of malnutrition and HIV), 60 (25%) received no injectable agent or
less than 1 month of injectable agent. Fifty (83%) of these children had successful treatment
outcomes.
Later generation fluoroquinolones were defined as moxifloxacin, gatifloxacin, sparfloxacin,
or high-dose levofloxacin. Only 63/885 (7%) children in total were treated with moxifloxacin
(44/641 [7%] in the confirmed and 19/244 [9%] in the clinically diagnosed groups). One child
with confirmed disease received both gatifloxacin and sparfloxacin. Information on the dose
of levofloxacin was available in only 93/885 (11%) of children. This infrequent use precluded
useful analysis of the clinical impact of fluoroquinolones on treatment outcome.
Discussion
This systematic review and IPD meta-analysis of pediatric MDR-TB represents a global collab-
orative effort of the pediatric TB community. It has for the first time, to our knowledge, gener-
ated a data set of children treated for MDR-TB in multiple countries, which has informed the
revised 2016 WHO MDR-TB treatment guidelines [4].
A striking finding is the high proportion (78%) of successful treatment outcomes amongst
all children, with 75% success in children with confirmed MDR-TB and 89% in those with
clinically diagnosed disease. These good outcomes are despite the high prevalence of comor-
bidities (37% infected with HIV; 34% malnourished), severe pulmonary (49%) and extrapul-
monary (13%) TB, and the abscence of the newer, safer, and more effective drugs. A previous
systematic review, without IPD, reported a similar proportion of children with MDR-TB suc-
cessfully treated (82%) [6]. These outcomes are considerably better than the treatment success
rates (54%) reported in adults [9].
Table 4. Comparing treatment success rates among children with MDR-TB infected with HIV, by timing of initiation of ART and by HIV statusa.
Characteristics No ART
during
MDR-TB
treatment,
number
treatment
successa/N (%)
ART during
MDR-TB
treatment,
number
treatment
successa/N
(%)b
Absolute
difference in
proportion
(ART versus
No ART) (95%
CI)
No data on
ART,
number
treatment
success/N (%)
Absolute
difference in
proportion
(ART versus No
data on ART)
(95% CI)
p-value All children
infected with
HIV, number
treatment
successa/N (%)
All children
not infected
with HIV,
number
treatment
successa/N (%)
Absolute
difference in
proportion
(HIV+ versus
HIV−) (95%
CI)
Bacteriologically
confirmed
MDR-TB
15/27 (56) 149/182 (82) 26% (5%–48%) 57/78 (73) 9% (−3%–21%) 0.006 221/287 (77) 291/312 (93) 16% (10%–
22%)
Clinically
diagnosed
MDR-TB, number
treatment success/
N (%)
1/4 (25) 21/21 (100) 75% (18%–
100%)
3/5 (60) 40% (−15%–
95%)
<0.001 25/30 (83) 180/183 (98) 15% (0%–30%)
aTreatment success is defined as cured or completed treatment, lost to follow-up excluded. The overall chi-squared p-values comparing treatment success rate by ART
status among bacteriologically confirmed and clinically diagnosed children infected with HIV, respectively, are p = 0.006 and p< 0.001.
bEither on ART before beginning MDR-TB treatment or ART started during MDR-TB treatment.
Abbreviations: ART, antiretroviral treatment; MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.t004
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Fig 4. Proportion of bacteriologically confirmed MDR-TB patients achieving successful treatment outcomes,
stratified by HIV infection and HIV ART. Data are stratified by HIV and ART status and by site. The 95% CIs were
estimated using exact (Clopper-Pearson) method. Children from countries with very low HIV prevalence who did not
have an HIV test were assumed not to be infected with HIV following consultation with site investigators. Unpublished
data. ART, antiretroviral treatment; MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.g004
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Table 5. Clinical variables associated with treatment outcome in children with MDR-TB:N = 975.
Characteristics Treatment success versus Failure/Deatha
Bacteriologically confirmed n = 641b Clinically diagnosed n = 224b
Clinical variable Adjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Age5 years 1.36 0.78–2.37 0.191 9.64 0.53–176.98 0.969
Male 0.72 0.44–1.18 0.321 0.63 0.04–11.22 0.267
Infected with HIVe 0.30 0.15–0.63 <0.001 0.49 0.02–14.97 <0.001
Severe disease on chest radiography 0.66 0.32–1.34 0.001 0.07 <0.01–5.76 0.042
Malnutritionc, e 0.33 0.19–0.60 <0.001 0.01 <0.01–1.92 <0.001
Severe extrapulmonary diseased 0.60 0.32–1.13 0.026 0.09 <0.01–2.68 0.013
aEstimated using random effects models (random intercept and slope) with quadrature approximation. Missing values for sex, HIV, and severe extrapulmonary disease,
severe disease on chest radiography, and malnutrition variables were imputed using the mean value of each variable for each site.
bLost to follow-up was excluded from analysis.
cMalnutrition is defined as being underweight or malnourished by clinical diagnosis, having nutritional edema, or having low weight for age (weight-for-age-adjusted z-
score of <−3).
dSevere extrapulmonary disease is defined as meningitis, miliary, abdominal, osteoarticlar, or
disseminated disease not otherwise specified.
eBolded results met the prespecified criteria for statistical significance.
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002591.t005
Table 6. Summary of association of use of individual drugs with treatment success in children treated for con-
firmed MDR-TB (n = 641)a,b,c,d.
Drug used N (%) aORe 95% CI p-value
Pyrazinamide 599 (93) 1.63g (0.41–6.56) 0.484
Second-line injectable agentsf, j 584 (91) 2.94g (1.05–8.28) 0.041
Ethionamide/ prothionamide 590 (92) 2.19 (0.42–11.54) 0.332
Cycloserine/ terizidone 356 (56) 1.66h (0.91–3.05) 0.104
Clofazimine 23 (4) 0.55 (0.02–19.20) 0.714
High-dose isoniazidj 133 (21) 5.86g (1.68–20.51) 0.007
Para-aminosalicylic acid 147 (23) 0.70i (0.25–1.96) 0.483
Clarithromycin 32 (5) 0.29i (0.05–1.53) 0.132
Treatment success was compared to Failure/Death by drug use.
aAdjusted estimates for the clinically diagnosed children were not possible due to very low rates of failure.
bLost to follow-up was excluded from analysis.
cAll random effects (random intercept and random slope) models used maximum likelihood estimation with
quadrature approximation and were specified with an unstructured variance–covariance matrix parameterized
through its Cholesky root unless otherwise stated.
dToo few children were treated with late-generation fluoroquinolones, carbapenems, and linezolid to be analyzed. No
children in these cohorts were treated with bedaquiline or delamanid.
eaOR, for use of drug, with nonuse as reference category. Adjusted for age, sex, HIV infection, malnutrition, severity
of disease on chest radiograph, and severity of extrapulmonary disease.
fSecond-line injectable agents are amikacin, kanamycin, and capreomycin.
gRandom-slope only model without random intercept, specified with standard variance components.
hRandom-intercept only model without random slope, specified with standard variance components.
iModel specified with standard variance components (not unstructured).
jBolded results met the prespecified criteria for statistical significance.
Abbreviations: aOR, adjusted odds ratio; MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002591.t006
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The association of HIV infection and malnutrition with reduced odds of successful TB
treatment is consistent with the published literature [24,40]. Children infected with HIV but
not receiving ART during their MDR-TB treatment were less likely to have successful treat-
ment compared to children who were on ART at some point during their MDR-TB treatment
episode. The 2016 WHO ART guidelines recommend that ART should be started as soon as
possible and at least within 8 weeks of starting TB treatment in all TB patients infected with
HIV, irrespective of CD4 count, with the possible exception of TB meningitis [41–44]. All data
on children infected with HIV but not receiving ART came from a single study from South
Africa (Fig 4) [21]; the data were collected from several public clinics throughout South Africa
and are representative of the care children were receiving. Although the data all coming from a
single study is a limitation, the finding that the lack of ART is associated with worse outcomes
in people coinfected with TB and HIV has been well established [41, 45]. Our data support the
importance of ART in children with TB who are infected with HIV, and highlight the need to
aggressively treat children infected with HIV for both TB and HIV and to include nutritional
support as part of standard care.
In this data set, children infected with HIV were more likely to have confirmed MDR-TB,
despite reports of higher rates of paucibacillary TB disease in adults infected with HIV. This
may be because the majority (95%) of children infected with HIV were from South Africa,
where diagnostic tools and approaches may differ. There may also be hesitancy to start
MDR-TB treatment in addition to ART; thus, treatment delays may lead to children having
more severe TB disease, resulting in more bacteriologically confirmed disease. Children
infected with HIV also tended to be older, as prevention of mother to child transmission
(PMTCT) initiatives were rolling out during the study period in South Africa; this may have
contributed to more children infected with HIV having a confirmed diagnosis.
A prominent finding was the benefit of high-dose (15–20 mg/kg/day) isoniazid. Twenty-
one percent of children with confirmed MDR-TB received high-dose isoniazid; however, the
majority of these children were from Cape Town. Despite attempts to statistically control for
site-specific effect, it is possible that other unmeasured site-related effects, including the quality
of clinical care, could have contributed to this finding. However, the fact that the point esti-
mate for the benefit of high-dose isoniazid remained unchanged when South African data
were examined demonstrates that this benefit remains, despite possible site-specific effect.
When high-dose isoniazid is considered as part of MDR-TB treatment but the mutation con-
ferring isoniazid resistance is unknown, the local epidemiology of isoniazid resistance muta-
tions should be considered (high-level isoniazid resistance is conferred by the katG mutation
and lower level resistance by the inhA mutations) [46]. High-dose isoniazid can overcome an
inhA mutation’s low-level isoniazid resistance but is unlikely to overcome the high-level isoni-
azid resistance due to a katG gene mutation [47]. The Western Cape Province, South Africa
(which includes Cape Town), has high rates of inhA mutations (61% of the isoniazid resistant
mutations among pediatric patients [46]), which may have contributed to this high-dose isoni-
azid treatment benefit. However, none of the children underwent testing for isoniazid muta-
tion and were therefore treated in a standard manner at the time the data were generated.
Despite these caveats, our observations are consistent with other reports that suggest that
high-dose isoniazid may have an important role in MDR-TB treatment as a component of
shorter treatment regimens and as an add-on agent to the longer MDR-TB treatment regimens
[1,48–50].
Among children with confirmed MDR-TB, the use of second-line injectable agents was
associated with successful treatment versus failure/death. Although we found improved out-
comes in children with confirmed disease when treated with injectable agents, we saw high lev-
els of treatment success in children with clinically diagnosed MDR-TB who received no
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second-line injectable agents or who had received these parenteral antibiotics for less than 1
month. Eighty-three percent (50/60) of the children with clinically diagnosed disease (who
tended to have less severe disease, with lower rates of HIV and malnutrition and less severe
disease on chest radiography) who received no or less than 1 month’s treatment with a second-
line injectable agent had successful treatment outcomes. These data need to be interpreted
with caution and the use of second-line injectable agents in children needs more study. We
did not collect data on the reason for using an injectable-free regimen, but possibilities include
less severe disease, the presence of resistance to an injectable agent (although not all sites had
access to extended drug-susceptibility testing), and perceived and actual injectable-associated
adverse events.
Nonetheless, our findings lend support to not using second-line injectable agents in chil-
dren with non-severe MDR-TB [6,18,51]. A previous study found hearing loss in 24% of chil-
dren treated for MDR-TB with a second-line injectable agent [51]. Hearing loss can be
devastating in children, impacting language acquisition and schooling, and administration of
injectables is painful and resource intensive, frequently requiring daily visits to healthcare
facilities. Avoiding second-line injectable agents should also be seen in the context of current
and future MDR-TB treatment options. The new and repurposed MDR-TB drugs—bedaqui-
line, delamanid, linezolid, late-generation fluoroquinolones—were not used enough to be eval-
uated, but emerging evidence suggests they could be as effective and safer than the injectable
agents [5,52].
Our results were used to inform the revision of the 2016 WHO MDR-TB treatment guide-
lines, which state that the harms associated with second-line injectable agents may outweigh
potential benefits, and therefore injectable agents may be excluded from the treatment regi-
mens of children with non-severe forms of MDR-TB disease [4].
A strength of our study was the inclusion of children with both bacteriologically confirmed
and clinically diagnosed TB. Because of the paucibacillary nature of pediatric TB and the chal-
lenges of obtaining clinical samples, approximately 60%–70% of children treated globally for
TB will be clinically diagnosed [25,35]. The inclusion of clinically diagnosed children makes
our findings relevant to a broader range of children treated for MDR-TB, even if the propor-
tion of children with clinically diagnosed MDR-TB (25%) was lower in our study than global
values cited elsewhere. Notably, the low proportion of children in this study with clinically
diagnosed MDR-TB may indicate potentially more severe pulmonary disease in our cohort,
because bacteriological yield correlates with chest radiographic findings in children with TB
[36]. The proportion of patients with bacteriologically versus clinically diagnosed TB differed
by site (Fig 3). The reasons for this are likely varied; in some places, healthcare workers are
reluctant to treat MDR-TB without bacteriological confirmation, and in some countries it is
national policy that a bacteriological diagnosis be made in order for a child to be treated for
MDR-TB, thereby excluding children with a clinical diagnosis from treatment. Some sites are
MDR-TB specialty sites, so these may be better equipped to obtain samples and complete labo-
ratory testing. Additionally, by the time children were evaluated at these tertiary centers, many
probably had more advanced disease, which is more likely to be bacteriologically confirmed.
Age may also explain some of our cohort’s attributes: some clinicians are less comfortable diag-
nosing TB in younger children, in whom the diagnosis is less likely to be confirmed and symp-
toms are frequently nonspecific. There are also likely publication biases involved here,
whereby studies may have been more likely to have been published if they included more
bacteriologically confirmed cases. However, in an attempt to combat this publication bias, we
actively sought out unpublished data.
A criticism of studies that include clinically diagnosed children is that some of these chil-
dren may not have MDR-TB and so treatment outcomes may not reflect true MDR-TB
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disease. In this study, among children with a clinical diagnosis, 67% had clinical TB with a
known MDR-TB source case, and another 6% had failure of first-line therapy despite good
adherence. Given that studies have shown that children are most likely to share the TB strain
of their household contact, it is likely that the majority of children in this cohort did in fact
have MDR-TB [37–39].
Limitations
The most significant limitation of this study is that the estimated treatment effects of individ-
ual drugs should be interpreted with caution because the analysis could not isolate the benefit
of each drug. We could only compare regimens with and without each drug. If particular
drugs were used or not used together—because of disease severity or resistance profiles or tox-
icity—there is potential for confounding by indication that would produce biased effect esti-
mates for each drug. Also, treatment decisions were based on the clinician’s perception of
illness, with resulting potential for bias.
Furthermore, we were not able to compare specific regimens given the large variation in
drugs used and treatment duration as part of individualized treatment. All studies included
were retrospective or prospective observational cohort studies; there were no clinical trials.
However, given that the study was an IPD, some adjustments could be made for covariates at
the individual level, which is not possible in study-level meta-analyses. This worked to mitigate
the risk of confounding and other potential biases. The sample size was modest compared to
adult IPD data sets, and estimates were frequently imprecise, while some associations were not
estimated because of limited data. There were no data available yet on the novel drugs, delama-
nid and bedaquiline, and data on linezolid were insufficient to include in this analysis. Data on
late-generation fluoroquinolones and clofazimine were sparse. Children who were lost to fol-
low-up and not evaluated (11% overall) were not included in this analysis, because their treat-
ment outcome was unknown. Relapse was also not evaluated, as data on outcomes after
completing antituberculosis treatment were rarely reported. This could have resulted in over-
estimation of favorable treatment outcome.
A further limitation is that, apart from DST for isoniazid and rifampicin, data about a
strain’s susceptibility to other drugs (especially the fluoroquinolones and second-line
injectable agents) were frequently not available for analysis; therefore, we could not assess the
association between combinations of likely effective drugs (based on DST results) and out-
comes. This may have also led to an underestimate of the benefit of drugs to which the strain
was susceptible. Additionally, data on adverse events were incompletely reported and could
not be included in the analysis. This scarcity of the reporting of adverse events also contributed
to us being unable to distinguish treatment failure due to lack of efficacy from treatment failure
due to drug intolerance.
Data were limited regarding the duration of posttreatment follow-up or posttreatment out-
comes; therefore, we could not evaluate recurrence, relapse, or the effect of total duration of
treatment on MDR-TB outcomes. Data on history of previous TB treatment were sparse and
could not be analyzed.
All studies used consecutive sampling of children enrolled in MDR-TB treatment, which
should have minimized selection bias. However, it is possible that the diagnosis of MDR-TB
could have been missed in some children due to passive case finding at most study sites and
general difficulties in diagnosing TB and MDR-TB in children. Children in whom the diagno-
sis may have been missed, often children with clinically diagnosed TB, who would usually have
less severe, more paucibacillary disease, might have had different clinical characteristics and
different outcomes than those included in the selected studies and therefore may have better
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treatment outcomes if they had in fact been enrolled. Thus, the likelihood of selection bias can-
not be ruled out.
An additional limitation of this study was that the literature published after October 2014
was not included. In order to determine what effect this may have on our findings, we did a
search of the pediatric MDR-TB literature from October 2014 to the present. The studies were
reviewed, either full studies or abstracts, and details of studies that had the potential to be
included in our study are included in S6 Table. As per the reasons listed in S6 Table, it is
unlikely that including these in our study would have changed our findings.
Conclusions
Children treated for MDR-TB have good treatment outcomes—even those with comorbidities
and severe disease. That children tend to have much better treatment outcomes than adults
raises the possibility that children may be specifically suited to do well with shorter, less intense
treatment regimens. This deserves further study. Our study provides evidence that a substan-
tial proportion of children with clinically diagnosed MDR-TB treated without second-line
injectable agents have successful outcomes and that high-dose isoniazid may improve treat-
ment success in some settings. Given the limitations of the current study, these findings should
be interpreted cautiously but deserve further evaluation in subsequent studies. The high mor-
tality and low treatment success rates among children infected with HIV who were not on
ART during TB treatment demonstrates the importance of testing children with TB for HIV
and initiating ART as soon as possible.
Data regarding the treatment outcomes and pharmacokinetic and safety profiles of beda-
quiline, delamanid, later generation fluoroquinolones, linezolid, and clofazimine in children
are urgently needed in children with MDR-TB, including in children infected with HIV.
Future research is also needed on pediatric outcomes involving the shorter MDR-TB regimen
[49,50]. Consensus on standardized reporting of demographic, clinical, and treatment charac-
teristics for childhood MDR-TB would enhance the value of observational data and improve
the comparability of results in published literature. It is notable that after extensive efforts to
identify all possible pediatric cohorts, including unpublished cohorts, over a period of 24
years, fewer than 1,000 children with MDR-TB could be included in this analysis. Given that
as many as 32,000 children develop MDR-TB each year [2], this represents a small fraction of
children with MDR-TB. This paucity of literature highlights the fact that children with
MDR-TB have been largely disregarded and underreported and that urgent attention needs to
be paid to diagnose, treat, and report on this neglected population.
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ABSTRACT
Introduction: New and repurposed antituberculosis drugs are urgently needed to more safely and
effectively treat multidrug-resistant (MDR) tuberculosis (TB) in children. Multiple challenges limit timely
access to new MDR-TB treatments in children.
Areas covered: Diagnosis of MDR-TB in children remains a barrier, with few children with MDR-TB
diagnosed and treated. Other barriers to timely access to new and repurposed drugs are discussed, and
include delayed initiation of paediatric trials, limited funding for paediatric drug development, frag-
mented regulatory systems and operational challenges. The status of access to current repurposed and
novel drugs is presented.
Expert commentary: More timely initiation of paediatric trials is needed and paediatric work should
happen and be funded in parallel with each phase of adult trials. Better quality data, increased regulator
resources and expertise, harmonization of regulatory requirements across borders/organisations and
registration fee waivers would improve registration timelines. Improved diagnosis, recording and
reporting will establish better demand. Improved systems for procurement and supply chain manage-
ment would reduce in-country operational barriers to getting medications to children. The challenges
must be addressed to ensure timely and equitable access to new drugs and regimens that are urgently
needed for effective, safe and shorter treatment of children with MDR-TB.
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1. Introduction
Tuberculosis (TB) in children accounted for approximately 1
million (10%) of the estimated 10.4 million new TB cases
globally in 2015 of which only 38% were reported [1]. There
were an estimated 580,000 cases of multidrug-resistant (MDR)-
TB (i.e. disease caused by Mycobacterium tuberculosis resistant
to at least isoniazid and rifampicin) in 2015; only 125,000
(20%) accessed appropriate MDR-TB treatment with only
52% successfully treated [1]. Model-based estimates suggest
25,000–32,000 new cases of MDR-TB in children annually [2,3];
however, the true burden is not known, as recording and
reporting of drug-resistant (DR)-TB in children is poor [4,5].
MDR with additional resistance, such as extensively drug-resis-
tant (XDR)-TB (i.e. MDR plus resistance to a fluoroquinolone
and a second-line injectable agent) and pre-XDR-TB (i.e. MDR
plus resistance to a fluoroquinolone or a second-line injectable
agent), is increasingly recognized in children [6,7].
New anti-TB drugs to more safely and effectively treat MDR-
TB are as much needed in children as in adults; however,
children, and especially very young children who develop
serious forms of disseminated TB, such as miliary TB and TB
meningitis, are always last to gain access to these drugs. In the
last decade, a number of new and repurposed drugs have
entered adult MDR-TB trials from phase 1 to 3. Bedaquiline
and delamanid have received accelerated or conditional
approvals in different countries for use in MDR-TB treatment
regimens, while clofazimine, linezolid, and the later-generation
fluoroquinolones are used off-label for MDR-TB treatment in
adults and children. Pretomanid has only been used in new
trial regimens for both drug-susceptible (DS-TB) and DR-TB in
adults and has not yet been registered.
In this review, we will highlight clinical, research, regula-
tory, and operational challenges to the use of new TB treat-
ments in children with MDR-TB, and propose potential
solutions.
2. Challenges to using new and repurposed drugs
for children with MDR-TB
2.1. Diagnostic challenges
A major challenge for using new TB drugs in children is the
underdiagnosis of pediatric MDR-TB. DR-TB and DS-TB in chil-
dren are clinically indistinguishable. Bacteriological confirma-
tion of TB, and therefore also drug susceptibility testing, in
children remains a challenge due to difficulty in obtaining
suitable specimens, poor sensitivity of available bacteriological
tests due to low organism burden of TB in children (pauciba-
cillary disease in most young children), and a lack of adequate
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laboratory facilities in many settings [8,9]. TB is often not
considered in young children and specimens are frequently
not collected. Despite mounting evidence that children with
TB who are in contact with infectious DR-TB source cases have
the same DR M. tuberculosis strain [10,11], some national TB
programs (NTPs) and clinicians remain reluctant to start appro-
priate DR-TB regimens in children without bacteriologic con-
firmation [12]. This hesitance is likely due to longer duration of
treatment with more toxic and expensive regimens needed to
treat these children for MDR-TB. New, safer, shorter, and less
expensive regimens may reduce the hesitation of clinicians to
treat presumed DR-TB cases. Although the number of children
diagnosed, recorded, reported, and treated for MDR-TB is
unknown, it is suspected that <5% of pediatric cases are
identified globally each year. Children cannot benefit from
new TB medications if they are never identified as having
probable or confirmed MDR-TB, and in the absence of much
improved case finding, much of the benefit of new medica-
tions in children will remain unrealized.
2.2. Challenges in pediatric TB drug development
The challenges for developing new and investigational drugs
in children lie at several levels. A recent consensus statement
on early inclusion of children in TB drugs trials recommends
that pharmacokinetic and safety studies in children should
start as soon as phase 2b studies have established appropriate
dosing, and therefore pharmacokinetic targets and safety, in
adults [13]. Studies of new drugs in children, including devel-
opment of child-friendly formulations should not wait for the
results of the long phase 3 clinical trials in adults. This remains
a challenge, as pharmaceutical companies are reluctant or
slow to develop such pediatric investigational plans (PIPs)
and implement pediatric trials, despite incentives and a man-
date from regulatory authorities in the United States and
Europe, respectively.
Efficacy trials for single new drugs are not necessary in
children unless these drugs are for specific pediatric indica-
tions, as efficacy in adult TB cases infers efficacy in children.
Clinicians are aware of this caveat. Therefore, if dose finding
and safety studies in children are not done early in new drug
evaluations, clinicians may start using these drugs without
properly established dosing and without evaluation of its
safety in children. An example is the Centers for Disease
Control and Prevention recommendation that bedaquiline
can be used in children if no alternative options are available,
but no bedaquiline doses in children have been established
nor any dosing guidelines provided [14]. Pharmacometric
modeling, using available pharmacokinetic data at established
effective doses in adults assists in determining likely effective
doses in children, taking into account physiological changes
that occur in children at different ages. However, pharmaco-
kinetic studies in children are still necessary to establish
whether these doses achieve adult targets.
The milligram strength, formulation, and taste (palatability)
of drugs are important considerations in using drugs in chil-
dren. Small children often need fractions of adult-sized tablets,
and breaking and crushing or dissolving tablets in solutions
may lead to changes in bioavailability or inaccurate dosing
(too high or too low). Furthermore, there may be huge differ-
ences in taste/palatability between a coated tablet swallowed
whole by an adult or an adolescent and crushed/suspended
tablets needed to be taken by young children. It is therefore
imperative that child-friendly formulations that consider milli-
gram strength, size, formulation, and palatability should be
developed for all new and investigational drugs.
2.3. Financial and market barriers to pediatric TB drug
development
The cost of bringing a novel drug to market is at least $110–
170 million [15]. As the vast majority of TB patients live in poor
countries, national health systems and individual patients
have limited ability to pay the substantial costs that would
allow drug companies to recoup these research and develop-
ment (R&D) investments. The markets for DR-TB are even
smaller, and, for children with DR-TB, smaller yet. A market-
based approach to drug development, based on the private
sector investing in R&D with the aim of later recouping costs
through sales is unlikely to be successful for the development
of new drugs for TB. However, other options exist.
Various push-and-pull mechanisms have been proposed to
incentivize the development of drugs for neglected diseases
[16–18]. Push mechanisms generally provide funds to support
the earlier stages of drug development and promote the
identification of novel entities that can enter the drug devel-
opment pipeline. These allow investigators and industry to
reduce the costs and risks associated with development and
include direct funding mechanisms and tax credits on R&D.
Pull mechanisms allow guaranteed or increased returns on
products when they get to market. These usually act further
along the drug and regimen development pipeline, support-
ing and encouraging early- and later-stage clinical trials. These
mechanisms include market guarantees (such as advanced
purchase commitments), prizes, orphan drug program incen-
tives/exemptions, patent extensions, priority review vouchers,
and patent buyouts. A recent approach, advocated by
Médecins Sans Frontières (MSF), the Life Prize, formerly the
3P project (Push, Pull, and Pool), formalizes some of these
mechanisms for TB drug development with the ultimate goal
of de-linking the cost of R&D from that of the end pro-
duct [19].
2.4. Pediatric TB drug R&D funding
In 2015, funders invested $620.6 million in TB R&D of which
$26.7 million went to pediatric research. $231.9 million overall
was provided for TB drug development, and of that $16.1
went to pediatric TB drug R&D [20]. The overall amount of
funding for TB R&D is far less than the estimated need accord-
ing to the Stop TB Partnership’s 2011–2015 Global Plan to
Stop TB; within this inadequate budget, the proportion of
the TB R&D budget that is being allocated for childhood TB
is very small. As 10% of the global burden of TB is in children
(<15 years) [1], it would seem appropriate that a similar pro-
portion of the R&D budget were allocated to this population.
The money for TB R&D comes from a number of sources
[20]. The majority (63% for all TB R&D) comes from the public
2 H. S. SCHAAF ET AL.
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sector. This includes government scientific agencies, national
development agencies, disease control agencies, regional poli-
tical entities, and publically funded trials networks. Further
funding comes from philanthropic organizations (20%), the
private sector (14%), and multilateral organizations (such as
Unitaid; 3%). The money is disbursed directly to researchers
and developers, through grants, as well as to Product
Development Partnerships (collaborations between aca-
demics, the public sector, and industry that work together to
develop new medicines, vaccines, or diagnostics). In 2013, TB
Alliance was awarded $16.7 million from Unitaid to catalyze
the market introduction of child-friendly formulations of first-
line TB medicines, a grant named STEP-TB. This led to the
development of appropriately dosed, dispersible formulations
for treating DS-TB in children. While second-line drugs were
not considered for inclusion under STEP-TB, Macleods has
developed WHO-prequalified pediatric dispersible tablets of
ethionamide, levofloxacin, moxifloxacin, and a mini capsule
of cycloserine; WHO-prequalified pediatric formulations of
linezolid and clofazimine are also forthcoming.
2.5. Regulatory challenges
In addition to the R&D necessary to determine appropriate
doses and formulations acceptable for children, regulatory and
procurement policies are critically important to facilitate
access to new and repurposed drugs for the treatment of
children with DR-TB.
2.5.1. Existing regulatory pathways and requirements
Regulatory authorities require data demonstrating the efficacy
and safety of new medicines in adults and often accept that
these efficacy data are applicable to children with the same
disease [21]. Only pediatric pharmacokinetic and safety data
are then necessary for regulatory authorities to include chil-
dren in the population for which the new drug they are
reviewing will be indicated, or to expand the indication for
an existing drug to include children. Regulatory pathways and
requirements for the registration of new and repurposed
drugs for use in children and for pediatric formulations vary
by country.
For pediatric formulations, many regulatory authorities
require demonstration (in healthy adults) of bioequivalence
between the pediatric and registered adult formulations.
However, some regulatory authorities require that these studies
be conducted locally, adding a significant amount of work for
the drug or formulation sponsor. In the absence of a TB indica-
tion, as is the case for repurposed drugs that are used off-label
for the treatment of DR-TB, including linezolid and clofazimine,
it is not possible to register a pediatric formulation in the
absence of a reference product without also submitting data
demonstrating safety and efficacy for the desired indication.
However, these data are often not available given the expecta-
tion that efficacy is demonstrated in adult populations, and
generics manufacturers don’t typically have the capacity or
experience necessary to conduct safety and efficacy studies.
2.5.2. Access in the absence of local registration
In the absence of in-country registration, and where country
import and other policies allow, adults and children can access
new drugs through company compassionate use or other
preapproval access programs. However, not all sponsors
have preapproval access programs, and those that do, often
limit the eligible population to exclude children. Preapproval
access programs are often conducted on a named patient
basis, which can be onerous for clinicians requesting the
product and often require weeks to get through necessary
sponsor and regulatory approval requirements, jeopardizing
clinical care. Furthermore, not all countries have legal or reg-
ulatory mechanisms for preapproval use. Import waivers can
be used to facilitate access to repurposed drugs that aren’t
registered locally for TB but have received approval from a
Stringent Regulatory Authority (SRA) and/or the WHO
Prequalification (PQ) Programme. Preapproval access pro-
grams and import waivers are critically important mechanisms,
but given the significant amount of additional effort and
paper work they require from already overburdened TB pro-
grams, and frequent limitations on number of treatment
courses allowed to be imported under the waiver or length
of the waiver, when possible, local registration is preferable.
Local registration is becoming an increasingly important issue
given anticipated shifts in the global donor landscape
expected to affect country procurement practices; however,
local registration in countries with smaller markets is often not
of interest to drug sponsors or manufacturers.
The Global Fund requires funding recipients to purchase all
DR-TB medications through the Global Drug Facility (GDF).
This policy was designed to ensure quality, stabilize supply,
and reduce prices and lead times for DR-TB medications,
which have a smaller market than first-line medicines. The
GDF facilitates obtaining import waivers to supply countries
with DR-TB medicines that have SRA approval or WHO PQ, but
that are not locally registered for TB. Without such a procure-
ment policy, as is the case for medications for DS-TB, countries
follow their domestic procurement policies, which often
require programs to buy drugs from domestic sources using
a local tendering process.
The Global Fund is in the process of transitioning a larger
proportion of TB, HIV, and malaria programs in many countries
to domestic financing. Without intervention pre-transition to
assist countries in finding ways to continue to purchase med-
icines from quality-assured sources, or interventions to ensure
that products for more fragile markets such as DR-TB medi-
cines are not transitioned from donor funding, countries will
likely have to revert back to buying DR-TB medications from
domestic sources. As a result, programs will no longer benefit
from the lower drug prices and stable supply the GDF has
been able to negotiate using its market share, and will also
have to take on the burden of applying on their own for
waivers in order to purchase medicines that have not been
locally registered if that is even possible.
The WHO PQ Programme has a collaborative registration
process, whereby the 31 participating country regulatory
authorities – mostly in Eastern Europe and Africa – agree to
review dossiers within 90 days of their approval by the WHO
EXPERT REVIEW OF CLINICAL PHARMACOLOGY 3
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PQ Programme. National regulatory authorities, especially in
countries with small markets for TB medicines, should sub-
scribe to the WHO PQ Programme’s collaborative registration
process to expedite review timelines and overcome the issues
that come up in the absence of local registration. Generics
manufacturers often prefer WHO PQ to SRA approval because
it has to date been a less expensive and onerous process,
though historically WHO PQ timelines have been unpredict-
able and at times lengthy.
Recently announced changes to the WHO PQ fee structure
may make this pathway less attractive to manufacturers of TB
medicines for small, fragmented, and non-lucrative markets,
like pediatric DR-TB, whose sales may not be sufficient to
cover fees and even marginal requisite profits. However, the
WHO created a waiver process that is hoped to keep suppliers
engaged in these low-volume markets. Tracking the impact of
new fees on engaging suppliers in the pediatric DR-TB market
will be critical.
2.6. Operational challenges
The small number of children currently being treated for MDR-
TB produces a vicious cycle throughout the supply chain.
Manufacturers are unwilling to produce large volumes of
medications unless demand is assured. NTPs are unwilling to
purchase appropriate stock unless they are confident that
drugs will be used. Finally, more regional pharmacies are not
keen to stock sufficient numbers of individual drugs as each
have limited shelf-lives and a mismatch between supply and
demand leads to wastage. This is compounded by inaccurate
forecasting, relatively short drug shelf-lives, long lag times
between ordering and production, long shipping and impor-
tation times, and frequently, complex internal distribution net-
works [22].
Introduction of new treatments requires substantial effort
for NTPs. Guidelines must be reviewed and updated. Program
monitoring tools, such as forms and registers, often must be
adapted to accommodate new treatments or regimens.
Healthcare workers must then be trained on the new treat-
ments and guidelines. All of this means there will necessarily
be delays in getting new treatments taken up in routine
program settings. Additionally, many pediatric trials to date
have been age de-escalation trials in which older children are
first enrolled, and after demonstrating safety and optimal
dose, progressively younger children are enrolled. This
means data likely to influence practice may emerge sporadi-
cally over the course of the trials. The WHO and NTPs should
develop processes to rapidly incorporate new data into prac-
tice, so that children can benefit from new treatments as
quickly as possible.
3. Individual repurposed drugs
3.1. Clofazimine
The rhiminophenazine antibiotic clofazimine (Lamprene;
Novartis Pharma AG, Basel, Switzerland) has been used for
decades in leprosy treatment, but has only recently been
studied for the treatment of MDR-TB, because of limited
existing treatment options. It has activity against nonreplicat-
ing and actively growing bacteria [23]. It is reduced by NADH
dehydrogenase (NDH-2) to release reactive oxygen species
upon reoxidation by O2 [24]. It competes with menaquinone
(MK-4), a key cofactor in the mycobacterial electron transfer
chain, for its reduction by NDH-2.
A clofazimine-containing MDR-TB regimen was able to
shorten treatment duration to 9–12 months with more than
80% cure in adult MDR-TB cases [25]. Further observational
studies in adults confirmed this outcome [26,27]. This shorter
regimen is now recommended by the WHO for pulmonary
rifampicin mono-resistant and MDR-TB without second-line
drug resistance in adults and children [28]. Preliminary data
of a randomized controlled trial of this shorter regimen com-
pared to the 20–24-month regimen (STREAM) in adults
showed 78.1% vs. 80.6% favorable outcome, respectively, for
these regimens [29].
Although clofazimine is only registered for use in leprosy, it
recently has been used off-label as a second-line anti-TB drug
in many MDR-TB regimens, including in children, and WHO
currently classifies clofazimine as a group C (other core sec-
ond-line agents) MDR-TB drug [28].
Clofazimine is a highly lipophilic drug; despite high varia-
bility in absorption, it can be administered orally. Available
evidence suggests that clofazimine should be administered
with food to enhance its absorption. It seems to be highly
protein bound [30]. Clofazimine has a large volume of distri-
bution, concentrating in fatty tissues and macrophages, the
latter of which may be therapeutically advantageous [23]. It is
metabolized in the liver with minimal renal excretion. The
elimination half-life of clofazimine is long (25–70 days); there-
fore, it takes months before plasma concentrations reaches
steady state. Early bactericidal activity studies found no activ-
ity over the first 14 days [31], but delayed bactericidal effect
was found with clofazimine in mice [32]. In experimental
studies, clofazimine seems to be important in possible short-
ening of MDR-TB treatment regimens [30]. Dosing of clofazi-
mine in MDR-TB is uncertain, but in the shorter MDR-TB
regimen 100 mg daily is recommended in adults. Doses of
200–300 mg of clofazimine were previously used in MDR-TB
patients with relatively few adverse effects [33,34].
The main adverse effect of clofazimine is skin discoloration
or darkening – in our experience occurring in the majority of
children receiving the drug. This may be distressing to
patients and lead to stigmatization. However, in our experi-
ence, it did not lead to discontinuation of the drug.
Discoloration may improve even while on treatment and in
most it clears within months of stopping clofazimine. Other
adverse effects noted are ichthyosis and gastrointestinal dis-
turbance. Clofazimine may cause dose-related QTc-interval
prolongation, so caution is advised when using clofazimine
in combination with other drugs with QT prolonging effects.
There is only limited pharmacokinetic study of clofazimine
in adults and none in children. Despite the lack of pharmaco-
kinetic data, clofazimine has become an important component
of MDR-TB regimens in adults and children. Clofazimine is
inexpensive but it currently seems difficult to procure espe-
cially given increased global demand with the rollout of the
shorter MDR-TB regimen in many countries. Recommended
4 H. S. SCHAAF ET AL.
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doses for children are 2–3 mg/kg/day and some experts
recommend up to 5 mg/kg/day because of the absence of
child-friendly formulations. In many settings, only 50 or
100 mg gel capsules are available which cannot be opened
or dissolved in water. Smaller children are therefore dosed
every second or third day depending on body weight and
available formulation. This could be acceptable due to the
drug’s long elimination half-life. However, there is an urgent
need for pharmacokinetic data, as well as child-friendly for-
mulations, to take this drug forward in MDR-TB treatment
shortening trials. Luna Innovations has done initial stability
testing on a clofazimine gummy formulation for children
[35]. Macleods Pharmaceuticals is developing a 50 mg disper-
sible clofazimine tablet.
3.2. Linezolid
The oxazolidinone class antibiotic, linezolid, has a novel
mechanism of inhibiting protein synthesis, making cross-resis-
tance with other protein-synthesis inhibitors unlikely. Linezolid
is active against gram-positive organisms, including resistant
gram-positive infections, but does not have an official indica-
tion for treatment of DR-TB [36]. However, the oxazolidinones
– including linezolid and more recently, sutezolid – have
shown excellent antimycobacterial activity [36,37], and line-
zolid has been effective for treating MDR-TB in adults in multi-
ple observational studies and in a delayed-start randomized
controlled trial [38–40]. Linezolid is currently used in the NiX
XDR-TB treatment salvage and shortening trial [41,42].
Since 2006, the WHO has recommended the use of line-
zolid in the treatment of MDR/XDR-TB and it is classified as a
group C MDR-TB drug [28]. Linezolid has a narrow therapeutic
window. The optimal dose that maximizes linezolid’s efficacy
while minimizing the substantial dose and duration toxicity
has not yet been determined, thus limiting its potential
impact [43].
Linezolid is well absorbed (almost 100%) after oral admin-
istration, with equally good absorption with the oral suspen-
sion and tablet formulation. Coadministration with a high fat
meal may delay absorption but does not affect exposure.
Linezolid has complex metabolism with two primary and mul-
tiple minor metabolites. The primary route of elimination is
nonrenal, accounting for approximately 65%. Increased clear-
ance and decreased drug exposure has been noted in ill
patients relative to healthy volunteers, as well as substantial
inter-patient variability, which raises the question of the role
of therapeutic drug monitoring [36].
Although there are pharmacokinetic data on linezolid used
as a short-term antibiotic in children, there are no data for
long-term TB treatment. Although optimal dosing in adults is
not yet known, the current target for pharmacokinetic studies
in children is to approximate exposures achieved in adults
with a 600 mg once-daily dose [44]. A linezolid suspension
exists, but it is expensive and access in resource-constrained
settings is limited. The adult 600 mg tablet is not suitable for
dosing young children due to the large tablet size and
strength, difficulty in suspending, and lack of data on impact
on crushing or suspending on bioavailability. A child-friendly
dispersible tablet formulation at reasonable cost is needed
[45]. The WHO has approved a call for the development of a
150 mg dispersible tablet and Macleods is expected to file for
WHO PQ soon [46]. A further challenge to its more widespread
use in children for MDR-TB is linezolid’s toxicity profile, includ-
ing bone marrow suppression, peripheral neuropathy, and
optic neuritis among others. This calls for close monitoring
of children treated with linezolid [47]. There is a need for
pediatric formulation development, and pharmacokinetic and
safety studies in children of sutezolid, a less toxic oxazolidi-
none which is now entering phase 2b studies in adults. Finally,
although linezolid has been registered in many countries for
use as an antibiotic in children, it is currently used off-label
for TB.
3.3. Fluoroquinolones (levofloxacin and moxifloxacin)
The later-generation fluoroquinolones levofloxacin and moxi-
floxacin have become such an integral part of current MDR-TB
regimens that they are hardly considered as repurposed drugs,
but they were originally developed as antibacterial drugs.
They inhibit DNA gyrases, preventing bacterial DNA synthesis
[48]. A huge body of evidence for their effectiveness in MDR-
TB in adults and children, despite the lack of randomized
controlled trials, their good bactericidal and sterilizing activity
and their favorable pharmacokinetics and toxicity profile have
made them the most important component of existing MDR-
TB treatment regimens [49]. However, there remain a number
of unresolved issues with fluoroquinolone use in both adults
and children, including the optimal dose of any given fluor-
oquinolone, the optimal duration of therapy, and the pre-
ferred fluoroquinolone, especially with other new and
repurposed drugs also having the potential of QT-interval
prolongation [48]. Further, there is concern about increased
fluoroquinolone resistance due to uncontrolled use in several
developing countries [50].
Characterization of the pharmacokinetics of levofloxacin
and moxifloxacin in children with TB is improving although
there remain important knowledge gaps. Levofloxacin is well
absorbed after oral administration and primarily eliminated
unchanged by the kidneys. The WHO dosage recommenda-
tions in children are 15–20 mg/kg/day divided twice daily in
children aged ≤5 years, and 10–15 mg/kg/day once daily in
children aged >5 years [51]. More recent data have shown that
doses closer to 20 mg/kg/day in children are required to
approximate target exposures in adults receiving a 750 mg
dose [52,53]. Ongoing pharmacokinetic and safety studies
(MDRPK2, TB-CHAMP lead-in PK study) [52,53], including with
a novel dispersible formulation, are expected to provide addi-
tional much needed information. There is less data on moxi-
floxacin pharmacokinetics in children. Moxifloxacin has >90%
oral bioavailability, with roughly 50% metabolized in the liver
and the remainder eliminated unchanged in the feces and
urine [54,55]. The current WHO-recommended dose in chil-
dren is 7.5–10 mg/kg once daily; however, this dose results in
exposures in young children well below targets seen in adults
receiving the usual 400 mg daily dose [56]. HIV infection is
associated with lower moxifloxacin exposures, due either to
the effects of HIV infection itself or drug–drug interactions
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(DDIs) with antiretrovirals [56]. The ongoing MDRPK2 study
[56] is expected to inform optimal moxifloxacin dosing across
ages.
Despite the good clinical toxicity profile documented in
children regarding musculoskeletal adverse effects [49],
neither levofloxacin nor moxifloxacin has been licensed for
TB in children <18 years of age by the US FDA [57,58]. In the
United Kingdom, the fluoroquinolones are not licensed for TB
in either adults or children. To date, safety concerns remain
the biggest challenge in the appropriate use of the fluoroqui-
nolones for MDR-TB treatment and prevention in children, as
was experienced by the V-Quin MDR-TB prevention trial in
Vietnam in 2016 not being able to get approval for levoflox-
acin use as preventive treatment in children [56].
The WHO recommends the use of levofloxacin and moxiflox-
acin for treatment of DR-TB in children. They have put out a call
for development of dispersible child-friendly formulations of
both drugs [46]. A levofloxacin 100 mg dispersible tablet
(Macleods, India) has already been manufactured and bioavail-
ability studies completed as part of TB-CHAMP trial (MDR-TB
prevention in children <5 years in South Africa). Macleods has
also produced a 100-mg dispersible moxifloxacin tablet [41].
4. Novel TB drugs
4.1. Bedaquiline
The diarylquinoline bedaquiline (Sirturo; Janssen
Therapeutics, New Brunswick, NJ, USA), previously known
as TMC207, kills both dormant and actively replicating
mycobacteria by a unique mechanism of inhibiting myco-
bacterial adenosine triphosphate (ATP) synthase [59]. It was
the first of the current new anti-TB drugs to receive accel-
erated approval in December 2012 by the FDA for the
treatment of MDR-TB, based on phase 2b trial data in adults.
At the time there was concern about significantly more
deaths occurring in the bedaquiline arm of a phase 2
study [60], which led to a black box warning in the packet
insert. Bedaquiline has since then also been approved for
MDR-TB by the European Medicines Agency (EMA) and the
South African Medicines Control Council [61]. It is also
included in the complementary list (essential medicines for
priority diseases, for which specialized diagnostic or moni-
toring facilities, and/or specialist medical care, and/or spe-
cialist training are needed) of WHO Model List of Essential
Medicines (March 2017). Further phase 3 studies and com-
passionate use programs have shown fewer deaths in MDR-
TB patients receiving bedaquiline compared to those not
receiving bedaquiline in their MDR-TB treatment regi-
mens [62].
According to the 2016 WHO DR-TB guidelines on bedaqui-
line and in the context of the new WHO recommendations for
the use of a shorter regimen to treat MDR-TB, bedaquiline is
indicated for MDR-TB patients who are NOT eligible for the
shorter regimen, that is, in case that a minimum of five effec-
tive TB drugs regimen cannot be composed with agents from
groups A to C and the addition of pyrazinamide. This means
bedaquiline continues to be indicated for the treatment of
adult MDR-TB patients with (i) confirmed additional resistance
to fluoroquinolones or second-line injectable drugs; (ii)
patients with XDR-TB; (iii) patients with known adverse drug
effects, poor tolerance, or contraindication to any component
of the WHO-recommended longer regimen; or (iv) in case of
unavailability or lack of guaranteed supply of a medicine
being part of the WHO-recommended longer regimen.
Pediatric pharmacokinetic and safety studies of bedaquiline
have been much delayed despite increasing routine access for
adults [63]. Two pediatric trials have started enrolment. The
Janssen-sponsored C211 trial (NCT02354014) is a phase 2 trial
of bedaquiline pharmacokinetics and safety in combination with
an optimized background regimen (OBR) in HIV-uninfected chil-
dren with MDR-TB. This age de-escalation trial began in 2016
and has completed enrolment (15 adolescents) in the 12- to
<18-year age-group; enrolment in the 6- to <12-year age-group
is progressing, but no results are yet available. The second trial,
sponsored by the U.S. National Institute of Allergy and Infectious
Disease Infant Maternal Pediatric Adolescent AIDS Clinical Trial
network (IMPAACT) (P1108; NCT02906007), will study pharma-
cokinetics and safety of bedaquiline in combination with OBR in
both HIV-infected and -uninfected children with MDR-TB and
opened September 2017.
Because the pharmacokinetics of adolescents are similar
to that of adults and the need for new drugs in difficult-to-
treat MDR-TB cases, this has led to bedaquiline being
recommended by the Sentinel Project (on DR-TB in children)
in children as young as 12 years of age and weighing
>33 kg in the absence of any studies and despite WHO
recommendations of use of bedaquiline only in adults
>18 years of age [47,64]. The delay in these pediatric dose
finding and safety studies has prevented access of younger
children to this effective new anti-TB drug other than off-
label use through organizations such as MSF for individual
cases [65].
Although bedaquiline is well absorbed (improved by a fatty
meal) and peak plasma concentrations are reached within 4–5 h,
steady-state conditions takes >7 days of treatment to be reached
in adults. Both bedaquiline and its M2 metabolite have very long
terminal half-lives in adults of 164 (range 62–408) and 159 (range
69–407) days, respectively, most likely due to its redistribution
from tissue compartments [59]. This complex pharmacokinetic
behavior and toxicity risk makes extrapolation of the adult dose
(400 mg daily for 2 weeks and then 200 mg three times weekly
for 22 weeks) to children difficult.
Although Janssen Therapeutics has developed a dispersible
child-friendly bedaquiline formulation that will be evaluated in
pediatric trials, this formulation may not be available for rou-
tine care in many settings for some time. The current adult
formulation is available as 100 mg tablets, is palatable and can
be suspended in water. A bioavailability study of whole vs.
suspended adult formulation tablets (TASK-002, NCT03032367;
sponsored by IMPAACT) has been recently completed.
Bioavailability was similar for crushed/suspended tablets com-
pared to whole tablets in healthy adult volunteers. This means
that once data on bedaquiline dosing in children are available
even if the pediatric formulation is not, young children can use
crushed or suspended adult 100-mg tablets off-label without
concern that this formulation manipulation will affect beda-
quiline’s bioavailability [66].
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4.2. Delamanid
The nitroimidazo-oxazole, delamanid (Deltyba, Otsuka Novel
Products GmbH, Munich, Germany), previously known as OPC-
67683 is another new drug shown to be effective when added
to an MDR-TB regimen in a randomized, placebo-controlled
phase 2b trial [67]. Delamanid is the first compound from a
new drug class (nitro-dihydro-imidazooxazoles) that is bacter-
icidal and specific to M. tuberculosis, including MDR strains.
Following bioreduction within M. tuberculosis by the mycobac-
terial F420 system (as it is thought to be a prodrug), it inhibits
mycolic acid biosynthesis. It has activity against both growing
and dormant mycobacteria. A phase 3 randomized controlled
trial of delamanid vs. placebo with an OBR for MDR-TB has
recently been completed (NCT01424670) [41]; provisional
results presented at the 48th Union World Conference on
Lung Health in Guadalajara, Mexico, showed similar outcomes
with or without delamanid under strict trial conditions, though
shorter times to culture conversion were observed among
those treated with delamanid. In April 2014, delamanid
received conditional approval by the EMA based on phase
2b data – since then it has also been approved in Hong
Kong, Japan, South Korea, Turkey, The Philippines, China,
Indonesia, and India and filed in Peru and South Africa; dos-
siers are also reportedly being prepared for registration in
Vietnam and Russia. It is also included in the complimentary
list (with age restriction >6 years) of the WHO Model List of
Essential Medicines (March 2017), the most effective and safe
medicines needed in a health system.
Delamanid Tmax is 4–6 h after oral administration and
absorption is increased 2–2.4-fold when it is taken with a
meal. Delamanid is converted by albumin to its primary meta-
bolite DM-6705, which is further metabolized by CYP3A4
[68,69]. Both delamanid and DM-6705 have extremely long
half-lives, with median (range) t1/2 of 30–38 and 150–600 h
respectively [70]. A DDI study in healthy adult volunteers
showed that administration of delamanid with first-line anti-
tuberculosis drugs resulted in a nearly 50% reduction in dela-
manid exposures which was hypothesized to be due altered
delamanid absorption; this has resulted in the recommenda-
tion to give delamanid at least 1 h apart from other TB
medications [71]. Delamanid exposures are not proportional
to dose, with exposures plateauing at a dose of 300 mg and
higher due most likely to saturated dissolution [71]. The WHO-
recommended adult delamanid dose is 100 mg twice daily
[72]. The Otsuka-sponsored delamanid phase 3 trial will study
a dose of 100 mg twice daily for 2 months, then 200 mg once
daily for an additional 4 months. Once-daily dosing is much
easier for patients and programs, and is beneficial for adher-
ence. The ACTG-IMPAACT led PHOENIx Trial (A5300B/12003B/
PHOENIx) will include a lead-in pharmacokinetic study evalu-
ating the pharmacokinetics and safety of once-daily delama-
nid dosing.
Otsuka-sponsored Phase 1 (242-12-232, NCT01856634) and
Phase 2 (242-12-233, NCT01859923) pediatric delamanid age
de-escalation trials started in 2013 in The Philippines and
South Africa [41]. Pharmacokinetic data from the first two
groups (Group 1: ages 12 to <18 years, adult dose and
Group 2: ages 6 to <12 years, half adult dose) of these trials
showed that delamanid exposures in children were within the
range seen in adults. On the basis of this data, WHO adapted
their delamanid policy guidance to include children from 6 to
17 years of age: recommended dose of delamanid in children
with MDR-TB (aged 6 to <12 years) is 50 mg BID for 6 months,
and in adolescents (aged 12 to <18 years) it is 100 mg BID for
6 months given with food [73]. Pharmacokinetic data from the
third group (ages 3 to <6 years) have already been collected
and final results are awaited; enrolment in the fourth age-
group (ages <3 years) has begun. Although clinically signifi-
cant DDIs with antiretrovirals have not been seen to date,
coadministration with lopinavir–ritonavir results in 20% higher
delamanid exposures. The trial IMPAACT 2005 expects to open
enrolment early 2018, and plans to address knowledge gap on
delamanid pharmacokinetics and safety in HIV-infected chil-
dren. Otsuka has successfully developed dispersible, taste-
masked pediatric formulations in two strengths, which are
being evaluated in younger age groups (<6 years of age) in
its pediatric trials, and will also be used in the IMPAACT 2005
study [45].
Despite the above advances, the registration and resulting
uptake of delamanid has been slow and few children have
managed to access it to date [74]. A compassionate use pro-
gram for children is available from Otsuka through approval
processes such as European Respiratory Society/WHO TB
Consilium and MSF, but the process is unfamiliar and cumber-
some for most potential users [74]. Although in South Africa a
Delamanid Clinical Access Programme was launched World TB
Day (24 March) 2017, this access program is aimed at treating
adults, and although children 6–18 years are supposed to be
included, this has not become available to clinicians managing
children <12 years of age (awaiting Medicines Control Council
approval) [75].
4.3. Pretomanid
The bicyclic nitroimidazole-like molecule (a nitroimidazopyran)
pretomanid, also known as PA-824, was developed by
Pathogenesis Corporation and later transferred to the TB
Alliance. Pretomanid is the second nitroimidazole to enter
phase 3 clinical trials. It has a mechanism of action similar to
delamanid and is active against DS- and DR-TB, both replicat-
ing and hypoxic, nonreplicating M. tuberculosis. In M. tubercu-
losis, the prodrug pretomanid is activated by F420-dependent
glucose-6-phosphate-dehydrogenase pathway [76]. Activation
of pretomanid within the mycobacteria results in production
of reactive nitrogen species (including nitric oxide) which
leads to nonspecific damage of intracellular macromolecules,
a decrease in intracellular ATP and anaerobic killing.
Pretomanid also kills aerobically by inhibiting cell wall mycolic
acid biosynthesis [76,77].
Pretomanid has been well tolerated in adults with constant
pharmacodynamic parameters when given once daily; Tmax is
4–5 h following oral administration. The mean half-life varies
from 16.1 to 23.8 h. Pretomanid has a large volume of dis-
tribution, indicating that the drug concentrates in tissues [78].
In adults, the drug appeared safe and efficacious when given
between 100 and 200 mg once daily; it may induce a mild QT-
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interval prolongation as well as a transient increase in creati-
nine levels [25]. Pretomanid has mainly been used in phase 2b
and 3 trials in combination regimens with other novel (e.g.
bedaquiline) and repurposed (e.g. moxifloxacin, linezolid)
drugs with or without pyrazinamide for both DS-TB and DR-
TB. These regimens are studied with the prospect of short-
ening both DS-TB and DR-TB treatment durations.
The NiX-TB trial (NCT02333799), an open-label phase 3
study sponsored by TB Alliance of bedaquiline, pretomanid,
and linezolid for 6–9 months in patients with XDR-TB and
failed MDR-TB, has shown promising preliminary results
[41,42]. In preliminary data on 40 patients who had finished
treatment, 31 had finished 6 months of follow-up; only 2 of
these 31 have relapse or reinfection [35].
Pretomanid has not yet been approved by any regulatory
authority, but there may be pressure on TB Alliance to work
with other stakeholders to arrange an access program before
regulatory approval is granted [59]. Although the use of pre-
tomanid had setbacks in some phase 3 trials, the promising
results of the NiX-TB trial should make pharmacokinetic and
safety studies in children a priority. Concern regarding possi-
ble testicular toxicity observed in rodents in preclinical studies
stalled pediatric pretomanid trials. Male reproductive hormone
data collected from participants in phase 2 and 3 studies by TB
Alliance have been submitted to the FDA to demonstrate
safety and allow children to be dosed with pretomanid. TB
Alliance plans to submit a PIP to the EMA during 2017 and has
already developed a child-friendly dispersible formulation [35].
5. Challenge of HIV infection and DDIs
DDIs between anti-TB and antiretroviral drugs are common,
and these should be carefully considered when using these
drugs in HIV coinfected children. Possible DDIs, based on
studies in adults only, are summarized in Table 1. Some
DDIs, such as between bedaquiline and the protease inhibi-
tors, may be barriers to using bedaquiline in some HIV-
infected children.
6. New regimens, future directions, and new
compounds
Combinations of new and investigational drugs have the
potential to greatly improve the treatment of MDR-TB, and
even potentially DS-TB. The goal is TB treatment regimens
which are shorter, better tolerated, and do not include an
injectable drug. The adult MDR-TB trial landscape is rapidly
evolving, with multiple late phase trials evaluating novel,
shorter regimens, many of which contain only orally adminis-
tered medications. New medications may also play a role in
preventive therapy. Delamanid is going to be evaluated in the
PHOENIx trial for prevention of TB in high-risk MDR-TB
exposed adults and children.
To date, pediatric TB drug trials have focused on dose
finding and safety for individual medications, with efficacy
extrapolated from adult studies. However, children have
much better outcomes than adults with MDR-TB (successful
outcomes in 75–90% of children vs. 50% of adults) most likely
due to the paucibacillary, less severe nature of pediatric TB
disease [79]. This raises the potential that children could do
equally well with even shorter, less intense treatment regi-
mens. There is now international consensus that an efficacy
trial of a shortened regimen is needed in children with MDR-
TB, and such a trial is in development through the IMPAACT
network [80]. SMaRT Kids is a multicenter phase 3 non-infer-
iority trial among children <15 years of age with probable or
confirmed MDR-TB, which will compare a 6-month, all-oral
regimen of delamanid, clofazimine, linezolid, levofloxacin,
and pyrazinamide vs. the 9–11-month shortened regimen
recommended by the WHO [28] (Personal communication AJ
Garcia-Prats). This study is early in development and unlikely
to open until 2019.
Additionally, there are a number of new compounds in
phase 1 and 2 clinical development. This includes the novel
oxazolidinones sutezolid and LCB01-0371; the DprE1 inhibitors
OPC-167832, PBTZ-169, and TBA-7371; the rhiminophenazine
TBI-166; and agents with other mechanisms of action includ-
ing Q203, nitazoxanide, and GSK070 [81]. Pediatric develop-
ment programs should occur in parallel with adult
development, as described elsewhere [56], to avoid the delays
seen with bedaquiline, pretomanid and to a lesser extent
delamanid.
7. Expert commentary
New and investigational drugs are urgently needed for chil-
dren with MDR-TB, and are likely to be increasingly important
depending on results of ongoing or planned trials. However,
Table 1. Possible drug–drug interactions between new and repurposed antituberculosis drugs and antiretroviral drugs.
Anti-TB drug Antiretroviral drug Drug–drug interaction
Bedaquiline (BDQ) (and its
M2 metabolite)
Lopinavir–ritonavir (boosted protease
inhibitor; PI) [83]
Increase in BDQ and M2 exposure due to reduced clearance; may lead to increased toxicity.
Dose adaptation required
BDQ (and its M2 metabolite) Nevirapine (NVP) [83] No significant interaction
BDQ Efavirenz (EFV) [84] About a 50% reduction in BDQ exposure when chronically coadministered with efavirenz
Delamanid EFV, NVP, Tenofovir and boosted PI
[85,86]
No relevant DDIs with any ARVs, as no induction or inhibition of CYP450 system
Pretomanid (PA824) EFV [87] CYP3A minor metabolic pathway for PA824. Reduces PA824 exposure by 35%
Pretomanid (PA824) Boosted PI (Lpv/r) [87] CYP3A minor metabolic pathway for PA824. Reduces PA824 exposure by 17%
Clofazimine No known DDIs with ARVs, but studies lacking.
Linezolid Antiretroviral drugs [88] No known DDIs, but possible increase risk of mitochondrial optic neuropathies with
nucleotide reverse transcriptase inhibitors (NRTIs)
Fluoroquinolones No known DDIs with ARVs
ARVs: antiretroviral drugs; DDI: drug–drug interactions; TB: tuberculosis.
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at each step their use is obstructed or delayed by clinical
research, drug development, financing, regulatory, and opera-
tional barriers. For most of these barriers, potential solutions
are known or have been proposed. One of the most important
changes needs to be more timely initiation of pediatric trials
for novel drugs. As described in Section 2.2, pediatric work
should happen in parallel at each phase of adult trials. In order
to facilitate timely pediatric work, other contributing barriers
must be addressed.
Additional funding and novel mechanisms are needed to
finance pediatric TB drug development, as there is little profit
incentive for pharmaceutical companies to do so. The Life
Prize, formally known as 3P, is a project that attempts to
speed TB drug development through push-and-pull mechan-
isms to incentivize different phases of drug development, and
through pooling of intellectual property [82].
Regulatory authorities, charged with protecting the public,
are often forced to walk a difficult line between ensuring
sufficient evidence of safety and efficacy while facilitating
access to new medications. This is especially true in the case
of medications for unmet medical needs or for conditions for
which the existing standard of care is suboptimal, like for DR-
TB. Generally, better quality data, increased regulator
resources and expertise, and harmonization of regulatory
requirements would greatly improve registration timelines.
For children, harmonization across regulatory authorities
regarding pediatric data requirements, and further, the estab-
lishment of an expedited review pathway for pediatric formu-
lations would greatly improve the speed at which pediatric
investigations and regulatory reviews are conducted.
Additionally, clear and harmonized regulatory guidance
regarding the pathway and data requirements necessary to
support a supplementary TB indication for repurposed drugs
are needed. Registration fee waivers could be used to incenti-
vize more local registrations of products that have limited
market potential, like pediatric formulations for DR-TB medi-
cines. Similarly, the impact of WHO PQ fee exemptions for
products for children with DR-TB and other fragile markets
should be monitored to ensure that manufacturers will con-
tinue to pursue WHO PQ status for their products. Finally,
policy change at the country level to enable procurement
using domestic resources for quality-assured medicines at
the lowest price possible (i.e. via the GDF or enabling GDF to
bid on national tenders) would help to prevent further market
fragmentation and to maintain the availability of good quality
medicines at low prices.
If regimens for MDR-TB treatment in children were more
standardized, then forecasting would be more straightforward.
Mechanisms for increasing demand would include more
extensive training, more inclusive guidelines, currently avail-
able diagnostic tests being more utilized in children, and the
development of better pediatric diagnostic tests. A more
streamlined approach to drug distribution, from manufacturer
to patient, would help significantly and the use of a centra-
lized procurement agency, such as the GDF, would allow small
regional demands to be aggregated and managed on a global
level.
Improved capacity and systems for procurement and sup-
ply chain management would reduce in-country operational
barriers to getting medications to children in the field.
Systems within TB programs for the rapid introduction and
scale-up of new medications, as well as other evidence-based
policies and other tools such as diagnostics, are needed.
Lastly, efforts to scale up the diagnosis and programmatic
management of children with MDR-TB must begin in earnest.
This must include improved recording and reporting of pedia-
tric MDR-TB cases, with pediatric data reported by the WHO
alongside adult data.
8. Five-year view
Clinicians managing MDR-TB in children are eager to use the
new drugs, especially delamanid and bedaquiline, in treat-
ment regimens, and to eliminate the injectable agents alto-
gether. Delamanid dose and safety data in young children
should be available in the next 1–2 years, while data on
dose and safety of bedaquiline should be available within
the next 5 years. Although child-friendly formulations have
been developed for both these drugs, there remains uncer-
tainty about their market introduction and availability, but
adult formulations in crushed and dispersed forms will be
available and bioavailability studies are being performed.
Repurposed drugs are already in use, but more data will be
known on optimal dosing in children at different ages, and
child-friendly formulations should be available. We are opti-
mistic that with all the treatment-shortening trials ongoing in
adults and planned for children that we will have a shorter 6-
month, all-oral MDR-TB treatment regimen for children. The
challenge of diagnosing more children with MDR-TB given the
limits of existing diagnostic tools remains an urgent priority.
The lessons learned in developing delamanid and bedaquiline
in children need to be applied to other new compounds as
they undergo evaluation, to avoid the same pitfalls and ensure
equitable access of important treatment advances for children.
Key issues
● New antituberculosis drugs to more safely and effectively treat
MDR-TB are needed asmuch for children as for adults; however,
children are always last to gain access to these drugs
● Confirmation of MDR-TB in children is challenging therefore
currently only a small proportion of MDR-TB cases in chil-
dren are diagnosed. Children cannot benefit from new TB
medications if they are not diagnosed as having probable
or confirmed MDR-TB, and in the absence of much
improved case finding or more sensitive diagnostic tests,
much of the benefit of new medications in children will
remain unrealised.
● Efficacy trials for new drugs are not necessary in children
unless these drugs are for specific pediatric indications, as
efficacy in adult TB cases infers efficacy in children. Dose
finding and safety studies in children should be done early
in new drug evaluations otherwise clinicians may start
using these drugs without properly established dosing
and without evaluation of their safety in children.
● Because of the lack of market incentive for antituberculosis
drugs, various push and pull mechanisms have been pro-
posed to incentivise the development of new drugs.
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● In addition to the research and development necessary to
determine appropriate doses and formulations acceptable
for children, improved regulatory and procurement policies
are critically important to facilitate access to new and
repurposed drugs for the treatment of children with
MDR-TB.
● Operational challenges should be addressed by organisa-
tions, such as the World Health Organization and
National TB Programmes, developing processes to rapidly
incorporate new data and tools into practice, so that
children can benefit from new treatments as quickly as
possible.
● Data is emerging from ongoing studies on the pharmaco-
kinetics and safety of new (bedaquiline, delamanid and
pretomanid) and repurposed (fluoroquinolnes, clofazimine
and linezolid) drugs.
● We are optimistic that with the available arsenal of newer,
repurposed, and existing drugs, and ongoing and planned
treatment shortening trials, that a 6-month, all-oral MDR-TB
treatment regimen for children will be possible within five
years.
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multidrug-resistant tuberculosis treatment in children
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S UMMA R Y
After decades of neglect, data are finally becoming
available on the appropriate, safe dosing of key second-
line anti-tuberculosis drugs used for treating multidrug-
resistant tuberculosis (MDR-TB) in children, including
levofloxacin (LVX), moxifloxacin (MFX), linezolid
(LZD) and delamanid (DLM). Much needed data on
some novel and repurposed drugs are still lacking,
including for bedaquiline (BDQ), pretomanid (PTM)
and clofazimine (CFZ). We review the status of pharma-
cokinetic (PK) and safety studies of key anti-tuberculosis
medications in children with MDR-TB, identify priority
knowledge gaps and note ongoing work to address those
gaps, in the context of planning for an efficacy trial in
children with MDR-TB. There is international consensus
that an efficacy trial of a novel, all-oral, shortened MDR-
TB treatment trial in children is both needed and feasible.
Key novel and repurposed second-line anti-tuberculosis
drugs include BDQ, DLM, PTM, MFX, LVX, CFZ and
LZD. The rapidly emerging PK and safety data on these
medications in children with MDR-TB from studies that
are underway, completed or planned, will be critical in
supporting such an efficacy trial. Commitment to
addressing the remaining knowledge gaps, developing
child-friendly formulations of key medications, improv-
ing the design of paediatric PK and safety studies, and
development of international trial capacity in children
with MDR-TB are important priorities.
K E Y WORD S : MDR-TB; children; PK; trials; safety
CHILDREN REPRESENTa substantial proportion of
the global burden of multidrug-resistant tuberculosis
(MDR-TB), defined as TB resistant to at least both
isoniazid and rifampicin, with an estimated 25000–
32000 incident cases globally each year.1,2 Recent
years have seen a rapidly evolving research landscape
for MDR-TB treatment in adults, which has included
the development and conditional registration of
multiple novel anti-tuberculosis medications, the
increased use of repurposed medications and the
evaluation of shorter, better-tolerated regimens. Chil-
dren also stand to benefit substantially from these
advances in treatment strategies for MDR-TB; how-
ever, there have been delays in evaluating these new
and repurposed medications in paediatric studies.
Understanding the pharmacokinetics (PK) and
safety of anti-tuberculosis medications in children,
and ensuring the availability of child-friendly formu-
lations, are critically important to providing access to
safe and effective treatment of MDR-TB in human
immunodeficiency virus (HIV) infected and non-
infected children. Furthermore, there is international
consensus that an efficacy trial of a shortened, all-oral
regimen is needed in children with MDR-TB.3 An
understanding of optimal, safe doses of medications to
be included in Phase III trial regimens is critically
important. We highlight here the status of PK and
safety studies of key novel and repurposed second-line
anti-tuberculosis medications in children with MDR-
TB, including bedaquiline (BDQ), delamanid (DLM),
pretomanid (PTM), moxifloxacin (MFX), levofloxa-
cin (LVX), clofazimine (CFZ) and linezolid (LZD), and
identifying priority knowledge gaps and ongoing work
to address those gaps, in the context of planning for an
efficacy trial in children with MDR-TB.
APPROACH TO DESIGN OF TRIALS OF THE
PHARMACOKINETICS AND SAFETY OF ANTI-
TUBERCULOSIS DRUGS IN CHILDREN
Well-designed and executed paediatric PK and safety
studies are central to anti-tuberculosis drug develop-
ment in children. The first step in the currently
accepted approach to determining the types of studies
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required for drug development in children is to assess
whether it is reasonable to extrapolate a drug’s
efficacy from adult trials to children.4 This depends
on whether, compared to adults, children could
reasonably be expected to have a similar disease
progression and a similar relationship between drug
exposure and response to the relevant treatment.4 In
the case of TB, the consensus has been that children
would be expected to have at least as good a response
to treatment as adults, given the paucibacillary nature
of TB disease in children.5,6 The priority then for
paediatric trials of anti-tuberculosis drugs is to
perform PK studies to identify the doses in children
that result in exposures approximating those in adults
receiving the recommended dose, and to establish
safety in children at those doses.5,6
Although common in routine clinical practice,
paediatric drug doses cannot reliably be directly
extrapolated from the mg/kg of body weight dose in
adults. This is because of both size-related and age-
related differences in PK. Size-related changes can be
described using allometry, which is the study of how
biological processes, volumes, body parts or organs
scale with body size.7 Many biological processes,
including clearance, which is a primary driver of drug
exposure, scale with body size at a less-than-
proportional rate, with the generally accepted 3/4
allometric scaling approach.8 The linear extrapola-
tion of mg/kg doses from adults to children therefore
results in lower drug exposures in children, with the
worst underexposure in the smallest children. Like
many other body volumes, volume of distribution,
also a key driver of drug exposures, scales more
proportionally with body size, although body com-
position differences alter this in the smallest infants.8
In addition to considerations of size, age-related
factors also affect anti-tuberculosis drug PK in
children.9 Most biological processes, many of which
have an important influence on drug disposition,
continue to mature and develop after birth. This
includes, but is not limited to, changes in gastroin-
testinal function and gastric pH, changes in renal
function, alterations in body composition, such as
proportion of body fat and body water, and
development of the capacity of enzymes responsible
for drug metabolism.9 The most dramatic changes
occur in the first weeks and months of life, and most
processes have reached near or full maturity by 2
years of age.
To establish the appropriate paediatric doses of TB
medications, carefully designed trials are thus needed
that include children across all relevant age groups,
with a particular focus on children aged ,2 years,
where the influence of size and age on PK is most
pronounced. Given the potential for drug-drug
interactions, it is also critically important that HIV-
infected children are included in these studies.
CONSIDERATIONS FOR ASSESSING SAFETY IN
CHILDREN
Adverse effects of anti-tuberculosis drugs are often
reported to be less common in children than in
adults.10,11 Although this observation may be correct,
it may be at least partly due to lower drug exposures
at the same mg/kg bodyweight doses in children than
in adults, as has been shown with the fluoroquino-
lones (FQs).12–14 Also complicating interpretation of
this is the distinct lack of prospective studies
accurately documenting adverse effects in children.
Due to the difficulty in assessment in children, some
adverse effects may be under-recognised, especially
those based on subjective report such as peripheral
neuropathy, pain and vision impairment, or those
requiring specialised testing such as hearing loss. The
majority of reported adverse effects in children are
mild or moderate and of little clinical importance.
However, these may still be unacceptable to children
or care givers/parents, leading to social stigmatisation
(e.g., skin discolouration with CFZ) or non-adher-
ence to medication (e.g., due to nausea and vomiting),
which may negatively impact treatment outcomes.
Data in juvenile animal studies and from trials in
adults should provide some additional insight into
anticipated adverse effects in children. It is tempting
to assume that adverse effect profiles in children are
similar to those in adults, given similar drug
exposures. Although they may be, this assumption
must be carefully tested in paediatric studies.15,16
Adverse effects seen in juvenile animal models or in
adults may not be seen in children at clinically
relevant doses, although such medications may be
perceived as poor candidates for paediatric treatment.
A relevant example is the persistent reluctance to use
FQs in children withMDR-TB in some settings due to
the arthropathy seen in juvenile animals,17 although
several human studies have documented the safety of
long-term FQ use in children.12,18 On the other hand,
children as developing organisms with developing
systems may be at risk for a spectrum or severity of
adverse effects not seen in adults. The classic example
is chloramphenicol, which was effectively and safely
used widely in adults with penicillin-resistant infec-
tions, but caused ‘gray-baby syndrome’ in infants due
to the immaturity of the hepatic uridine 50-diphos-
pho-glucuronyl transferase enzymes in children,
which hampered metabolism of the drug.19 The
safety of new medications or repurposed medications
with new doses must be carefully evaluated, partic-
ularly in young children.
Monitoring safety in studies of MDR-TB treatment
has its own inherent challenges. Given that these
multidrug regimens include as many as 5–7 different
medications, with potentially overlapping adverse
effects, assessing the attribution of individual drugs
for certain adverse effects is challenging. This may be
S16 The International Journal of Tuberculosis and Lung Disease
 280
Stellenbosch University  https://scholar.sun.ac.za
more challenging in HIV-infected children who will
also be taking antiretrovirals. Even where the adverse
effects of individual drugs are described, it may be
difficult to predict whether there will be an additive
risk of adverse effects where there is overlap. QT
interval prolongation, a known adverse effect of
BDQ, DLM, CFZ, and the FQs, is such an example.
For repurposed medications for which there may be
some paediatric experience, such as for LZD, the long
duration of treatment for TB may result in a different
risk of adverse effects compared to short-term
treatment of non-tuberculosis infections. Particularly
for the novel medications, the number of adults or
children who have ever been treated with these
medications remains small. An efficacy trial enrolling
a large number of children would therefore need to
carefully monitor for previously unreported adverse
effects.
The adverse effects of the priority anti-tuberculosis
medications listed above have been described in detail
elsewhere;12 key safety considerations and knowl-
edge gaps are shown in Tables 1 and 2.
DEVELOPMENTS IN PHARMACOKINETIC TRIAL
DESIGN IN CHILDREN WITH TUBERCULOSIS
The study of the PK of anti-tuberculosis drugs in
children has historically often been through observa-
tional studies, with sample size and sampling
schedule primarily pragmatically based on available
resources and experience from adult studies. More
recently, the use of model-based clinical trial simula-
tions using pharmacometrics methodology has been
introduced; this ensures sufficient statistical power
while simultaneously minimising the burden on the
participating children and the resources used.20
Pharmacometrics is a rapidly advancing field, aimed
at developing and applying mathematical models to
represent physiology, pharmacology and disease
progression. Because of the insight pharmacometrics
provides into PK-pharmacodynamic relationships, it
has been demonstrated to be highly useful in drug
development.20,21 There is clear regulatory guidance
on the expectations for paediatric PK studies which
states that paediatric studies should be designed to
have at least 80% power to fulfil defined precision
criteria for key PK parameters.22 Clinical trial
simulations using appropriately adjusted pharmaco-
metric models developed from adult data were used in
designing the above-mentioned IMPAACT (Interna-
tional Maternal Pediatric Adolescent AIDS Clinical
Trials) sponsored paediatric studies of BDQ (P1108)
and DLM (P2005). By evaluating the likelihood of
fulfilling these precision criteria for a diverse range of
design options and sample sizes, the simulations
played an integral part in the design decision-making
process for these key paediatric PK studies.
For novel medications not previously used in
children, an age de-escalation approach, starting
enrolment with a cohort of older children and
subsequently moving down in age, has traditionally
been used. Information gathered in the oldest
children can be added to the existing knowledge
from adults to generate more confidence in the
Table 1 Status of PK and safety data on novel anti-tuberculosis medications in children and ongoing or planned paediatric studies
Current data in children Key knowledge gaps Ongoing or planned studies
BDQ
PK No data in children Data on PK and optimal paediatric
doses in all ages
Janssen C211: BDQ PK and safety in
non-HIV-infected children with
MDR-TB aged 0–17 years (n ¼ 60)
IMPAACT P1108: BDQ PK and safety in
HIV-infected and non-infected
children with MDR-TB aged 0–17
years (n ¼ 72); includes HIV-infected
children on selected ARVs
Safety No data in children Data on safety at paediatric doses
in all ages
Drug-drug
interactions
Important interactions with ARVs
expected; no data in children
Data on interactions with ARVs in
HIV-infected children
DLM
PK Data on PK in non-HIV-infected
children aged 6–17 years (n ¼ 13);
drug exposure in children within
adult range
Data on PK and optimal doses in
children aged,6 years; potential
for once daily dosing (twice daily
dosing being studied)
Otsuka 232/233: DLM PK and safety in
children with MDR-TB aged 0–17
years (n ¼ 36)
IMPAACT 2005: DLM PK and safety in
HIV-infected and non-infected
children with MDR-TB aged 0–17
years (n ¼ 36–48)
Safety Data on safety in non-HIV-infected
children aged 6–17 years (n ¼ 13);
safe with minimal QT prolongation
Data on safety at paediatric doses
in children aged ,6 years
Drug-drug
interactions
Important interactions with ARVs not
expected; no data in children
Data on interactions with ARVs in
HIV-infected children
Pretomanid
PK No data in children Data on PK and optimal paediatric
doses in all ages
None
Safety No data in children Data on safety at paediatric doses
in all ages
Drug-drug
interactions
Important interactions with some ARVs
expected; no data in children
Data on interactions with ARVs in
HIV-infected children
PK¼ pharmacokinetic; BDQ¼ bedaquiline; HIV¼ human immunodeficiency virus; MDR-TB¼multidrug-resistant tuberculosis; ARV¼ antiretroviral; IMPAACT¼
International Maternal Pediatric Adolescent AIDS Clinical Trials; DLM¼ delamanid.
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prediction of doses to be tested in the next, younger
cohort. A model-based approach leveraging data
from adults and older children may provide the best
chance of selecting adequate doses for further study.23
The age de-escalation approach, however, is very time
consuming and cumbersome, with many interim trial
stoppages for analysis and dose adjustment, and is
not a formal requirement for paediatric trials by
stringent regulatory authorities. Modified approach-
es, such as enrolling children aged .3 years in
parallel, or using single-dose followed by multiple-
dose trials in all ages concomitantly, have been
proposed and are being considered.24
Historically, a lack of capacity to implement PK
studies in children with MDR-TB has been a
limitation to efficient anti-tuberculosis medication
evaluation in children. Until recently there was no
support for or recognition of the need for such
studies, and highMDR-TB burden settings frequently
lacked sufficient clinical, research or regulatory
capacity for them. This situation is now rapidly
evolving, with much needed clinical trial capacity
being built, partly due to the opening of the paediatric
trials sponsored by Otsuka (Tokyo, Japan) and
Janssen (Beerse, Belgium). Furthermore, the IM-
PAACT network is beginning to leverage its existing,
Table 2 Status of PK and safety data on key re-purposed anti-tuberculosis medications in children and ongoing or planned
paediatric studies
Current data in children Key knowledge gaps Ongoing or planned studies
LVX
PK Data in children with MDR-TB
across all ages (n ¼ 73), limited
in children aged ,2 years; low
exposures at currently used doses
Data on PK in young children, and
optimal paediatric doses in all
ages
MDRPK1: PK and safety of second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–14 years with MDR-TB (data
expected on .100 children on LVX)
MDRPK2: PK and safety of model-
optimised doses of key second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–17 years (data expected on
80–100 children on LVX)
Safety Some data across all ages at
currently used doses; generally
safe and well tolerated at
currently used doses
Data on safety at optimal paediatric
doses in all ages
Drug-drug
interactions
Important interactions with ARVs
not expected; limited data in
children
Confirm no important interactions
with ARVs in HIV-infected
children
MFX
PK Data in children with MDR-TB aged
7–14 years (n ¼ 23) showing low
exposures at current doses; no
data for ages ,7 years
Data on PK in children aged ,7
years, and optimal paediatric
doses in all ages
MDRPK1: PK and safety of second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–14 years with MDR-TB (data
expected on n ¼ 40 on MFX)
MDRPK2: PK and safety of model-
optimised doses of key second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–17 years (data expected on n
¼ 80–100 on MFX)
Safety Data in children with MDR-TB aged
7–14 years (n ¼ 23), safe at
current doses; no data for ages
,7 years
Data on safety at optimal paediatric
doses in all ages
Drug-drug
interactions
Some evidence for possible
interactions with ARVs; limited
data in children
Data on interactions with ARVs in
HIV-infected children
LZD
PK Data in children with non-
tuberculous infections; no
published data in children with
TB
Data on PK and optimal paediatric
doses for anti-tuberculosis
treatment in all ages
MDRPK1: PK and safety of second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–14 years with MDR-TB (data
expected on ,10 on LZD)
MDRPK2: PK and safety of model-
optimised doses of key second-line
anti-tuberculosis drugs in HIV-
infected and non-infected children
aged 0–17 years (data expected on
LZD PK in n ¼ 80–100 children,
long-term safety in 10–20)
Safety Limited data in children treated for
long courses (.28 days) for
MDR-TB
Data on safety at current and
optimal paediatric doses used
long-term for anti-tuberculosis
treatment
Drug-drug
interactions
Important interactions not
expected
Data on overlapping toxicity with
ARVs in HIV-infected children
CFZ
PK No data in children Data on PK and optimal paediatric
doses for anti-tuberculosis
treatment in all ages
No planned trials
Small amount of opportunistic PK data
possible from MDRPK1 and MDRPK2
Safety Some experience in children
treated for leprosy
Data on safety at optimal paediatric
doses; safety data when
combined with other QT
prolonging anti-tuberculosis
drugs
Drug-drug
interactions
Interactions possible with ARVs,
but limited data in adults or
children
Data on interactions with ARVs in
adults and children
PK¼pharmacokinetic; LVX¼ levofloxacin; MDR-TB¼multidrug-resistant tuberculosis; ARV¼antiretroviral; MFX¼moxifloxacin; HIV¼human immunodeficiency
virus; LZD¼ linezolid; CFZ¼ clofazimine.
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experienced network of trial sites, which to date have
been more focused on HIV, to study paediatric TB
and MDR-TB. These efforts, with continued invest-
ment of resources, are important to ensure timely
access to children of advances in MDR-TB treatment
and prevention, and to support increased interna-
tional collaboration and advocacy.
CURRENT STATE OF KNOWLEDGE, GAPS AND
PLANNED OR ONGOING PAEDIATRIC STUDIES
The landscape of trials evaluating novel medications
and regimens in adults with MDR-TB is rapidly
evolving. To ensure that children will be able to
benefit from MDR-TB regimens found to be effica-
cious and/or safer in adult trials, paediatric PK and
safety studies should focus on the anti-tuberculosis
drugs that are being prioritised in adult studies and
that are likely to play key roles in future TB
regimens.25 An examination of ongoing or planned
trials in adults with MDR-TB shows that the
following novel and repurposed anti-tuberculosis
medications are key components of many MDR-TB
treatment regimens under evaluation: BDQ, DLM,
PTM, MFX, LVX, CFZ and LZD.26 This group of
drugs should therefore be the focus of future
paediatric studies.
Ensuring the development and availability of child-
friendly formulations is another key consideration.
Child-friendly characteristics include small tablet/
capsule size and strength (in mg), ability to be mixed
with juice or water, measurability even at very small
doses, and flavour/palatability. The lack of many of
these characteristics in currently available formula-
tions creates the need for imprecise manipulations
such as splitting or crushing adult tablets, dissolving
them in water or mixing themwith food. This impairs
accurate dosing, particularly in the youngest children,
introduces complexity in administration for parents
and health care workers, reduces medication palat-
ability, and may affect bioavailability in unknown
ways.27,28 These myriad effects have the potential to
adversely influence adherence, which is vitally
important for ensuring optimal treatment out-
comes.29,30 The acceptability of formulations for
children and their care givers must be considered and
should be formally evaluated in studies of anti-
tuberculosis drugs. Novel approaches, such as the
development of gummy formulations, are being
explored and deserve consideration.31
Specific PK characteristics of anti-tuberculosis
medications in children have been reviewed else-
where, and such a discussion is beyond the scope of
this article.32 We summarise below the current state
of paediatric knowledge and key gaps, and ongoing
or planned trials for priority anti-tuberculosis med-
ications forMDR-TB (in Tables 1 and 2). Much of the
PK and safety data described, other than from the
multicentre trials, are from a single site in South
Africa. Data from diverse settings and populations
are needed to better account for pharmacogenetic and
other potential differences in PK and safety of these
medications. Table 3 shows the current status of
paediatric formulation development for these same
medications.31 It should be noted that delays in
studying these medications and developing paediatric
formulations are in part related to regulatory and
economic barriers. A detailed consideration of these
issues is beyond the scope of this review, but they have
been discussed elsewhere.24 Although the need for
improved treatment among affected children is great,
the market is small. Innovative solutions will be
needed to accelerate this important work to ensure
equitable access to anti-tuberculosis treatment in
children.
Bedaquiline
The opening of paediatric BDQ trials has been much
delayed. Despite global roll-out and increasing access
to BDQ for adults, even in routine care settings,33 to
date there are no PK data in children. Two paediatric
trials will begin to fill this gap. The Janssen-sponsored
Table 3 Current status of paediatric formulation development for novel and key repurposed anti-tuberculosis medications for
multidrug-resistant tuberculosis treatment
Adult formulation Paediatric formulation
Bedaquiline 100 mg unscored tablets Dispersible paediatric tablets developed by Janssen (Beerse, Belgium)
for C211 trial
Delamanid 50 mg unscored tablets Dispersible paediatric tablets developed by Otsuka (Tokyo, Japan) for
232/233 trials
Pretomanid 100 mg, 200 mg tablets (trial formulations) Dispersible paediatric tablets developed by Dr Reddy’s Laboratories
(Hyderabad, India), TB Alliance (Geneva, Switzerland)
Levofloxacin 250 mg tablets Paediatric suspension exits, but not widely available and not preferred
formulation; dispersible tablets developed by Macleods (Mumbai,
India) for TB-CHAMP trial
Moxifloxacin 400 mg tablets Gummy formulation being developed by Luna Innovations (Roanoke,
VA, USA)
Linezolid 600 mg tablets Paediatric suspension exists, but prohibitively expensive and not widely
available
Clofazimine 50 mg and 100 mg gel capsules Gummy formulation being developed by Luna Innovations
TB-CHAMP¼ Tuberculosis CHild and Adolescent Multidrug-resistant Preventive.
PK/safety studies in paediatric MDR-TB S19
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C211 paediatric trial (NCT02354014) is a Phase II
study of BDQ PK and safety in combination with an
optimised background regimen (OBR) in children with
MDR-TB; only non-HIV-infected children are includ-
ed. Enrolment in this age de-escalation trial began in
2016. The P1108 trial (NCT02906007) sponsored by
the US National Institute of Allergy and Infectious
Disease (NIAID; Bethesda,MD, USA) InfantMaternal
Pediatric Adolescent AIDS Clinical Trial (IMPAACT)
networkwill also evaluate the PK and safety of BDQ in
combination with OBR in both HIV-infected and non-
infected children with MDR-TB; the trial is expected
to open in early 2017. Janssen has developed a
dispersible paediatric BDQ formulation, which will
be evaluated in their trial; however, this formulation
may not be available in the field for some time. The
IMPAACT network has sponsored a trial comparing
the bioavailability of whole and dissolved BDQ
(TASK-002, NCT03032367), which will inform the
use of the dissolved adult formulation for children who
cannot swallow whole tablets. It is also conceivable
that local economic or regulatory barriers will limit the
widespread availability of the paediatric dispersible
tablets for some time. Bioavailability data on crushed
adult tablets will help bridge the expected time gap
when data on BDQdosing in children are available but
the BDQ paediatric formulation is not.
Delamanid
The Otsuka-sponsored Phase I (242-12-232,
NCT01856634) and Phase II (242-12-233,
NCT01859923) paediatric DLM trials opened in
2013. DLM PK data fromGroup 1 (ages 12–17 years,
adult dose) and Group 2 (ages 6–11 years, half adult
dose) of these age de-escalation trials showed that
exposure in children was within the range seen in
adults. This led the World Health Organization
(WHO) to recommend doses and indications for
DLM use for children aged 6–17 years with MDR-
TB.34 PK data from Group 3 (ages 3–5 years) and
Group 4 (ages 0–2 years) from this trial are expected
in 2017. HIV-infected children were excluded from
Groups 1–3, but will be allowed in Group 4.
IMPAACT 2005 is a planned trial on DLM PK and
safety in both HIV-infected and non-HIV-infected
children with MDR-TB to address this gap, and is
expected to open in 2017. Otsuka has developed a
dispersible, taste-masked paediatric formulation in
two strengths, which is being evaluated in Groups 3
and 4 of its paediatric trials, and will also be used for
the youngest children (age ,6 years) in the IM-
PAACT 2005 study.
Pretomanid
There are no PTM pharmacokinetic data in children,
and no ongoing or immediately planned paediatric
trials. This delay is at least in part due to concerns
with PTM safety. Testicular toxicity was seen in some
animal models, as it has been with other nitro-
imidazole compounds such as metronidazole;35 how-
ever, the clinical significance in humans is not entirely
clear. Moreover, the Shortening Treatment by Ad-
vancing Novel Drugs (STAND) trial evaluating a
regimen comprising PTM-MFX-pyrazinamide for
both drug-susceptible and MDR-TB in adults
(NCT02342886) was temporarily put on hold due
to hepatotoxicity in the experimental arm; the trial
has been cleared by the Data Safety Monitoring
Committee to re-start.26 A substudy within the
STAND trial aims to evaluate the presence of any
testicular toxicity.36 Particularly given emerging
evidence on the success of PTM-containing regimens
in adult Phase II and III trials,37,38 the paediatric trials
should start as soon as safety concerns have been
sufficiently alleviated. A prototype paediatric formu-
lation of PTM has been developed.39
Moxifloxacin
The paediatric development of MFX for non-tuber-
culosis bacterial indications was limited, at least
partly due to its bitterness and poor palatability. The
only published PK data are for 23 children aged 7–15
years treated for MDR-TB,14 from a US National
Institutes of Health (NIH; Bethesda, MD, USA)
funded observational PK study in Cape Town, South
Africa (MDRPK1, Pharmacokinetics and toxicity of
second-line anti-tuberculosis drugs in HIV-infected
and -uninfected children). This study showed low
MFX exposures in children who received the recom-
mended paediatric doses (10 mg/kg) relative to
exposures seen in adults after a 400 mg dose.14 PK
data in children aged ,7 years and analysis to
determine more optimal doses across all ages are
thus urgently needed. An NIH-funded study of the
PKs of model-based doses of key second-line TB
medications in children routinely treated for MDR-
TB in Cape Town opened in 2015, and should address
some of these knowledge gaps (MDRPK2, Optimiz-
ing and operationalizing pediatric drug-resistant
tuberculosis treatment). There is no child-friendly
formulation of MFX, and the existing adult formu-
lation is an exceedingly large tablet, difficult to split
and bitter when crushed, making accurate and
tolerable dosing in children problematic. A taste-
masked dispersible tablet with lower strength is
needed for reliable paediatric dosing.
Levofloxacin
A growing body of observations in children receiving
LVX for MDR-TB has shown that currently recom-
mended paediatric doses for MDR-TB (15–20 mg/kg
once daily) result in exposures well below those in
adults receiving the most frequently used dose of 750
mg once daily.40,41 Optimal paediatric doses of LVX,
and safety at those doses, remain to be established;
the MDRPK2 study aspires to address this gap.
S20 The International Journal of Tuberculosis and Lung Disease
 284
Stellenbosch University  https://scholar.sun.ac.za
Although an LVX suspension does exist, it is not
available in most high TB burden settings, and
suspensions are not preferred either by health
systems, because of challenges with storage and
shelf-life, or by patients and care givers.42 A 100 mg
dispersible LVX tablet (Macleods Pharmaceuticals
Ltd, Mumbai, India) has been developed for a
paediatric trial of LVX for MDR-TB preventive
therapy (Tuberculosis CHild and Adolescent Multi-
drug-resistant Preventive [TB-CHAMP] therapy trial,
ISRCTN92634082), and could potentially become
available more widely after the trial has been
completed. The PK of this formulation is being
evaluated in a lead-in phase of that trial.
Clofazimine
Although CFZ has been used for decades for the
treatment of leprosy in children, there are no
published, or to our knowledge unpublished, paedi-
atric PK data available. There are no ongoing or
planned trials of CFZ PKs in children with TB.
Limited data from a few patients in the MDRPK1
study are available, and there may be the possibility
to opportunistically study CFZ in theMDRPK2 study
as the routine use of CFZ becomes more widespread
in response to new guidelines from the WHO.43 CFZ
is only available in 50 mg and 100 mg gel capsules.
These are not flexible formulations, cannot be split or
opened, and may be challenging for young children to
swallow. Given the potentially important role in
future TB treatment regimens, CFZ PK, safety and
acceptability studies in children, and the development
of a child-friendly formulation, are therefore a
priority.
Linezolid
As LZD has been used for the treatment of resistant
Gram-positive bacterial infections, there are data on
its PK and safety in children with non-tuberculous
infections for short-term use (,28 days).44 However,
there are no published PK data in children with TB,
and the doses needed in children to approximate
exposures in adults after the 600 mg once daily dose
used for TB are not yet known.45 TheMDRPK2 study
is aimed at evaluating LZD PKs in children with
MDR-TB; combined with data from MDRPK1, this
will provide much-needed information on optimal
and safe LZD paediatric dosing for TB treatment. An
LZD suspension exists, but its use for long courses for
MDR-TB treatment is cost-prohibitive, and access in
many settings is limited. Manipulation of the adult
600 mg tablet for paediatric dosing may be problem-
atic and is not a long-term solution, due to the large
tablet size and strength, difficulty in suspending and
lack of data on impact on bioavailability. A reason-
ably priced flexible solid-oral dosage formulation for
children is needed.
IMPLICATIONS FOR AN EFFICACY TRIAL IN
CHILDREN WITH MDR-TB
There is a critical need for shorter duration,
injectable-sparing, safe, acceptable and efficacious
regimens for children, and there is consensus that an
efficacy trial is also urgently needed. A clearer
understanding of the safety and appropriate dosing
of medications to be included in a Phase III paediatric
MDR-TB efficacy trial is required. The lack of
comprehensive data or knowledge of perfect doses
should not be used to delay such a trial going
forward, in which dosing based on the best available
evidence should be used. Data from ongoing studies
are expected to inform paediatric dosing of MFX,
LVX, LZD and DLM in the near future. The lack of
planned paediatric studies of CFZ is worrying.
Although it is already recommended and being used
in the field for MDR-TB treatment in children, and it
is reassuring that there is substantial experience
supporting its safety in children treated for leprosy,
pharmacokinetic studies of CFZ in children with
MDR-TB should be prioritised. The lack of paediat-
ric-specific data on BDQ and PTM will likely
preclude their use in a paediatric efficacy trial in the
immediate future.
It is also worth noting that existing paediatric PK
data clearly add support for an efficacy trial in
children. The FQs, with their potent bactericidal
activity, are considered the most important compo-
nent of existing MDR-TB regimens. Alarmingly,
published data have shown that children with
MDR-TB treated with currently recommended doses
of ofloxacin, LVX and MFX have plasma FQ
exposures well below those in adults.14,40,41 Howev-
er, despite these low exposures, treatment outcomes
in children are much better than in adults with MDR-
TB, with 80–90% of children successfully treated
globally compared to 50% of adults in most high-
burden settings.46,47 Low drug exposures in children,
combined with already improved outcomes com-
pared to adults, clearly call into question the
assumption that children have a similar disease
progression and response to treatment to that of
adults; these factors combined provide a clear
justification for an efficacy trial in children. Improved
paediatric dosing of these medications is still impor-
tant in promoting optimal outcomes with a shortened
regimen in such a trial.
CONCLUSION
Although much remains to be done, there has been
substantial progress in recent years in studying and
understanding second-line and novel anti-tuberculo-
sis medications in children. Precisely because they
differ from adults withMDR-TB, children represent a
group that is uniquely poised to benefit from shorter,
PK/safety studies in paediatric MDR-TB S21
 285
Stellenbosch University  https://scholar.sun.ac.za
less toxic and less burdensome treatments for MDR-
TB. It is imperative that the rigorous investigation of
such treatments continues and accelerates. Expand-
ing global clinical trial capacity for MDR-TB in
children, and closer collaboration between research-
ers, industry, funders and affected communities, will
be required to ensure that the progress made thus far
is not lost, and that children with MDR-TB continue
to benefit.
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R E´ S U M E´
Apre`s des de´cennies de ne´gligence, nous disposons
finalement de donne´es relatives a` la posologie
approprie´e et suˆre des principaux me´dicaments
antituberculeux de deuxie`me ligne utilise´s pour le
traitement de la tuberculose multire´sistante (TB-MDR)
des enfants, dont la le´vofloxacine (LVX), la
moxifloxacine (MFX), le line´zolide (LZD) et le
de´lamanide (DLM). Mais on manque toujours de
donne´es relatives a` certains me´dicaments nouveaux et
recycle´s, incluant la be´daquiline (BDQ), le pre´tomanide
(PTM) et la clofazimine (CFZ). Nous revoyons le statut
des e´tudes de pharmacocine´tique (PK) et de se´curite´ des
principaux me´dicaments antituberculeux chez les
enfants atteints de TB-MDR, identifions les lacunes
prioritaires en matie`re de connaissances et notons le
travail en cours pour affronter ces lacunes, dans le
contexte de la planification d’un essai d’efficacite´ chez
des enfants atteints de TB-MDR. Il y a un consensus
international sur le fait qu’un essai d’efficacite´ d’un
traitement de TB-MDR nouveau, exclusivement oral et
raccourci chez des enfants est a` la fois ne´cessaire et
faisable. Les me´dicaments antituberculeux de deuxie`me
ligne principaux, nouveaux et recycle´s, incluent la BDQ,
le DLM, le PTM, la MFX, le LVX, la CFZ et le LZD. Les
donne´es, en rapide expansion, de PK et de se´curite´
relatives a` ces me´dicaments chez les enfants atteints de
TB-MDR, e´manant d’e´tudes qui sont en cours, acheve´es
ou pre´vues, seront cruciales pour soutenir un tel essai
d’efficacite´. Un engagement a` affronter les lacunes
re´siduelles de connaissances, l’e´laboration de formules
des principaux me´dicaments adapte´es aux enfants,
l’ame´lioration de la conception des e´tudes pe´diatriques
de PK et de se´curite´ et le de´veloppement d’une capacite´
internationale de re´alisation d’essais parmi les enfants
atteints de TB-MDR sont des priorite´s majeures.
R E S UM E N
Tras decenios de negligencia, por fin se han publicado
datos sobre la posologı´a apropiada y segura de los
principales fa´rmacos antituberculosos de segunda lı´nea
en el tratamiento de la tuberculosis multirresistente (TB-
MDR) de los nin˜os, que incluyen el levofloxacino (LVX),
el moxifloxacino (MFX), el linezolid (LZD) y el
delamanid (DLM). Au´n faltan datos muy necesarios
sobre algunos fa´rmacos nuevos y fa´rmacos a los cuales se
ha asignado una nueva utilizacio´n, como la bedaquilina
(BDQ), el pretomanid (PTM) y la clofazimina (CFZ). En
el presente artı´culo se analiza la situacio´n de los estudios
farmacocine´ticos (PK) y de toxicidad de los
medicamentos antituberculosos en los nin˜os con TB-
MDR, se definen las prioridades en las carencias de
conocimientos y se mencionan los trabajos en curso que
abordan estas lagunas en el contexto de la planificacio´n
de un ensayo clı´nico de eficacia en nin˜os con TB-MDR.
Existe una opinio´n internacional una´nime sobre la
necesidad y la factibilidad de un ensayo clı´nico de
eficacia de un nuevo tratamiento de la TB-MDR
pedia´trica que sea corto y de administracio´n oral
exclusiva. Entre los fa´rmacos antituberculosos de
segunda lı´nea nuevos y con nuevas indicaciones se
cuentan los siguientes: BDQ, DLM, PTM, MFX, LVX,
CFZ y LZD. Los numerosos datos PK y de toxicidad que
surgen en la actualidad sobre la utilizacio´n de estos
fa´rmacos en la TB-MDR de los nin˜os, provenientes de
estudios en curso, estudios finalizados o ensayos
planificados sera´n esenciales para fundamentar el
ensayo clı´nico de eficacia antes mencionado. Otras
prioridades importantes se relacionan con el estudio de
los vacı´os que persisten en los conocimientos, el
desarrollo de presentaciones de los principales
fa´rmacos que sean adecuadas para los nin˜os, el
perfeccionamiento del disen˜o de los estudios PK y de
toxicidad en pediatrı´a y el refuerzo de la capacidad para
realizar ensayos internacionales en los nin˜os con
diagno´stico de TB-MDR.
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S U M M A R Y
On June 17, 2016, RESIST-TB, IMPAACT, Vital Strategies, and New Ventures jointly hosted the Pediatric
Multidrug Resistant Tuberculosis Clinical Trials Landscape Meeting in Arlington, Virginia, USA. The
meeting provided updates on current multidrug-resistant tuberculosis (MDR-TB) trials targeting
pediatric populations and adult trials that have included pediatric patients. A series of presentations
were given that discussed site capacity needs, community engagement, and additional interventions
necessary for clinical trials to improve the treatment of pediatric MDR-TB. This article presents a
summary of topics discussed, including the following: current trials ongoing and planned; the global
burden ofMDR-TB in children; current regimens forMDR-TB treatment in children; pharmacokinetics of
second-line anti-tuberculosis medications in children; design, sample size, and statistical considerations
for MDR-TB trials in children; selection of study population, design, and treatment arms for a trial of
novel pediatric MDR-TB regimens; practical aspects of pediatric MDR-TB treatment trials; and strategies
for integrating children into adult tuberculosis trials. These discussions elucidated barriers to pediatric
MDR-TB clinical trials and provided insight into necessary next steps for progress in this ﬁeld.
Investigators and funding agencies need to respond to these recommendations so that important studies
can be implemented, leading to improved treatment for children with MDR-TB.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
The global epidemic of multidrug-resistant tuberculosis (MDR-
TB), i.e., Mycobacterium tuberculosis that is resistant to isoniazid
and rifampicin, is a major threat to human health.1 In the past
decade, there have been substantial improvements in our ability to
diagnose and treat MDR-TB; however efforts have mainly focused
on MDR-TB in adults. MDR-TB also has a substantial impact in
children; currently, most MDR-TB (and drug-susceptible TB)
treatment guidelines for children are extrapolated from adult
data and rely on clinical experience instead of controlled trials.
However, differences in the pathophysiology, diagnosis, and
treatment of childhood TB relative to TB in adults are well
described, and have limited the beneﬁt children have received
from recent advances in adult MDR-TB care.2 There are relatively
few trials that have focused speciﬁcally on childhood TB. In order* Corresponding author.
E-mail address: semcanaw@gmail.com (S.E. McAnaw).
http://dx.doi.org/10.1016/j.ijid.2016.11.423
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to address this deﬁcit and begin the process of developing a
science-based framework on which to base recommendations, the
International Maternal Pediatric Adolescent AIDS Clinical Trials
Network (IMPAACT) and Research Excellence to Stop TB Resistance
(RESIST-TB) networks organized a meeting to bring together
investigators and clinicians working in this ﬁeld. The aim was to
summarize the current status of knowledge, identify important
areas of research, and develop plans for future research for
pediatric MDR-TB. This report summarizes the results of this
meeting – the Pediatric MDR-TB Landscape Meeting, held June 17,
2016, in Washington DC.
2. Update on current pediatric MDR-TB studies in progress
Prior to 2008, no clinical trials of MDR-TB treatment had ever
been performed in adults or children, and treatment was based
entirely on clinical opinion.3 Since then, phase 2 clinical trials have
demonstrated the efﬁcacy of three new anti-TB drugs –bedaqui-
line, delamanid, and pretomanid – for the treatment of MDR-TB
and extensively drug-resistant (XDR-TB).4 Moreover, linezolid,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Table 1
PK/safety studies in children with MDR-TB disease
Study Intervention Design Target population Aim Sample size
MDR-PK 1 PK and safety of levoﬂoxacin,
moxiﬂoxacin, oﬂoxacin,
amikacin, high-dose isoniazid,
ethionamide, para-
aminosalicylic acid, terizidone,
and cycloserine at routine doses
Observational
cohort
Children 0–2 years, 3–5 years,
6–15 years old; all enrolled
simultaneously
PK, drug–drug interactions, and
safety in children treated for
MDR-TB with/without HIV
co-infection
318
MDR-PK 2 Moxiﬂoxacin, levoﬂoxacin, and
linezolid
Observational
cohort
Children 0–<2 years, 2– <6
years, 6–<12 years, 12–<18
years old
PK, drug–drug interactions, and
safety in children treated for
MDR-TB with/without HIV
co-infection
100
Jansen C211 Bedaquiline in combination with
other second-line agents
Open-label,
single-arm
HIV-uninfected children ages
0–1 year, 2–4 years, 5–11 years,
12–17 years old
PK, safety, and anti-
mycobacterial activity of
bedaquiline in combination with
other second-line drugs
60
IMPAACT P1108 Bedaquiline in combination with
other second-line agents
Open-label,
single-arm
HIV-infected and uninfected
children with MDR-TB under an
FDA IND; children 6–17 years
currently enrolled; children 3–5
years and 0–2 years to follow in
parallel
Dose-ﬁnding and safety study of
bedaquiline in combination with
other second-line drugs
Not yet
enrolling
Otsuka 232 and 233 Delamanid Open-label,
multiple-dose
HIV-uninfected children ages
0–2 years, 3–5 years, 6–11 years,
12–17 years
PK, safety, and tolerability of
delamanid
36
IMPAACT 2005 All-oral, injectable-sparing,
delamanid-based MDR-TB
regimen
Open-label,
single-arm
clinical trial
Children 0–<3 years, 3–<6
years, 6–<12 years, 12–<18
years old
PK, safety, and tolerability of
intervention regimen; assess
effect of HIV and ART on
delamanid PK
Not yet
enrolling
PK, pharmacokinetic; MDR-TB, multidrug-resistant tuberculosis; FDA IND, Food and Drug Administration Investigational New Drug; ART, antiretroviral therapy.
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for MDR-TB) have been recognized to have activity against M.
tuberculosis and therefore to be potential companion agents in new
regimens for MDR-TB treatment.4 This has led to a long-overdue
increase inMDR-TB treatment trials. By 2016, four phase 2 and one
phase 3 MDR-TB treatment trials had been completed,5–9 and an
additional eight phase 2 and eight phase 3 trials were under way.10
While this represents a welcome increase in activity that will
hopefully expand treatment options for MDR-TB, only two of these
trials are enrolling children under the age of 12 years, while one is
enrolling adolescents aged 13–17 years. Thus, there is a substantial
unmet need for data that will guide the treatment of children with
MDR-TB. This meeting reviewed clinical trials and observational
cohort studies of pediatric MDR-TB to identify knowledge gaps and
generate momentum for new studies to address those gaps.
Planned and ongoing pediatric MDR-TB studies can be divided
into two groups. The ﬁrst is treatment studies in which the
pharmacokinetics (PK) and safety in children with MDR-TB are
characterized. The goal of these studies is to deﬁne the optimal
doses for children with TB, taking into account efﬁcacy–toxicity
tradeoffs (shown in Table 1). The second is studies of preventive
therapies, in which pediatric household contacts of MDR-TB
patients are treated to prevent disease (shown in Table 2).Table 2
Trials of MDR-TB preventive therapy in children
Study Intervention Design Target po
V-QUIN Levoﬂoxacin,
6 months
Randomized, double-blind,
placebo-controlled phase
3 trial
Adult, ch
househol
pulmona
TB-CHAMP Levoﬂoxacin,
6 months
Randomized, double-blind,
placebo-controlled phase
3 trial
Children
are house
pulmona
A5300/P2003 Delamanid Open-label, phase 3 trial Adult and
househol
TB patien
MDR-TB, multidrug-resistant tuberculosis.Missing from these tables are studies speciﬁcally evaluating the
efﬁcacy of novel regimens for the treatment of pediatric MDR-TB;
none are ongoing. It is hoped that a better understanding of the PK
and safety of new and existing drugswill lead to the rational design
of trials to evaluate optimized regimens speciﬁcally tailored to
pediatric patients.
3. Global burden of MDR-TB in children
TB remains substantially under-diagnosed among children due
to challengeswithmicrobiological conﬁrmation,11 a dearth of good
diagnostics, and limitations in the recording and reporting of
pediatric TB.12 These challenges are further exacerbated in
children with MDR-TB. Until 2012, the World Health Organization
(WHO) did not provide estimates of the burden of pediatric TB.
Two recent studies have provided evidence that the proportion of
children with MDR-TB reﬂects the proportion of new (i.e., never
previously treated for TB) adult TB cases with MDR-TB in the same
setting.13,14 The ﬁrst estimate of pediatric MDR-TB incidence,
published in 2014 by Jenkins et al., was 32 000 annual incident
cases (3.2% of their overall TB incidence estimate).14 In 2016, Dodd
et al. published an extension of their mathematical model to
estimate the number of children with several different forms ofpulation Aim Sample size
ild, and adolescent
d contacts of
ry MDR-TB patients
Evaluate intervention
compared to placebo for
prevention of MDR-TB in
household contacts
Not yet enrolling
children
<5 years old who
hold contacts of
ry MDR-TB patients
Evaluate efﬁcacy and safety
of levoﬂoxacin compared to
placebo for prevention of
MDR-TB
Not yet enrolling
child (0–17 years)
d contacts of MDR-
ts
Evaluate efﬁcacy and safety
of delamanid compared to
standard-dose isoniazid for
TB prevention
Not yet enrolling
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oped MDR-TB annually (i.e., 2.9% of incident TB cases).
The proportion of children with MDR-TB who are diagnosed,
and the proportion of those children who receive appropriate
treatment, is also unknown. However, it is likely a very small
proportion of the 25 000–32 000 children who develop MDR-TB
annually. Although children who are diagnosed and receive
treatment for MDR-TB are likely to recover and have good
treatment outcomes,16 those who remain undiagnosed have a
high risk of death. A recent literature review from the pre-
treatment era demonstrated highmortality in childrenwho did not
receive treatment for TB. Given the high number of children with
MDR-TB who are untreated, mortality is likely to be signiﬁcant.17
4. Regimens for MDR-TB treatment in children: preclinical–
clinical translation?
To assess whether or not preclinical models can help inform
clinical assessments of anti-TB drugs for children, the character-
istics of TB disease in children must ﬁrst be understood. Pediatric
and adult TB are very different. The clinical manifestations of
pediatric TB are highly variable and roughly correlate with age;
very young children more commonly develop disseminated
disease than older children and adults, and children aged 2–12
years commonly have paucibacillary, non-cavitary disease limited
to the lung or lymph nodes, without caseous necrosis (see
Figure 1). Children over the age of 12 years can present with
adult-like pulmonary disease, often with lung cavitation and high
bacterial burden.2 Since younger children tend to have pauciba-
cillary TB (approximately 30% culture-conﬁrmed and <10%
sputum smear-positive) they can reasonably be expected to
respond to treatment better than adults. Improved treatment
outcomes amongst children with MDR-TB compared to adults are
already achieved despite substantially lower drug exposures in
children for many key second-line drugs. However, this variability
in disease severity, pathology, and mycobacterial burden (104 in
paucibacillary versus 107 to 109 in cavitary disease)18 presents a
challenge for the selection of a single regimen and treatment
duration to test for ‘pediatric MDR-TB’.
A critical concern for successful TB treatment is delivery of
effective drugs at adequate concentrations to the site of disease.
Penetration of TB drugs into macrophages, the central nervous
system, lymphnodes, lung parenchyma, and cavitary contentsmay
be needed for the treatment of pediatricMDR-TB, depending on the
age of the child and his or her associated TB-related pathology.
Penetration coefﬁcients of drugs into these different compart-
ments vary widely.19 Studies assessing the spatial distribution of
anti-TB drugs in relevant preclinical models may help inform the
selection of drugs and/or drug combinations for further testing in
speciﬁc populations (e.g., children with disseminated intracellular
disease, or lymphadenitis or meningitis). Drugs also differ in their[(Figure_1)TD$FIG]Figure 1. Manifestations of pediatric tuberculosis, by age, adapted from Marais
et al.2 Disease in children aged 5–10 years of age is generally rare.ability to protect each other against the emergence of resistance. In
patients with a high bacillary load, chromosomally mediated
resistance is invariably present in a subpopulation of organisms, so
drugs must be given in combination to prevent the emergence of
these pre-existing resistant strains. So for adolescents with
cavitary disease, it is likely that drugs must both penetrate into
cavitary contents and achieve concentrations sufﬁcient to protect
companion drugs against the emergence of resistance in that
compartment. For children with paucibacillary disease, the
number of drugs needed to prevent the emergence of resistance
is unknown, but may be fewer than in adults.
There is no single best animal model for pediatric TB disease. In
the ‘standard’ mouse TB treatment model in BALB/c mice, the
disease is largely intracellular, and the mice do not typically
develop caseous necrosis or cavities, and thus their pathology is
similar to that seen in young children.20 Animal models that
develop necrotic lesions and/or cavitary disease (e.g., so-called
Kramnik (C3HeB/FeJ) mice or select rabbit models) may be more
akin to, and informative of, adolescent TB disease. Thus, no single
animal model has been validated as a pediatric TB treatment
model. Indeed, given the wide spectrum of disease burden and
manifestations, a one-size-ﬁts-all approach to regimen composi-
tion, dosing, and treatment duration for pediatric MDR-TB in both
practice and clinical trials may result in under- or over-treatment
of many children.
5. Pharmacokinetics of second-line anti-TB medications in
children
The approach to studying individual anti-TB medications in
children has been to perform PK and safety studies, to establish
doses in children that achieve exposures similar to those in adults
receiving standard doses, and evaluate safety at those doses.
Extrapolation of mg/kg doses directly from adults to children is
often inappropriate because of age-related changes in drug
disposition and metabolism, also known as ‘developmental
pharmacology’. Speciﬁc studies are therefore needed in children
across the age spectrum (with a particular focus on very young
children in whom drug handling is rapidly changing), and many
important knowledge gaps remain.21 Emerging evidence on
ﬂuoroquinolone PK in children with MDR-TB has shown much
lower exposures in children relative to adults with currently
recommended doses.22–24 Age-speciﬁc PK data for ethionamide,
terizidone, and para-aminosalicylic acid (PAS) are expected soon
(MDR-PK1 study).
Research priorities should be centered on those medications
expected to be components of novel MDR-TB regimens; this
includes levoﬂoxacin, moxiﬂoxacin, linezolid, clofazimine, and the
novel medications bedaquiline and delamanid. Work on optimiz-
ing pediatric doses of levoﬂoxacin, moxiﬂoxacin, and linezolid is
ongoing (MDR-PK2). Data on the PK and safety of delamanid in
children aged 6–17 years have been disseminated, with work
ongoing in younger children, including with a pediatric formula-
tion. Pediatric bedaquiline studies are just starting. Clofazimine PK
is poorly understood in adults, and no data for children are
available, representing an important gap. Of note, PK parameters
and values associated with optimal efﬁcacy for second-line drugs
are poorly deﬁned for adults, so PK targets for children are not well
established. In general, dose-ﬁnding studies aim to identify doses
that give equivalent exposures in adults and children. However,
despite ‘low’ drug exposures of key medications like the
ﬂuoroquinolones, outcomes in children with MDR-TB are good
relative to adults.16 This suggests that children may need less
intense treatment and provides justiﬁcation for an efﬁcacy trial of a
shortened regimen in children with MDR-TB. Few child-friendly
formulations of second-line anti-TB medications exist; however 291
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to children in the ﬁeld.
6. Design, sample size, and statistical considerations for MDR-
TB trials in children
As with other aspects of TB trials, there are similarities and
differences between studies of children and adults. Phase 3 studies
of TB regimens are typically designed as superiority or non-
inferiority trials. Although a number of design innovations have
been proposed to increase information gained and/or efﬁciency,
speciﬁcally multi-arm multi-stage (MAMS) designs25,26 and
adaptive randomization,27 these designs are dependent on an
easily identiﬁable intermediate outcomemeasure such as 2-month
sputum culture conversion. Since this endpoint cannot be
measured in many children, the usefulness of such innovations
in trial design for studies in children may be limited.
A design issue that is of greater relevance in children is that of
stratiﬁcation by factors that are likely to inﬂuence treatment
outcomes. Since age, extent or type of disease, and severity of
disease are variable in children, these factors should be controlled
for by stratiﬁcation. If regimen effectiveness is expected to vary by
these factors, it may be necessary to perform separate sample size
calculations for each stratum. In some situations a factorial design
may be employed to achieve greater efﬁciency, but this depends on
effects being similar across strata.
An issue that is more prominent in pediatric trials is the
presence of imperfect ﬁnal stage outcomes. By this we are referring
to the lack of clarity about whether a patient’s TB has been cured. If
the diagnosis was clinical (i.e., not conﬁrmedmicrobiologically), or
if a microbiologically conﬁrmed diagnosis required invasive
procedures to establish, it may not be possible to conﬁrm that
the disease has been eradicated; a long post-treatment observation
period without relapse may increase certainty, but at the cost of a
prolonged study timeframe and consequent delay in determining
the success of the investigational treatment. A ﬁnal, more practical
issue faced in TB trials is the inability to blind the study or provide
placebo control for some study agents. For example, replacing an
injectable agent with an equally effective oral drug is highly
desirable; however, an injectable placebo raises ethical issues, and
it would likely be unacceptable to patients and families.
7. Selection of study population, design, and treatment arms
for a trial of a novel pediatric MDR-TB regimen
7.1. Which children to include?
Consideration could be given to treating all children less than
18 years of age (the near universal age of majority), which includes
adolescents, who are frequently neglected and for whom safety is
rarely established. Alternatively, one might include all children
less than 15 years of age, to align with the age brackets used by the
WHO for reporting TB statistics. Finally, a younger age cut-off could
be considered to try to capture those children whose pathophysi-
ology (and drug disposition and metabolism) is most different
from adults. Including all children, irrespective of extent of disease,
is more inclusive and representative. However, speciﬁc issues exist
around the treatment of childrenwithmore limited, paucibacillary
disease, where shorter, less intensive regimens may be possible
and for whom there are clear differences in response to treatment
compared to adults. A useful classiﬁcation system has been
proposed by Wiseman et al. which provides guidance on how to
classify children as having severe vs. non-severe disease.28 It may
be appropriate to include only children with a conﬁrmed diagnosis
(i.e., microbiological conﬁrmation of the presence ofM. tuberculosis
shown to be resistant by genotypic or phenotypic testing), as thisgives an unambiguous entry point and allows changes in
microbiological status to provide microbiological endpoints.
However, this excludes the majority of children with MDR-TB
forwhom the diagnosis ismade clinically. A trial that included only
microbiologically conﬁrmed cases (in whom disease severity or
bacterial burden is often higher) would not be representative of all
children with MDR-TB. Regarding the drug resistance proﬁle, it
may be appropriate to only include children with MDR-TB with
preserved susceptibility to the ﬂuoroquinolones and injectables, as
this is a more homogeneous population, and regimens (both
control and intervention) could be standardized.
7.2. Trial design
It may be appropriate to use the same control and intervention
regimens for all children in the trial, as this will provide simplicity,
improved power to determine endpoints, and transferability into
practice. However, it would likely mean that many children will be
over-treated (children with limited disease and less extensive
resistance) and some may be undertreated (children with
extensive disease and more extensive resistance). Alternatively,
it may be possible to divide children in the trial into different
categories (based on resistance proﬁle, extent of disease, or
whether the diagnosis is microbiologically conﬁrmed or not) and
provide different intervention and control arms to each.
7.3. Composition of regimens
For the control arm, a number of options are available. First, a
standard-duration, traditionalWHO-recommended regimen could
be selected, where all children in the trial receive the same drugs
for the same duration. Standard treatment includes up to 6months
of an injectable and a total duration of 18 months of therapy. A
second option is for all children to have an individualized control
regimen whose component drugs and treatment duration is
designed based on each patient’s disease severity, drug resistance
proﬁle, and response to treatment. Third, a number of distinct, pre-
deﬁned control regimens could be used based on resistance proﬁle
or severity. Finally, the new WHO-endorsed shortened regimen
could be used. This has the advantage of being a 9–12-month
regimen, which may be more desirable for patients and also for
standardization of study endpoints. However, there is limited
experience using this regimen in children, and it is currently only
recommended for patients who have TB caused by isolates that are
known to be susceptible to ﬂuoroquinolones and injectable agents,
or for whom resistance to these drug classes is unlikely.
When designing the intervention regimen it is important to
construct a combination regimen that includes drugs that, together,
achieve the following goals: (1) good early bactericidal activity, (2)
potent sterilizing activity, (3) robustness to resistance, and (4)
adequate penetration into relevant sites of disease. Regimens with
limited drug–drug interactions, both with companion TB drugs and
also with antiretroviral drugs, are also highly desirable. Finally, it is
important to consider how easy the regimen would be to use
programmatically, in terms of procurement, formulations, require-
ment for laboratory or safety testing, shelf life, etc. A ﬂuoroquino-
lone (likely levoﬂoxacin, because it has a limited effect on the QT
interval) plus a novel drug (delamanid or bedaquiline), together
with linezolid and clofazimine provides a potential core set of drugs
in such a regimen. The ﬂuoroquinolone provides potent bactericidal
activity and reduces bacterial burden quickly, the novel drugs have
good sterilizing activity, linezolid has a high barrier to resistance
and protects companion drugs, while clofazimine has good
sterilizing activity.29–31 The addition of other drugs, such as
ethionamide, cycloserine, pyrazinamide, and/or high-dose isoniazid
can be considered following careful assessment of the potential 292
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intervention arm would need to be considered. With multiple
active drugs, some with good sterilizing efﬁcacy, a shorter duration
of therapy is a realistic possibility. Also, given that children
frequently have paucibacillary disease, a shortened treatment of as
little as 6 months may be more likely to be successful in children
than adults.
8. Practical aspects of a pediatric MDR-TB treatment trial
For pediatric MDR-TB research, disease severity must be
carefully collected and documented, as disease severity will
assuredly inﬂuence treatment outcomes. End-points for such
trials should include sub-analyses of patients with culture-
conﬁrmed disease looking at bacteriological cure, even if the main
study outcome is favorable versus unfavorable outcomes. Other
measures of treatment response may include weight gain, clinical
improvement (symptoms/physical signs), radiological improve-
ment, and changes in potential biomarkers. Given that the adverse
effects (AEs) associated with individual drugs are fairly well-
described and standard treatment commonly causes signiﬁcant
toxicity, it is especially important to carefully measure and report
safety outcomes for new versus control regimens in all pediatric
MDR-TB trials. Lastly, every effort should be made to conﬁrm the
presence of MDR-TB in enrolled patients (to avoid misdiagnosis or
misclassiﬁcation), by employing multiple diagnostic methods,
including culture and phenotypic drug susceptibility testing, as
well as molecular methods such Xpert and line probe assay .
9. Integrating children into adult TB trials
Despite substantial urging by pediatricians, clinical trialists,
and regulatory authorities, subjects under the age of 18 years are
rarely included in phase 3 clinical trials of TB. A recently completed
trial of treatment of TB infection, the PREVENT TB Trial, was
successful in enrolling adults and children as young as 2 years of
age and provides an instructive example of both the challenges and
some potential solutions to this problem.32 PREVENT TB was a
randomized, open-label, non-inferiority trial of once-weekly,
directly-observed rifapentine + isoniazid for 3 months (3HP)
compared to daily self-administered isoniazid for 9 months (9H)
for the treatment of latent TB infection (LTBI) in high-risk
tuberculin skin test (TST) reactors. The target population
comprised TST-positive close contacts of a culture-conﬁrmed TB
case, TST-converters, HIV-infected persons with a positive TST or
close contacts to a TB case regardless of TST, and TST-positive
persons with ﬁbrosis on chest radiography consistent with prior
untreated TB. The primary aim of the study was to evaluate the
effectiveness of weekly 3HP versus daily 9H in preventing
progression to TB disease.
The study started enrolling adults and children aged 12–17
years in 2001, as there were no PK data available to guide dosing in
younger children. Doses were subsequently established for
younger children in PK/safety studies, and in 2005 the protocol
was amended to include children aged 2–11 years. Final accrual of
children was achieved by 2010, and collaboration with a pediatric
clinical trials network (IMPAACT) facilitated enrolment of a large
number of children. The study found 3HP to be as well-tolerated
and as effective as 9H for preventing TB in children; 3HP had
signiﬁcantly higher treatment completion rates and was less
hepatotoxic. Revision of the Centers for Disease Control and
Prevention (CDC) LTBI guidelines to allow 3HP for children ages 2–
11 years is now under consideration. Ideally, children should be
included from the outset. However, if this is not feasible, it may be
possible to start the trial in adults butwith a clear plan to gather PK
and safety data while the trial starts, and then subsequentlyinclude children when PK data are available. It would also be
possible to do age de-escalation, where adults are initially
included, with older children then younger children included
later. There is little reason to exclude persons >12 years old from
any adult trial.
10. Conclusions
The topics identiﬁed in this report identify the critical issues in
pediatric MDR-TB that need to be addressed and provide a
blueprint for moving forward. Investigators and funding agencies
need to respond to this agenda so that important studies can be
implemented, leading to improved treatment for children with
MDR-TB.
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Abstract
It is estimated that 33,000 children develop multidrug-resistant
tuberculosis (MDR-TB) each year. In spite of these numbers,
children and adolescents have limited access to the new and
repurposedMDR-TB drugs. There is also little clinical guidance for
the use of these drugs and for the shorter MDR-TB regimen in the
pediatric population. This is despite the fact that these drugs and
regimens are associated with improved interim outcomes and
acceptable safety proﬁles in adults. This review ﬁlls a gap in the
pediatric MDR-TB literature by providing practice-based
recommendations for the use of the new (delamanid and
bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB
drugs and the new shorter MDR-TB regimen in children and
adolescents.
Keywords: multidrug-resistant tuberculosis;
Mycobacterium tuberculosis; child; adolescent; pediatric
Each year, approximately 33,000 children
develop multidrug-resistant tuberculosis
(MDR-TB, Mycobacterium tuberculosis
with in vitro resistance to at least isoniazid
and rifampin), but diagnosis and treatment
remain problematic (1, 2). Although
children have better treatment outcomes
than adults with MDR-TB, global treatment
success rates still remain unacceptably low
and children suffer from the serious side
effects of the older second-line MDR-TB
drugs (3, 4). Unfortunately, children have
limited access to the new drugs bedaquiline
and delamanid and to the repurposed
drugs clofazimine and linezolid that have
shown improved interim outcomes and
acceptable safety proﬁles in adults (5, 6).
Children also have limited access to the
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shorter MDR-TB treatment regimen1 that
has shown promise in adult and adolescent
patients (7, 8) and has been recommended
by the World Health Organization
(WHO) for selected individuals with
MDR-TB (9).
This differential standard of care is due,
in part, to the exclusion of children from
most TB clinical trials (10). There is some
consensus that adolescents should be
included in adult TB efﬁcacy trials, but it
may not be necessary to repeat efﬁcacy
trials in younger children. It is important,
however, that children of all ages be
included in both pharmacokinetic and
safety studies of TB drugs and new
regimens, to ensure there is appropriate
pediatric dosing and safety information (11).
Such inclusion should be done quickly to
prevent unnecessary delays in pediatric
access to therapeutic advances.
While awaiting data from studies,
front-line providers must make decisions
about how to treat children with MDR-TB,
including how to use the new and
repurposed drugs. Despite positive
experiences with these interventions in
adults, there are no recommendations
regarding their clinical use in children (12).
This review ﬁlls a gap in the pediatric
MDR-TB literature by providing practice-
based recommendations for the use of new
and repurposed drugs and novel regimens.
Some of the results of these studies have
been previously reported in the form of
abstracts (13–17).
Methods
Articles identiﬁed from a comprehensive
literature review were consulted using a
methodology previously described (18).
Brieﬂy, articles from a systematic review
were complemented via a comprehensive
literature search using PubMed and a
review of recent WHO guidelines. A
writing committee (E.P.H. and J.F.) wrote
the initial draft and then incorporated
comments from the remaining coauthors.
In accordance with recommendations from
an expert panel on inclusion of children in
TB clinical studies, assessments of efﬁcacy
in adults were applied to children, although
there may be limitations to this approach (11).
However, data on safety and dosing in
children were reviewed and considered
separately from these data in adults. This
was done as it is accepted that adult
efﬁcacy data can be applied to children;
however, safety and dosing data need to
be pediatric speciﬁc. Because there are
limited published data on the use of new
drugs and regimens in children, expert
consensus was reached where evidence
was lacking. The consensus was generated
by clinical health professionals working
within the Sentinel Project on Pediatric
Drug-Resistant Tuberculosis (19). The
process differed from that used by some
normative bodies (e.g., the WHO) as it
considered practice-based experience, and
its target audience is clinical providers.
The authors of this review have more
than two decades of experience in caring
for children with MDR-TB in the
international context, including the use
of new and repurposed drugs.
Treatment Recommendations
Summary recommendations are provided in
Table 1. Clinical studies of new and
repurposed drugs are summarized in
Table 2. Information on formulations and
procurement is summarized in Table 3.
Because of length constraints,
recommendations for the short MDR-TB
regimen are available as an online
supplement. For every medication and
regimen discussed, it is recommended that
informed consent be obtained, active
pharmacovigilance be performed, and
monitoring of patients be performed
according to WHO recommendations for
adult patients (20). Children should also
receive adherence counseling, social
support, and nutritional supplementation
as recommended for the treatment of
children with MDR-TB (21, 22).
Delamanid
Efﬁcacy and safety in adults. Delamanid
(Otsuka Pharmaceutical, Tokyo, Japan) is a
nitroimidazole shown to be effective when
added to an MDR-TB regimen in a
randomized, placebo-controlled phase IIb
trial (23). In this phase IIb trial, patients
were randomized to receive an optimized
background regimen (OBR) with either
placebo or delamanid added for 8 weeks.
After the initial 8 weeks, there was a 4-week
period of continued OBR treatment, and
then all participants were offered open-
label delamanid for an additional 24 weeks.
When participants who received at least
6 months of delamanid were compared
with participants who received less than
2 months of delamanid, there were
statistically signiﬁcant differences seen in
the time to culture conversion, the rates of
culture conversion at both 8 and 24 weeks,
and treatment success, with those who had
at least 2 months of therapy doing better
(24). The drug was well tolerated with mild
to moderate QTc prolongation (12.1 ms)
observed but no clinical cardiac
complications (25). This study led to
conditional marketing approval for
delamanid in the European Union and
Japan in 2013 and later in South Korea
(26). A phase III randomized, placebo-
controlled trial of delamanid has completed
enrollment and the period of study drug
administration; treatment outcome results
are expected in 2017–2018 (27).
Delamanid was recommended by the
WHO in 2014 for treatment of adults with
MDR-TB. WHO guidelines state that
delamanid may be given to adults with
MDR-TB in whom a four-drug regimen plus
pyrazinamide cannot be constructed due to
resistance or signiﬁcant intolerance to other
medications and that delamanid be given to
adults at “high risk” of poor treatment
outcomes. These guidelines stress that
delamanid should be used as part of
programmatic management of MDR-TB
under the following conditions: (1) proper
patient inclusion; (2) close clinical and
programmatic monitoring; (3) used as part
of a regimen that follows WHO guidelines;
(4) due process followed for informed
consent; and (5) active monitoring and
management of adverse events. The WHO
guidelines offer no recommendation on the
use of delamanid in persons less than
18 years old, noting that there was insufﬁcient
evidence to make such a recommendation at
the time of review in 2014 (28).
Dosing and safety in children. Otsuka
has led a pediatric development program for
delamanid, with enrollment in phase I and II
pediatric trials beginning in 2013. Since the
WHO interim guidelines were published in
2014, two studies of pharmacokinetics and
safety in HIV-uninfected children as young
as 6 years old have been presented at
international meetings (13, 14). These
studies follow an age de-escalation protocol
in which the drug is ﬁrst given to older
1“Shorter regimen” refers to the 9- to 12-month
regimens that have been assessed under
operational research conditions and are often
referred to as the “Bangladesh” or “9-month”
regimen.
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Table 1. Summary Recommendations for New and Repurposed Drugs and Regimens for Multidrug-Resistant Tuberculosis in
Children and Adolescents
Delamanid
Recommended dose
.35 kg: 100 mg twice daily
20–34 kg: 50 mg twice daily
,20 kg: consult with expert
Duration: 24 wk; longer duration could be considered on a case-by-case basis (no alternative drug option)
Indications for use: children >6 yr old and >20 kg
d Conﬁrmed MDR-TB when a four-drug regimen plus pyrazinamide cannot be constructed owing to resistance or signiﬁcant intolerance
d Probable MDR-TB with a source case with known or suspected additional resistance to second-line agents
d Conﬁrmed or probable MDR-TB with a high risk of treatment failure
Indications for use: children ,6 yr old and ,20 kg
It is recommended that consultation with expert clinicians be sought before administering delamanid to children in this age range via
consultation with the European Respiratory Society–hosted TB Consilium (https://www.tbconsilium.org) or the Sentinel Project on
Pediatric Drug-Resistant Tuberculosis (tbsentinelproject@gmail.com)
Contraindications
d Baseline QTc interval greater than 500 ms that does not correct with medical management
d Allergy to delamanid or metronidazole
d Prior treatment with nitroimidazole agents (i.e., pretomanid/PA-824)
Monitoring
Baseline: ECG to assess QTc interval and albumin in addition to standard MDR-TB assessments
Follow-up: Monthly ECG to assess for QTc prolongation (although less frequent monitoring could be considered after 8 wk in children
with a normal baseline and follow-up QTc intervals if access to electrocardiographic monitoring is a challenge) in addition to standard
MDR-TB assessments
Bedaquiline
Recommended dose
Adolescents >12 yr old who weigh 33 kg or more: 400 mg daily for 14 d followed by 200 mg given three times weekly for an additional
22 wk
Duration: 24 wk; longer duration could be considered on a case-by-case basis
Indications for use: children >12 yr old and who weigh .33 kg
d Conﬁrmed MDR-TB in whom a four-drug regimen plus pyrazinamide cannot be constructed because of resistance or signiﬁcant
intolerance and where delamanid is not available
d Probable MDR-TB with a source case with known or suspected additional resistance to second-line agents and where delamanid is
not available
Indications for use: children ,12 yr old or who weigh ,33 kg
It is recommended that consultation with expert clinicians be sought before administering bedaquiline to children in this age range via
consultation with the ERS-hosted TB Consilium (https://www.tbconsilium.org) or the Sentinel Project on Pediatric Drug-Resistant
Tuberculosis (tbsentinelproject@gmail.com)
Contraindications
d Baseline QTc interval greater than 450 ms that does not correct with medical management
d Patient or family history of cardiac arrhythmias
d Severe cardiac disease
d Allergy to bedaquiline
Monitoring
Baseline: ECG to assess QTc interval in addition to standard MDR-TB assessments
Follow-up: Monthly ECG to assess for QTc prolongation in addition to standard MDR-TB assessments
Linezolid
Recommended dosing
Children >12 yr: 10 mg/kg once daily
Children ,12 yr of age: 10 mg/kg twice daily
Duration: entire course of treatment as long as the child tolerates it
Indications for use
d Conﬁrmed or probable MDR-TB as part of the core second-line regimen
d If adverse events cannot be monitored, linezolid is best used in patients with additional resistance or intolerance to other
second-line medications
Contraindications and monitoring
d Avoid in children with signiﬁcant anemia, leukopenia, or thrombocytopenia
d Avoid in children with signiﬁcant peripheral neuropathy
d Monthly screening for peripheral neuropathy and monthly complete blood counts should be assessed while the child is receiving
linezolid
Clofazimine
Recommended dosing
2–3 mg/kg given daily for a maximum daily dose of 100 mg or every other day in smaller children (gelcaps cannot be split)
Duration: entire course of treatment as long as the child tolerates it
(Continued )
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children and, when shown to be safe with
established dosing, it is given to younger
children. Although age bands were used to
design the study, the ultimate dosing
recommendations are based on weight, and
weight should guide the dose selection for
children. For children at least 13 years of
age and weighing at least 35 kg, a dose of
100 mg twice daily was safe and achieved
adequate serum concentrations. For
children 6–12 years of age and weighing
20–34 kg, a dose of 50 mg of delamanid
twice daily achieved adequate
serum concentrations. A safety and
pharmacokinetics study of delamanid in
children 3–5 years old is currently enrolling
patients; when dosing and safety are
established, then children and infants less
than 3 years of age will be evaluated.
A pediatric dispersible formulation of
delamanid is being assessed as part of these
trials. In addition, studies in children who are
HIV coinfected are planned. Delamanid is
available for pediatric patients at least 6 years
of age and with a body weight greater than
20 kg via compassionate use from Otsuka.
Of note, there are more pediatric data on the
safety and dosing of delamanid than for some
other second-line drugs that are frequently
used to treat children for MDR-TB, such as
cycloserine and clofazimine (29).
Recommendations for delamanid use in
children. Delamanid may be included in the
treatment regimens of children at least
6 years old and who weigh at least 20 kg for
the same indications as for adults: those with
MDR-TB in whom a four-drug regimen plus
pyrazinamide cannot be constructed due
to resistance or signiﬁcant intolerance or
those with a high risk of treatment failure.
Because MDR-TB may be difﬁcult to
bacteriologically conﬁrm in children,
delamanid may be used in children if they
have an MDR-TB source case with known
or suspected resistance to second-line
agents. Children at high risk for
treatment failure include those with
immunocompromising conditions (e.g.,
HIV, diabetes, malnutrition) or those
with extensive disease (deﬁned as
extrapulmonary TB other than isolated
lymphadenitis; or pulmonary TB with
bilateral inﬁltrates and/or cavities) (4).
Children in this age and weight group
receiving standard MDR-TB therapy and
who develop signiﬁcant toxicity in response
to any of their medications should have
the causative agent discontinued and
delamanid started as a substitute. Avoid
adding a single drug to a failing regimen.
Delamanid can be considered on a
case-by-case basis in children less than
6 years old and who weigh less than 20 kg, if
the children meet the criteria previously
described and no suitable alternatives are
available. Although studies of delamanid in
this age group are ongoing, there may be
cases in which the beneﬁts of including
delamanid outweigh the risk (30). As with
other second-line drugs, the delamanid
dose for this age and weight range would
have to be extrapolated from the dosages
used in older children and adults (31).
Until the dispersible tablet is available,
administration of delamanid to younger
children might involve crushing and mixing
the drug, which could affect its stability and
bioavailability, although this is true for
most second-line drugs. It is recommended
that consultation with expert clinicians be
sought before administering delamanid
to children in this age range. Such
consultation is available through the
European Respiratory Society–hosted TB
Consilium (https://www.tbconsilium.org)
(32) or through the Sentinel Project on
Pediatric Drug-Resistant Tuberculosis
(tbsentinelproject@gmail.com).
As with adults, programs treating
children with delamanid should meet the
ﬁve conditions recommended by the WHO
for its use in adults (28). All children should
undergo the standard baseline testing for
MDR-TB treatment. They should also
undergo a baseline ECG to assess the QTc
interval2 and a baseline serum albumin
level. Children with a baseline QTc interval
greater than 500 milliseconds should not be
started on delamanid until the interval is
corrected by medical management (33).
Delamanid is metabolized by albumin and
there may be higher rates of adverse events
in children with hypoalbuminemia;
therefore children with serum albumin
levels less than 2.8 g/dl should receive
protein supplementation during delamanid
Table 1. (Continued )
Indications for use
d Conﬁrmed or probable MDR-TB as part of the core second-line regimen
Contraindications and monitoring
d Avoid in children with a baseline QTc interval greater than 500 ms that does not correct with medical management
d Baseline and monthly ECGs to assess QTc interval
Shorter MDR-TB regimen (“9- to 12-mo regimen”)
Recommended doses
As per published guidelines. Of note, there are no pediatric safety data yet on the doses of moxiﬂoxacin (12 mg/kg) used in
this study
Duration: 9–12 mo, depending on culture conversion and/or clinical response
Indications for use
d Probable or conﬁrmed MDR-TB in which resistance to second-line drugs is unlikely
d Probable or conﬁrmed MDR-TB with no previous second-line drug treatment in the child or source case
Contraindications and monitoring
d Avoid in children with known resistance to any component of the shortened regimen except isoniazid
d Avoid in children whose source cases have known resistance to any component of the shortened regimen except isoniazid
d Avoid in children with an allergy to any of the medications in the shortened regimen
d Baseline and monthly ECG to assess QTc interval
Definition of abbreviations: ERS = European Respiratory Society; MDR-TB =multidrug-resistant tuberculosis; TB = tuberculosis.
2The QTc interval is a measure of cardiac myocyte
readiness for depolarization. A prolonged QTc
interval (defined as greater than 500 ms) may be a
risk factor for the development of fatal cardiac
arrhythmias. The most commonly used correction
for the QT interval in children is by the Fridericia
correction (QTcF).
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therapy. Children with an allergy to
delamanid or metronidazole or who have
been treated with other nitroimidazole
drugs (i.e., pretomanid/PA-824) should not
be treated with delamanid. While receiving
delamanid, children should undergo a
monthly ECG to assess for QTc
prolongation, although less frequent
monitoring after 8 weeks could be
considered in children with a normal
baseline and follow-up QTc intervals if
access to electrocardiographic monitoring is
a challenge. Combination with drugs that
also prolong the QTc interval should be
done with caution, and substitution of
levoﬂoxacin (which has less effect on the
QTc interval) for moxiﬂoxacin is advised.
Ofﬁcial recommendations are for
delamanid to be given for 24 weeks total,
although longer courses of therapy have
been given to adults and children with
limited therapeutic options. In the initial
phase IIb trials in adults, a substantial
number of individuals (192 of 421) received
8 months of delamanid without any
additional safety signals (23). Phase I
studies in adults show that delamanid did
not have any signiﬁcant drug–drug
interactions with antiretroviral therapy,
including tenofovir, efavirenz, and
lopinavir–ritonavir (15).
Replacement of the injectable agent with
delamanid? Children tend to tolerate
second-line medications better than adults
do; however, the second-line injectable
medications are problematic (34). Although
there are currently no data to support the
routine substitution of delamanid for a
second-line injectable agent within the
MDR-TB regimen, providers could
consider using delamanid instead of the
injectable drug in the initial regimen in
children with MDR-TB. This substitution
could substantially beneﬁt children given
the risk of permanent sensorineural hearing
loss in children (reported in up to 25% of
children) due to the second-line injectable
agents and the pain and hospitalization
requirements that are associated with daily
intramuscular injections (34). These drugs
have been assessed only when given in
combination with other agents; it is
therefore challenging to tease out the
individual contribution of speciﬁc drugs in
an MDR-TB regimen (35, 36). However,
there is higher quality evidence for the
inclusion of delamanid than there is for the
inclusion of the injectable given that
delamanid has been assessed in randomized
placebo-controlled clinical trials for MDR-TB
whereas the injectable agents have not. There
also exists substantial clinical experience in
treating children with nonsevere MDR-TB
disease with an injectable-sparing regimen,
with good results (3).
Bedaquiline
Efﬁcacy and safety in adults. Bedaquiline
(Janssen Pharmaceuticals, Beerse, Belgium)
is a diarylquinoline that was effective when
added to an MDR-TB regimen in a
randomized, placebo-controlled phase IIb
trial (37). In this phase IIb trial, patients
were randomized to receive an OBR with
either placebo or bedaquiline for 24 weeks.
When compared with placebo, bedaquiline
was associated with signiﬁcantly reduced
time to culture conversion, increased rates
of culture conversion at 24 weeks, and
increased cure rates (38). The drug was
associated with moderate QTc prolongation
(15.7 ms), and although there were higher
rates of cure and lower rates of failure and
loss to follow-up in the bedaquiline group,
there was also a signiﬁcantly higher rate of
all-cause mortality (although the number of
deaths was small) in the bedaquiline group
compared with the placebo group (39).
This study led to conditional approval of
bedaquiline for the treatment of MDR-TB
by the U.S. Food and Drug Administration
(FDA) in 2012 and subsequently by a
number of other stringent regulatory
authorities in the European Union, South
Africa, and India (40). In 2013, the WHO
and the U.S. Centers for Disease Control
and Prevention (CDC) published interim
guidelines on the programmatic use of
bedaquiline in speciﬁed adult patients
with MDR-TB (41, 42). The STREAM-II
(Evaluation of a Standard Treatment
Regimen of Antituberculosis Drugs for
Patients with MDR-TB) trial, which is a
phase III randomized, placebo-controlled
trial of bedaquiline, began enrolling
patients in May of 2016 (27). A number of
observational cohort studies conﬁrming
the efﬁcacy and safety of bedaquiline have
been reported from a variety of settings
(5, 6). There are currently more than
3,000 individuals receiving bedaquiline
worldwide (43).
The WHO and CDC guidelines state
that bedaquiline may be offered to adults
with MDR-TB in whom a four-drug
regimen plus pyrazinamide cannot be
constructed for reasons of resistance or
signiﬁcant intolerance to other medications.
The WHO guidelines also stress that
bedaquiline should be used as part of
programmatic management of MDR-TB
under the same ﬁve conditions as delamanid,
although they specify the need for a signed
informed consent for bedaquiline. The WHO
guidelines state there was not sufﬁcient
evidence to make a recommendation regarding
bedaquiline use in persons less than
18 years old at the time the evidence was
reviewed in 2013 (41). The CDC also
stated that there is insufﬁcient evidence
to provide guidelines for the use of
bedaquiline in children, but that its use
can be considered on a case-by-case basis,
given the high mortality and limited
treatment options for MDR-TB (42).
Dosing and safety in children.
Bedaquiline has not yet been formally
assessed in children less than 18 years old.
However, a Janssen Pharmaceuticals safety
and pharmacokinetics study in children
(ages 5–11 yr) and adolescents (ages 12–18 yr)
opened for enrollment in South Africa in
May of 2016 (27). Younger children will
be included in this trial, based on the
data obtained from older children and
following an age de-escalation protocol. A
20-mg dispersible tablet formulation will
be assessed in this trial. A second trial
of bedaquiline in HIV-infected and
uninfected children sponsored by the U.S.
National Institutes of Health (NIH)
IMPAACT (International Maternal
Pediatric Adolescent AIDS Clinical
Trials) network, is being planned and
may begin enrolling in 2016 (44).
A compassionate use protocol for
children is also being developed by
Janssen Pharmaceuticals.
There has been some programmatic
experience using bedaquiline in adolescents
not exceeding 12 years of age (16, 17).
When adolescents weighing at least 33 kg have
been given bedaquiline, they have received the
same dosages that are given to adults: 400 mg
daily for 14 days followed by 200 mg three
times weekly for 22 weeks.
Recommendations for bedaquiline use
in children. Bedaquiline could be
considered for the treatment of children at
least 12 years old and weighing at least 33 kg
for the same indications extrapolated from
adults: those with MDR-TB in whom a four-
drug regimen plus pyrazinamide cannot be
constructed due to resistance or signiﬁcant
intolerance. Bedaquiline may be included in
treatment regimens for children with
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Table 2. Summary of Ongoing, Planned, or Completed Pediatric Studies Involving New Drugs, Repurposed Drugs, and New
Regimens*
Drug/
Regimen Study/Reference Number Design Status of Study Findings
Bedaquiline Janssen-sponsored PK,
safety, and tolerability trial
in children and
adolescents/
NCT02354014
A phase II, open-label, multicenter,
single-arm study to evaluate PK,
safety, tolerability, and
antimycobacterial activity of
TMC207 in combination with a
background regimen of MDR-TB
medications for the treatment of
children and adolescents 0 mo
to ,18 yr of age who have
conﬁrmed or probable pulmonary
MDR-TB
Enrolling 11–17 yr; will
begin enrolling
5–10 yr with IRB
approval; will enroll
younger cohorts
once data available
from older cohorts
Pending
IMPAACT PK and
safety/P1108
Phase I/II, open-label, single-arm
study to evaluate PK, safety, and
tolerability of bedaquiline in
combination with optimized
individualized MDR-TB therapy in
HIV-infected and HIV-uninfected
infants, children, and
adolescents with MDR-TB
disease
Not yet open to
enrollment
Pending
NiX trial/NCT02333799 A phase III open-label trial assessing
the safety and efﬁcacy of
bedaquiline plus PA-824 plus
linezolid in subjects with pulmonary
infection of either XDR-TB or
treatment-intolerant/nonresponsive
MDR-TB (NiX-TB)
Enrolling, includes
adolescents ages
14 yr and older
Pending
Observational cohorts Bedaquiline is being given to
adolescent patients as part of
programmatic management of
MDR-TB, compassionate
use protocols, and operational
research projects in multiple
countries
Cohort data collection
and analysis is
ongoing
Pending
Delamanid Otsuka-sponsored
long-term safety, efﬁcacy,
and pharmacokinetic
study of delamanid in
pediatric patients with
MDR-TB/NCT01859923
Phase II, open-label, multiple-dose
trial to assess the safety, tolerability,
PK, and efﬁcacy of delamanid in
pediatric patients with MDR-TB
and receiving therapy with an
optimized background regimen of
anti-TB drugs over a 6-mo
treatment period
Enrollment completed
for cohorts age 61
yr; enrollment open
for cohort age ,6 yr
Plasma concentrations in
the pediatric patients were
within the range observed
in the open-label trial in
adults. Delamanid was
well tolerated after 6 mo of
therapy in the 12-to 17-yr
age group
Otsuka-sponsored
short-term
pharmacokinetic and
safety trial of delamanid to
determine the appropriate
dose for pediatric patients
with MDR-TB
Phase I, open-label, multiple-dose,
and age de-escalation trial to
assess the PK, safety, and
tolerability of delamanid (OPC
67683) in pediatric patients with
MDR-TB receiving therapy with an
optimized background regimen of
anti-TB drugs
Enrollment completed
for cohorts aged
6–11 and 12–17 yr;
enrollment for
cohort aged 3–5 yr
open
Median delamanid
exposures were higher in
the population of patients
ages 6–17 yr compared
with adults but within the
ranges observed in
the adult population.
Delamanid was well
tolerated in the
short term in these
cohorts
(Continued )
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probable MDR-TB if they have a source case
who meets these criteria. Children in this
age group receiving standard MDR-TB
therapy and who develop clinically
signiﬁcant toxicity in response to any of
their medications should have the causative
agent discontinued and bedaquiline started
as a substitute, but it should not be added as
a single drug to a failing regimen. The adult
dose of bedaquiline should be given (400 mg
daily for 14 d and then 200 mg three times
per week for 22 wk).
Bedaquiline could be considered in
children less than 12 years old if the children
meet the criteria described previously and
no suitable alternatives are available.
Delamanid, however, is the preferred novel
agent in this population, given that there
Table 2. (Continued )
Drug/
Regimen Study/Reference Number Design Status of Study Findings
Observational cohorts Delamanid is being given to pediatric
patients as part of compassionate
use protocols and operational
research projects in multiple
countries
Cohort data collection
and analysis is
ongoing
Early results from 19
pediatric patients
receiving delamanid as
part of multidrug therapy
for MDR-TB show that
the drug is well tolerated
and appears to be
efﬁcacious
Linezolid Pharmacokinetics and
toxicity of the second-line
anti-TB drugs in
HIV-infected and
uninfected children
Prospective, longitudinal,
hospital-based, observational PK
study in HIV-infected and uninfected
children aged 0–15 yr who are
routinely receiving chemotherapy or
chemoprophylaxis for the treatment
or prevention of DR-TB
By the end of 2014,
a total of 230
participants had
already been
enrolled; target
enrollment is 318
children
Pending
NiX trial/NCT02333799 A phase III open-label trial assessing
the safety and efﬁcacy of
bedaquiline plus PA-824 plus
linezolid in subjects with pulmonary
infection with either XDR-TB or
treatment-intolerant/nonresponsive
MDR-TB (NiX-TB)
Enrolling, includes
adolescents ages
14 yr and older
Pending
Observational cohorts Linezolid is being given to pediatric
patients as part of programmatic
management of MDR-TB and
operational research projects in
multiple countries
Cohort data collection
and analysis is
ongoing
Clofazimine Pharmacokinetics and
toxicity of the second-line
anti-TB drugs in
HIV-infected and
uninfected children
Prospective, longitudinal,
hospital-based, observational PK
study in HIV-infected and uninfected
children aged 0–15 yr who are
routinely receiving chemotherapy or
chemoprophylaxis for the treatment
or prevention of DR-TB
By the end of 2014,
a total of 230
participants had
already been
enrolled; target
enrollment is 318
children
Pending
Observational cohorts Clofazimine is being given to pediatric
patients as part of programmatic
management of MDR-TB and
operational research projects in
multiple countries
Cohort data collection
and analysis is
ongoing
Pending
Shorter
regimens
Observational cohorts Shortened regimens are being given
to pediatric patients as part of
programmatic management of
MDR-TB and operational research
projects in multiple countries
Cohort data collection
and analysis is
ongoing
Case reports show that the
shortened regimens are
safe and effective in the
limited number of pediatric
patients who have
received them
Definition of abbreviations: DR-TB = drug-resistant tuberculosis; IMPAACT = International Maternal Pediatric Adolescent AIDS Clinical Trials; IRB =
institutional review board; MDR-TB =multidrug-resistant tuberculosis; PK = pharmacokinetics; TB = tuberculosis; XDR-TB = extensively drug-resistant
tuberculosis.
*Adapted from the RESIST-TB site (http://www.resisttb.org/?page_id=1602) and from the 2016 TAG Pipeline Report (http://www.pipelinereport.
org/2015/tb-pediatrics).
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are more data on safety and dosing of
delamanid. As with other second-line drugs,
the bedaquiline dosage for these lower age
and weight ranges would have to be
extrapolated from adult dosages. Furthermore,
there is no currently available pediatric
formulation of bedaquiline, and administration
of this drug to younger children would involve
crushing and mixing of the drug, which could
affect stability and bioavailability. It is
recommended that consultation with expert
clinicians be sought before administering
bedaquiline to children in this age range.
As with adults, programs treating
children with bedaquiline should meet the
ﬁve conditions recommended by the WHO
(41). All children being considered for
bedaquiline should undergo the baseline
testing normally undertaken before
MDR-TB treatment but should also undergo
a baseline ECG to assess the QTc interval.
Contraindications for bedaquiline use are
a baseline QTc interval greater than 450
milliseconds that does not correct with
medical management, a patient or family
history of arrhythmia, or severe cardiac
disease. While receiving bedaquiline,
children should undergo a monthly ECG
to assess for QTc prolongation and should
also have monthly potassium levels
determined. As with delamanid, caution
should be used when other QTc-prolonging
medications are used and levoﬂoxacin should
be substituted for moxiﬂoxacin. Guidelines
recommend that bedaquiline be given for
24 weeks total, although longer courses have
been given to individuals with limited
therapeutic options (45).
Studies in adults show that bedaquiline
should not be given with efavirenz, as
efavirenz reduces bedaquiline levels.
Therefore, children receiving antiretroviral
therapy and for whom bedaquiline is being
considered should be switched to a regimen
containing nevirapine or raltegravir for the
duration of bedaquiline therapy (46). If a
nevirapine- or raltegravir-containing
regimen is not appropriate, a triple
nucleoside reverse transcriptase inhibitor
(NRTI) regimen could be considered,
keeping in mind the lower potency of such
regimens. Of note, lopinavir–ritonavir is
used in adults receiving bedaquiline, but
two- to threefold higher concentrations of
bedaquiline are predicted and have been
observed when the two are given together
(47). Although the clinical implications
of this are unknown, this combination
should be avoided if possible in children
until more data and experience are
available.
Regimens combining bedaquiline and
delamanid. Case reports of successful use of
the combination of bedaquiline and
delamanid in adults are emerging (48, 49).
Treatment regimens containing both
bedaquiline and delamanid in children
could be considered on a case-by-case basis,
if no other treatment options exist, in
consultation with expert clinicians. The use
of combined delamanid and bedaquiline in
this population should follow more recently
proposed guidelines, which recommend it be
used only when an effective regimen cannot
otherwise be designed; the clinical center has
expertise with treatment of MDR-TB; the
patient and caregivers are counseled as part of
informed consent for both drugs;
Table 3. Formulations and Procurement of New and Repurposed Drugs for Multidrug-Resistant Tuberculosis
Drug Formulation Procurement Cost and Funding Comments
Delamanid 50-mg tablet GDF 1,700 USD for 6-mo course This price is available for GF-eligible
countries
GF grants will cover the cost of
GDF-procured delamanid
Countries not eligible for GF can
obtain delamanid from Otsuka
Single-patient compassionate use still
available from Otsuka*
Bedaquiline 100-mg tablet GDF USAID donation for GF-eligible
countries. Tiered pricing for
non–GF-eligible countries:
6-mo course of 188 tablets is
900 USD for low-income
countries and 3,000 USD for
middle-income countries
Information on the USAID donation
program can be found at
http://www.stoptb.org/news/
stories/2014/ns14_025.asp
Linezolid 600-mg tablet; 20-mg/ml
suspension
GDF; country-
speciﬁc
2.50–6.00 USD for each
600-mg tablet (64);
country-speciﬁc
GF will support the procurement of
linezolid
Clofazimine 50-mg gelcaps; 100-mg
gelcaps
GDF 1.10 USD for each 100-mg
tablet; 0.55 USD for each
50-mg tablet
GF will support the procurement of
clofazimine
Shortened regimen All components except
gatiﬂoxacin are
available via the GDF
Definition of abbreviations: GDF =Global Drug Facility; GF = Global Fund for AIDS, Tuberculosis, and Malaria; USAID = U.S. Agency for International
Development; USD = U.S. dollars.
*For additional information on compassionate use of delamanid, contact Alexandra Martin at amartin@otsuka-onpg.com.
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pharmacovigilance is in place; and an
independent, qualiﬁed organization considers
the use of both drugs to be appropriate (50).
Linezolid
Linezolid is an oxazolidinone antibiotic
indicated for the treatment of gram-positive
bacteria that has been effective for treating
MDR-TB in adults in multiple observational
studies (51, 52) and in a delayed-start
randomized controlled trial (53). The
main factor limiting wider use is the
drug’s toxicity proﬁle, especially bone
marrow suppression, and that an optimal
dose has not been established in adults
(54, 55). Bone marrow suppression is
reversible on cessation of linezolid. The
outcome of peripheral neuropathy on
drug cessation is more variable; it may not
be reversible, although it is unclear
whether resolution may be seen with
longer follow-up.
There have been studies of linezolid in
children with MDR-TB showing the drug is
effective, but safety issues have been
reported with longer durations and higher
doses, including hematologic toxicity and
peripheral neuropathy (56–58). Linezolid
has been recommended in children when
close clinical monitoring is possible, and
the WHO recommends that linezolid be
included in the treatment regimens of
children with conﬁrmed or probable
MDR-TB as part of the “other core
second-line agents” that can be used to
build a treatment regimen of at least four
effective drugs (9, 59). However, because
of the risk of adverse events, if the patient
cannot be monitored, linezolid is best used
in patients with additional possible
resistance or intolerance to other second-line
medications. Linezolid has excellent
penetration into the cerebrospinal ﬂuid, and
thus should be considered for MDR-TB
meningitis. Dosages of 10 mg/kg once
daily for children at least 12 years old and
of 10 mg/kg twice daily for children less
than 12 years are recommended because
younger children have increased
metabolism of the drug (not to exceed a
maximum dose of 600 mg daily). Children
should be closely monitored for adverse
events, especially for peripheral
neuropathy, anemia, thrombocytopenia,
lactic acidosis, and optic neuropathy.
Linezolid should be given for the entire
duration of therapy or for as long as it is
tolerated. It can be safely given with
antiretroviral therapy, although there
should be close monitoring due to
potential for overlapping toxicity if used
with NRTIs, given the potential for both
linezolid and NRTIs to inhibit
mitochondrial protein synthesis (60).
Clofazimine
Clofazimine is a lipophilic riminophenazine
antibiotic, traditionally used for leprosy
treatment. It was effective for treatingMDR-
TB in adults in observational studies and in
a nonplacebo randomized controlled trial
(61, 62). There is a resurgence of interest in
it, given its use in shorter MDR-TB
regimens. Although there have been no
formal studies of clofazimine in children
with TB, there is substantial experience in
using it to treat children with leprosy. In a
leprosy trial of 422 children in China and
India, clofazimine was well tolerated (63).
The main adverse events associated with
clofazimine include prolongation of the
QTc interval, and reversible skin
pigmentation. The WHO has included
clofazimine as part of the “other core
second-line agents” that can be used to
build a treatment regimen of at least four
effective drugs (9). A dose of 2–3 mg/kg per
day (maximum dose, 100 mg daily) is
recommended for children; however, there
is limited published pharmacokinetics to
support this dose. Clofazimine comes in
50- and 100-mg gelcaps that cannot be
split, and therefore if lower doses are
needed children could be given doses every
other day because of the drug’s long half-
life. Children receiving clofazimine should
have monthly ECGs assessed when
possible, especially when more than one
QTc-prolonging agent is used. Children
and their caregivers should be advised
about associated skin color changes, which
may take a long time to resolve.
Clofazimine should be given for the entire
duration of therapy or as long as it is
tolerated. It can be safely given with
antiretroviral therapy.
Conclusions
The use of new and repurposed drugs for the
treatment of MDR-TB has improved
interim outcomes and helped manage
toxicity in adults. Years after they have been
recommended for adults, children facing the
same challenges have not beneﬁted from
these therapeutic advances. This has caused
a concerning disparity, in which vulnerable
children with MDR-TB are left behind. This
is occurring even in the setting of a robust
pediatric drug development program for
delamanid and multiple calls to action for
inclusion of children in clinical research
for MDR-TB. These practice-based
recommendations can assist front-line
providers treating children with MDR-TB
and provide a base for national TB
programs and the donor community to
further support the use of new and
repurposed drugs in the pediatric
population, especially as additional data on
safety and optimal dosing of these drugs in
children continue to emerge. Children and
adolescents with MDR-TB have had to
endure the problems with the current
treatment regimen for far too long, and it is
time they too beneﬁt from these exciting
developments. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
References
1. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S,
Pe´rez-Ve´lez CM, Pagano M, Becerra MC, Cohen T. Incidence
of multidrug-resistant tuberculosis disease in children:
systematic review and global estimates. Lancet 2014;383:
1572–1579.
2. Brigden G, Furin J, Van Gulik C, Marais B. Getting it right for
children: improving tuberculosis treatment access and new
treatment options. Expert Rev Anti Infect Ther 2015;13:
451–461.
3. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High
treatment success in children treated for multidrug-resistant
tuberculosis: an observational cohort study. Thorax 2014;69:
458–464.
4. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment
outcomes for children with multidrug-resistant tuberculosis: a systematic
review and meta-analysis. Lancet Infect Dis 2012;12:449–456.
5. Guglielmetti L, Le Duˆ D, JachymM, Henry B, Martin D, Caumes E, Veziris N,
Me´tivier N, Robert J; MDR-TB Management Group of the French
National Reference Center for Mycobacteria and the Physicians of
the French MDR-TB Cohort. Compassionate use of bedaquiline for
CONCISE CLINICAL REVIEW
1308 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 10 | May 15 2017 303
Stellenbosch University  https://scholar.sun.ac.za
the treatment of multidrug-resistant and extensively drug-resistant
tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015;
60:188–194.
6. Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H,
Maartens G, Mametja D, Meintjes G, Padanilam X, et al. Treatment of
drug-resistant tuberculosis with bedaquiline in a high HIV prevalence
setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015;19:
979–985.
7. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder
HL. Short, highly effective, and inexpensive standardized treatment of
multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:
684–692.
8. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA,
Rieder HL. Successful “9-month Bangladesh regimen” for multidrug-
resistant tuberculosis among over 500 consecutive patients. Int J
Tuberc Lung Dis 2014;18:1180–1187.
9. World Health Organization (WHO). WHO treatment guidelines for drug
resistant tuberculosis: 2016 update. WHO/HTM/TB/2016.04. Geneva,
Switzerland: World Health Organization; 2016.
10. Becerra MC, Swaminathan S. Commentary: a targets framework:
dismantling the invisibility trap for children with drug-resistant
tuberculosis. J Public Health Policy 2014;35:425–454.
11. Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R,
Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, et al.
Towards early inclusion of children in tuberculosis drugs
trials: a consensus statement. Lancet Infect Dis 2015;15:
711–720.
12. Monedero I, Furin J. Programmatic management of children with drug-
resistant tuberculosis: common sense and social justice. Public
Health Action 2015;5:92.
13. Hafkin J, Frias M, Hesseling A, Garcia-Prats AJ, Schaaf HS, Gler M, Hittel
N, Wells C, Geiter L, Mallikaanjun S. Pharmacokinetics and safety of
delamanid in pediatric MDR-TB patients, ages 6–17 years. Poster
presented at the International Conference on Antimicrobial Agents
and Chemotherapy. September 18–21, 2015, San Diego, CA. Poster
A-960.
14. Hafkin J, Frias M, De Leon A, Hittel N, Geiter L, Wells C, Mallikaarjun
S. Long-term safety, tolerability, and pharmacokinetics of
delamanid in pediatric MDR-TB patients ages 12–17 years.
Poster presented at the 46th Union World Conference on Lung
Health. December 2–6, 2015, Cape Town, South Africa. Poster
EP-115-04.
15. Paccaly A, Peterson C, Patil S, Briemont P, Kim J, Harlin M, Wells C.
Absence of clinically relevant drug interaction between delamanid, a
new drug for multidrug-resistant tuberculosis (MDR-TB) and
tenofovir or lopinavir/ritonavir in healthy subjects. Presented at the
International AIDS Conference. July 22–27, 2012, Washington, DC.
WEPE043.
16. Ndjeka N. Incorporation of bedaquiline in the South African National TB
Programme. Poster #754 presented at the International Conference
on Retroviruses and Opportunistic Infections. February 2016,
Boston, MA. Available from: http://www.croiconference.org/
sites/default/ﬁles/posters-2016/754.pdf [accessed 2016 June 10].
17. Furin J. The use of new and repurposed drugs in children with MDR-TB.
Presented at the 5th Regional TB Symposium—Eastern Europe and
Central Asia. March 22, 2016, Tbilisi, Georgia. Available from:
http://www.tb-symposium.org/ [accessed 2016 June 10].
18. Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM,
Amanullah F, Ford N, Starke JR, Schaaf HS; Sentinel Project on
Pediatric Drug-Resistant Tuberculosis. Caring for children with drug-
resistant tuberculosis: practice-based recommendations. Am J
Respir Crit Care Med 2012;186:953–964.
19. Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Boston, MA
[accessed 2016 Sept 17]. Available from: www.sentinel-project.org
20. World Health Organization (WHO). Active tuberculosis drug safety
monitoring and management (aDSM): a framework for
implementation. WHO/HTM/TB/2015.28. Geneva, Switzerland:
World Health Organization; 2015.
21. World Health Organization (WHO). Nutritional care and support for
persons with tuberculosis. ISBN: 978 92 4 150641 0. Geneva,
Switzerland: World Health Organization; 2013.
22. World Health Organization (WHO). Companion handbook to the WHO
guidelines for the programmatic management of multidrug-resistant
tuberculosis. ISBN 978 92 4 154880 9. Geneva, Switzerland: World
Health Organization; 2014.
23. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G,
Kummik T, Cirule A, Leimane V, Kurve A, Levina K, et al. Delamanid
improves outcomes and reduces mortality in multidrug-resistant
tuberculosis. Eur Respir J 2013;41:1393–1400.
24. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL,
Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al.
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J
Med 2012;366:2151–2160.
25. Gupta R, Geiter LJ, Hafkin J, Wells CD. Delamanid and QT prolongation
in the treatment of multidrug-resistant tuberculosis. Int J Tuberc
Lung Dis 2015;19:1261–1262.
26. Me´decins Sans Frontie`res. Call to action: accelerate access
to DR-TB drugs. Available from: http://www.msfaccess.
org/content/call-action-accelerate-access-dr-tb-drugs
[accessed 2016 June 10].
27. RESIST-TB. DR-TB clinical trials progress report. Available from:
http://www.resisttb.org/?page_id=1602 [accessed 2016 April 26].
28. World Health Organization (WHO). The use of delamanid in the
treatment of multidrug-resistant tuberculosis: interim policy
guidance. WHO/HTM/TB2014.23. Geneva, Switzerland: World
Health Organization; 2014.
29. Garcia-Prats A, Donald P, Hesseling A, Schaaf HS. Second-line
antituberculosis drugs in children: a commissioned review for the
World Health Organization 19th Expert Committee on the
Selection and Use of Essential Medicines. January 11, 2013.
Available from; http://www.who.int/selection_medicines/
committees/expert/19/applications/TB_624_C_R.pdf [accessed
2016 May 5].
30. Esposito S, D’Ambrosio L, Tadolini M, Schaaf HS, Caminero Luna J,
Marais B, Centis R, Dara M, Matteelli A, Blasi F, et al. ERS/WHO
Tuberculosis Consilium assistance with extensively drug-resistant
tuberculosis management in a child: case study of compassionate
delamanid use. Eur Respir J 2014;44:811–815.
31. Seddon JA, Hesseling AC, Schaaf HS. Retooling existing tuberculosis
drugs for children. Clin Infect Dis 2013;56:167–168.
32. Tadolini M, Garcia-Prats AJ, D’Ambrosio L, Hewison C, Centis R,
Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S,
et al. Compassionate use of new drugs in children and adolescents
with multidrug-resistant and extensively drug-resistant
tuberculosis: early experiences and challenges. Eur Respir J 2016;
48:938–943.
33. Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc
prolongation and treatment of multidrug-resistant tuberculosis. Int J
Tuberc Lung Dis 2015;19:385–391.
34. Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS.
Hearing loss in children treated for multidrug-resistant tuberculosis. J
Infect 2013;66:320–329.
35. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN,
Becerra MC, Benedetti A, Burgos M, Centis R, et al.; Collaborative
Group for Meta-Analysis of Individual Patient Data in
MDR-TB. Multidrug resistant pulmonary tuberculosis treatment
regimens and patient outcomes: an individual patient
data meta-analysis of 9,153 patients. PLoS Med 2012;9:
e1001300.
36. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R,
Hollm-Delgado MG, Palmero D, Pe´rez-Guzma´n C, Vargas MH, et al.;
Collaborative Group for Meta-Analysis of Individual Patient Data in
MDR-TB. Drug resistance beyond extensively drug-resistant
tuberculosis: individual patient data meta-analysis. Eur Respir J
2013;42:169–179.
37. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E,
Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, et al.;
TMC207-C208 Study Group. Multidrug-resistant tuberculosis and
culture conversion with bedaquiline. N Engl J Med 2014;371:
723–732.
38. Be´lard S, Heuvelings CC, Janssen S, Grobusch MP. Bedaquiline for the
treatment of drug-resistant tuberculosis. Expert Rev Anti Infect Ther
2015;13:535–553.
CONCISE CLINICAL REVIEW
Concise Clinical Review 1309 304
Stellenbosch University  https://scholar.sun.ac.za
39. Pontali E, Sotgiu G, D’Ambrosio L, Centis R, Migliori GB. Bedaquiline
and multidrug-resistant tuberculosis: a systematic and critical
analysis of the evidence. Eur Respir J 2016;47:394–402.
40. DR-TB STAT. April 2016 task force update [accessed 2016 Apr 26].
Available from: http://www.stoptb.org/wg/mdrtb/taskforces.asp?tf=4
41. World Health Organization (WHO). The use of bedaquiline in the
treatment of multidrug-resistant tuberculosis: interim guidance. ISBN
978 92 4 150548 2. Geneva, Switzerland: World Health Organization;
2013.
42. Centers for Disease Control and Prevention. Provisional CDC
guidelines for the use and safety monitoring of bedaquiline fumarate
(Sirturo) for the treatment of multidrug-resistant tuberculosis.MMWR
Recomm Rep 2013;62:1–12. [Published erratum appears in MMWR
Recomm Rep 62:906.]
43. Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. Global
progress and challenges in implementating new medications
for treating multidrug-resistant tuberculosis. Emerg Infect Dis
2016;22(3).
44. International Maternal Pediatric Adolescent AIDS Clinical Trials
Network (IMPAACT). IMPAACT protocols snapshot: in development
through closed to accrual. November 29, 2016. Available from:
http://impaactnetwork.org/DocFiles/Index/StudyStatusTbl.pdf
[accessed 2016 June 10].
45. Lewis JM, Hine P, Walker J, Khoo SH, Taegtmeyer M, Squire SB, Sloan
DJ. First experience of effectiveness and safety of bedaquiline for 18
months within an optimised regimen for XDR-TB. Eur Respir J 2016;
47:1581–1584.
46. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir–ritonavir or
nevirapine on bedaquiline exposures and potential implications for
patients with tuberculosis–HIV coinfection. Antimicrob Agents
Chemother 2014;58:6406–6412.
47. Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F,
Variava E, Maartens G. Drug–drug interactions between bedaquiline
and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-
infected patients with drug-resistant TB. J Antimicrob Chemother
2016;71:1037–1040.
48. Lachaˆtre M, Rioux C, Le Duˆ D, Fre´chet-Jachym M, Veziris N, Bouvet E,
Yazdanpanah Y. Bedaquiline plus delamanid for XDR tuberculosis.
Lancet Infect Dis 2016;16:294.
49. Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D’Ambrosio L,
Sadutshang TD, Centis R, Migliori GB. First case of extensively drug-
resistant tuberculosis treated with both delamanid and bedaquiline.
Eur Respir J 2016;48:935–938.
50. Matteelli A, D’Ambrosio L, Centis R, Tadolini M, Migliori GB.
Compassionate and optimum use of new tuberculosis drugs. Lancet
Infect Dis 2015;15:1131–1132.
51. Cox H, Ford N. Linezolid for the treatment of complicated drug-
resistant tuberculosis: a systematic review and meta-analysis. Int J
Tuberc Lung Dis 2012;16:447–454.
52. Sotgiu G, Centis R, D’Ambrosio L, Alffenaar JW, Anger HA, Caminero JA,
Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, et al. Efﬁcacy, safety
and tolerability of linezolid containing regimens in treating MDR-TB
and XDR-TB: systematic review and meta-analysis. Eur Respir J
2012;40:1430–1442.
53. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC,
Kang E, Jin B, et al. Linezolid for treatment of chronic extensively
drug-resistant tuberculosis. N Engl J Med 2012;367:1508–1518.
54. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS,
Kim DS, Kim WD, et al. Efﬁcacy and tolerability of daily-half dose
linezolid in patients with intractable multidrug-resistant tuberculosis.
J Antimicrob Chemother 2006;58:701–704.
55. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS.
Daily 300 mg dose of linezolid for the treatment of intractable
multidrug-resistant and extensively drug-resistant tuberculosis.
J Antimicrob Chemother 2009;64:388–391.
56. Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-
containing regimens for the treatment of drug-resistant tuberculosis in
South African children. Int J Tuberc Lung Dis 2012;16:1588–1593.
57. Kjo¨llerstro¨m P, Brito MJ, Gouveia C, Ferreira G, Varandas L. Linezolid in
the treatment of multidrug-resistant/extensively drug-resistant
tuberculosis in paediatric patients: experience of a paediatric
infectious diseases unit. Scand J Infect Dis 2011;43:556–559.
58. Tan TQ. Update on the use of linezolid: a pediatric perspective. Pediatr
Infect Dis J 2004;23:955–956.
59. Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the
treatment of drug-resistant tuberculosis in children: a review and
recommendations. Tuberculosis (Edinb) 2014;94:93–104.
60. Madariaga MG, Swindells S, McKee EE. Oxazolidinones and human
immunodeﬁciency virus. Antimicrob Agents Chemother 2007;51:
1130, author reply 1130.
61. du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy:
current drug delivery approaches. Respir Res 2006;7:118.
62. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, Li M, Li F, Wu M, Zhu Y,
et al. Clofazimine for the treatment of multidrug-resistant
tuberculosis: prospective, multicenter, randomized controlled study
in China. Clin Infect Dis 2015;60:1361–1367.
63. Kroger A, Pannikar V, Htoon MT, Jamesh A, Katoch K, Krishnamurthy P,
Ramalingam K, Jianping S, Jadhav V, Gupte MD, et al.
International open trial of uniform multi-drug therapy regimen
for 6 months for all types of leprosy patients: rationale,
design and preliminary results. Trop Med Int Health 2008;13:
594–602.
64. Stop TB Partnership. Stop TB Partnership’s Global Drug Facility
announces a 70% price reduction for linezolid: another critical step
towards achieving equitable access to MDR-TB treatment. April 28,
2016. Available from: http://www.stoptb.org/news/stories/2016/
ns16_013.asp [accessed 2016 May 5].
CONCISE CLINICAL REVIEW
1310 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 10 | May 15 2017 305
Stellenbosch University  https://scholar.sun.ac.za
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ieds20
Download by: [Anthony Garcia-Prats] Date: 05 November 2016, At: 05:21
Expert Opinion on Drug Safety
ISSN: 1474-0338 (Print) 1744-764X (Online) Journal homepage: http://www.tandfonline.com/loi/ieds20
The safety and tolerability of the second-line
injectable antituberculosis drugs in children
Anthony J. Garcia-Prats, H. Simon Schaaf & Anneke C. Hesseling
To cite this article: Anthony J. Garcia-Prats, H. Simon Schaaf & Anneke C. Hesseling (2016) The
safety and tolerability of the second-line injectable antituberculosis drugs in children, Expert
Opinion on Drug Safety, 15:11, 1491-1500, DOI: 10.1080/14740338.2016.1223623
To link to this article:  http://dx.doi.org/10.1080/14740338.2016.1223623
Accepted author version posted online: 12
Aug 2016.
Published online: 22 Aug 2016.
Submit your article to this journal 
Article views: 72
View related articles 
View Crossmark data
 306
Stellenbosch University  https://scholar.sun.ac.za
REVIEW
The safety and tolerability of the second-line injectable antituberculosis drugs
in children
Anthony J. Garcia-Prats, H. Simon Schaaf and Anneke C. Hesseling
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University,
Tygerberg, South Africa
ABSTRACT
Introduction: A growing number of children globally are being treated for multidrug-resistant tuber-
culosis (MDR-TB). The second-line injectable antituberculosis medications amikacin, kanamycin and
capreomycin, traditionally a mainstay of MDR-TB treatment, cause important adverse effects including
permanent sensorineural hearing loss, nephrotoxicity, electrolyte abnormalities, injection pain and local
injection site complications.
Areas covered: To characterize the safety and tolerability of the second-line injectables in children
treated for MDR-TB, we reviewed data on the mechanism of injectable associated adverse effects, risk
factors for their development, and the incidence of injectable-associated adverse effects in adults and
children treated for MDR-TB.
Expert opinion: Despite a substantial evidence base in adults demonstrating the frequent and
potentially serious adverse effects of second-line injectables, important knowledge gaps remain.
Improved characterization of the incidence of injectable-associated adverse effects will inform rational
guidance on monitoring children with TB on injectables. Eliminating the need for injectables in MDR-TB
treatment regimens is a high priority, and will rely on the use of novel antituberculosis TB drugs.
Strategies to reduce the risk of adverse effects of injectables, if used, deserve evaluation. This includes
evaluation of potentially otoprotective medications N-acetylcysteine or aspirin, high frequency hearing
screening for earlier detection of ototoxicity and therapeutic drug monitoring.
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1. Introduction
There is a substantial global burden of multidrug-resistant
tuberculosis (MDR-TB), defined as TB resistant to at least
both isoniazid and rifampicin. Accurate figures of cases in
children are lacking, however, two models have provided
similar estimates of 32,000 pediatric cases of MDR-TB in 2010
[1] and 27,500 cases in 2014 [2]. Although a small percentage
of children with MDR-TB are appropriately diagnosed and
treated, there are ongoing efforts to reduce and eliminate
this ‘treatment gap’ [3]. Thus, more children will be accessing
MDR-TB treatment in coming years.
The treatment of MDR-TB relies on the so-called second-
line antituberculosis medications. Current guidance from the
World Health Organization (WHO) on MDR-TB treatment
recommends building a regimen with at least four TB medica-
tions confirmed or likely to have activity, which should include
a second-line injectable medication for a minimum duration of
8 months [4]. The second-line injectable antituberculosis drugs
collectively refer to the aminoglycosides amikacin, kanamycin,
and the cyclic polypeptide capreomycin. These are considered
together because of their similar characteristics, including
mechanism of action of protein synthesis inhibition, pharma-
cokinetics, administration requirements, and adverse effect
profiles [5]. All of these medications are rapidly degraded
when given orally, so must be administered intravenously or
by intramuscular injection. Given the current limited existing
treatment options for MDR-TB, despite recent registration of
the novel drugs bedaquiline and delamanid for use in adults
with MDR-TB, the injectables have traditionally been consid-
ered key components of current regimens [4]. Even a shor-
tened 9-month regimen which has demonstrated good
outcomes in observational studies in adults, and is being
evaluated in an ongoing clinical trial, still includes an inject-
able drug for 4 months [6].
As opposed to adults for whom MDR-TB treatment out-
comes remain poor, outcomes in children with MDR-TB are
generally good, with successful outcomes reported in 80% of
children and higher in some cohorts [7,8]. However, current
treatment regimens are associated with frequent and poten-
tially severe adverse effects [8]. The second-line injectables can
cause a number of serious adverse effects including nephro-
toxicity, electrolyte abnormalities, vestibular toxicity, and most
importantly permanent sensorineural hearing loss [5].
Additionally, their requirement to be given by intramuscular
injection in many settings makes them poorly tolerated, result-
ing in substantial pain, distress, and local injection-related
complications. An overview of the second-line injectables is
shown in Table 1. A thorough understanding of the adverse
effects of the second-line injectables is important for
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healthcare workers caring for children with MDR-TB, and for
persons designing and evaluating novel MDR-TB treatment
regimens.
The carbapenem antimicrobials meropenem, imipenem,
and ertapenem, when combined with a β-lactamase inhibitor
such as clavulanate, have demonstrated antimycobacterial
activity. However, because of the limited efficacy data in
humans, high cost, and the need for multiple daily intravenous
doses, these medications have been mostly used in salvage
regimens for patients with very limited treatments options in
higher-resourced settings. There may be renewed interest in
the carbapenems as antituberculosis medications, as a recent
study has now shown a substantial early bactericidal activity of
meropenem/amoxicillin-clavulanate [9].
The objective of this review is to examine current knowl-
edge of the adverse effects of the second-line injectable anti-
tuberculosis medications and the carbapenems in children,
and to highlight knowledge gaps and priority questions for
future research.
2. Ototoxicity and vestibulotoxicity
2.1. Overview of ototoxicity
Ototoxicity is a well-known complication of the second-line
injectables, and aminoglycoside-induced ototoxicity has been
studied in depth. An understanding of the pathophysiology
helps provide improved understanding of many of the clinical
findings of ototoxicity in injectable-treated patients.
Very early after administration, the injectable antitubercu-
losis medication enters the cochlear hair cells through a mem-
brane channel [10]. This channel acts like a one-way valve,
trapping the injectable medication in the hair cell where they
are not metabolized; the half-life for disappearance of amino-
glycosides from hair cells appears to be >30 days [11]. This
results in accumulation of injectable medication in the hair
cells over time, and explains why hearing loss can occur or
progress after their discontinuation. Once in the hair cells, the
injectable medications form complexes with iron (Fe), gener-
ating reactive oxygen species; along with direct interactions
between the injectable medication and hair cell mitochondrial
rRNA; this results in disruption of mitochondrial integrity
which ultimately results in apoptotic cell death [10]. This cell
death begins at hair cells responsible for recognizing higher-
frequency sounds, above the speech threshold, and pro-
gresses to lower frequencies [10]. This has important implica-
tions for clinical management, as hair cell damage may occur
prior to any perceived loss of hearing by participants. As such,
subjective patient report cannot be relied on for detection of
ototoxicity; audiological testing which includes high frequen-
cies, at least 6000–8000 kHz or higher, is therefore important
for early identification of ototoxicity and prompt
management.
Studies exploring potential risk factors for aminoglycoside-
associated ototoxicity have reported conflicting results.
Trough concentrations of injectables have been associated
with ototoxicity in some studies, but not in others; older age,
duration of use, and cumulative dose are associated with
hearing loss in some, but not in others [12–15]. A number of
genetic mutations have been identified which increase the risk
of injectable-associated ototoxicity [10,16–18]. These muta-
tions are in the gene (MT-RNR1) encoding the mitochondrial
12 s rRNA, making it more similar to bacterial rRNA and
increasing its affinity for aminoglycosides, with a resultant
Article highlights
● Permanent sensorineural hearing loss occurs in at least 20% of
children treated long term with the second-line injectable medica-
tions amikacin, kanamycin, and capreomycin, and is associated with
cumulative drug exposure
● There is limited data on electrolyte abnormalities and renal dysfunc-
tion in children treated with the second-line injectables, but the risk
appears to be low; there may be a higher risk with capreomycin use
so closer monitoring may be warranted
● Local injection site adverse effects have been poorly described, how-
ever the injections are painful and poorly tolerated by adults and
children
● The carbapenems are generally well-tolerated agents, but their safety
with long-term use for MDR-TB in adults or children has not been
well characterized
● Given the adverse effect profile of the second-line injectables, devel-
oping efficacious all-oral regimens that don’t require their use is an
urgent priority
● Potential strategies deserving evaluation for reducing second-line
injectable adverse effects include the use otoprotective agents, addi-
tion of local anesthetic to reduce injection pain, therapeutic drug
monitoring, and improved audiologic monitoring.
This box summarizes key points contained in the article.
Table 1. Overview of the second-line injectable antituberculosis medications.
Medications ● Amikacin and kanamycin (aminoglycosides)
● Capreomycin (cyclic polypeptide)
Key characteristics ● Administration intravenously or intramuscular injection
● All have similar pharmacokinetics and similar spectrum of adverse effects
Current WHO-recommended role in multidrug-resistant tuberculosis
treatment
● To be included in all treatment regimens in adults and children for at least
4 months
Key adverse effects and risk factors ● Ototoxicity, resulting in permanent sensorineural hearing loss
● Vestibular toxicity, resulting in vertigo and balance problems
● Nephrotoxicity, resulting in oliguric renal failure
● Electrolyte abnormalities, hypokalemia, hypomagnesemia most frequent
● Injection pain and local injection site complications
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decrease in mitochondrial protein synthesis [10,16–18]. When
present, severe hearing loss can occur rapidly, even after a few
doses. However, these mutations are relatively infrequent in
the general population, present in anywhere from 0–1.8% of
populations representing a broad geographic distribution; no
specific populations to date have been identified with a parti-
cularly high prevalence of these mutations [10,16,19]. In a
cohort of South African adults with MDR-TB, none of 153
patients with hearing loss had any of these known mutations,
demonstrating that the overall contribution of these genetic
predisposition to ototoxicity in MDR-TB treatment is likely
small [16,19].
The most important risk factor for ototoxicity appears to be
cumulative drug exposure. A number of elegant studies in
guinea pigs provided some important insights into this rela-
tionship, which appears to be consistent with experience in
humans [20,21]. In guinea pigs treated with continuous ami-
kacin infusions at various rates, ototoxicity was closely asso-
ciated with total dose and total cumulative drug exposure
(total area under the time–concentration curve [AUC])
[20,21]. The infusion rate and plasma concentrations were
not associated with ototoxicity and did not affect the total
dose or total AUC at which ototoxicity occurred. This may
explain the limited value of peak and trough measurements
as predictors of ototoxicity. This also has important implica-
tions for dosing strategies, and suggests that intermittent
dosing (thrice weekly versus daily) will not impact on the risk
of ototoxicity. In addition to an association with incidence of
ototoxicity, the total dose and total AUC were also associated
with the magnitude of hearing loss. There was also a signifi-
cant negative relationship between total dose/total AUC with
the hearing frequency at which hearing loss occurred, mean-
ing ototoxicity occurs at higher frequencies at a lower total
dose/total AUC, and progresses to lower frequencies as the
total dose/total AUC increases. This is consistent with clinical
experience in humans. The relationship between total dose/
total AUC and ototoxicity fit a sigmoid curve which had a very
steep slope, which could result in large differences in inci-
dence and magnitude of ototoxicity over relative small ranges
in total dose/total AUC, and could partly explain the large
variability and unpredictability of ototoxicity in humans. The
proposed explanation for all of these findings was that ami-
noglycosides enter hair cells at a rate that is linearly related to
the plasma concentration through an essentially one-way pro-
cess, accumulating over time and resulting in ototoxicity once
a certain threshold concentration is reached [20,21].
These guinea pig studies are consistent with and explain
many of the findings in human studies. In a study comparing
the impact of dosing strategy on ototoxicity in adults, there
was no difference in risk of ototoxicity between persons trea-
ted with a daily dose of streptomycin, kanamycin, or amikacin
of 15 mg/kg/dose (5 days a week) compared to those receiv-
ing a three times weekly dose of 25 mg/kg/dose [22]. Neither
maximum plasma concentration nor trough concentration
were associated with risk of hearing loss. However older age,
total dose and the related duration of treatment, were asso-
ciated with ototoxicity, with a 6.9-fold increase in ototoxicity
for every 10-fold increase in total dose received [22]. These
confirm the limited value of intermittent dosing and
measuring peak/trough concentrations for reducing ototoxi-
city risk, and confirm the importance of cumulative dose. In a
cohort of 28 adults with MDR-TB in Botswana treated with
amikacin 750–1000 mg/day, 11 (39%) had hearing loss [23].
Amikacin peak and trough concentrations were not associated
with hearing loss, however cumulative days of therapy and
cumulative amikacin AUC were predictive of hearing loss. As in
the animal studies, the relationship between cumulative AUC
and cumulative days of therapy was a sigmoid curve; the
modeled estimated risk of hearing loss began to sharply
increase around 6 months of cumulative therapy and was
nearly 100% at 9 months of therapy.
The relative risk of ototoxicity between the different sec-
ond-line injectables has not been well characterized, but could
potentially be clinically relevant. Although not a second-line
injectable, streptomycin was found to be less ototoxic than
kanamycin or amikacin in one adult study [22]. In a retro-
spective review of adults with MDR-TB treated with either
amikacin or kanamycin in routine care, the risk of hearing
loss was higher with amikacin, with an adjusted odds ratio
(aOR) of 2.3 (95% CI 1.0–5.4); the association of amikacin with
more severe hearing loss was even higher, with an aOR of 4.0
(95% CI 1.5–10.8) [24]. Duration of treatment and total dose
were not reported or controlled for in this study, however,
these results are suggestive of a higher ototoxicity risk with
amikacin. In some sources, it has been stated that capreomy-
cin is less ototoxic than amikacin or kanamycin, however,
evidence for this assertion is limited and somewhat conflict-
ing. In a cohort of adults with MDR-TB in the UK, 11 of 29
(38%) treated with amikacin had ototoxicity, however, none of
11 treated only with capreomycin as their injectable agent
experienced ototoxicity [25]. In a small Irish cohort, 1 of 4
(25%) adults treated with capreomycin had hearing loss, com-
pared to 7 of 34 (20.6%) treated with amikacin and 4 of 26
(15.4%) treated with kanamycin [26]. These reports should be
interpreted with caution given the small numbers and retro-
spective observational design. We have observed clinicians
substituting capreomycin for other injectables in MDR-TB
patients once early hearing loss has been detected, or sug-
gesting a preferential use of capreomycin presuming a
reduced risk of ototoxicity; we would suggest caution in
using such approaches in the absence of better evidence, as
there is still a risk of ototoxicity with capreomycin, and other
serious adverse effects may be related to capreomycin use as
discussed below [27]. The injectables have concentration-
dependent activity against Mycobacterium tuberculosis, with
the ratio of the maximum plasma concentration (Cmax) to
the minimum inhibitory concentration (MIC) being the phar-
macodynamics measure most closely associated with efficacy
[5]. Amikacin has been consistently shown to be the more
potent second-line injectable against M. tuberculosis in vitro,
with a lower MIC compared to kanamycin and capreomycin
[5], and for that reason may be the injectable of choice for
MDR-TB treatment. This is a consideration that should be
weighed against a potentially higher risk of ototoxicity with
amikacin.
Other factors have been shown to increase the risk of
ototoxicity, and clinicians should at least be aware of them.
The concomitant use of loop diuretics has been shown to
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increase aminoglycoside ototoxicity in animals, and there are
descriptions in adults [28–30]. Although the risk in adults and
children has been poorly characterized, clinicians should at
least be aware of the theoretical increased potential for oto-
toxicity with co-treatment with these two classes of medica-
tions. Concomitant administration of iron also increases
ototoxicity risk in gentamicin-treated guinea pigs; it was pos-
tulated that this was related to the role of Fe in the generation
of reactive oxygen species and free radicals [31]. The contribu-
tion of these factors relative to other risk factors, like cumula-
tive drug exposure, is not entirely clear
2.2. Incidence of ototoxicity in second-line injectable-
treated adults and children with MDR-TB
The incidence of hearing loss reported among adults with
MDR-TB treated with second-line injectables is quite variable;
this may be related at least in part to the inconsistency in the
quality of reporting, methods of assessments, and definitions
of ototoxicity [32]. In a 2012 systematic review of hearing loss
in drug-resistant TB patients, the percent of reported hearing
loss ranged from 2.6–61.5% [32]. In cohorts reported after this
systematic review, the stated risk of ototoxicity remains quite
variable. However, among studies in which comprehensive
audiology assessments are done and reported, the risk of
hearing loss is high and quite concerning. In a South African
cohort of adults, 57% developed hearing loss [19]. HIV-
infected persons in this study had a higher risk of hearing
loss; HIV-infected persons might receive longer injectable
treatment because of more severe disease or slow treatment
response, however, duration of injectable treatment was not
controlled for in this analysis. In 12 adults with MDR-TB in the
UK treated with amikacin (15 mg/kg once daily) who received
careful audiology assessments, 7 (58%) had documented hear-
ing loss, 3 reported tinnitus; 8 (67%) had their amikacin inter-
rupted because of these abnormalities, and 4 patients had
further progression of hearing loss after this interruption
[33]. A large cohort of adults with MDR-TB treated with ami-
kacin (15–25 mg/kg daily, maximum 1000 mg) in Botswana
reported similar results, with 270 of 437 (62%) reporting hear-
ing loss, with 147 (54%) of these confirmed by audiology; dose
and duration of treatment were associated with hearing loss
[34]. A similar risk was reported in a Namibian adult cohort,
with overall 58% having any hearing loss, with 10% of these
having severe and 15% having profound hearing loss [24].
Given the prolonged half-life of the injectables in cochlear
hair cells, recent previous treatment with streptomycin, as in
patients receiving a WHO Category II regimen, would be
expected to increase the risk of hearing loss with subsequent
injectable-containing MDR-TB treatment. This has not been
well quantified, but clinicians should be aware of this potential
increased risk.
Data on ototoxicity in children treated for MDR-TB is more
limited. This may in part be due to the challenges with accu-
rately assessing hearing in young children, and the limited
published reports of pediatric MDR-TB in the literature.
Young children often cannot cooperate with the pure tone
audiometry (PTA) assessments used in adults and older chil-
dren. Alternative methods of hearing testing are available for
younger ages, including otoacoustic emission (OAE) testing,
which is feasible with the appropriate equipment in most
settings. Other audiology testing used in young children,
such as auditory brainstem evoked response (ABER), play
audiometry, and conditioned response audiometry requires
more specialized training and equipment, and access may be
limited in many settings. A detailed discussion of these differ-
ent testing modalities, approaches to audiological assessment
in different ages, interpretation of results and classification of
hearing loss is beyond the scope of this review, but important
and has been previously written in about in detail [32,35,36].
The lack of capacity for audiological testing in many high-
burden settings, particularly for children, is problematic. In a
2009 survey of 18 sub-Saharan African countries, only South
Africa, had more than 1 audiologist per 100,000 population,
and many had no audiologist. Only 2 of 18 countries had an
audiology training program, and access to services such as
basic audiology, ABER, and routine hearing screening was
rated as nil to poor in most countries and where present
was centralized and not widely accessible [37]. This contri-
butes to the limited data, and results in inadequate monitor-
ing of children treated with the second-line injectables,
putting them at risk for more severe hearing loss.
Taking a conservative approach and using a strict definition
of hearing loss, 24% of children in a retrospective cohort of
children treated for MDR-TB had confirmed hearing loss [38]. A
high proportion of children with hearing loss was reported in
the same setting in a follow-up prospective cohort study [8]. In
this study, 25 of 142 (17.6%) children treated for MDR-TB had
hearing loss; however in this cohort, only 94 (66%) children
(those with more severe MDR-TB disease) were treated with an
injectable, and the median duration of injectable use was only
4 months (interquartile range 4–6). This therefore likely under-
estimates the risk of hearing loss in children receiving the
current routinely recommended 6 months of injectable treat-
ment. Two other pediatric cohorts reported a lower risk of
ototoxicity, with hearing loss in 2 of 38 (6.7%) and 1 of 10
(10%), however, audiological monitoring was not well
described in these studies [7,39,40].
Children are known to have a higher clearance of amino-
glycosides, resulting in lower drug exposure relative to adults
given the same mg/kg dose [5]. If cumulative drug exposure is
the most predictive risk factor for injectable-associated oto-
toxicity, then children would be expected to have a lower risk
compared to adults treated for the same duration and same
mg/kg dose of injectable. However, children younger than
6 months of age may have a reduced aminoglycoside clear-
ance relative to older children and adults due to immature
renal function, resulting in higher drug exposures and a
potentially higher risk of ototoxicity. Although devastating at
any age, hearing loss in young children is particularly harmful
as it occurs during critical periods of neurodevelopment and
may have a profound impact on speech development.
2.3. Otoprotective strategies
Understanding the cellular and molecular pathogenesis of
ototoxic drug-induced hair cell loss, has led to exploration of
a number of potential antidotes or preventive treatments,
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mainly focusing on counteracting reactive oxygen species and
free radicals [10]. Iron chelators such as deferoxamine may
inhibit formation of reactive oxygen species, and in animals
such agents reduce aminoglycoside-induced ototoxicity
[10,41,42]. Acetylsalicylate has the dual benefit of being an
iron chelator and an antioxidant, and reduces gentamicin-
induced ototoxicity in animals [10]. Many other antioxidants,
including D-methionine, glutathione, N-acetylcysteine (NAC)
have also demonstrated benefit in animal models [10]. There
is some evidence for the benefit of a number of these agents
in humans for prevention of ototoxicity. In a randomized
controlled trial in adults receiving short courses of gentamicin
for acute infections, ototoxicity was shown in 13% receiving
placebo and 3% of those receiving aspirin (3 grams daily,
divided doses) [43,44]. This study acts as a proof of concept,
and demonstrates the potential benefits of coadministration
with the widely available aspirin. Concerns, however, particu-
larly with long-term high-dose aspirin treatment, include the
risk of tinnitus from aspirin itself, an association of Reye syn-
drome with aspirin use in children with viral infections, and a
risk of gastrointestinal ulcerations and bleeding. A recent sys-
tematic review assessed the safety and otoprotective potential
of NAC [45]. There is no data in MDR-TB; however, in this
review, aminoglycoside-treated dialysis patients receiving
NAC had a substantially reduced risk of ototoxicity, though
numbers were small and overall quality of evidence was low.
The safety of NAC when given for at least 6 weeks duration
was also evaluated, and it was found that abdominal pain,
nausea, vomiting, diarrhea, and arthralgia were more common
in NAC-treated groups compared to controls, however, severe
adverse events were limited. NAC may be an attractive oto-
protective agent in MDR-TB and should therefore be evaluated
in children with MDR-TB.
2.4. Vestibulotoxicity
The vestibular system located in the inner ear and composed
of the utricle and sacule which detect linear movement, and
the semicircular canals which detect rotational movement, is
responsible for balance and spatial orientation. Treatment
with the injectables can also result in vestibulotoxicity through
effects on the hair cells of the vestibular system, however, this
has been less studied than ototoxicity. It may occur in the
absence of ototoxicity. It may present with feelings of dizzi-
ness, vertigo, lightheadedness, which may be subtle at the
onset [46]. In adults treated for MDR-TB, vestibulotoxicity is
variably reported. In one study of adults receiving long-term
injectable treatment, objective measures of vestibular dysfunc-
tion were documented in 8 of 87 (9%); there may be some
reversibility of symptoms over time, but changes may persist
[22]. Subjective vestibular symptoms were much more com-
mon in this cohort, with 41% reporting subjective balance
changes and 47% reporting dizziness; these were mostly
mild, associated with the injectable infusion and resolved
over time [22]. In a cohort of 53 South African adults treated
for MDR-TB, vestibular complaints were common, with vertigo
reported in 45%, sensation of falling in 38% and imbalance in
26%; information about progression or resolution over time
was not provided [47]. There is little data on vestibulotoxicity
in children treated for MDR-TB. In our experience, we have not
seen clinically apparent vestibulotoxicity, however, this may
be related to difficulties in eliciting symptoms in young chil-
dren and it is possible that this is an under-recognized adverse
effect.
3. Nephrotoxicity and electrolyte abnormalities
3.1. Nephrotoxicity
The second-line injectables are well known for their potential
to cause renal impairment. The injectables elicit renal injury
primarily by causing renal tubular dysfunction [48,49]. After
glomerular filtration, the injectables enter renal tubular cells
and accumulate there, ultimately resulting in renal tubular cell
death via apoptosis or necrosis through an as yet unspecified
mechanism. In addition to tubular dysfunction, the injectables
have also been shown to induce altered glomerular filtration
and reduced renal blood flow [49]. The clinical result of these
effects is oliguric renal failure, however, this may be preceded
by more subtle evidence of tubular dysfunction such as mild
wasting of glucose, protein, and electrolytes [48,49]. This renal
injury is generally reversible after discontinuation of the
injectable.
Uptake of the injectables into renal tubular cells is a satur-
able phenomenon at clinically relevant concentrations [48].
This phenomenon has been exploited through a strategy of
higher less-frequent dosing to potentially reduce nephrotoxi-
city. In a randomized trial of once vs. twice daily dosing of
aminoglycosides in adults, nephrotoxicity occurred in 15% of
adults receiving twice-daily therapy, and in 0% of those receiv-
ing once-daily therapy; the dosing strategy was closely asso-
ciated with occurrence of nephrotoxicity, as was AUC [50].
Meta-analyses in adults have shown no difference in efficacy
with once- vs. multiple-daily dosing strategies of aminoglyco-
sides, however, there are conflicting results with regard to
nephrotoxicity, with one showing a reduced incidence with
extended interval dosing [51] but others showing no differ-
ence [52,53]. A meta-analysis of extended interval dosing in
children found no difference in nephrotoxicity [54,55]. Given
the programmatic simplicity and benefits for cost and adher-
ence, in MDR-TB treatment the injectables are therefore given
as once-daily or thrice-weekly doses.
The proportion of adults treated for MDR-TB with reported
renal impairment ranges from <1% to 9.8% [27,56–60]; this
may reflect the heterogeneity in definitions, monitoring, and
treatment approaches between studies. The risk of nephro-
toxicity in children has not been well described, but appears
to be low. In a systematic review of children treated for MDR-
TB, only 1 of 182 children was reported to have any renal
impairment, an asymptomatic elevation of creatinine [7]. In
our personal experience, renal impairment is quite uncommon
in children with once-daily administration of the recom-
mended doses of injectables. In a prospective observational
cohort study of children treated for MDR-TB [8], no cases of
abnormal renal function were seen among injectable-treated
children, although this was not specifically reported in the
paper (personal communication, H.S. Schaaf).
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There are no direct comparisons of the relative risk of
nephrotoxicity between the second-line injectables, however,
the limited existing evidence does point to a higher risk with
capreomycin. In a cohort of 151 patients in South Africa with
extensively drug-resistant TB (XDR-TB), 61 (58%) experienced a
total of 161 adverse events during treatment [27]. In total, 6 of
the 161 adverse events resulted in death, and all 6 were due
to capreomycin (5 cases of renal failure, 1 case of hypokale-
mia); 5 of these 6 were in HIV-infected persons. The deaths
occurred at a median of 14 days after starting capreomycin
(range 9–73) [27]. This high risk of death due to capreomycin-
associated renal failure is concerning, and there should be
close monitoring of renal function when capreomycin use is
required.
3.2. Electrolyte abnormalities
Hypokalemia, hypomagnesemia, and hypocalcemia are well-
described adverse effects of the injectables, most likely due to
renal electrolyte wasting, although other mechanisms may
also contribute [56,61]. Reported risk factors for the develop-
ment of electrolyte abnormalities include cumulative dose,
low body weight, and choice of injectable. The available evi-
dence suggests a substantially higher risk of electrolyte
abnormalities with capreomycin [61–63]. The most compre-
hensive description in MDR-TB treatment is from a cohort of
115 adults in Peru, where 34.8% had an electrolyte abnorm-
ality detected [61]. Hypokalemia was the most frequent, found
in 31.3%, with hypomagnesemia detected in 15.7% and with
12.2% of patients having both abnormalities; capreomycin-
treated patients had a higher risk, with 68.2% having hypoka-
lemia. In multivariable analysis, hypokalemia was associated
with capreomycin use and low body weight. Capreomycin-
attributed hypokalemia was responsible for one death in a
cohort of South African XDR-TB patients, and in this cohort
capreomycin was the most frequent drug discontinued
because of adverse effects [27].
A systematic review of children treated for MDR-TB
reported only one episode of electrolyte abnormality in 182
children [7]. This is consistent with our experience; our prac-
tice is routine monitoring of electrolytes every 4–8 weeks in
children with MDR-TB during their injectable treatment, how-
ever, we have identified few abnormalities. Given the concerns
in adults, particular care may be warranted in children treated
with capreomycin, with more frequent monitoring of electro-
lytes prudent (every 2–4 weeks if feasible).
4. Injection site adverse events
Local site adverse effects of the injectable agents, including
infection, pain, subcutaneous and muscle abscess formation,
muscle contracture and fibrosis, and neurovascular injury have
been poorly reported to date. Although the risk of an adverse
effect after a single injection is low, given the very large total
number of injections over the treatment course, adverse
effects would be expected to occur regularly [64]. A painful,
inflamed injection site was reported as an adverse effect in 4%
of an adult MDR-TB cohort, with abscess formation in <1%
[58], but most published MDR-TB cohort data does not report
on such effects. This has similarly not been well described in
children. The smaller size and lower muscle mass introduces
additional challenges in children, and some injection-related
adverse effects would be expected to be more common in
children, such as neurovascular injury. Suggested best prac-
tices for intramuscular injections in children exist, but this has
not carried over into MDR-TB treatment recommendations
[64]. This is a common challenge for frontline healthcare work-
ers, and guidance would be valuable given the large number
of required injections and age-related changes in optimal
injection site.
The pain associated with the intramuscular injections is an
important source of distress for MDR-TB patients, and is often
mentioned by patients as one of the worse aspects of treatment
[65]. Strategies to reduce the pain associated with daily intra-
muscular injections of the second-line injectables are needed.
The addition of a local anesthetic has been shown to reduce the
pain of intramuscular injections of penicillin and ceftriaxone
without substantially altering their pharmacokinetics [66–68]. A
similar strategy is being evaluated in a randomized blinded
crossover study of the effect of added lignocaine on pain and
pharmacokinetics of intramuscular amikacin in older children
and adolescents with MDR-TB (PACTR201401000670381), with
results expected soon. Implanted catheters or peripherally
inserted central venous cannulas may be used in some settings,
and would clearly eliminate the need for intramuscular injec-
tions. However, this approach has its own risks, including com-
plications of line placement and line infection. In most high TB-
burden settings, the regular use of such long-term venous access
is not feasible due to a lack of capacity for line placement and the
difficulty in caring for lines.
5. Carbapenems for TB treatment
The carbapenems are generally well tolerated, with the most
common adverse events being diarrhea, rash, and nausea/
vomiting, which are mostly mild [69–71]. As with other β-
lactams, there is a risk of hypersensitivity (anaphylactic) reac-
tions that may be severe. Imipenem in particular has been
associated with seizures, with a higher risk in those with
existing central nervous system disease or meningitis,
although the absolute risk is low [70,72,73]. A systematic
review of carbapenem-containing regimens for MDR-TB iden-
tified nine eligible studies; carbapenem-attributed adverse
events were reported in 0–13.5% of patients depending on
the cohort, with 0–40% of these adverse events resulting in at
least temporary interruption of the carbapenem [74]. This
review is limited by the high variability in treatment regimens,
disease and drug-resistance spectrum, specific carbapenem
used and dose. These cohorts only included two children, so
no conclusions can be drawn regarding long-term carbape-
nem safety in children with MDR-TB from the existing data. In
addition to data on the safety of carbapenems, adverse effects
related to the need for long-term vascular access in children
would also need to be considered given the lack of a current
orally administered carbapenem and the need for multiple-
daily dosing for most of these agents. Complications from
central lines or peripherally inserted central venous catheters
are not infrequent in children [75].
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6. Conclusion
The second-line injectable antituberculosis medications
remain a component of currently recommended treatment
regimens for MDR-TB. Their clinically important adverse effects
include ototoxicity, vestibulotoxicity, nephrotoxicity, electro-
lyte abnormalities, and injection site complications. However,
the incidence of these adverse effects and risk factors for their
occurrence have not been well described in children with
MDR-TB. Clinicians caring for children with MDR-TB should
be aware of these potential adverse effects, so that appropri-
ate screening and management can occur, to ensure that
MDR-TB treatment is as safe as possible.
7. Expert opinion
Although there is a substantial body of evidence on the safety
of the second-line injectable antituberculosis medications,
mostly in adults, a number of priority areas remain for future
research, including improved characterization of adverse
effects in children treated with injectables for MDR-TB, devel-
opment of strategies to reduce or eliminate the need for
injectables in MDR-TB treatment, and evaluation of strategies
to reduce the risk of injectable-related adverse effects when
they are truly required to be used in MDR-TB regimens
(Table 2).
There is limited high-quality data on the risk of adverse
effects due to the second-line injectables in children treated
for MDR-TB. There is likely systematic under-detection and
under-reporting in children of some injectable-related adverse
effects, such as ototoxicity, local injection site complications,
and pain and distress due to injections; this may be partly
related to challenges in assessing some of these effects in
children. For other potential adverse effects, such as nephro-
toxicity and electrolyte abnormalities, the risk in children may
be relatively low. Improved data would help inform practical
guidance for monitoring of adverse effects in children treated
for MDR-TB, would make a case for devoting resources for
appropriate safety monitoring in children, such as equipment
and training for audiological monitoring in young children,
and ultimately could provide motivation for urgently identify-
ing MDR-TB treatment strategies that exclude the use of
injectables.
The most obvious approach to reducing the risk of second-
line injectable-related adverse effects is to limit or eliminate
their use in MDR-TB treatment altogether. As described above,
children with non-severe MDR-TB can be successfully treated
without injectable treatment or at a minimum, with reduced
duration of injectables [8]. Such a strategy should be
employed wherever possible, and updated treatment recom-
mendations should reflect the potential of such a strategy
when carefully employed. This would rely on early identifica-
tion of MDR-TB in children before progression to more severe
disease, which is much more likely when children are identi-
fied by active contact investigation of infectious MDR-TB
cases. In adults, multiple trials are underway to evaluate
novel regimens for MDR-TB treatment, most of which include
one of the new TB medications bedaquiline or delamanid, and
many of which do not use an injectable medication. However,
efficacy data on these regimens is unlikely to be available
soon. A shortened, all oral MDR-TB treatment regimen for
children is a research priority, but data on such a regimen
would likewise be unavailable for some time. In the interim, an
important way forward may be the careful exploration of
whether another TB drug or drugs, such as delamanid, beda-
quiline, or even linezolid, could be substituted for the inject-
able in pediatric MDR-TB treatment regimens.
In addition to efforts to eliminate or reduce second-line
injectable use, strategies to reduce the risk of injectable-
related adverse effects should be pursued in parallel. It is likely
that the injectables will continue to play a role in MDR-TB
treatment for the foreseeable future, while data, experience
with, and access to novel regimens accumulate. Additionally,
resistance to novel agents may develop with their more wide-
spread use [76], and the injectables may again become impor-
tant agents in future salvage regimens. Improved risk
reduction approaches aimed at making the injectables safer
and more tolerable when their use is required, should be
pursued in parallel to strategies of eliminating or reducing
their use. Many such risk reduction strategies are relatively
Table 2. Summary of research priorities related to the safety and tolerability of the second-line injectable antituberculosis medications in children with multidrug-
resistant tuberculosis (MDR-TB).
Improved characterization of incidence of injectable-associated adverse effects in children with MDR-TB
● Cohort data on incidence and severity of adverse effects in children
Strategies to eliminate or reduce the duration of injectable treatment of MDR-TB
● Trials of all oral MDR-TB regimens
● Omission of injectable use in children with non-severe MDR-TB
● Reduced duration of injectable use in children with non-severe MDR-TB
● Substitution of injectable with novel or repurposed TB drugs in otherwise standard MDR-TB treatment regimens
Reduce the risk of adverse effects when injectables are used for MDR-TB
● Formal guidance on safe intramuscular injection in children, including age-appropriate injection site selection
● Addition of local anesthetic (lignocaine) to intramuscular injections for pain reduction
● Use of potentially otoprotective medications such as N-acetylcysteine, aspirin
● Therapeutic drug monitoring
● Inhaled injectable treatment
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simple and straightforward. Formal guidance is needed on
safe intramuscular injection techniques in children. The addi-
tion of local anesthetic to intramuscular injections as the
potential to greatly reduce injection pain, and data is urgently
needed. Strategies to reduce the risk of ototoxicity, the most
serious and concerning injectable-related adverse effect, are
urgently needed. The use of NAC, aspirin, or other antidotes
deserves evaluation in trials in adults and/or children, and
could be done within the context of other planned studies.
Audiological screening of high- and ultra-high frequency hear-
ing, could potentially lead to earlier detection of ototoxicity
and discontinuation of injectables prior to more severe hear-
ing loss that would be more likely to affect speech thresholds.
Improved capacity to deliver basic audiology services in high
TB burden countries is needed. Strategies that utilize age-
appropriate testing and can be delivered in a decentralized
fashion by non-audiologists with minimal training, such as
tele-audiology and the use of smart phone technology, should
be explored [77–79]. Although traditional peak and trough
measurements are unlikely to predict ototoxicity, appropri-
ately timed therapeutic drug monitoring could potentially
help predict the risk of ototoxicity and inform a safer duration
of treatment [80]. Inhaled therapy with the second-line inject-
ables may also be a way to deliver these medications to the
site of disease while limiting systemic exposures and thus
reducing adverse effects [81]. Information on the safety and
efficacy of inhaled injectable treatment is relevant, however,
the feasibility of delivering inhaled therapy at a programmatic
level could be an important limitation. Inhaled therapy tar-
geted to achieve similar systemic exposures as parenteral
therapy would negate many of the benefits of inhaled delivery
[82].
Work to address these priority issues would greatly
improve the overall safety and tolerability of MDR-TB treat-
ment in children.
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Adverse effects of oral second-line antituberculosis drugs in children
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ABSTRACT
Introduction: Increasing numbers of children with drug-resistant tuberculosis are accessing second-line
antituberculosis drugs; these are more toxic than first-line drugs. Little is known about the safety of new
antituberculosis drugs in children. Knowledge of adverse effects, and how to assess and manage these,
is important to ensure good adherence and treatment outcomes.
Areas covered: A Pubmed search was performed to identify articles addressing adverse effects of
second-line antituberculosis drugs; a general search was done for the new drugs delamanid and
bedaquiline. This review discusses adverse effects associated with oral second-line antituberculosis
drugs. The spectrum of adverse effects caused by antituberculosis drugs is wide; the majority are mild
or moderate, but these are important to manage as it could lead to non-adherence to treatment.
Adverse effects may be more common in HIV-infected than in HIV-uninfected children.
Expert opinion: Although children may experience fewer adverse effects from oral second-line anti-
tuberculosis drugs than adults, evidence from prospective studies of the incidence of adverse events in
children is limited. Higher doses of second-line drugs, new antituberculosis drugs, and new drug
regimens are being evaluated in children: these call for strict pharmacovigilance in children treated
in the near future, as adverse effect profiles may change.
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1. Introduction
Children with drug-resistant tuberculosis (DR-TB) are increas-
ingly accessing care. An estimated 850,000 children develop
tuberculosis (TB) every year; of these, approximately 25,000
will have multidrug-resistant tuberculosis (MDR-TB; i.e., resis-
tance to at least isoniazid and rifampicin) [1]. Although the
proportion of children accessing appropriate second-line anti-
tuberculosis treatment for mainly MDR-TB is still relatively
small, the number of children treated is increasing due to
changes in global guidelines for diagnosis and treatment.
MDR-TB is treated with combinations of the second-line anti-
tuberculosis drugs, which the World Health Organization
(WHO) recently reorganized into four groups (Table 1) [2].
Two novel TB drugs, bedaquiline and delamanid, now
included in WHO Group D2, have recently received conditional
approval for use in adults with MDR-TB and will become more
frequently used components of MDR-TB treatment in the near
future. Currently recommended MDR-TB treatment regimens
in children typically include five to seven medications for as
long as 18 months. Second-line antituberculosis drugs have
more adverse effects than the first-line drugs. This, combined
with the large number of medications used for long duration,
lead to frequently observed adverse effects in children on
MDR-TB treatment. However, there is a paucity of high-quality
prospective data on the safety and tolerability of these drugs
in children.
There are a number of reasons why the safety of the
second-line antituberculosis drugs should be reviewed in chil-
dren. First, children may experience a different spectrum,
frequency, or severity of adverse effects compared to adults,
and although efficacy trials of antituberculosis drugs or regi-
mens are usually not required in children with tuberculosis,
dose finding, safety, and tolerability studies of these drugs
remain critically important in children [3]. However, few such
studies have been done to date. Adverse antituberculosis drug
effects are often reported to be less common in children
compared to adults; possible reasons may be lower concen-
trations of drugs at the same mg/kg body weight doses in
children compared to adults and the difficulty in assessing
adverse effects in children.
Second, health-care providers caring for children with MDR-
TB should have a detailed knowledge of the possible adverse
effects of the second-line antituberculosis drugs in order to safely
and successfully manage children’s treatment. Antituberculosis
treatment includes a number of drugs, which all have potential
adverse effects, which may be more severe if certain drugs are
combined, and children with MDR-TB may have comorbid con-
ditions, such as HIV coinfection, requiring medications which
could have similar adverse effects to the antituberculosis drugs.
In current complicated multidrug regimens, it can be difficult to
determine the culprit drug(s). It is also important to do baseline
testing (before starting treatment), as abnormalities from other
causes may already be present.
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Severe adverse effects, such as severe hepatotoxicity or
severe cutaneous adverse effects, should lead to immediate
discontinuation of the likely drug(s) responsible, as there is
a high risk of mortality. Even so, with some severe adverse
effects (e.g. hepatotoxicity), patients can be rechallenged
with the likely responsible drug(s), while in others, a rechal-
lenge with the responsible drug may be fatal. Some
adverse effects are not fatal but could cause irreversible
morbidity. Although many adverse events are mild or mod-
erate and do not require stopping or changing of drugs, if
these are not addressed by the health-care workers,
adverse events may lead to non-adherence because they
are unpleasant or unacceptable to the patient or their
family [4,5]. Health-care workers managing patients with
MDR-TB should also be aware of possible rare but severe
adverse effects, which can occur with antituberculosis
drugs. In some cases, there may be no alternative drug
options to those drugs causing adverse effects, and it
may be necessary to weigh the risks of tolerating poten-
tially serious adverse effects versus poor or failed response
to treatment.
Finally, MDR-TB treatment outcomes in children are usually
better than that in adults, with more than 80% successfully
treated [6,7]. However, improving the safety and tolerability of
treatment while maintaining the efficacy is an important prior-
ity in children. In designing novel MDR-TB regimens for chil-
dren, the safety of component drugs will be a key
consideration. An in-depth understanding of individual drugs
and any potential overlapping or synergistic adverse effects
will be important for constructing future safe and well-toler-
ated MDR-TB regimens in children.
In this review, we provide a brief description of the more
important adverse effects of the currently available oral sec-
ond-line antituberculosis drugs (injectable agents are
reviewed separately in this journal). We also include the new
antituberculosis drugs soon to be available in children: dela-
manid and bedaquiline.
2. Methods
We searched PubMed without date or language restrictions,
using the following search terms: ‘tuberculosis, second-line
drugs, adverse effects or side-effects, child*’; ‘tuberculosis,
multidrug-resistant, treatment, adverse effects or side-effects,
child*’; and ‘tuberculosis, drug-resistant, treatment, toxicity,
child*’; many abstracts were not applicable to the review,
and there was a great overlap between search results. We
also searched adverse effects or toxicity for each individual
drug in children and used a general search where no pub-
lished data were available in children, such as with the new
drugs. Abstracts were reviewed and full-text articles retrieved
for studies with relevant information. The reference lists of
identified articles were searched for additional relevant
reports.
3. Definitions
Published literature on toxicity of drugs often uses differ-
ent terms inconsistently. Therefore, we clarify our use of
terms for this review as follows: an adverse (drug) effect
(adverse drug reaction) is an unintended symptom, sign,
condition, or abnormal laboratory test finding caused by
taking a specific drug (or in some cases, a combination of
two or more drugs). An adverse event refers to any unfa-
vorable and unintended symptom, sign, condition, abnor-
mal laboratory finding, or disease temporally associated
with the use of a drug regardless of whether it is consid-
ered related to the drug [8]. An adverse effect is a special
type of adverse event in which a causative relationship can
be shown [8].
Article highlights
● The number of children accessing second-line antituberculosis drugs
is increasing and new antituberculosis drugs are entering the child
tuberculosis treatment armamentarium
● There is a lack of high quality prospective data on the safety and
tolerability of second-line antituberculosis treatment in children
● Health care providers managing children with drug-resistant tuber-
culosis should have detailed knowledge of possible adverse effects of
second-line antituberculosis drugs
● In designing new multidrug-resistant tuberculosis regimens for chil-
dren, the safety of component drugs must be a key consideration
● Some adverse effects, such as hypothyroidism, are more common in
HIV-infected children compared to HIV-uninfected children
● Mild to moderate adverse events, such as abdominal disturbance,
pruritis and skin rash are common, and may lead to non-adherence.
However, severe adverse events, such as severe cutaneous adverse
drug effects and hepatotoxicity leading to interruption or permanent
discontinuation of drugs, are relatively rare
This box summarizes key points contained in the article.
Table 1. World Health Organization drug groups for second-line drugs recom-
mended for the treatment of rifampicin resistant and multidrug resistant.
Drug groups Drug names Abbreviations
Group A. Levofloxacin Lfx
Fluoroquinolones Moxifloxacin Mfx
Gatifloxacin Gfx
Group B. Amikacin Am
Second-line injectable
agents
Capreomycin Cm
Kanamycin Km
(Streptomycin – only if
susceptible in special cases)
(S)
Group C. Ethionamide/prothionamide Eto/Pto
Other core second-line
agents
Cycloserine/terizidone Cs/Trd
Linezolid Lzd
Clofazimine Cfz
Group D. D1 Pyrazinamide Z
Add-on agents (not part of
the core multidrug-
resistant TB regimen)
Ethambutol E
High-dose isoniazid Hh
D2 Bedaquiline Bdq
Delamanid Dlm
D3 p-Aminosalicylic acid PAS
Imipenem–cilastatin Ipm
Meropenem Mpm
Amoxicillin–clavulanate
(only used with
imipenem or
meropenem)
Amx-Clv
(Thioacetazone – only for
HIV-negative cases)
(T)
TB: tuberculosis.
Data taken from Ref. [2].
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Standard grading of many adverse events is available, such
as in the Division of AIDS table of adverse events, and can
assist in decisions of whether to discontinue treatment or not
and for safety monitoring purposes in clinical research [8].
4. Prevalence of adverse events from second-line
antituberculosis drugs in children
Children, especially those younger than 10 years of age, seem
to tolerate second-line combination antituberculosis therapy
better than adults [9,10]. There are few studies of MDR-TB in
children which have monitored adverse events closely [7,9]. In
a systematic review and meta-analysis, adverse events were
documented in 39.1% (95% confidence interval [CI]: 28.7–49.4)
of HIV-infected and HIV-uninfected children treated for DR-TB
[6]. However, in a small cohort of adolescents coinfected with
HIV, adverse effects were documented in 8/11 (72%) cases,
and in a systematic review and meta-analysis of MDR-TB in
HIV-infected adults and children, adverse events were docu-
mented in 92.5% (95% CI: 83.7–100) of HIV-coinfected children
[11,12]. Our own experience in children is also that HIV-
infected patients have higher rates of adverse events com-
pared to HIV-uninfected children [13,14]. However, the major-
ity of adverse events in children are mild to moderate, not
necessitating interruption or complete cessation of treatment,
and even with the few severe adverse events, permanent
discontinuation of drugs is rarely necessary [7,9].
5. Adverse effects associated with the second-line
antituberculosis drugs
Table 2 summarizes the most common adverse effects with
the drugs that could be responsible and how to monitor for
these adverse effects. Table 3 summarizes adverse effects by
antituberculosis drug, including rare adverse effects.
5.1. Fluoroquinolones (WHO Group A)
The fluoroquinolones used for antituberculosis therapy are
ofloxacin (Ofx) and, more frequently, its L-isomer levofloxacin
(Lfx) and moxifloxacin (Mfx). The fluoroquinolones inhibit the
mycobacterial DNA gyrase (topoisomerase II) leading to dis-
ruption of bacterial DNA synthesis, resulting in cell death [15].
The fluoroquinolones have bactericidal activity against meta-
bolizing bacilli, with a relative potency against Mycobacterium
tuberculosis of Mfx>Lfx>Ofx [16]. They are also active against
dormant mycobacteria [17]. Fluoroquinolones are well
absorbed after oral administration and distribute widely in
the body including in cerebrospinal fluid (CSF).
The most frequent adverse effects of fluoroquinolones are
gastrointestinal disturbances (0.9–4.7%) including loss of
appetite, nausea and vomiting, abdominal discomfort, and
anorexia [18,19]. In rare cases, fluoroquinolones have been
associated with Clostridium difficile infections causing mild
diarrhea to life-threatening pseudomembranous colitis [20].
Central nervous system (CNS) adverse effects occur in up to
5% of patients, although less than 0.5% are serious [21,22].
These are often dose dependent and generally reversible after
cessation of the fluoroquinolone [18,19]. Dizziness, headache,
and drowsiness are the most common complaints, while more
severe effects such as hallucinations, agitation, anxiety, rest-
lessness, paranoia, depression, suicidal ideation, psychosis, and
convulsions are rare [18,19,23]. Cases of peripheral neuropa-
thy, Guillain–Barré syndrome, and secondary intracranial
hypertension associated with fluoroquinolone use have been
reported [19,24,25]. In children receiving Ofx, mood/sleep dis-
turbances have been reported and may be underrecog-
nized [18].
Dermatological problems occur in less than 0.5% of
patients. Photosensitivity, usually mild but which may be
severe, is a fluoroquinolone class effect, but the phototoxic
potential of Ofx, Lfx, and Mfx seems to be minimal [22,26].
Cutaneous hypersensitivity reactions can present as rash, prur-
itus, urticaria, erythema, and angioedema [22,27]. Although
rare, severe reactions such as toxic epidermal necrolysis or
Stevens–Johnson syndrome have been reported in adults
and children following fluoroquinolone therapy [28–30].
Concern about musculoskeletal adverse effects, particularly
chondrotoxicity, has historically limited the widespread fluor-
oquinolone use in children. In studies on juvenile animals,
fluoroquinolones as a class exhibit a potential to induce irre-
versible cartilage damage on weight-bearing joints [31].
Nevertheless, data from multiple observational studies con-
cluded that there is no documentation of sustained injury on
bone or joint growth or severe or irreversible arthropathy in
children although there may be some association between
fluoroquinolones and reversible arthralgia [19,32,33].
Data on the risk of arthropathy in children on long-term
fluoroquinolone therapy, as for antituberculosis treatment, are
limited. In children receiving Ofx for between 6 and 18 months,
Grade 1 to 2 musculoskeletal disorders [8] occurred in 3–9% of
patients with no signs of severe arthropathy [7,18,34]. In a
small case series on five children on Lfx-containing antituber-
culosis regimens, two children experienced joint pain necessi-
tating discontinuation of Lfx in one [35]. The arthropathic
potential of long-term Mfx therapy in children is difficult to
assess due to limited reports; of 23 children 7–15 years of age
in one study, five reported arthralgia, which resolved sponta-
neously without discontinuation of Mfx [36]. Tendonitis and
Achilles tendon rupture are extremely rare in children. We
could not find a single case report of tendon rupture in
children; this agrees with our clinical experience, having trea-
ted hundreds of children with fluoroquinolones for long dura-
tions (6–24 months).
Fluoroquinolones, especially Mfx, may cause QT-interval
prolongation [19]. Studies in children receiving Mfx (n = 32)
and Lfx (n = 23) for DR-TB treatment found no evidence of QT
prolongation >450 ms [36–38]. We did not identify any report
on arrhythmia or sudden death associated with fluoroquino-
lone use in children. Nevertheless, clinicians should be aware
of this possible adverse effect especially when
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fluoroquinolones are used with other drugs with QT-prolong-
ing potential (e.g. delamanid, bedaquiline, clarithromycin, or
clofazimine).
Disordered glucose regulation associated with fluoroquino-
lones, especially gatifloxacin, has been reported in adults (not
in children) with differences between the fluoroquinolones
and very low risk for Lfx and Mfx [19]. Further rare adverse
effects of the fluoroquinolones include hemolytic anemia,
hepatotoxicity, pancreatitis, interstitial nephritis, and ophthal-
mological problems [19]. None of these adverse events have
been reported in children. However, ongoing surveillance is
critically important as more children will receive long-term
fluoroquinolone therapy as part of MDR-TB regimens in future.
5.2. Thioamides (WHO Group C)
The thioamides, ethionamide (Eto), and its propyl analog
prothionamide (Pto) form important components in the
treatment of MDR-TB and drug-susceptible disseminated TB
(e.g. TB meningitis). Eto and Pto are prodrugs that, following
enzymatic activation by mycobacterial EthA, inhibit InhA, a
target shared with isoniazid [39], resulting in inhibition of
mycolic acid biosynthesis and cell lysis [40]. Eto and Pto are
bacteriostatic drugs but can be bactericidal at higher
doses [41].
The main adverse effects of thioamide are gastrointestinal
disturbances, resulting in nausea, abdominal discomfort,
vomiting, diarrhea, and, as a result of these symptoms, weight
loss [42]. Pto was developed to improve tolerability, but gas-
trointestinal adverse effects still occur in the majority of
patients. Gastrointestinal intolerance is dose dependent, gen-
erally improves after the first weeks of therapy, and can often
be reduced by dose ramping (increasing the dose over a few
days) or giving divided daily doses at the beginning of therapy
[43]. In children, we do not recommend antiemetics, although
in adolescents this may be an option.
Table 2. An alphabetical list of more common adverse effects due to drugs used in multidrug-resistant tuberculosis treatment, likely drugs that could be
responsible, and how to monitor for these adverse effects.
Adverse drug effect Possible causative drugs How to monitor Frequency of testsa
Arthralgia/arthritis FQNs, Z (especially in
combination), Rfb
Painful joints, watch gait, examine joints
Uric acid levels (Z)
Routine follow-upa
Uric acid levels (not done routinely)
Blood dyscrasias H, Eto/Pto, Rfb, Z, E,
FQNs, PAS, Cm, Cla
Clinically – anemia, petechiae
Full blood count when suspected
Routine follow-up
Central nervous system toxicity: headache,
drowsiness, seizures, weakness, insomnia,
and hallucinations
FQNs (insomnia and
hallucinations), H, Eto/
Pto, Cs/Trd, Cla
History from parent/patient Routine follow-up
Depression/psychosis H, Eto, Cs/Trd History and observation Routine follow-up
Endocrine effects
- hypothyroidism Eto/Pto, PAS TSH/fT4/fT3 2 to 3 monthly
- gynecomastia Eto/Pto, H Physical examination Routine follow-up
Flu-like symptoms Rfb, PAS Clinical examination/history Routine follow-up
GIT disturbances: nausea, vomiting,
abdominal pain, and diarrhea
Very common, mainly
Eto/Pto, E, PAS, FQNs,
Cfs, Lzd, Bdq
Mainly history of abdominal complaints. With
new-onset vomiting or abdominal pain,
consider hepatitis
Routine follow-up
Alanine transferase and bilirubin if
new-onset symptoms
Hearing impair/ototoxicity Am, Km, Cm, S Audiology Monthly while on SLID and 6 months
after completion of SLID
Hair loss H, Eto/Pto History/clinical examination Routine follow-up
Intracranial hypertension FQNs History/ophthalmoscopy and CT scan/LP when
suspected
Routine follow-up
Jaundice/hepatotoxicity H, Z, Eto/Pto, PAS, FQNs
(Mfx more likely)
New-onset vomiting, abdominal pain, and
jaundice
Alanine transferase and bilirubin –
usually as clinically indicated but
can do 2-monthly
K+ (potassium) loss Cm, PAS K+ levels 2-monthly
Lactic acidosis Lzd Clinical examination and lactate levels if
suspected
Routine follow-up
Myelosuppression Lzd Full blood count Monthly
Nephrotoxicity Cm, Am, Km, S Serum creatinine 2-monthly
Optic neuritis: vision acuity/color blindness E, Lzd, H, Eto/Pto, PAS Vision and color blindness testing Routine follow-up
Peripheral neuropathy Lzd, H, Eto/Pto, Cs/Trd History of pain in hands/feet, watch mobility
and gait, test sensation, position
Routine follow-up
Pancreatitis Lzd Abdominal pain/clinically, serum amylase if
suspected
Routine follow-up
QTc-interval prolongation Bdq, Dlm, FQN (Mfx), Cfz,
Cla
ECG Currently not routinely done except
with Dlm and Bdq
Rashes/cutaneous adverse drug effects
including pruritus
Z, FQNs, Cs/Trd, PAS, and
many other
History and clinical examination Routine follow-up
Skin discoloration – red skin Cfz Clinical examination Routine follow-up
Tendinitis/tendinopathy FQNs Clinical examination Routine follow-up
Uveitis Rfb Examination of eyes Routine follow-up
Vasculitis H, FQNs Clinical examination Routine follow-up
Vestibular toxicity S, Am, Km, Cm History, clinical observation Routine follow-up
Am: amikacin, Bdq: bedaquiline; Cfz: clofazimine: Cla: clarithromycin; Cm: capreomycin; Cs: cycloserine; Dlm: delamanid; E: ethambutol; Eto: ethionamide; FQNs:
fluoroquinolones; H: isoniazid; Km: kanamycin; Lzd: linezolid; Mfx: moxifloxacin; PAS: para-aminosalicylic acid; Pto: prothionamide; Rfb: rifabutin; S: streptomycin;
Trd: terizidone; Z: pyrazinamide; CT: computed tomography; ECG: electrocardiogram; GIT: gastrointestinal; LP: lumbar puncture; QTc: corrected QT; SLID: second-
line injectable drug; TSH: thyroid-stimulating hormone.
aRoutine follow-up would be at least monthly initially and then 2-monthly.
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During therapy with Eto and Pto, asymptomatic elevation
of liver transaminases frequently occurs in adults and children,
and hepatotoxicity has been reported in about 2% of adult
patients [44]. Following cessation of thioamide therapy, liver
transaminases generally normalize, and it has been shown
that thioamides can be restarted without recurrence of hepa-
totoxicity in children [45].
Thioamides inhibit thyroid hormone synthesis by blocking
organification and uptake of iodine into thyroid cells. During
long-term therapy, hypothyroidism occurs frequently (20–70%)
in adults and in children [13,46,47]. HIV infection and concomi-
tant treatment with para-aminosalicylic acid (PAS) are associated
with an increased risk for hypothyroidism [13,48]. Although the
clinical significance of hypothyroidism due to thioamide therapy
has not yet been evaluated, our practice is to supplement thyr-
oxine in children with elevated thyroid-stimulating hormone
(TSH) and low free thyroxine levels, given the potential impact
of hypothyroidism on neurodevelopment in young chil-
dren [7,13].
Thioamide use has also been associated with CNS toxicity
including peripheral neuropathy, psychosis, behavioral disorders,
seizures, or pellagra-like encephalopathy in adults, but there are
no reports in children [42]. Niacin or pyridoxine supplementation
might be beneficial in case of nervous system toxicity [49].
Other rare adverse effects of thioamides include gyneco-
mastia, alopecia, hypoglycemia, pellagra-like rash, and blood
count alterations [42].
5.3. Cycloserine/terizidone (WHO Group C)
Cycloserine is an analog of the amino acid D-alanine and
inhibits enzymes needed for synthesis of peptidoglycan, a
key component of the M. tuberculosis cell wall [50].
Terizidone is a molecule formed by the combination of two
molecules of D-cycloserine [51]. Cycloserine and terizidone are
bacteriostatic drugs with relatively weak antimycobacterial
activity at currently recommended doses, yet are still currently
routinely used for MDR-TB treatment in adults and in children.
They do have the advantage of good CSF penetration, which
is important for the treatment of tuberculous meningitis.
Cycloserine is known to exert CNS effects as an agonist of
N-methyl-D-aspartate receptors and at low doses is being
explored as a potential treatment for a number of neuropsy-
chiatric conditions [52]. At the much higher doses used in TB
treatment, cycloserine has well-known CNS adverse effects.
These are highly variable, ranging from relatively mild effects
including dizziness, headache, tremor, slurred speech, insom-
nia, anxiety, lethargy, inability to concentrate, to more serious
effects including severe depression, suicidal ideation, psycho-
sis, seizures, and encephalopathy [53,54]. In a small study,
when cycloserine dosing was targeted to maintain peak con-
centrations between 20 and 40 µg/ml, only 4 of 60 partici-
pants experienced CNS adverse effects; all four had
concentrations >40 µg/ml [55]. This suggests that these effects
are dose related and concentration related, and symptoms are
reversible upon cycloserine discontinuation or dose reduction.
Cycloserine may lead to peripheral neuropathy via direct
antagonistic effects on pyridoxine and by increasing its renal
elimination; pyridoxine should be coadministered to reduce
this risk [56]. Other more rare adverse effects, including
Stevens–Johnson syndrome have been reported [57]. There
is limited published information on terizidone. It has been
suggested that terizidone has fewer adverse effects than
cycloserine; however, there are no published data to our
knowledge to support this assumption.
A recent systematic review and meta-analysis attempted to
describe the frequency of cycloserine- and terizidone-asso-
ciated adverse effects in adults treated for MDR-TB [58]. This
review included 27 studies reporting cycloserine safety data,
which included 2164 patients, and 10 studies reporting terizi-
done safety data, which included 707 patients. The pooled
frequency of any adverse effect due to cycloserine was 9.1%
(95% CI: 6.4–11.7), with the majority of these being psychiatric
adverse effects. Reporting of terizidone safety was highly vari-
able, with serious adverse effects described in 0–31% of parti-
cipants in these studies. In adults, there is a large burden of
preexisting and incident mental illness during MDR-TB
Table 3. Adverse effects (AEs) associated with second-line antituberculosis
drugs in children.
Antituberculosis
drugs Adverse effects (AEs)
Fluoroquinolones
- Moxifloxacin
- Levofloxacin
- Ofloxacin
Common: Gastrointestinal disturbance; central nervous
system (CNS) AEs (e.g. dizziness, headache,
drowsiness, and hallucinations); arthralgia; cutaneous
AEs (usually mild, e.g., pruritus, rash, and
photosensitivity)
Rare: Arthritis; tendonitis; QT prolongation (Mfx>Lfx/
Ofx); severe cutaneous AEs; hemolytic anemia;
hepatotoxicity; pancreatitis; secondary intracranial
hypertension; and ophthalmologic problems
Thioamides
- Ethionamide
- Prothionamide
Common: Gastrointestinal disturbances; hepatotoxicity;
and hypothyroidism
Rare: CNS AEs (peripheral neuritis, seizures, and
psychosis); gynecomastia; alopecia; hypoglycemia;
pellagra-like rash; and blood dyscrasias
Cycloserine/
terizidone
Common: CNS AEs (dizziness, headache, tremor,
insomnia, anxiety, lethargy, inability to concentrate,
and depression)
Rare: severe CNS AEs (peripheral neuropathy, suicidal
ideation, psychosis, seizures, and encephalopathy);
severe cutaneous AEs
Para-aminosalicylic
acid
Common: Gastrointestinal disturbances;
hypothyroidism
Rare: Hepatotoxicity; hypokalemia; hypersensitivity
reactions (fever and maculopapular rash); severe
cutaneous AEs; and blood dyscrasias
Linezolid Common: Myelosuppression (anemia,
thrombocytopenia, and leucopenia); peripheral
neuropathy
Rare: Pancreatitis; vision loss (optic neuritis);
hyperlactatemia and lactic acidosis, and
rhabdomyolysis
Clofazimine Common: Gastrointestinal disturbances; red–brown
discoloration of the skin
Rare: QT prolongation
Delamanid Little experience in children. QT prolongation;
hepatotoxicity in adults
Bedaquiline No experience in children. QT prolongation;
gastrointestinal AEs in adults
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treatment, which complicates attribution of these psychiatric
events; aggressive management with psychiatric medications
appears to be very effective and may limit the need for
cycloserine or terizidone dose adjustment [59]. There are lim-
ited published safety data for either cycloserine or terizidone
in children with MDR-TB. A systematic review of children
treated for MDR-TB reported 6 of 182 children had cycloser-
ine-associated adverse effects, which included depression,
anxiety, hallucinations, psychosis, and blurred vision [6].
Neurologic and psychiatric symptoms may be more difficult
to elicit especially in young children, and a high index of
suspicion is required. In our experience in children younger
than 14 years of age, severe adverse effects with terizidone are
rare.
5.4. Linezolid (WHO Group C)
Linezolid, an oxazolidinone class antibiotic, selectively inhibits
bacterial protein synthesis. Its high durable efficacy against
extensively drug-resistant (XDR)-TB (i.e. MDR-TB plus resis-
tance to a fluoroquinolone and a second-line injectable
agent) [60,61] and good CSF penetration have made it an
increasingly important antituberculosis drug [62]. It is being
evaluated as a component of multiple novel TB regimens,
including treatment shortening regimens, currently under eva-
luation; however, severe toxicity remains a concern, and it is
currently often reserved for the difficult-to-treat MDR-TB and
XDR-TB cases in children.
Overall, adverse effects with linezolid are reported to be
less frequent in children than in adults [63]. The mechanisms
of most adverse effects are thought to be due to the inhibition
of mitochondrial protein synthesis [64]. Gastrointestinal distur-
bances, such as vomiting and diarrhea, are the most common.
These are usually mild, occurring before 1 month, and rarely
require treatment modification [61].
Neurologic adverse effects are well described with linezolid
in adults and children and are an important concern [65].
Peripheral neuropathy is the most frequent, occurring
among patients on prolonged durations of linezolid therapy.
It presents as paresthesia and numbness of the distal extre-
mities in a ‘stocking and glove’ distribution and is not respon-
sive to pyridoxine; although reversible, the improvement may
be slow [66,67]. Optic neuropathy presents as painless, pro-
gressive loss of color vision and visual acuity, with onset
generally after 3–12 months of linezolid treatment; it may
improve after linezolid discontinuation but can result in per-
manent visual deficits [66].
Hematological adverse effects of linezolid are not uncom-
mon and include reversible anemia, thrombocytopenia, and
leucopenia [66,68]. These should be screened for routinely and
usually respond to dose reduction. Other adverse effects are
less common, but potentially serious and important to be
aware of. Linezolid-associated hyperlactatemia and lactic
acidosis have been described, which usually resolve over 1
to 2 weeks after linezolid discontinuation [66]. This has been
reported in children, most frequently in association with liver
disease or other serious comorbidities [69–71].
Rhabdomyolysis [72] and serotonin syndrome in patients
receiving a serotonin agonist drug have rarely been reported
with linezolid [66,73]. The majority of these adverse effects
appear to be dose and time dependent, with higher doses and
longer treatment durations greatly increasing the risk; how-
ever, the specific risks have not been well described.
In a systematic review including 107 adults treated with
linezolid for MDR-TB/XDR-TB, 59% experienced an adverse
effect, of which 69% required linezolid discontinuation or
dose adjustment. The most common adverse effects were
peripheral neuropathy (47%), anemia (38%), gastrointestinal
disorders (17%), optic neuritis (13%), and thrombocytopenia
(12%) [74]. Subsequent studies confirmed these findings [75].
There is a significant increase in risk of experiencing an
adverse effect when using a dose >600 mg daily [74].
A 2014 literature review identified 18 children from eight
different reports treated with linezolid for MDR-TB [76]. Fifty
percent experienced an adverse effect, with peripheral neu-
ropathy the most common (4/18, 22%); 2 (11%) had line-
zolid permanently discontinued, and 5 (28%) had a dose
reduction. Gastrointestinal disturbances, hepatotoxicity, ane-
mia, and thrombocytopenia were also reported. Subsequent
reports have shown similar findings [77,78]. The single life-
threatening adverse event was a case of severe pancreatitis
and lactic acidosis [71]. Other antituberculosis drugs have
overlapping toxicities and may have contributed to some of
these adverse events. Peripheral neuropathy may be caused
by high-dose isoniazid, ethionamide, and cycloserine/terizi-
done; therefore, close monitoring of these patients is espe-
cially important. HIV-infected children appear to be at
higher risk for adverse events, possibly due to overlapping
toxicities with the nucleoside reverse transcriptase inhibitor
class of antiretrovirals which also inhibit mitochondrial DNA
synthesis [79]. A recent study in 86 HIV-uninfected children
with TB meningitis found no significant increase in fre-
quency of adverse events when receiving additional line-
zolid for 1–4 months (linezolid group 33.3% [n = 36] versus
control group 32%) [62].
Substantial inter-patient variability in linezolid clearance
occurs, which could justify the role of therapeutic drug mon-
itoring (TDM) in future. A center conducting TDM for linezolid
in adults has reported a 0% adverse event rate [75].
5.5. Clofazimine (WHO Group C)
Clofazimine is a riminophenazine compound that has been
used for the treatment of leprosy but is only now being
explored for use in antituberculosis treatment. To date, its
mechanism of action remains unclear. Clofazimine is a pro-
drug, which is reduced by type 2 NADH-quinone oxidoreduc-
tase (NDH-2), which then releases reactive oxygen species
upon spontaneous reoxidation by O2 [80]. It competes with
menaquinone, the only quinone present in mycobacteria, and
a key electron acceptor, for its reduction by NDH-2 [80].
To date, clofazimine has been used mostly in salvage anti-
tuberculosis treatment regimens, but the success of a shor-
tened clofazimine-containing regimen for MDR-TB has
generated interest in its more widespread use [81].
Clofazimine is now included in the WHO–recommended 9–
12-month shortened treatment regimen for MDR-TB [2] and is
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being evaluated as a component of multiple novel TB regi-
mens in adults.
The most frequently reported adverse effects attributed to
clofazimine are gastrointestinal and dermatologic problems.
The most common gastrointestinal complaints include nausea,
vomiting, diarrhea, and abdominal pain [82]. These are usually
mild but can occasionally be severe [83]. Dermatologic
adverse effects are more frequent and concerning. The major-
ity of clofazimine-treated patients will develop reddish-black
or orange discoloration of the skin, eyes, and body fluids [84].
This resolves slowly over the course of months, but can persist
for longer [85]. Ichthyosis, a skin disorder with thickened, dry,
scaly skin which can be quite distressing to patients, may
occur in up to a quarter of patients treated with clofazimine
[82]. Clofazimine is known to prolong the QT-interval; how-
ever, this has been poorly characterized. This is of particular
concern if clofazimine is to be combined with Mfx and the
novel TB drugs bedaquiline, delamanid, or pretomanid, all of
which also cause QT-interval prolongation.
Most clofazimine safety data are from leprosy patients, and
there is relatively little experience with clofazimine in the
treatment of MDR-TB or in children. In a systematic review of
the safety of clofazimine in MDR-TB and XDR-TB treatment,
including five studies with 602 clofazimine-treated patients,
the proportion experiencing a clofazimine-attributed adverse
effect ranged from 0 to 11%; however, only 0.1% overall
discontinued clofazimine [86]. Data from more recent studies
have been somewhat variable. In a randomized controlled trial
in 105 adults with MDR-TB who received an optimized back-
ground regimen (OBR) with or without clofazimine, in clofazi-
mine-treated patients skin discoloration was reported in 94.3%
and ichthyosis in 47.2%; there was no difference in gastroin-
testinal adverse effects between the two groups [87].
However, in a South African cohort, dermatologic adverse
effects were reported less frequently, with a dermatologic
reaction reported in only 6 of 42 (14%); only three participants
in this cohort discontinued clofazimine [88]. There are limited
data on children with MDR-TB treated with clofazimine. In a
recently reported case series, seven children with MDR-TB
were treated with clofazimine for a median of 20-month dura-
tion [78]. Clofazimine-attributed adverse effects were reported
in four children, including one with transient gastritis, one
with ichthyosis, one with red skin discoloration, and one
with ichthyosis and red skin discoloration; clofazimine was
not interrupted or discontinued in any case. Additional data
in children are important, given the potentially increased use
of clofazimine for MDR-TB treatment.
5.6. High-dose isoniazid (WHO Group D1)
Isoniazid is a bactericidal drug in drug-susceptible M. tubercu-
losis. It is a prodrug that is converted by a mycobacterial
catalase-peroxidase to an active metabolite. Following activa-
tion, isoniazid inhibits the biosynthesis of mycolic acids in the
mycobacterial cell wall [89]. Resistance to isoniazid is con-
ferred mainly by mutations in either katG gene (usually inter-
mediate- to high-level resistance) or InhA promoter region
(usually low-level resistance) [90]. Patients infected with low-
level isoniazid-resistant M. tuberculosis isolates may benefit
from treatment with high-dose isoniazid [91].
Isoniazid is arguably the most used antituberculosis drug,
and adverse effects are well-characterized. Hepatotoxicity is
most serious: slight elevation of liver enzymes (less than three
times upper limit of normal [ULN]) occurs in up to 40% with
preventive therapy [92]; in this study, 16/227 (7%) had transa-
minase levels greater than three times ULN – four were
switched to rifampicin preventive therapy. In an extensive
review, Donald [93] showed that there is no significant influ-
ence of dose regarding those with increased serum transami-
nases; increased transaminase levels were reported in 141/
1762 (8%) children receiving isoniazid at 10 mg/kg compared
to 139/1406 (9.8%) children receiving doses of 10–20 mg/kg.
However, persons with increased isoniazid concentrations or
its metabolites, as found in slow acetylators of isoniazid,
seemed more likely to experience rise of transaminase levels
above normal [93]. New-onset vomiting and abdominal pain
are early warning signs of significant hepatotoxicity; jaundice
is a late sign, in which case all hepatotoxic drugs should
immediately be discontinued, as continuation of these drugs,
including isoniazid, could lead to rapidly fatal hepatic failure.
Once transaminases and bilirubin levels have returned to
normal, isoniazid can be reintroduced, but with high-dose
isoniazid in an isoniazid-resistant case, the benefit of this
should be weighed against the risk.
Dose-related neurotoxicity, such as peripheral neuropathy,
seizures, psychosis, ataxia, and optic neuritis, is rare in children
and can be prevented in high-dose isoniazid by adding pyr-
idoxine to the regimen. Very rare hematological adverse
effects, also responsive to pyridoxine, are sideroblastic anemia,
hemolytic anemia, thrombocytopenia, and aplastic anemia.
Skin rashes are common; in adolescents, acneiform eruptions
are common [94].
5.7. Delamanid (WHO Group D2)
Delamanid (Deltyba®), previously OPC-67683, is a new antituber-
culosis drug derived from the nitro-dihydro-imidazooxazole class
of compounds that inhibits mycolic acid synthesis [95]. The drug
has been approved by the European Medicines Agency (EMA)
and several other countries for treatment of MDR-TB in adults
and is now also available through the Global Drug Facility. It is
not yet approved by the United States Food and Drug
Administration (FDA). It has been available through compassio-
nate use from themanufacturer to children older than 12 years of
age and more recently for children down to 6 years of age and
more than 20 kg body weight [96].
Delamanid is likely a prodrug activated by mycobacterial
F420-dependent Ddn coenzymes and is eliminated directly
from plasma. It is not excreted in the urine but metabolized
largely by plasma albumin. It is largely converted to its primary
metabolite, DM-6705, which is thought to be mainly respon-
sible for its effect of QTc prolongation [97].
Adverse events were similar in a study comparing delama-
nid 100 mg twice-daily, 200 mg twice-daily, and placebo
group in patients on background MDR-TB treatment except
for QTc prolongation, which differed significantly between the
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three groups in pairwise comparisons (highest in the delama-
nid 200-mg twice-daily group). No patients with prolonged
QTc interval were symptomatic, and no patient stopped dela-
manid due to QTc prolongation [95]. Administration of con-
comitant drugs with QT prolongation effect or CYP3A4
inhibitors (as the delamanid metabolite DM-6705 is metabo-
lized by CYP3A4) and hypoalbuminemia may be associated
with an increased risk of QTc prolongation [95,97].
Hepatotoxicity was found at a rate of 3% across all three
adult MDR-TB groups in the study by Gler et al. [95]. However,
a single report of severe hepatotoxicity in a 25-year-old male
was reported to the EMA [98]. The EMA therefore advises to
avoid delamanid in patients with moderate-to-severe hepatic
impairment [97].
Two studies, a Phase 1, open-label, multiple-dose, age de-
escalation trial to assess the pharmacokinetics, safety, and
tolerability and a Phase 2 open-label, multiple-dose trial to
assess the safety, tolerability, pharmacokinetics, and efficacy of
delamanid in children with MDR-TB, are ongoing [99].
Provisional results have been presented in older children: of
13 HIV-uninfected children 6–17 years of age (six children
<12 years of age), none experienced any serious adverse
events, and no child had an absolute corrected QT by
Fridericia’s formula (QTcF) of >500 ms or an increase in QTcF
from baseline >60 ms [100]. Although delamanid therefore
seems safe and well tolerated in children, more data on dose
and safety in children are required, especially in HIV-infected
and in younger children; younger children are currently being
enrolled.
5.8. Bedaquiline (WHO Group D2)
Bedaquiline (TMC 207) is a diarylquinoline, a new class of
antituberculosis drug and the first new drug to be approved
for tuberculosis treatment since rifampin in 1971 [101]. It is
an adenosine triphosphate synthase inhibitor specific for M.
tuberculosis and some nontuberculous mycobacteria; it kills
both dormant and actively replicating mycobacteria [101].
Bedaquiline received accelerated approval by the FDA in
2012 for adults >18 years of age with MDR-TB [102]. WHO
does not recommend using bedaquiline in children since
there are no pediatric data available [103]; however, the
Centers for Disease Control and Prevention has allowed for
bedaquiline to be used off-label on a case-by-case basis in
children [104]. No reports of bedaquiline use in children
have yet been published. Two studies on dose finding,
safety, and tolerability in children with MDR-TB and with
and without HIV coinfection are planned – Janssen
Therapeutics C211 (in HIV-uninfected children) has recently
started enrolling children >11 years of age, and IMPAACT
P1108 (HIV-infected and uninfected children) is scheduled
to open late 2016 [105].
Nausea was the only adverse effect more common in the
bedaquiline plus OBR MDR-TB treatment group compared to
the control OBR MDR-TB treatment group in adults [106].
Other frequent adverse effects noted were headache and
arthralgia [107]. QTc-interval prolongation is a known adverse
effect, which usually is minimal, but in one study, 7/35 (20%)
experienced a ≥60-ms increase in QT interval, leading to
bedaquiline discontinuation in 2/35 (6%) cases [108]. Caution
is therefore advised in using bedaquiline with other antituber-
culosis drugs with the potential of QT prolongation.
A higher mortality rate was found in the bedaquiline group
in one randomized controlled trial comparing placebo plus
OBR with bedaquiline plus OBR for treatment of MDR-TB. In
this adult Phase 2 study (C208), 10 of 79 in the bedaquiline
group vs. 2 of 81 in the placebo group died; only one death
occurred within the 24-week trial period while receiving beda-
quiline. No specific association with bedaquiline was identified
in any of the other deaths, which occurred long after stopping
bedaquiline [109]. This led to a black box warning and was
included in the adverse effects section of the bedaquiline
(Sirturo) product insert [102,110]. However, subsequent stu-
dies in adults under more programmatic conditions have not
found increased mortality with bedaquiline [106].
5.9. PAS (WHO Group D3)
PAS was the first effective antituberculosis drug to be used in
1944; however, its mechanism of action remains unclear.
Mutations in the thymidylate synthase gene, found in PAS-
resistant M. tuberculosis strains, imply that PAS may inhibit
thymidylate synthesis, and it could also interfere with the
organism’s acquisition of iron [111]. PAS is primarily consid-
ered a bacteriostatic drug, but a single high daily dose PAS
might have bactericidal activity [112]. PAS is now mainly used
as an enterically coated granular formulation.
PAS is often poorly tolerated mainly because of its gastro-
intestinal adverse effects. The granular PAS formulation seems
to be better tolerated than older formulations; nevertheless,
half of 12 patients reported mild nausea, vomiting, diarrhea, or
bloating [113]. A recent study of once-daily compared to
twice-daily dose of PAS granules showed little difference in
tolerance in adult MDR-TB patients [114]. Gastrointestinal
intolerance led to withdrawal of PAS in 5–7% of patients in
two studies in adults [115,116]. No specific data are available
in children, but in our experience, gastrointestinal distur-
bances, in particular diarrhea, are common, but usually resolve
after 1 to 2 weeks.
Hypothyroidism, a common adverse effect associated with
PAS, is caused by inhibition of thyroid peroxidase [13]. It is
more frequent when PAS is used together with the thioamides
and in HIV-infected children. In one small study, 15 of 19 (79%)
children with a high rate of HIV infection developed hypothyr-
oidism while on both PAS and ethionamide [117]. Our practice
is to do thyroid function tests at baseline to exclude disease-
related thyroid dysfunction and thereafter every 2 to 3 months.
If both the TSH is raised and the free T4 is low, we supplement
children with levothyroxine until the end of antituberculosis
treatment [13]. Symptomatic hypothyroidism and goiter in
children are rare.
Although hypokalemia is not specifically associated with
PAS, it may occur in children who are severely malnourished
and have diarrhea, especially in HIV-infected children [117].
Hepatotoxicity may occur in 0.3–0.5% of patients on PAS
[94]. Although PAS and its metabolite are eliminated mainly in
the urine, PAS is acetylated in the liver and intestines to
N-acetyl-PAS; the latter is an inactive but hepatotoxic
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metabolite [118]. If discontinuation of hepatotoxic drugs is
required, as is the case with moderate or severe hepatotoxi-
city, PAS may be rechallenged once hepatic enzymes have
normalized.
Hypersensitivity reactions, mainly fever and maculopapular
rash and a case of drug reaction with eosinophilia and sys-
temic symptoms syndrome, have been described with PAS,
but these are rare [119,120].
The specific role of PAS as the cause of adverse effects in
MDR-TB regimens has not often been studied. In a study from
Korea, PAS was associated with adverse effects in 47/192
(24%) patients, the majority of which were gastrointestinal
[121]. No such studies are available in children.
5.10. Amoxicillin/clavulanate (WHO Group D3; to be
used with meropenem or imipenem)
The combination of a beta-lactam and a beta-lactamase inhi-
bitor (clavulanate) has its effect on the mycobacterial cell wall
[122]. M. tuberculosis produces a chromosomally encoded
beta-lactamase enzyme, and therefore, the use of clavulanate
is essential for killing M. tuberculosis. The efficacy of these
combinations against M. tuberculosis is controversial, espe-
cially in cases where this is most needed, such as XDR-TB
[122–125]. However, a few clinical studies have shown some
positive effect [126].
Common adverse effects are gastrointestinal disturbances,
including diarrhea, and skin rashes. Hypersensitivity reactions are
known with amoxicillin, but can also be associated with clavula-
nate [127]. Severe hypersensitivity reactions or anaphylaxis should
lead to discontinuation of the drug. Hepatotoxicity has been asso-
ciated with amoxicillin/clavulanate, although a recent systematic
review and meta-analysis has shown a low incidence of drug-
induced liver injury with amoxicillin/clavulanate [128]. A number
of cases have been described in children [129].
6. Conclusion
An increasing number of children with drug-resistant TB are
being treated with second-line antituberculosis drugs, and new
drugs are starting to be introduced. The second-line drugs are
generally seen as more toxic, and they have many additional
adverse effects compared to first-line drugs, which the health-
care worker managing children with drug-resistant TB should be
aware of. As children often cannot effectively communicate drug
adverse effects, caregivers and health-care workers have a spe-
cial responsibility to evaluate for these effects. Fortunately, the
majority of currently known adverse effects are mild to moder-
ate, but some adverse effects may be severe and irreversible and
thus important to diagnose and to act upon early.
7. Expert opinion
The spectrum of adverse events due to second-line antituber-
culosis drugs in children is wide. It is often difficult to tease
out the role of individual drugs as cause of specific adverse
events, since antituberculosis drugs have overlapping toxici-
ties and they are always used in combination regimens.
Identifying the culprit drug is even more difficult if TB treat-
ment is used with other medications, such as antiretroviral
drugs. In this review, we have not addressed drug–drug inter-
actions in depth, which could complicate matters even further.
Although it is frequently anecdotally reported that children
experience fewer adverse events than adults on antituberculosis
treatment, there is limited evidence from rigorous prospective
clinical studies. Retrospective studies rely on health-care workers
accurately documenting adverse events, which are frequently
omitted. Furthermore, adverse events are difficult to monitor in
children: a history of symptoms may be difficult to obtain in
children; clinical examination for adverse events such as periph-
eral neuritis, hearing or vision loss, and depression or other CNS
features is complicated and often not possible in young chil-
dren; and special investigations such as laboratory tests and
age-appropriate ophthalmological or hearing evaluation are
rarely available in resource-limited settings where the majority
of children with MDR-TB are treated. High-quality prospective
studies in children of the safety of second-line containing MDR-
TB treatment regimens are needed; such data are important for
informing safety monitoring recommendations and for inform-
ing future regimen design.
There are currently few widely available child-friendly formu-
lations of the second-line drugs, which results in children receiv-
ing split or crushed adult tablets or capsules. There is a potential
for inaccurate dosing, which may increase the risk of adverse
effects if this results in higher than recommended doses being
given. Additionally, crushing or splitting adult tablets can wor-
sen palatability and can contribute to drug-associated vomiting.
The development of child-friendly formulations that are more
palatable and allow more accurate dosing may improve the
safety and tolerability of MDR-TB treatment in children.
The observed lower rate of adverse events in childrenmay also
be due to lower drug exposure in children than in adults using the
currently recommended doses of second-line drugs, as has been
found in several studies [34,36,38,130]. Adverse events may there-
fore increase as higher TB drug doses are recommended because
many adverse events are dose related; this should be prospec-
tively monitored. The aim is to dose a drug at its maximum
effective concentration, but keeping adverse events to a mini-
mum; to determine this optimal benefit vs. risk ratio, careful long-
term prospective clinical studies of safety and tolerability and
pharmacokinetic/pharmacodynamics in children are needed.
New and innovative methods may be necessary to better
evaluate adverse events of antituberculosis drugs in children.
Body mapping (drawing a life-size ‘self’ and writing on it what
children experience) was used in a recent study with older
children and teenagers to express what they feel; this helped
children to articulate adverse events and experiences while on
MDR-TB therapy [131]. Exploration of these and other innovative
methods of adverse event assessment in children may improve
our understanding of the safety profile of these drugs.
Regimens for DR-TB are changing; new drugs are becoming
available, and new combinations to shorten treatment dura-
tion and exclude the injectable agents are currently being
evaluated in adults and will soon follow in children. Careful
pharmacovigilance is needed to document adverse events, of
which some may be unexpected or new. Special investigations
such as electrocardiogram monitoring and additional
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laboratory tests will be required to determine optimal and safe
drug use in new MDR-TB regimens in children.
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S UMM A R Y
There is a growing number of children worldwide
accessing second-line anti-tuberculosis drugs for multi-
drug-resistant tuberculosis (TB); however, there are very
few child-friendly formulations. For paediatric use,
dispersible tablets offer distinct advantages over liquid
formulations and other approaches. This is particularly
relevant for TB, where stability, long shelf-life and
reduced manufacturing, transport and storage costs are
all critical to ensuring that drugs are accessible and
affordable. In addition, fixed-dose combinations that
reduce the pill burden and provide adequate taste
masking may promote long-term adherence to anti-
tuberculosis treatment and prevention regimens likely to
last many months in children. Partial adherence may
result in treatment failure and the further selection and
spread of resistant mycobacteria. Unfortunately, no
second-line TB paediatric drugs exist in dispersible
formulations. We discuss here the main obstacles to
developing such tablets and present strategies for
overcoming them. We also advocate for timely antici-
pation of paediatric use when new TB drugs are being
developed, and for the development of child-friendly
anti-tuberculosis formulations in general.
K E Y WORD S : CMC; TB; FDC; rifampicin; linezolid
TUBERCULOSIS (TB) is a serious health problem
among children worldwide, causing an estimated
136 000 deaths and at least 1 million new cases each
year.1Moreover, there appears to be an increase in the
number of children with multi- (MDR) and exten-
sively drug-resistant TB (XDR-TB).2 Unfortunately,
the development of paediatric TB medications trails
behind those made available to adults. As the orally
formulated, immediate-release, adult-strength tablets
available were generally not designed for flexible/
alternate dosing, they are difficult to adapt to
redosing based on age and/or weight, which is
customary in children.
One common makeshift solution is to crush tablets
normally intended for adults and administer a portion
of the powder to the child, a procedure that comes
with a number of problems: inaccurate dosing (due to
lack of information of what is appropriate), disrup-
tion of the coating (potentially affecting exposure and
worsening palatability), improper/imprecise dose
administration and a potential waste of the active
pharmaceutical ingredient (API). These problems
may worsen adherence, as these drugs are generally
to be taken over a period of many months, often at
home.
As an alternative, some of the second-line TB drugs
are provided as liquid solutions or in suspension.
However, these come with their own problems: the
containers that contain these are bulky; liquids are
generally less stable even when refrigerated; taste-
masking is difficult; storage, packaging and safe
transportation are expensive; and care givers prefer
tablet formulations over suspensions for chronic
conditions such as HIV.3
A third, and now preferred option, as outlined in
the World Health Organization (WHO)/United Na-
tions Children’s Fund (UNICEF) new 2008 children’s
medicine guide is dispersible tablets,4 which are
dispersed in water before intake. Their main advan-
tages are ease of administration, transport, storage
and opportunities for taste masking. One successful
example of taste masking in a drug for another
condition is Coartemw Dispersible (Novartis, Basel,
Switzerland), an anti-malarial developed especially
for children as a sweet-tasting, cherry-flavoured
tablet (www.mmv.org). Another example of taste-
masking for paediatric use is the development of a
quinine formulation with decreased solubility that
ensures that the bulk of this bitter API is not released
in the mouth but further down in the gastrointestinal
tract.5
Another advantage of dispersible tablets is that
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different pill strengths can be produced in order to
finetune dosing by age and/or weight. These tablets
can be scored (shaped with break-marks to allow easy
division into two or four equal-sized parts) to provide
further dosing flexibility. Unfortunately, no second-
line dispersible anti-tuberculosis tablets exist today
(Table 1). We review here the main obstacles that
prevent the development of such formulations and
how these problems could be successfully tackled.
DEFINING THE NEEDS
Policy and dosing guidelines
One of the key difficulties in developing dispersible
tablet formulations of second-line TB medications is
the absence of paediatric dosing guidance. Simple
allometric scaling and extrapolating adult exposure
to children usually will not suffice due to adult/child
differences in gastric emptying and pH, gastrointes-
tinal tract permeability in absorption surface area,
expression of some drug transporters, biliary func-
tion, drug metabolism and renal clearance.16 The
required absolute drug dose in children may thus vary
100-fold,17 and it is dangerous to assume that
exposure will be comparable (can simply be scaled)
even between older and younger children. Because of
well-established differences between older and youn-
ger children and infants, the International Conference
of Harmonization has recommended that childhood
be divided into five stages with respect to clinical drug
use.18 Establishing paediatric exposure will therefore
require dedicated clinical studies.
A summary of the pharmacokinetic data that are
available to date is presented in Table 1, and a
detailed discussion on paediatric dose-finding is
provided in another article in this Supplement.19
Once age-dependent dosing requirements have been
established, dispersible tablets can be scored or
manufactured in a small set of easily distinguishable
shapes and strengths to accommodate dosing require-
ments. Established dosing guidelines are essential
before the regulatory authorities can approve the
Table 1 Paediatric formulations of second-line anti-tuberculosis medications: overview of challenges, ongoing work and
recommendations
LVX MFX Ethionamide
Existing formulations 250 mg scored tablets
500 mg scored tablets
Suspension/solution of 25 mg/ml
(not available via GDF)
Note: some film-coated 250 mg
tablets are not scored
400 mg non-scored, film-coated
tablet
250 mg film coated, non-scored
tablet; non-film coated tablet
PK work in children
(summary of data/
ongoing work)
10–20 mg dose needed, with
higher doses needed for MIC of
.0.25 lg/ml6
Levofloxacin dose 15–20 mg/kg in
children of all ages7
Ongoing work in Cape Town
evaluating dosing of 15–20 mg/
kg
Dose of 7.5–10 mg/kg in children
of all ages7
No published PK data in children
aged ,7 years
Ongoing work in Cape Town
15–20 mg/kg is appropriate dose8
Ongoing work in Cape Town
unlikely to result in dose change
Dosing recommended
for children14
WHO: 7.5–10 mg/kg once daily
Expert opinion: 15–20 mg/kg once
daily.
WHO: 7.5–10 mg/kg once daily WHO: 15–20 mg total daily dose
given twice daily; Expert
opinion: 15–20 mg/kg total
daily dose, given once daily
twice daily if not tolerated
Challenges with existing
formulations
Difficult to crush and mix; may
reduce exposure when mixed
with certain food and drinks
Not scored, difficult to crush, may
reduce exposure when mixed
with certain foods and drinks
Not scored, difficult to crush, may
reduce exposure when mixed
with certain foods and drinks
Increasing demand,
clinical
Given to almost all children treated
for DR-TB
Use can be promoted by global
networks providing training of
treatment and prevention of
DR-TB
Given to children treated for DR-
TB; needed for XDR-TB regimens
Use can be promoted by global
networks
Given to almost all children treated
for DR-TB. Use can be promoted
by global networks.
Potential for inclusion in
future research studies
MFX or LVX essential part of most
backbone regimens
Essential in preventive therapy
trials
MFX or LVX essential part of
backbone regimen
Could be part of preventive
therapy trials
Needs to be part of most
backbone regimens
LVX¼ levofloxacin; MFX¼moxifloxacin; PAS¼para-aminosalicylic acid; GDF¼Global Drug Facility; MIC¼minimum inhibitory concentration; MDR-TB¼multidrug-
resistant TB; PK¼ pharmacokinetic; TB¼ tuberculosis; WHO¼World Health Organization; DR-TB¼ drug-resistant TB; XDR-TB¼ extensively drug-resistant TB.
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submitted information package for the dispersible
tablets for registration and approval. Dosing guide-
lines have recently been specified for first-line anti-
tuberculosis drugs for drug-susceptible TB; however,
to date there have been no such recommendations for
MDR-TB.
Stability and compatibility challenges with dispersible
formulations
A dispersible tablet has to meet the specifications of
the disintegration test (dispersal under 3 min) and
‘fineness of dispersion test’ (dispersed powder should
pass through a 710 lM pore aperture sieve).20 A
common approach to generating dispersible tablets is
the inclusion of high amounts of disintegrants such as
sodium starch glycollate, microcrystalline cellulose,
crospovidone and/or croscarmellose, excipients that
swell upon contact with moisture and help disinte-
grate the tablet. The problem with many of these
excipients is that they are highly hygroscopic (mois-
ture absorbing), resulting in spontaneous softening
and swelling of the tablets over time. Moreover,
storage conditions in most of the high TB burden
countries have high temperature and humidity.
Dedicated manufacturing procedures and special
packaging can reduce the risks of moisture ingress,
using, for example, double-aluminium blisters. When
flavourings and sweeteners are added, it is important
to exclude the risk of interaction with the API(s); this
means that long-term stability studies are necessary.
Finally, all other excipient components in the mix
should be thoroughly evaluated in combination for
compatibility issues with the API. For example, the
binding of quinolone antibiotics to divalent cations
has been well-documented.21
Taste masking
The second-line anti-tuberculosis drugs available
today comprise only a small set of chemical classes,
and most have a highly bitter and obnoxious taste, for
which children in particular have low tolerance. It is
critical that these medicines, as used for children, are
effectively taste masked and in addition contain child-
adapted flavours. Poor palatability of medications
has been shown to negatively impact treatment
adherence in children,22 which in the case of TB
Table 1 (continued)
Cycloserine PAS Linezolid Clofazimine
250 mg film coated hard caplet
250 mg capsule
Granules in sachets of 4 g or
mixed; dosing spoon
600 mg non-scored tablets
Suspension at 20 mg/ml (not
available via GDF)
50 mg, 100 mg soft capsules
Limited work; 15–20 mg/kg is
likely appropriate dose9
Ongoing work in Stellenbosch
University, on terizidone;
unlikely to result in dose
change
150 mg/kg total daily dose given
once or twice daily in 10
children with MDR-TB10
Ongoing work in Cape Town
Some work in children with
cystic fibrosis shows need for
higher dosing ,10 years11
Additional work needed,12 as
even adult dose not yet well
established13
No data on children with TB;
ongoing work in Cape Town
No published PK in children
WHO: 10–20 mg/kg once daily WHO: 150 mg/kg total daily
dose given as split dose twice
or thrice daily. Expert opinion:
150 mg/kg total daily dose
given once or twice daily
WHO: None
Expert opinion14: 10 mg/kg per
dose given twice daily for
children ,10 years; 300 mg
daily for children .10 years
WHO: none
Expert opinion: 2–3 mg/kg or 3–
5 mg/kg given once daily; if
calculated mg/kg dose is lower
than tablet/soft-gel
formulation, could be given
every other day15
Unable to be split, must open
capsules and mix ’compound’,
may reduce exposure when
mixed with certain foods and
drinks
Dosing spoon limited at lower
weight bands
Not scored, difficult to crush;
suspension not widely
available
Cannot be crushed or split
Given to children treated for DR-
TB. Use can be promoted by
global networks.
Given to children treated for DR-
TB; needed for XDR-TB
regimens. Use can be
promoted by global networks.
Important for a growing number
of children with XDR-TB; may
become very important if the
9 month regimen/STREAM
trial shows non-inferiority.
Use can be promoted by global
networks
Could be part of backbone
regimen
Component of some oral,
injectable-sparing shorter
regimens being tested in
future regimens
Is being tested in STREAM part 2
trial; may become part of
standard of care
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could result in treatment failure, promote the
emergence and spread of MDR-TB and waste
resources. Today’s anti-tuberculosis APIs are soluble
and rapidly released, which tends to overwhelm taste
masking and flavouring efforts. One strategy to mask
the drug’s taste involves adsorbing the drug onto a
complex forming agent.23,24 This can be achieved
using ion-exchange resins that release their ligands at
increased pH (upon entry in the duodenum). How-
ever these resins tend to display an unreliable ligand-
release rate, complicating drug exposure. The API
may also be complexed with cyclodextrins, but as
these are required in large quantities, this leads to
increased tablet size and manufacturing costs. Finally,
barrier coating can be used to minimise the contact
between the API and taste receptors with the help of
insoluble polymers. Various manufacturing tech-
niques are available to achieve such a formulation,
for example spray drying, bottom spray, solvent
evaporation, etc. These techniques require the use of
specialised equipment to achieve a good barrier coat;
moreover, the coatings may affect the API’s release
and exposure. Taste masking therefore needs to be
balanced with effective drug release, and this process
requires extensive experimentation; in most cases,
changes in exposure that result from different
formulations will need to be formally evaluated in
pharmacokinetic studies in children.
Work on taste masking should be planned for and
performed during the product development stage.
Once a product is approved, significantly changing
the composition requires extensive stability testing
(72 years). The early use of tools such as the
‘artificial tongue’25 and well-planned taste testing
panels (involving children) would pay generous
dividends.
Bioequivalence studies
Dispersible tablets represent an alternative solid
dosage form to the existing immediate-release tablets.
As previously mentioned, dispersible tablets contain
different excipients and tend to release the API earlier.
Bioequivalence studies are therefore required to
characterise the rate and extent of API absorption
and compare it with a comparator product repre-
senting the currently available dosage form. The
paediatric dispersible tablet will contain a substan-
tially lower amount of API than the currently
available adult formulation. Multiple dispersible
tablets will therefore need to be administered and
compared with a single adult immediate-release
tablet, or in some cases with multiple immediate-
release tablets to achieve dose equivalence. The
difference in release characteristics of the APIs and
the formulations, combined with the different num-
ber of tablets, result in a complex bioequivalence
evaluation scenario. Failure to properly evaluate all
these parameters may trigger the need for further
clinical efficacy studies conditional to successful
registration. Timely development and acceptance of
dosing guidelines and a decision on the appropriate
comparator products may facilitate the process.
Funding these important studies is problematic. As
bioequivalence studies are typically performed in
adults, funding sources that focus on paediatric
applications usually do not pay for them, and because
the results are applied to children, sponsors who
primarily address TB in adults do not pay for them
either.
Fixed-dose combinations
All TB regimens today involve multiple drugs;
combining these as fixed-dose combinations (FDCs)
is highly desirable, mostly for reasons of patient
adherence. However, the development of FDCs
further complicates the previously described chal-
lenges, making this task even more formidable for
most combinations. Another problem is that the
combination ratio is indeed ‘fixed’; if the planned
combination consists of one drug that is given at a
single dose to all populations and a second one that
requires finely tuned age- or weight-based dosing
adjustments, then the required FDC cannot be
designed (or multiple FDCs may have to be designed
wherein one drug is kept at a constant dose while the
other is varied).
Ideally, FDC dispersible tablets are manufactured
so that they can be dosed in multiples to meet the
requirements of different age groups. Dosing guide-
lines become a critical factor in deciding the
quantities of each API in dispersible tablets. Even in
its simplest form, formulating a FDC tablet in which
the APIs are uniformly distributed is challenging, and
is further complicated by the need to use suitable
taste-masking strategies. There is also the risk that the
APIs themselves may interact. Physical interactions
between the first-line anti-tuberculosis drugs have
been well documented.23,24 This can be overcome by
designing bilayered tablets, i.e., FDC tablets in which
the APIs are deposited in layers.26 However, the
manufacture of bilayered tablets with stable formu-
lations is challenging and may require special
equipment and multiple trials.
Finally, bioequivalence must be demonstrated for
each API and compared to the individual pharmaco-
kinetics observed in clinical efficacy studies; this may
fail if the drugs have different release profiles. Given
the rapidly evolving anti-tuberculosis treatment
landscape, pursuing paediatric FDCs of second-line
drugs may be challenging.
Regulatory challenges
One of the main problems in providing worldwide
patient access to new, innovative formulations is that
registration, a lengthy, bureaucratic process, needs to
occur on a country-by-country basis for the most
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part, with requirements that vary by country.
Examples of these differences include batch size,
number of batches, how and how many stability
studies were performed, disagreement over dissolu-
tion profile interpretation, bioequivalence study
design, and choice and formulation of the comparator
in the studies.
Some countries may refuse on principle to accept a
new dispersible tablet on the basis of bioequivalence,
requiring instead the demonstration of equivalent
efficacy in clinical studies. Other countries do not use
any FDCs. In some cases, it is mandatory that the
reference product be sourced from within the country
where approval is sought or the bioequivalence study
be conducted in that country. Advances in this area
include the WHO Prequalification Programme,
which facilitates a joint review process and comprises
an expanding set of countries and the introduction of
the ‘biowaiver procedure’.27 The WHO Prequalifica-
tion Programme is a ‘quiet revolution’ that addresses
drug quality problems in countries with weak
regulatory and legal monitoring.28 The biowaiver
implies that bioavailability and/or bioequivalence can
in some cases be based on dissolution tests instead of
new in vivo studies.
Supply management
The demand for second-line anti-tuberculosis drugs is
very limited compared to first-line drugs. Manufac-
turers generally tend to maintain a low inventory to
avoid expiration-related losses. Batch sizes are
typically determined by production (equipment)
capacity, shelf life and market demand. As a rule,
batch manufacturing is to be initiated when 80% of
the batch is covered by existing orders. In the
subsequent steady-state marketing situation, batches
are to be shipped with no less than 75–85% of shelf
life remaining. In practice, however, the initial
required order volume is often not reached, and an
exhibit batch size is kept that is as small as possible,
normally 125 000–200 000 tablets. A frequent prob-
lem is mass drug expiration. There is clearly room for
suppliers, procurement agencies, customers and
donors to overcome this waste by streamlining the
production-to-patient flow. Stocking of these drugs
through a central procurement mechanism such as the
Global Drug Facility is another possible solution.25
This option would ensure the ready availability of the
product as needed.
LESSONS FROM DEVELOPMENT OF
DISPERSIBLE AND FIXED-DOSE COMBINATIONS
FOR FIRST-LINE PAEDRIATIC ANTI-
TUBERCULOSIS DRUGS
For first-line treatment of paediatric TB, dispersible
tablets and FDCs have already been developed,
overcoming the challenges listed above. Most of the
dispersible FDCs include rifampicin (RMP). One of
the biggest hurdles in developing these was the
stability problems associated with the combination
of RMP and isoniazid (INH), and these APIs tend to
generate a complex that results in a reduction in RMP
bioavailability.23,24 Problems associated with other
APIs stem from hygroscopicity (a tendency to absorb
water) of ethambutol, problematic divisibility of
scored INH/RMP dispersible tablets and other
difficulties. Other challenges included taste masking
and bioequivalence when comparing with reference
(comparator) capsules or film-coated tablets.
Progress in this area of development was made
thanks to the productive collaboration between
funders, regulators, manufacturers and the TB
Alliance. Creative solutions such as adding RMP
later in the blend of ingredients to minimise contact
with INH and moisture and the judicious selection of
packaging materials have helped create elegant drug
products. These products are tested to very high
standards under varying storage conditions. Many of
the hard-earned lessons learned in the above under-
takings will instruct future efforts in developing
paediatric dispersible tablets for second-line anti-
tuberculosis medications.
PROGRESS IN DEVELOPING DISPERSIBLE AND
FIXED-DOSE COMBINATIONS FOR SECOND-
LINE PAEDIATRIC ANTI-TUBERCULOSIS DRUGS
Table 1 shows key APIs that are being considered for
second-line paediatric TB treatment regimens, along
with their key characteristics important for formula-
tion-related decisions, and demonstrates the many
knowledge gaps that must be addressed to move each
of these forward as dispersible tablets. Many of the
existing drugs and formulations have clearly been
developed without considering their potential use in
children; for example, some tablets are not scored. A
more serious and recurring problem is that the
pharmacokinetics/pharmacodynamics relation has
not been established for children. Some prototypes
of child-friendly formulations are early in develop-
ment (Macleods Pharmaceuticals Ltd), including
levofloxacin 100 mg dispersible tablets, moxifloxacin
100 mg dispersible tablets, ethionamide 125 mg
dispersible tablets, cycloserine 125 mg capsules, and
linezolid 150 mg dispersible tablets. However, sub-
stantial additional work would be needed on these
formulations to bring them tomarket, including work
on bioequivalence, quality assurance and regulatory
approvals. These formulations are therefore unlikely
to be available in the field in the short term; they are,
nevertheless, an important step forward.
Table 2 summarises challenges faced in developing
dispersible formulations of existing second-line anti-
tuberculosis drugs, and some potential solutions. Of
note, the newly approved drug delamanid has an
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advanced paediatric development programme, has
completed pharmocokinetic testing in children as
young as 6 years, is enrolling children aged ,6 years
in current PK studies, and has developed a scored,
dispersible tablet of DLM (https://clinicaltrials.gov/
show/NCT01856634). The other recently approved
drug, bedaquiline, is just beginning to undergo
pharmocokinetic testing in older children (Table 3).
An important final consideration is the price of the
product. Efforts must be made to ensure that the cost
of developing a paediatric formulation does not result
in a product that is too expensive for TB programmes
to procure and use in the field.
CONCLUSIONS
While challenging, much can be learned from earlier
reformulation successes for first-line TB treatments,
and this can be used to guide development of
subsequent formulations; their successful develop-
ment also illustrates how the process can be driven by
productive partnerships. However, many gaps in
knowledge in the use of most of second-line anti-
tuberculosis drugs in children remain, especially
regarding optimal dosing.29 It is of the greatest
importance that existing clinical trials and formula-
tion efforts already take into account how new
regimens can be administered to children, and that,
at the very least, adequate data on adult drug
exposure are available to guide subsequent paediatric
formulation development. The need for paediatric
formulations and, in particular, the development of
dispersible tablets for the treatment of TB in children
is a medical necessity.30 Because most TB APIs have
an unpleasant taste but must be taken over a long
period of time, the importance of developing taste-
masked dispersible tablets for children remains a high
priority, forming an essential link in the chain that
runs from patient detection and diagnosis and drug
access to adherence and treatment success.
Table 2 Challenges with the development of child-friendly formulations of second-line anti-tuberculosis medications in children
Challenges Way forward
Policy and dosing guidelines Currently a lack of existing dosing
guidelines for existing second-line anti-
tuberculosis medications
Lack of guidelines inhibit regulatory
agencies from approving paediatric
formulations
Support PK studies of existing second-line
anti-tuberculosis drugs in children of all
ages
International paediatric dosing
recommendations based on PK data in
children
Stability and compatibility challenges with
dispersible tablets
Dispersible tablets use excipients which are
highly moisture absorbing, and sensitive
to high temperature and humidity
conditions; long-term stability studies
may be necessary
Excipients in final formulation must be
evaluated together for interactions with
the API
Dedicated manufacturing procedures,
such as use of double-aluminium blister
packs, can limit the risk of moisture
absorption
Taste masking Existing second-line drugs are mostly bitter
compounds, requiring substantial taste
masking
Taste-masking may impact drug exposure,
increase tablet size, require specialised
manufacturing techniques and increase
manufacturing costs
Work on taste masking should be
anticipated and performed early in
product development
Well planned tasting panels, including
children where appropriate, and newer
tools such as the ‘artificial tongue’
should be used
Bioequivalence studies Bioequivalence studies are required for
dispersible tablets
Limited funding, as studies are for
paediatric products but typically
performed in adults
Ensure appropriate funding or incentives
for these important studies
Fixed-dose combinations Challenges with possible interactions
between multiple APIs and excipients;
may affect drug release, impacting
bioequivalence
May require specialised manufacturing
techniques
Anticipate challenges and ensure
appropriate funding and incentives
Ensure PK of APIs are well described
Regulatory challenges Need for country-by-country registration
Regulatory processes may differ by country
Limited market, so no financial incentive to
register
Use and expand the WHO Prequalification
Programme
Use biowaivers to limit the need for
bioequivalence studies, simplifying
registration
Supply management Limited demand results in challenges for
production, storage and supply
Streamline production-to-patient flow of
medication
Use central procurement mechanisms,
such as the Global Drug Facility
PK¼ pharmacokinetic; API¼ active pharmaceutical ingredient; WHO¼World Health Organization.
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R E S U M E
Il y a dans le monde un nombre croissant d’enfants ayant
acce`s aux me´dicaments antituberculeux de deuxie`me
ligne pour traiter une tuberculose (TB) multire´sistante,
mais il y a peu de formulations vraiment pratiques pour
les enfants. En me´decine pe´diatrique, les comprime´s
dispersibles ont des avantages nets sur les formes liquides
et d’autres approches. Ceci est particulie`rement
pertinent en matie`re de TB, ou` une bonne stabilite´,
une longue dure´e de conservation et des couˆts re´duits de
fabrication, de transport et de stockage sont tous
cruciaux pour s’assurer que les me´dicaments sont
accessibles and abordables. De plus, les combinaisons
a` dose fixe qui re´duisent le nombre de comprime´s et
masquent suffisamment leur gouˆt contribuent a` une
bonne adhe´sion a` long terme aux protocoles de
traitement et de pre´vention de la TB pour les enfants,
car ces protocoles peuvent durer de longs mois. Une
adhe´sion partielle peut aboutir a` un e´chec du traitement
et a` davantage de se´lection et de propagation de
mycobacte´ries re´sistantes. Malheureusement, aucun
traitement de TB pe´diatrique de deuxie`me ligne
n’existe sous forme dispersible. Nous discutons ici des
principaux obstacles a` l’e´laboration de tels comprime´s et
pre´sentons des strate´gies sur la manie`re dont on pourrait
les surmonter. Nous plaidons e´galement pour une
anticipation pre´coce de l’utilisation pe´diatrique lors de
l’e´laboration de nouveaux me´dicaments antituberculeux
et pour l’e´laboration de formulations anti-tuberculeuses
en ge´ne´ral acceptables par les enfants.
R E S UM E N
Cada vez un mayor nu´mero de nin˜os en el mundo tiene
acceso a los medicamentos de segunda lı´nea contra la
tuberculosis (TB) multidrogorresistente, pero existen
muy pocas formulaciones de estos medicamentos que
sean adaptadas al uso pedia´trico. Los comprimidos
dispersables, cuando se utilizan en pediatrı´a, ofrecen
ventajas claras con respecto a las presentaciones lı´quidas
y otras preparaciones. Esta ventaja adquiere un intere´s
especial en el caso de la TB, donde la estabilidad
adecuada, un perı´odo de conservacio´n prolongado y los
bajos costos de produccio´n, transporte y
almacenamiento son caracterı´sticas primordiales que
favorecen la accesibilidad y la asequibilidad de los
medicamentos. Adema´s, las asociaciones en dosis fijas
que disminuyen la cantidad de comprimidos y
enmascaran el sabor facilitan el cumplimiento del
tratamiento antituberculoso y los regı´menes
preventivos, que suelen durar muchos meses. Un
cumplimiento terape´utico parcial puede llevar a un
fracaso y favorecer una mayor seleccio´n y la
diseminacio´n de las micobacterias resistentes.
Desafortunadamente, no se cuenta aun con
tratamientos antituberculosos de segunda lı´nea en
forma dispersable. En el presente artı´culo se analizan
los principales obsta´culos al desarrollo de este tipo de
comprimidos y se proponen estrategias encaminadas a
superarlos. Se preconiza tambie´n la anticipacio´n
oportuna del uso pedia´trico de los medicamentos
antituberculosos que esta´n en vı´a de desarrollo y la
obtencio´n de formulaciones mejor adaptadas al uso
pedia´trico en general.
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